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Abstract :
Heterogeneity within an adriamycin-selected multidrug resistant (MDR) human 
squamous lung carcinoma, DLKP-A, was examined by establishing and characterising nine 
clones of the cell line. MDR variants of the same lung cell line were established by selecting 
with VP-16. The resulting cell lines, DLKP/VP-3 and DLKP/VP-8, were characterised and 
their resistance profiles and mechanisms of resistance were compared with the DLKP-A cell 
line.
All the subpopulations of DLKP-A were found to possess an MDR profile, but 
their resistance to adriamycin spanned a 9-fold concentration range. The VP-16 selected cells 
were also MDR. All the cell lines were resistant to vincristine, adriamycin and VP-16 but not 
to 5-fluorouracil and the VP-16-selected cells were hyper-sensitive to cisplatin. The rank order 
of resistance was similar in all the cell lines. Heterogeneity was observed in the DLKP-A cell 
line pertaining to the cells’ drug- and radiation-sensitivity, cell doubling time and biochemical 
alterations associated with the acquisition of an MDR profile. MDR, induced by the exposure 
of DLKP cells to adriamycin, did not confer cross-resistance to radiation. Alternatively, 
irradiation of the DLKP cell line did not result in an MDR cell line. The DLKP-A clones could 
be mixed to generate a cell population with a toxicity profile similar to the original DLKP-A 
population.
All the MDR cell lines exhibited biochemical alterations; P-glycoprotein 
expression was increased and mdrl mRNA levels were overexpressed in the MDR cell lines. 
Adriamycin accumulation by VP-16-selected cells was reflective of their P-glycoprotein levels 
and was completely reversible by the circumventing agents, verapamil and cyclosporin A. 
These circumventing agents also enhanced the toxicity of chemotherapeutic drugs to DLKP 
variants. In addition, topoisomerase II levels were altered in the drug resistant cell lines. A 
significant decrease in the enzyme level was found in DLKP/VP-8 and DLKP-A, with other 
cells exhibiting a slight decrease. The topoisomerase II alterations were due to a decrease in the 
a  subunit and these modifications were confirmed by mRNA analysis.
Metabolic co-operation was observed in all the variants of the DLKP cell line. 
While functional gap junctions were observed within the cell lines, intercellular adriamycin 
transfer did not occur and in general, gap junction inhibitors did not enhance the cells’ 
sensitivity to the drug. Sensitivity to chemotherapeutic drugs was found to be a cell density- 
dependent phenomenon. Conditioned medium from a highly resistant variant of DLKP-A 
enhanced the adriamycin-sensitivity of a low resistant variant. This suggests that a factor, 
secreted by the cells and whose secretion and/or production was enhanced by the presence of 
adriamycin, could modify the sensitivity of the cells to the drug.
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Introduction
1.1 General Introduction
Lung cancer is the leading cause of cancer death, with approximately 90% of 
affected patients dying within one year of diagnosis (Makela e t  a l . ,  1991). On the basis of 
both clinical behaviour and prognosis, lung cancers can be divided into small cell lung cancer 
and non-small cell lung cancers (DeVita e t  a l . ,  1985). Small cell lung cancer accounts for 
approximately 25 % of all new cases of lung cancer. Long-term survival or complete remission 
in small cell lung cancer is directly related to its response to cytotoxic therapy; surgical 
treatment is not a useful alternative due to the aggressive growth and metastatic activity of the 
cancer. Non-small cell lung cancers include adenocarcinomas, which account for 30% of all 
new lung cancer cases, squamous cell carcinoma, accounting for 25% of new cases and large 
cell carcinomas which account for approximately 15% of new lung cancer cases. For all non­
small cell lung cancers, resection of the primary tumour is the major treatment used.
Due to its poor prognosis, lung cancer accounts for 22% of all cancers in men 
and 9% in women and is responsible for 35% of cancer-related deaths in men and 17% in 
women, research is ongoing into improving treatment for lung cancer patients. Small cell lung 
cancer differs both biologically and clinically from other histologic forms of lung cancer. Its 
unique response to chemotherapy, compared with that of non-small cell lung cancer, is well 
established and has led to improved survival and a small, but definite, cure rate. Combination 
chemotherapy is standard therapy for both extensive and limited small cell lung cancers. 
However, second line chemotherapy, after relapse following the initial combination 
chemotherapy, is largely unsuccessful, with only modest response rates of brief duration.
Therefore, non-small cell lung cancer tumours exhibit intrinsic chemoresistance, 
whereas small cell lung cancer tumours manifest an acquired drug resistance. The mechanisms 
underlying the various forms of lung cancer chemotherapy are complex and not completely 
understood. To help determine the molecular mechanisms of drug resistance in human lung 
tumours, researchers have made resistant sublines from drug-sensitive lung cell lines, by 
exposing them to cytotoxic drugs i n  v i t r o .  The sensitive parental cell line can act as a control 
for the mechanism of resistance being investigated. Drug-resistant cell sublines have been 
derived, not only from lung cell lines, but from cell lines of all tumour types. From analysis 
of these cell lines, and tumour samples, it is apparent that a range of mechanisms of resistance 
exist in cells and tumours. These resistance mechanisms may be occurring individually or in 
combinations. The two most widely studied, and most commonly found, are the overexpression
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of the P-glycoprotein drug efflux pump and alterations in DNA topoisomerase II (topoisomerase 
II) (Clynes e t  a l . ,  1993; Volm e t  a l . ,  1991, 1992(a,b)). However, the altered expression of 
other proteins has been noted in resistant cells and/or tumours; such proteins include 
glutathione-S-transferase (GST) and proteins homologous to, but distinct from, P-glycoprotein.
3
1.2 P-glycoprotein
In general, multidrug resistant (MDR) cells, generated by exposure to 
chemotherapeutic drugs (either anthracyclines, colchicine, vinca alkaloids, actinomycin D or 
epipodophylltoxins), express cross-resistance to the range of the other structurally unrelated 
drugs but exhibit unaltered sensitivity to 5-fluorouracil and platinum compounds (Clynes e t  a l . ,  
1993; Nielson and Skovsgaard, 1992; Beck and Danks, 1991; Hill, 1993). Although a number 
of biochemical changes have been associated with MDR cells, one of the most important early 
biochemical studies on MDR was the identification of the overexpression of a 170 kDa. 
membrane associated glycoprotein, P-glycoprotein, in resistant cells, by comparison with their 
sensitive parental counterparts (Juliano and Ling, 1976). It has been well documented that a 
major determinant of the MDR phenotype is the overproduction of this protein, which acts as 
an energy dependent drug efflux pump (Safa e t  a l . , 1987). Therefore, the protein functions by 
removing drug from the cells and thereby facilitating their survival in the presence of 
concentrations of drugs which are toxic to the parental cells.
Gene-associated cytogenetic abnormalities were observed in the early established 
MDR cell lines (Biedler e t  a l . , 1980; Baskin e t  a l . , 1981). Microscopically detectable aberrant 
chromosomal structures usually appear as non-banded homogeneously staining regions, 
abnormally banding regions of metaphase chromosomes or small paired extrachromosomal 
chromatin bodies, termed double minutes. These cytogenetic abnormalities have been observed 
in cell lines selected for vincristine-resistance (Meyers e t  a l ,  1985; Benard e t  a l . ,  1989; Fojo 
e t  a l . ,  1987) and adriamycin-resistance (Slovak e t  a l . ,  1987; Fairchild e t  a l . ,  1987; Redmond 
e t  a l . ,  1990; Clynes e t  a l . ,  1992). The finding of these genetic markers in MDR cells 
suggested that MDR was associated with gene amplification. Genetic analysis of resistant cell 
lines has revealed that a family of genes, the mdr gene family, is responsible for the acquisition 
of a drug resistance profile by cells. This family consists of two members in humans and three 
in rodents, as shown in Table 1.1.
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Table 1.1 : The MDR gene family
Class Human1 Hamster2 Mouse3 
Scheme A Scheme B
I mdrl pgpl mdr3 mdrla
II pgp2 mdrl mdrlb
in mdr3/2 pgp3 mdr2 mdr2
1 Van der Bliek et a l .  (1986(a, b)); Roninson et a l .  (1986); Chen et a l .  (1986; 1990a); Schinkel et a l .  
(1991); Chin et a l .  (1989)
2 Endicott et a l .  (1987); Ng et a l .  (1989).
3 Gros et a l .  (1986(a, b); 1988); Hsu et a l .  (1989); Croop et a l .  (1989); Raymond et a l .  (1990)
Both the hamster and mouse mdr gene families include three members, 
designated pgpl, pgp2 and pgp3, in the case of hamster. The human mdr cDNA sequence 
which shares homology with the hamster pgp3 gene was designated mdr3 by Van der Bliek e t  
a l .  (1988(b)). This corresponds to the human mdr2 gene described by Roninson e t  a l .  (1986). 
Among the two rodent homologues of the human mdrl gene, the pgpl in Chinese hamster and 
the mdr3 in mouse (also called mdr la) showed the most sequence similarity to human mdrl.
Although mdrl and mdr3 genes encode highly homologous proteins, suggesting 
that the mdr3 gene product also functions as an efflux pump, the mdr3 gene does not appear 
to be involved in MDR. Expression of the human mdr3 or mouse mdr2 cDNA, inserted into 
mamm alian expression vectors, does not result in resistance to drugs associated with MDR 
(Gros e t  a l . ,  1988; Van der Bliek e t  a l . ,  1988(b)).
The two human mdr genes are located on chromosome 7; at position 7q21.1 and 
approximately 300bp apart. The human mdr locus covers about 230kb (Lincke e t  a l . ,  1991). 
The mdr3 gene is located downstream of the mdrl gene and both genes are transcribed in the 
same direction (Lincke e t  a l . ,  1991). The nucleotide sequence of all MDR genes share 
extensive homology. Sequence conservation in the nucleotide-binding regions is maintained by 
gene conservation (Endicott e t  a l . ,  1987; Van der Bliek e t  a l . ,  1988; Hsu e t  a l . ,  1989). The 
mdrl gene includes 28 introns, 26 of which interrupt the protein coding sequence. Although 
both halves of the protein-coding sequence are composed of approximately the same number of 
exons, only two intron pairs, both within the nucleotide-binding domain, are located at 
conserved positions in the two halves of the protein (Chen e t  a l . ,  1990a). This suggests that 
the mdrl gene originated by the fusion of genes coding for two related but distinct proteins, 
rather by internal duplication. The mdrl gene codes for a 4.5-5.0 kb mRNA that is 
overexpressed in MDR cell lines of human, mouse and hamster origin (Roninson e t  a l . , 1986; 
Gros e t a l . ,  1986(a,b)).
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Analysis of nucleotide and deduced amino acid sequences of human, Chinese 
hamster and mouse P-glycoprotein genes (Gerlach e t  a l . , 1986; Gros e t  a l . , 1986a; Chen e t  a l . , 
1986) provide suggestive evidence for the structure and function of the protein. The gene 
products are of approximately 1,280 amino acids (Chen e t  a l . ,  1986) and contain two 
homologous halves, joined by a linker region. That P-glycoprotein requires the presence of 
both intact halves to confer drug-resistance has been confirmed by transfection studies (Currier 
e t  a l . ,  1989). The degree of homology varies throughout the sequence and is much stronger 
near the C terminus, than in the rest of the protein. Each half has a short hydrophilic amino 
terminal segment, six hydrophobic membrane spanning domains that form three transmembrane 
loops and a hydrophilic carboxy-terminal region containing consensus sequences for a 
nucleotide-binding site. There are several potential glycosylation sites on the first external loop, 
near the amino terminal of the molecule. It is proposed that the 12 trans-membrane domains 
associate to form a pore or channel-like structure, through which substrates, including the drugs 
involved in MDR, are transported from the cytoplasm to the outside of the cell. Other 
researchers (Higgins and Gottesman, 1992) suggest that the protein acts as a ‘flippase’. In this 
model, following drug binding to the protein in the inner lipid bilayer of the cell membrane, 
the protein flips the drug to the outer lipid bilayer and into the extracellular medium.
P-glycoprotein shares notable homology with various bacterial transporters (Gros 
e t  a l . , 1986a; Chen e t  a l . , 1986; Gerlach e t  a l . , 1986). There is strong homology between P- 
glycoprotein and the bacterial a-haemolysin transport protein, HlyB (Gerlach e t  a l . , 1986; 
Holland e t  a l . , 1991). Homology also exists between P-glycoprotein and the yeast STE6 gene 
product responsible for the export of the hydrophobic a-factor pheromone, the £/mdrl gene 
implicated in chloroquine resistance in P l a s m o d i u m  f a l c i p a r u m  (Foote e t  a l . ,  1989) and the 
human cystic fibrosis gene product, CFTR (Hyde e t  a l . ,  1990).
That mdrl codes for P-glycoprotein has been verified by the transfection of the 
gene into drug-sensitive cells, resulting in the generation of MDR cells and the detection of gene 
product expression. The transfection of genomic DNA from MDR cells into sensitive cells, has 
resulted in the generation of cells exhibiting an MDR phenotype and overexpressing mdrl gene 
product (Roninson e t  a l . , 1991; Gros e t  a l . , 1991; Robertson e t  a l . , 1984). Transfection with 
full length mdrl cDNA, in a mammalian expression vector, has also resulted in MDR cell lines 
(Gros e t  a l . , 1986a). In contrast, transfection of the mdr3 gene does not confer drug resistance 
(Schinkel e t  a l . , 1991; van der Bliek e t  a l . ,  1988). The transfection of cells with genomic DNA 
or mdrl cDNA, require the selection of transfected cells, by exposing them to drug. The 
selective agent is generally one of the drugs whose exposure to cells naturally results in the 
generation of an MDR profile. Therefore, the extent of the cells’ resistance to a drug, due to 
the presence of the foreign DNA, is unclear. However, insertion of DNA which codes for a
stretch of the antisense strand of mdrl into MDR cells, has led to a decrease in P-glycoprotein 
expression and drug-resistance in the cell lines (Rivoltini e t  a l . , 1990; Efferth and Volm, 1993; 
Clynes e t  a l . ,  1992, 1993). These experiments were carried out without exposing the cells to 
drug, and so the decrease in P-glycoprotein and drug-resistance can be directly associated with 
expression of the mdrl gene. Kobayashi e t  a l .  (1994) also reported that transfection of an mdrl 
ribozyme, in a mammalian expression vector, into a P-glycoprotein overexpressing human acute 
leukaemia cell line, resulted in a reduction of the level of resistance and the amount of mdrl 
RNA expressed by the cell.
The drug cross-resistance profile exhibited by cells is associated with the 
sequence of the P-glycoprotein which is expressed. Several point mutations have been shown 
to influence the cross resistance profile conferred by P-glycoprotein, presumably because they 
are at sites involved in recognition, binding or release of drug. Dhir e t  a l .  (1993) observed that 
changing the serine residues located at position 939 of the P-glycoprotein coded by the mouse 
mdr3 gene and at position 941 of the P-glycoprotein coded by the mouse mdrl gene, limited 
the ability of the resulting altered P-glycoproteins to confer resistance to vinblastine. When 
alanine or cysteine were inserted at these positions no alteration in the adriamycin and colchicine 
cross-resistance profile was noted. However, when tyrosine tryptophan or aspartic acid were 
inserted, almost complete loss of adriamycin and colchicine resistance was observed. Devine 
e t  a l .  (1992) also observed that transfection of the mutated form of P-glycoprotein, which was 
expressed by DC-3F cells selected for resistance to actinomycin D, conferred a cross-resistance 
phenotype on the transfected cells. However, the resistance profile was altered significantly 
from that conferred by transfection of cDNA coding for the normal protein. Choi e t  a l .  (1988) 
have found that drug-resistant KB cells exhibit preferential resistance to colchicine, accompanied 
by a decrease in vinblastine resistance. This resistance profile occurred simultaneously with a 
cluster of point mutations in the mdr 1 gene, leading to a Glycine185 - *  Valine substitution in 
the P-glycoprotein sequence. Transfection studies (Safa e t  a l . , 1990) utilizing both the normal 
and mutated forms of the mdr 1 cDNA, have resulted in the conferring of altered cross­
resistance patterns on cell lines.
P-glycoprotein has been detected in a variety of normal tissues, most notably 
tissue which is inherently resistant to chemotherapy. In humans, high levels of mdrl mRNA 
and P-glycoprotein have been detected in liver, kidney, pancreas, adrenal glands, small intestine 
colon and placenta, whereas low levels are detected in most other tissue (Fojo e t  a l . ,  1987; 
Sugawara e t  a l . , 1988; Cordon-Cardo e t  a l . , 1989, 1990; Favrot e t  a l . , 1991). The localisation 
of P-glycoprotein to specialised cells in human tissue (Tatsuta e t  a l . , 1992; Sugawara e t  a l . , 
1990; Cordon-Cardo e t  a l . ,  1989, 1990; Thiebaut e t  a l . ,  1989), together with its homology to 
a number of transport proteins, implies that it may have a function in the secretion of toxins.
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1Chao Yeh e t  a l .  (1992) have described MDR breast cancer MCF-7 cells, with increased P- 
glycoprotein expression, which are cross resistant to benzo[a]pyrene, and the rates of efflux of 
benzo[a]pyrene were higher in MDR cells than in sensitive parental cells, suggesting the P- 
glycoprotein function in the efflux of benzo[a]pyrene in these cells.
P-glycoprotein is a functional component of the blood-brain barrier (Tatsuta e t  
a l . ,  1992) and it is confined to the luminal surface of epithelial cells which comprise the 
capillary vessels of the brain and spinal cord (Sugawara e t  a l . , 1990). P-glycoprotein has also 
been localised to the luminal surface of the brush border of proximal renal tubule; the luminal 
surface of biliary hepatocytes and on the mucosal surface of the columnar epithelial cells of the 
small and large intestine (Thiebaut e t  a l . ,  1987).
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1.3 Modifications, other than P-glycoprotein, observed in MDR cells
Reduced drug accumulation and its perturbed distribution may account for a 
form of resistance observed in some cells, both those overexpressing P-glycoprotein and those 
exhibiting no alteration in P-glycoprotein levels. For drugs to be effective chemotherapeutic 
agents, they must be capable of entering cells and reaching their intracellular target. Any 
alterations in these capabilities may result in the cells exhibiting resistance to the drugs.
Alterations in the intracellular distribution of drugs has been reported in the 
literature. Coley e t  a l .  (1993) reported observing this shift in adriamycin location, from the 
nucleus to a cytoplasmic- or Golgi-location, in both P-glycoprotein overexpressing MDR cells 
and resistant cells not exhibiting altered P-glycoprotein expression. Gervasoni e t  a l ,  (1991) also 
reported altered drug distribution in MDR cells which are both positive and negative for P- 
glycoprotein overexpression. Perturbed intracellular adriamycin localisation was noted in a 
number of MDR variants of the human lung cell line, SW-1573 (Keizer e t  a l . , 1989; Schuurhuis 
e t  a l . ,  1991; Mulder e t  a l . , 1993). A decrease in the nuclear- to cytoplasmic-fluorescence ratio 
(due to drug location) was observed, by comparison with drug sensitive parental cells and 
although some MDR variants did not overexpress P-glycoprotein, they accumulated less drug. 
Versantvoort e t  a l .  (1992) observed a decrease in daunorubicin accumulation in the SW- 
1573/2R120 and GLC4/ADR variants of the human lung cell lines. In GLC4/ADR cells, 
enhanced drug efflux was noted and the intracellular pH was decreased by 0.3 pH units.
The enhanced drug efflux in the absence of P-glycoprotein overexpression 
implies that other proteins, that also function as drug efflux pumps, may be overexpressed in 
the MDR cells. Cole e t  a l .  (1992a) have reported the expression of a 36 kDa. membrane- 
associated phosphorylated protein in the MDR small cell lung carcinoma H69AR, a cell line that 
does not overexpress P-glycoprotein. DNA sequencing and restriction endonuclease mapping 
revealed this protein to be a member of the annexin II/lipocortin family of Ca2+ and 
phospholipid-binding proteins. Cole e t  a l .  (1992b; 1993) also reported the overexpression of 
a member of the adenosine triphosphate (ATP)-binding transporter family, distinct from P- 
glycoprotein, in these cells. This multidrug resistant related protein (MRP) was also 
overexpressed in the small cell lung carcinoma selected for resistance to adriamycin 
(GLC4/ADR) but not in ten MDR sublines of SW-1573, a non-small cell lung carcinoma 
(7 ,am an e t  a l . , 1993). Direct evidence that MRP can confer MDR on cells has been presented 
by Grant e t  a l .  (1994). Transfection of MRP cDNA into HeLa cells has resulted in cells 
overexpressing a 190 kDa. membrane protein recognised by anti-MRP antibodies and which 
were resistant to adriamycin, vincristine and VP-16, but exhibited unaltered sensitivity to
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cisplatin. MRP was also expressed, and associated with MDR, in HL60/ADR cells 
(Krishnamachary and Centre, 1993).
Altered expression of cell surface membrane proteins (of 24.5 kDa. to 34.5 
kDa.) and non-membrane associated proteins (36 kDa., 47 kDa. and 55 kDa.) have also been 
observed in the H69AR and the MDR human fibrosarcoma cells (Mirski and Cole, 1989). The 
adriamycin-selected MDR human large cell lung cancer cell line, COR L23/R, which lacked 
P-glycoprotein but exhibited reduced drug accumulation, expressed a 190 kDa. membrane 
protein, distinct from P-glycoprotein (Barrand e t  a l . ,  1993). Marquardt e t  a l .  (1990) also 
reported the overexpression of a 190 kDa. membrane protein in MDR variants of HL-60 cells, 
overexpressing P-glycoprotein. In addition, March and Center (1989) noted that the leukaemia 
HL-60/ADR cells contained a 150 kDa. membrane glycoprotein. Although this protein was also 
expressed in drug-sensitive HL-60 cells, the protein in the resistant cells was modified by 
phosphorylation. An 85 kDa. membrane protein was also overexpressed in another drug- 
resistant leukaemia cell line, K562/ADR, but transfection studies have shown that expression 
of the protein does not result in the acquisition of a resistance profile (Sugimoto e t  a l . , 1993). 
An 85 kDa. membrane protein and a 42 kDa. membrane-associated protein, were also detected 
in a mitoxantrone-resistant human MCF-7 breast cancer subline, using a polyclonal antibody 
directed against a synthetic peptide corresponding to the putative ATP binding domain of P- 
glycoprotein (Nakagawa e t  a l . ,  1992). A 95 kDa. membrane protein was expressed in two 
small cell lung cancer cell lines which possessed inherent resistance to VP-16 and has been 
detected in small cell lung cancer cell lines obtained from patients following relapse after 
chemotherapy (Doyle e t  a l . ,  1993).
Alterations in epidermal growth factor (EGF) receptor levels have been 
associated with the acquisition of an MDR profile by cells. However a direct correlation cannot 
be made between levels of EGF receptors in cells and their resistance to chemotherapeutic 
drugs. While Reeve e t  a l .  (1990) observed reduced levels of EGF receptors in the drug- 
resistant lung cell line, COR L23/R, Meyers e t  a l .  (1993) and Shin e t  a l .  (1991) observed the 
simultaneous amplification in the expression of EGF receptors and mdrl, in lung cells.
The acquisition of drug-resistance by cells is often associated with alterations 
in the levels of glutathione and glutathione-related enzymes (Cole e t  a l . , 1990; Chen e t  a l . , 
1990b; Chao Yeh e t  a l . , 1992; Kramer e t  a l . , 1988). However, the transfection of GST cDNA, 
in m a m m alia n  expression vectors, into human cell lines has generally resulted in little alteration 
in the cells’ resistance to drugs (Fairchild e t  a l . ,  1990; Leyland-Jones e t  a l . ,  1991; Lavoie e t  
a l . ,  1992). GST is a multifunctional phase II detoxification enzyme that catalyses the 
conjunction of electrophilic substances and endogeneous xenobiotics to glutathione, forming 
stable secretable metabolites. As the formation of free-radicals is one of the mechanisms by
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which adriamycin exerts its toxicity on cells (Booser and Nortobagyi, 1994), the expression of 
a detoxification system by cells may enable them to survive in the presence of toxic levels of 
adriamycin.
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1.4 Topoisomerase II
I n  v i v o ,  DNA topology is regulated by two classes of highly conserved enzymes 
known as type I and type II DNA topoisomerases. These enzymes catalyse the interconversion 
of topological forms of single stranded and double-stranded DNA, respectively. Wang (1969) 
reported that activity in E .  c o l i  extracts was capable of relaxing supercoiled DNA due to a 
single enzyme, topoisomerase I. Gellert e t  a l .  (1976) reported the presence of a DNA gyrase- 
like enzyme (topoisomerase II) which reduced the linking number of a double-stranded DNA 
ring in an ATP-dependent fashion. Topoisomerase II (EC 5.99.1.3), is an enzyme that alters 
the Unking number of DNA by a factor of two. Topoisomerase II was isolated from 
mammahan cells (Liu e t  a l . ,  1980; Miller e t  a l . ,  1981a) and has been characterised as a 
homodimeric protein, with a molecular weight of approximately 170 kDa./subunit.
Topoisomerase II is required for the relaxation of supercoiled DNA, the 
unlinking activity necessary for fork propagation during DNA replication and segregation of 
newly synthesised daughter molecules. It is also necessary for chromosome condensation and 
is a structural component of mitotic chromosome scaffolds (Osheroff e t  a l . , 1983; Yang e t  a l . ,  
1987; Adachi e t  a l . ,  1991; Earnshaw e t  a l . ,  1985).
Topoisomerase II was first isolated from human cells, HeLa, by Miller e t  a l .  
(1981). cDNA encoding human topoisomerase II has been sequenced and localised to a single 
copy gene on chromosome 17q21-22 (Tsai-Pflugfelder e t  a l . ,  1988). The topoisomerase II 
cDNA encodes a 6.2kb mRNA which in turn codes for a 1,530-amino-acid protein of deduced 
molecular mass of 174 kDa. This topoisomerase II shares extensive homology with other 
eukaryotic topoisomerase II enzymes. Purification of topoisomerase II from 4’-(-9- 
Acridinylamino)methanesulfin-m-anaiside (amsacrine)-resistant P388 leukaemia cells revealed 
two forms of the protein possessing catalytic activity; a 170 kDa. and a 180 kDa. form (Drake 
e t  a l . ,  1987). These two forms of the enzyme are now referred to as topoisomerase II-a and 
topoisomerase 11-13, respectively. The two enzymes possessed similar requirements for ATP. 
However, the optimum KC1 concentration for catalytic activity of the 180 kDa. form was 20- 
30mM higher than for the 170 kDa. form, while the 170 kDa. form was the more thermally 
stable. When Chung e t  a l .  (1989) characterised cDNA clones coding for the two forms of 
human topoisomerase n , the cDNA coded for the 170 kDa. protein was identical to that 
previously described by Tsai-Pflugfelder e t  a l .  (1988). Topoisomerase 11-13 shares extensive 
nucleotide (75%) and predicted peptide (92%) sequence homology with the first two-thirds of 
topoisomerase II-a (Chung e t  a l ,  1989). The coding region of topoisomerase II-B is 4,863 
and encodes a polypeptide of predicted molecular weight of 183.705 kDa. (Jenkins e t  a l . ,
12
1992). The extreme N terminus and the last 25% of the C terminal domain show the greatest 
divergence. Topoisomerase 11-13 has been mapped to chromosome 3p24 (Tan e t  a l . ,  1992; 
Jenkins e t  a l . ,  1992). Austin e t  a l .  (1993) also published the complete coding sequence of the 
topoisomerase Il-il isoform in HeLa cells, which coded for a 1,621-amino-acid protein. Davies 
e t  a l .  (1993) revealed a second form of topoisomerase 11-13, which arose due to differential gene 
splicing. The topoisomerase 11-151 described by Davies e t  a l .  (1993) is similar to the 
topoisomerase 11-13 described by Jenkins e t  a l .  (1992), while the topoisomerase 11-132 encodes 
a protein containing an extra 5 amino acids after valine^ of the topoisomerase 11-131 sequence.
Topoisomerase II alters the topological state of DNA by passing an intact helix 
of DNA through a transient double-stranded break, which it generates in a separate DNA helix 
(Osheroff, 1989). Topoisomerase II produces the double-stranded breaks in a non-random 
manner with a 4 base pair (bp) 5’ overhang. The two enzyme subunits covalently bind to the 
5’ phosphoryl ends of the DNA break (Liu e t  a l . , 1983; Sander and Hsien, 1983). The removal 
of supercoils in DNA is accompanied by the hydrolysis of ATP to inorganic phosphate and the 
corresponding nucleoside diphosphate (Osheroff e t  a l . , 1983). Magnesium is also required as 
a cofactor, but it is not known when the cofactors interact with the enzyme and/or DNA (Sander 
and Hsien, 1983; Osheroff, 1986). Magnesium is not necessary for enzyme binding to the 
DNA but is required for its activity (Osheroff, 1987; Osheroff and Zechiedrich, 1987). The 
beta- and gamma-phosphate groups, the 2’-OH of the ribose sugar and the C6-NH2 of the 
adenine ring of the ATP molecule are important for its interaction with the enzyme. The 
binding of ATP to topoisomerase II is sufficient to induce DNA strand passage events, but ATP 
hydrolysis is required for enzyme turnover (Osheroff e t  a l . ,  1983).
Osheroff e t  a l . ,  (1991) suggested that the steps involved in topoisomerase II 
catalytic activity can be outlined as follows and as shown in Figure 1.1.
•  Substrate recognition and binding to DNA
•  DNA cleavage / ligation
•  DNA strand passage
•  DNA cleavage / ligation
•  ATP hydrolysis
•  Enzyme dissociation from DNA
Topoisomerase II binding to the double-stranded DNA initiates its catalytic 
reaction. The specificity of topoisomerase II binding to the DNA is determined by both the 
topological structure and the nucleotide sequence of the DNA. The enzyme preferentially 
interacts with negative supercoiled DNA rather than with relaxed molecules and also 
preferentially binds to DNA crossovers (Osheroff e t  a l . ,  1983; Zechiedrich and Osheroff, 
1990). It therefore recognises DNA topology and can distinguish between its substrate and product.
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Topoisomerase II-mediated cleavage of DNA is highly site-specific. However, 
different research groups have shown that topoisomerase II-cleavage sites vary in different cells. 
Kas and Laemmli (1992) found a major characteristic of a topoisomerase II binding site to be 
a prominent GC-rich core, flanked by an extensive array of oligo(dA).oligo(dT) tracts. Haung 
e t  a l .  (1992) found porcine spleen topoisomerase II cut preferentially in an energetically 
unstable region at the 3’ side of an adenine, leaving the 5’ protruding end with a 2 base pair 
stagger. Spitzner e t  a l .  (1990) have shown that topoisomerase II cleavage occurred 
predominantly at sites located within, or at the boundary of, alternating purine/pyrimidine tracts, 
whereas Fosse e t  a l .  (1991) demonstrated that thymidine is always present at the 3’ end of at 
least one strand of the cleavage site and the dinucleotide AT or GC at the 3’ end of the break 
plays a major role in complex stability. Drake e t  a l .  (1989) showed that topoisomerase II-a 
preferentially cut an AT-rich sequence and topoisomerase II-B a GC-rich sequence, although 
topoisomerase II-a possessed the capacity to cut both types of sequences.
Following binding of topoisomerase II to DNA, the enzyme cleaves the DNA. 
DNA cleavage requires the presence of a divalent cation, and while Mg2+ is the cation most 
associated with the enzyme function, Ca2+ can also sustain DNA cleavage and re-ligation 
(Osheroff, 1987; Osheroff and Zechiedrich, 1987). Topoisomerase II breakage of DNA results 
in a 4 base pair 5’ overhang (Sander and Hsieh, 1983; Liu e t  a l . , 1983). Following cleavage, 
the subunits of topoisomerase II covalently attach to the 5’ termini of the cleaved DNA v i a  O4- 
phosphotyrosine bonds (Rowe e t  a l . , 1986a), resulting in the generation of a temporary structure 
known as the topoisomerase II-DNA cleavage complex. Succeeding the generation of a double­
stranded DNA break, topoisomerase II passes a separate intact double-stranded DNA helix 
through the break, in a step requiring the presence of both the divalent cation and ATP. Upon 
completion of the DNA strand passage event, the cleaved DNA is re-ligated. This post-strand 
passage topoisomerase II-DNA cleavage complex is the target for many antineoplastic drugs 
(Robinson and Osheroff, 1990). As a prelude to enzyme turnover, bound ATP is hydrolysed 
to ADP and orthophosphate (Osheroff, 1989).
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Figure 1.1 : Figure 1.1(a) depicts the catalytic cycle o f topoisomerase II (as described by Osheroff et 
al., 1991). The homodimeric enzyme is represented by paired circles (1). The reaction involves the 
recognition and binding o f the enzyme to the supercoiled DNA (2), followed by the transient breaking 
of one double-stranded DNA helix (3). The enzyme is covalently bound to the 5 ’ end o f the broken DNA  
strand. A  second D N A  strand passes through the transient break. The enzyme then detaches from the 
DN A  and the DNA is re-ligated (4). The reaction requires the presence o f a divalent cation and the 
hydrolysis of ATP. A  more detailed outline o f  the strand passaging event (3) is depicted in  Figure 
1.1(b).
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Topoisomerase II is generally located in the nucleus but the protein is 
differentially localised during various stages of the cell cycle. Berrios e t  a l .  (1985) noted that 
topoisomerase II in D r o s o p h i l a  larvae was located in the nucleus. However, in interphase 
nuclei it was excluded from the nucleolus and equally distributed throughout the remainder of 
the nucleus. During mitosis the topoisomerase II was distributed diffusely throughout the cell. 
Monoclonal antibodies to the a  and B forms of topoisomerase II gave distinct staining patterns 
in HeLa and K652 human myeloid cells (Negri e t  a l . , 1992; Zini e t  a l . , 1992). Topoisomerase 
II-a antibodies stained mainly the nucleoplasm while anti-B antibodies stained only the nucleolus 
(mainly the dense fibrillar component). Topoisomerase II-a was more abundant during 
logarithmic cell growth and the R  form was mainly present during the plateau phase. Wolverton 
e t  a l .  (1992) observed a ’patchy’ topoisomerase II staining in nucleus of human 
rhabdomyosarcoma cells and exposure of the cells to a topoisomerase II inhibitor increased the 
intensity and homogeneity of nuclear staining in a subpopulation of the cells. Petrov e t  a l .  
(1993) have localised topoisomerase II in Chinese hamster fibroblasts using antibodies described 
by Chung e t  a l .  (1989). Both the a  and fi forms were present in the nucleolus and nucleoplasm. 
In the nucleoplasm, both forms localised at the periphery of heterochromatin regions. The 
nucleolus contained more detectable topoisomerase II-a and B than the nucleoplasm and both 
forms localised in the fibrillar zone. During mitosis, both isoforms were detected in the 
cytoplasm.
Topoisomerase II is a sensitive and specific marker for proliferating cells (Heck 
and Earnshaw, 1986). The appearance of the enzyme parallels the onset of replication. 
Therefore, topoisomerase II levels are cell cycle dependent and the enzyme activity fluctuates 
with cell cycle progression (Chou and Ross, 1987). In synchronised HeLa cells topoisomerase 
II activity was 4-fold to 15-fold greater when the cells were in M phase than in S phase, while 
cells in and G2 phases had an intermediate level of activity (Estay e t  a l . , 1987). The activity 
was acquired abruptly in late G2 and was lost abruptly in early G, phase. Kaufmann e t  a l .  
(1991) also noted that the topoisomerase II levels in HL-60 human progranulocytic leukaemia 
cells increased 2-fold from G, to G2/M and when the cells were induced to mature the levels 
of topoisomerase (both a  and B) diminished. Heck e t  a l .  (1988) also found that topoisomerase 
II underwent significant cell cycle dependent alterations in both amount and stability. During 
transition from M to GL much of the topoisomerase II was degraded. Topoisomerase II levels 
in primary human skin fibroblasts decreased to non-detectable levels due to serum starvation, 
while the re-addition of serum led to an increase in topoisomerase II (Hsaing e t  a l . ,  1988a). 
The topoisomerase II levels were decreased when the fibroblast cells were confluent. Chapuis 
e t  a l .  (1992) found a significant increase in VP-16 and VM-26 resistance in unfed plateau 
compared to exponential phase cells. This was reflected in the 5-fold to 15-fold increase in
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quiescent cells present in the plateau phase.
The two forms of topoisomerase II are distinguishable by their association with 
different stages of the cell cycle. The 170 kDa. form decreases as the cells reach plateau and 
the 180 kDa. form, which is low during rapid cell proliferation, increases (Drake e t  a l . ,  1989). 
Prosperi e t  a l .  (1992) found levels of topoisomerase II-a to be 3-fold higher than those of the 
B form in exponentially growing cells, whereas topoisomerase II-a, but not the B form, was 
markedly reduced in plateau cells. Woessner e t  a l .  (1991) also found topoisomerase II-a and - 
B to be differentially expressed in NIH-3T3 cells. Following serum starvation, topoisomerase 
II-a levels were undetectable until the cells reached the late S phase, peaked in G/M phase and 
decreased as cells completed mitosis. The B form was constantly expressed when the cells 
entered the cell cycle. When the cells were induced to enter the G0 phase (by serum starvation), 
levels of topoisomerase II-a decreased in parallel with the cells’ exit from S and G2/M phases, 
and were undetectable once all cells entered G0. Topoisomerase II-B was still present once all 
cells entered G0 and was more tightly associated with chromatin than the a  form. Differential 
expression of topoisomerase II-a and -B was also noted during murine brain development 
(Tsutsui e t  a l . , 1993). Topoisomerase II-a levels were found to be high in embryonic brain and 
2-day-old newborn murine cerebellum, followed by rapid decrease to undetectable levels 4 
weeks after birth. Topoisomerase II-B was present throughout embryonic and postnatal stages. 
In developing cerebellum, topoisomerase II-a containing cells were confined to the external 
granular layer but topoisomerase II-B was detected over the entire region. Therefore, 
topoisomerase II-a appeared to be associated with cell proliferation and the B form associated 
with a process not directly related to proliferation.
The activity of topoisomerase II in cells is not only modified by altering the 
enzyme levels but also the level of phosphorylation. Topoisomerase II is phosphorylated i n  
v i v o ,  with phosphate incorporation being highest in the G2 and M fraction of the cell cycle 
(Heck e t  a l . ,  1989). Ackerman e t  a l .  (1985) showed that the phosphorylation of D r o s o p h i l a  
m e l a n o g a s t e r  topoisomerase II stimulated its DNA relaxation activity. Topoisomerase II activity 
in Chinese hamster ovary cells was dependent on the degree of phosphorylation of the protein, 
not just the protein level (Burden e t  a l . , 1993) and both were cell-cycle-dependent. The protein 
levels were maximum in G2 phase, intermediate in S and M phase and minimum in G^ 
Phosphorylation was maximum in M phase, lower in S, and lowest in G2, while topoisomerase 
II activity was maximum in M, lower in Gj and minimum in S phase. DeVore e t  a l .  (1992) 
also noted that the sensitivity of topoisomerase II to induce DNA strand breaks in the presence 
of VP-16 and amsacrine could be modulated by altering the phosphorylation state of the 
enzyme. Phosphorylated enzyme had an increased rate of DNA relaxation. Phosphorylation 
had little effect on the cleavage/re-ligation equilibrium in the absence of drug, but in the
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presence of drug, phosphorylated enzyme has a decreased ability, compared to the 
unphosphorylated enzyme, to cleave DNA and so alters the enzyme’s ability to form DNA 
strand breaks.
A range of drugs currently in use as chemotherapeutic agents function v i a  
topoisomerase II-mediated cell kill. This is accomplished by stabilising a ternary complex that 
is formed between the cleaved DNA and the covalently bound enzyme (Liu, 1989). VP-16 and 
VM-26 stimulated site-specific DNA cleavage by purified calf thymus topoisomerase II (Ross 
e t  a l . ,  1984) and Chen e t  a l .  (1984) have shown that VP-16 and VM-26 interfere with the 
breakage/re-ligation reaction of topoisomerase II, by stabilising the cleavable complex. I n  
v i t r o ,  topoisomerase II-mediated DNA damage by adriamycin has been demonstrated by Tewey 
e t  a l .  (1984). Nelson e t  a l .  (1984) noted that mammalian topoisomerase II was a primary target 
for amsacrine and that drug-induced complex formation between the DNA and enzyme was the 
cause of cytotoxicity. Investigations into drug induced DNA damage resulted in specific 
cleavage at different sites in the presence of different drugs (Pommier e t  a l . , 1991(a, b); 1992; 
Capranico e t  a l . , 1990) whereby a preference for A at the 3’ end in the presence of doxorubicin 
and C at the 3’ end in the presence of VM-26 was noted.
Quantitative and qualitative alterations in the a  form of topoisomerase II have 
been associated with cellular resistance to chemotherapeutic drugs. These modifications include 
alterations in both enzyme level and activity, genetic mutations and post-translational 
modifications. Topoisomerase II-mediated drug-resistance may be the only identified 
mechanism of resistance in cells or it may co-exist with alternative resistance mechanisms. To 
gain a better understanding of the clinical implications of the modification of topoisomerase, 
especially in relation to chemotherapeutic drug resistance, topoisomerase II has been studied in 
MDR cell lines.
Decreased topoisomerase II levels, and therefore reductions in enzyme activity, 
are commonly noted characteristics of drug-resistant cells. Kamath e t  a l .  (1992) observed that 
both topoisomerase II levels and the enzyme’s cleavage activity were decreased in MDR cells 
of P388, while Friche e t  a l .  (1991) also found decreased topoisomerase II levels and activity 
in MDR EHR2/DNR+ cells that did not overexpress P-glycoprotein. Topoisomerase II and 
I activity is decreased in a P388 cell line selected for resistance to amsacrine (Per e t  a l . , 1987) 
and both the topoisomerase II protein and the a  and B mRNA levels was decreased in MDR 
K562 leukaemia cells selected for resistance to VP-16 (Ritke e t  a l . ,  1994). VP-16-induced 
damage and DNA-topoisomerase II-cleavable complexes also disappeared faster, following VP- 
16 removal, in the resistant cells. Hoban e t  a l .  (1992) showed that MDR Chinese hamster 
ovary cells, derived by exposing the cells to increasing concentrations of adriamycin, exhibited 
several mechanisms of resistance including P-glycoprotein and GST overexpression and a
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reduction in transcripts coding for topoisomerase II. Cole e t  a l .  (1991) found reduced levels 
of topoisomerase II in adriamycin-selected MDR NCI-H69 cells, when compared to the parental 
cells. The cells did not overexpress P-glycoprotein but were cross-resistant to vinca alkaloids, 
implying other mechanisms of resistance must also be present.
Alterations in topoisomerase II levels in MDR cell lines generally do not occur 
in isolation. The most commonly observed other modifications in cells exhibiting altered 
topoisomerase II are either the overexpression of P-glycoprotein and/or an alteration in the level 
and activity of topoisomerase I. The topoisomerase I enzyme is also involved in the 
modification of the topological form of DNA. However, unlike topoisomerase II, it modifies 
the topological state of DNA by transiently breaking and rejoining one of the two strands of the 
DNA helix. Modifications in topoisomerase I are generally associated with resistance to a range 
of drugs (most notably, camptothecin and its analogues) not included in the MDR profile of 
resistance (reviewed by Pessina, 1993; Liu, 1989). Nevertheless, alterations in topoisomerase 
II levels and activity may by balanced by modifications in topoisomerase I, thereby balancing 
the physiological functions of the topoisomerases. Ferguson e t  a l .  (1988) showed that human 
nasopharyngeal carcinoma KB cells, selected for resistance to VP-16, had decreased 
topoisomerase II levels and activity, while the topoisomerase I levels were increased slightly in 
the resistant cells. Lefevre e t  a l .  (1991) found a decrease in topoisomerase II activity and an 
increase in topoisomerase I and GST activity in MDR human breast cancer cells selected by 
exposure to amsacrine. Sugimoto e t  a l .  (1990) showed that camptothecin-resistant human lung 
(A549) and colon (HT-29) cell lines have reduced levels of topoisomerase I activity but 
increased topoisomerase II activity over the parental cells. However, Matsuo e t  a l .  (1990) 
found a decrease in topoisomerase II protein, mRNA and activity in VM-26 resistant KB cells, 
but topoisomerase I activity was similar in resistant and sensitive cells. De Jong e t  a l .  (1990) 
also showed that topoisomerase II and the decatenation activity in the cell extract were reduced 
in adriamycin-selected human small cell lung cancer cells which did not overexpress P- 
glycoprotein. Again the cells’ topoisomerase I levels were unaltered. Therefore, although 
modifications in topoisomerase I are associated with alterations in topoisomerase II, the 
association varies from cell line to cell line.
Alteration in the quantity of topoisomerase II present in cells, is not the only 
modification of topoisomerase II observed in MDR cells. Post-translational modifications, 
resulting in either altered cellular localisation of the protein or an alteration in enzyme activity 
have also been reported.
Deffie e t  a l .  (1992) noted that while topoisomerase II levels and the enzyme’s 
cleavage and catalytic activities were reduced in adriamycin-resistant Chinese hamster ovary 
cells and mitoxantrone resistant HeLa cells by comparison with their parental cell lines, no
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differences were noted by Northern or Southern analysis. Glisson e t  a l .  (1986a) also found that 
a Chinese hamster ovary cell line resistant to VP-16 had levels of topoisomerase II activity 
similar to the parental cells but the enzyme in the resistant cells was more resistant to drug- 
induced stimulation of its activity. Although equal levels of topoisomerase II activity were 
observed in CHOK1 cells and a DNA-break-repair-deficient subpopulation of the cell line, the 
mutant cells were more sensitive to drug-induced cytotoxicity (Warters e t  a l . , 1991). Schneider 
e t  a l .  (1994) also found that the human breast cancer cell line, MCF7/VP, selected for 
resistance to VP-16, possessed similar topoisomerase Il-a and B levels to the parental cells but 
topoisomerase II from the resistant cells was more resistant to drug-induced cleavage complex 
formation than the parental cells. No mutation was detected in either the putative ATP binding 
or breakage/resealing regions of either the a  or B form of topoisomerase II, suggesting a 
possible post-translational modification. Although the topoisomerase II activity in two VP-16 
resistant KB cell lines was similar to that in the parental cell line (Takano e t  a l . ,  1991), the 
protein and RNA levels were lower in the resistant lines. VP-16 induced DNA cleavage was 
reduced in the resistant cells and the relative specific phosphorylation was higher in the resistant 
cells. Phosphorylation occurred at a serine residue in both parental and resistant cells.
In cases where the topoisomerase II protein was purified and characterised, 
although altered enzyme activity was observed in drug-resistant cells, the activity of the purified 
protein was similar to that of the enzyme isolated from sensitive cells. Campain e t  a l .  (1993) 
reported that a VP-16-selected melanoma cell line, which possessed equal levels of 
topoisomerase II as the parental cell line, was less susceptible to drug-induced cleavable 
complex formation. This was only observed when live cells or cell lysates were tested and not 
isolated nuclei, suggesting some component of the cytoplasm, cell membrane or a factor 
removed during nuclei isolation is responsible for the resistance to VP-16 exhibited by these 
cells. Zwelling e t  a l .  (1990) noted that the difference between VP-16-induced DNA cleavage 
in HT1080 cells and in an adriamycin-resistant variant was much greater in cell extract than in 
isolated nuclei, suggesting some cytosolic factor influences the susceptibility of cells to the DNA 
cleavage activity of drugs. De Isabella e t  a l .  (1990) noted that in MDR P388 leukaemia cells, 
which exhibited a 1.7-fold reduction in their topoisomerase II activity in comparison to the 
parental cells, although the drug stimulated cleavage was 10-fold lower in the resistant cells, 
partially purified topoisomerase II from the resistant and sensitive cells exhibited similar drug 
sensitivities. This suggests that a modulating factor was present in the resistant cells, which was 
lost during purification.
Modifications occurring in topoisomerase II protein levels and/or activity due 
to genetic mutations usually occur in one of two domains; the putative ATP-binding domain 
(located at amino acid 416 to 513, in the protein sequence) or the putative breakage/resealing
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domain (located around the active tyrosine^, which is situated at amino acid 686 to 882) (based 
on sequence homology with gyrase A of E .  c o l i  (Wyckoff e t  a l . ,  1989; Worland and Wang, 
1989)).
Lee e t  a l .  (1992) found that the topoisomerase Il-a gene in two independently 
derived MDR leukaemia cell lines, both of which had been selected with amsacrine, had 
arginine486 mutated to a lysine. Sequence comparison indicated that the position of the mutation 
of the topoisomerase II-a corresponded to that of a point mutation in the gyrase B gene of 
E s c h e r i c h i a  c o l i  which conferred nalidixic acid resistance. Hinds e t  a l .  (1991) also noted that 
topoisomerase II in a human leukaemia cell line selected for resistance to amsacrine, HL- 
60/AMSA, was more resistant to drug induced inhibition of its activity than the enzyme of the 
parental line. A single base change was observed in the topoisomerase II genomic DNA of the 
resistant cells, which changed base pair 1493 from G -> A and so also changed an arginine to 
a lysine in the enzyme. Danks e t  a l .  (1988) found that nuclear extracts of CCRF-CEM 
leukaemic cell lines selected for resistance to VM-26, CEM/VM-1 and CEM/VM-1-5, possessed 
similar levels of immunodetectable topoisomerase II but had altered levels of catalytic activity, 
when compared to the parental cells. The extract required higher ATP levels to achieve levels 
of activity equal to that of the enzyme in the parental cells (Danks e t  a l . ,  1989). Bugg e t  a l .
(1991) have detected the expression of a mutant topoisomerase II in these cells. The cDNA was 
found to contain an altered sequence, having a G - » C  base change in the region corresponding 
to the consensus ATP-binding region. The base change resulted in the replacement of the 
arginine at position 449 with a glutamine. Both the normal and altered sequences were present 
in the drug- resistant cells, while only the normal sequence was present in the parental cells. 
An extra mutation, the substitution of - >  A, resulting in serine^ -*■ proline was noted by 
Danks e t  a l .  (1993). However, no mutation in the putative ATP or DNA binding regions of 
15 blast cell samples from patients with relapsed acute lymphocytic leukaemia, previously 
treated with VP-16 or VM-26, was noted. Chan e t  a l .  (1993) found that, although 
topoisomerase II expression was similar in drug-resistant, VpmR-5, and sensitive Chinese 
hamster ovary cell lines, the DNA cleavage activity in the resistant line was not stimulated by 
drug. A mutation from G - *  A at nucleotide 1478 was observed in the cDNA of the resistant 
cells, changing amino acid 493 from arginine to glutamine. This alteration is also located 
adjacent to the putative ATP binding site of topoisomerase II.
Although point mutations have resulted in the modification of topoisomerase II 
in drug-resistant cell lines, most notably by affecting their ATP-binding potential, alternative 
splicing of topoisomerase II mRNA has also been detected in a number of resistant cell hnes. 
This production of an alternative length mRNA may result in production of a non-functional
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protein, or of a functional protein which is located at an alternative site within the cell. 
Northern blot analysis of topoisomerase II in an adriamycin-resistant P388 leukaemia cells 
(Deffie e t  a l ,  1989a) revealed two mRNA splices; a 6.6 kb transcript in sensitive cells and 
reduced by 7-fold to 8-fold in resistant cells, and a shorter transcript only present in resistant 
cells (Deffie e t  a l . , 1989b). Southern blot analysis revealed two different alleles in the resistant 
cells, one identical to that found in sensitive cells but with lower gene copy number and a 
second allele containing a mutation. This suggests that the decrease in the topoisomerase II 
noted in the resistant cells (Deffie e t  a l . ,  1989a) was due to decreased gene levels and that the 
mutated gene codes for the shortened transcript. Me Pherson e t  a l .  (1993) investigated this 
gene rearrangement and determined that the shorter 4.5 kb transcript only contained 3.5 kb of 
the topoisomerase II sequence, from the 5’ terminus onwards. This encodes topoisomerase II-a 
until nucleotide 3494 with the remaining 956 bases encoding the promoter, exon 1 and part of 
the first intron of the murine retinoic acid receptor a  gene locus, in an antisense orientation. 
Retenoic acid a  receptor expression has also been reported in tumour samples expressing 
topoisomerase II (Keith e t  a l . ,  1993). Tan e t  a l .  (1989) noted that a gene re-arrangement had 
occurred in one topoisomerase II allele and that this gene was hyper-methylated in the 
amsacrine-resistant P388 cell line previously described by Per e t  a l .  (1987). The resistant cells 
exhibited reduced topoisomerase II activity and mRNA levels in comparison to the parental 
cells. The VP-16 resistant variants of the small cell lung carcinoma, H209, which exhibited 
decreased levels of topoisomerase II-a also possessed an a  form of the protein with an apparent 
molecular weight of 160 kDa. (Mirski e t  a l . ,  1993). The level of corresponding mRNA was 
reduced and a second topoisomerase II-a mRNA of 4.8 kb was also present in the resistant 
cells. When Binaschi e t  a l .  (1992) characterised a rearrangement at the 3’ terminus of one 
allele of the topoisomerase II gene, in a drug-resistant small cell lung carcinoma cell line NCI- 
1169, in addition to the normal 6.2 kb mRNA, the resistant cells expressed a 7.4 kb transcript. 
Although longer than the normal mRNA, the 7.4kb transcript lacked a substantial portion of the 
3’ terminus. Feldhoff e t  a l .  (1994) demonstrated that human small cell lung cancer cell line 
H209 contained the 170 kDa. form of topoisomerase II-a, but VP-16-selected variants contained 
a 160 kDa., and no 170 kDa., form of the enzyme. The resistant cells had a 5-fold decrease 
in topoisomerase II-a and a 2- to 3-fold decrease in topoisomerase II activity, although both 
forms of purified topoisomerase II-a have similar catalytic activities. The 160 kDa. 
topoisomerase II-a was located in the cytoplasm but the 170 kDa. topoisomerase II-a and 
topoisomerase Il-fl were located in the nucleus, suggesting the deleted sequence was not 
necessary for catalytic activity but was required for nuclear localisation of the enzyme.
When the alterations in topoisomerase II observed in cell lines are correlated 
to clinical settings, it is observed that alterations in topoisomerase II exist in a large range of
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tumours and that enzyme levels are a good indication of the susceptibility of the tumour to 
chemotherapy. In general, topoisomerase II is not altered in isolation in cancers, but co-exists 
with other genetic alterations.
In the clinical setting, highest levels of topoisomerase II are associated with cells 
undergoing cell proliferation. When Holden e t  a l .  (1992) measured topoisomerase II activity 
in a variety of normal and neoplastic tissues, highest activity was noted in spleen and thymus 
normal tissue. Therefore, the highest levels were observed in tissues that have high 
proliferation rates and the highest level of enzyme activity in neoplastic tissue was in the same 
range as that found in normal non-proliferating tissue. Holden e t  a l .  (1990(a, b)) also noted 
that tissue in which a high proportion of the cells were proliferating (melanoma, hepatocellular 
carcinoma) contained predominantly topoisomerase II-a and small amounts of the J3 subunit, 
which corresponds to what is found in cell lines. In terminally differentiated organs or 
neoplastic tissue with low cell cyclings, topoisomerase II levels were undetectable in whole cell 
extracts. In term placenta this was because the tissue contained predominantly the 13 form in 
low concentrations, which could be detected after partial concentration. However, Nelson e t  
a l .  (1987) found elevated levels and activity of topoisomerase II in rat prostatic 
adenocarcinomas, compared with levels detected in normal rat dorsal prostate. A greater 
fraction of the adenocarcinoma cell nuclei containing detectable levels of topoisomerase II, than 
the normal tissue cell nuclei.
Most of the literature on topoisomerase II levels in tumour samples concentrates 
on the correlation between enzyme levels and the responsiveness of the tumour to 
chemotherapy. Ramachandran e t  a l .  (1993) found that adriamycin-induced DNA breaks and 
topoisomerase II activity inversely correlated to the degree of adriamycin sensitivity in 5 human 
melanoma cells. Van der Zee e t  a l .  (1994) also noted topoisomerase II catalytic activity to be 
lower in ovarian tumours which had undergone platinum/cyclophosphamide chemotherapy, in 
comparison with untreated tumours, while no difference in topoisomerase I activity was noted. 
Topoisomerase II-a was detected in 4 of the 8 untreated and 3 of the 9 treated tumours, while 
all tumours possessed topoisomerase 11-13 (detected as the 150 kDa. protein, using the antibodies 
described by Negri e t  a l .  (1992)). Giaccone e t  a l .  (1992) correlated topoisomerase II levels and 
sensitivity to topoisomerase II inhibitors in eight human lung cancer cell lines. Kim e t  a l .
(1992) investigated the relationship between mRNA expression of mdrl, GST-7T and 
topoisomerase II and the responsiveness of the tumour to adriamycin, in two oesophageal, two 
gastric and two colon cancers. Topoisomerase II levels were detected in all tumours and higher 
levels corresponded to responsiveness to adriamycin. Kim e t  a l .  (1991) also noted that 
topoisomerase II mRNA expression significantly correlated with the clinical responsiveness of 
6 breast cancers, 3 hepatocellular carcinomas, 5 liver metastatic breast cancers and 1 gastric
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cancer. Brain tumours, which are inherently resistant to chemotherapy, have been associated 
with overexpression of P-glycoprotein (Becker e t  a l . , 1991; Favrot e t  a l . , 1991; Cardon-Carlo 
e t  a l . ,  1989; Sugawara e t  a l . ,  1990). However, Mousseau e t  a l .  (1993) also correlated the 
resistance in 67 human brain tumours with altered topoisomerase II. Topoisomerase II RNA 
was absent in all normal brain and 64% of the tumours, with GST-?r overexpressed in only 38% 
of tumours (mdrl and dihydrofolate reductase were only occasionally expressed). Volm e t  a l .
(1993) noted an inter-relationship between increased expression of P-glycoprotein and GST-7T 
and down regulation of topoisomerase II in 38 human renal cell carcinomas, while in previous 
studies (Volm e t  a l . ,  1991; 1992(a, b)) a relationship was noted between the cells’ resistance, 
measured i n  v i t r o ,  and overexpression of P-glycoprotein or GST-ir and down-regulation of 
topoisomerase II in renal and non-small cell carcinomas. Efferth e t  a l .  (1992) also found a 
tendency for increased P-glycoprotein and a decrease in topoisomerase II in kidney carcinoma 
cell lines, while Keith e t  a l .  (1993) showed that, in a survey of 50 breast cancer biopsy 
samples, prior to treatment, where 6 samples had an amplified erbB2 region, the topoisomerase 
Il-a locus was co-amplified in 3 cases. Amplification was accompanied by high levels of 
topoisomerase Il-a expression. Amplification of the retinoic acid oc receptor was also observed 
in the same three samples.
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1.5 Correlation between chemoresistance and radioresistance
Most patients with locally advanced lung cancer are not curable by either 
chemotherapy or radiotherapy alone and therefore, the combination of the two has been used 
to improve the treatment outcome. Radiation therapy is effective for the reduction of tumour 
volume in localised recurrent lung cancer after chemotherapy. However, there is a growing 
field of research examining the cross-resistance between anti-cancer drugs and radiation.
It is the size and localised nature of the energy-deposition events caused by 
ionizing radiations which explains its efficacy in damaging biological systems. Radiation’s 
toxicity to cells is mediated by causing DNA damage. Radiation damage also delays the 
progression of cells through the cell cycle by blocking the cells at the G2 phase of the cell cycle.
Cells may manifest resistance to radiation by a variety of mechanisms. One of 
the most important is through disturbance of the cell cycle. Although different cell lines have 
different sensitivities to radiation (Grenman e t  a l . ,  1991) and proliferating cells are more 
sensitive to radiation-induced cell kill than quiescent cells (Swarts e t  a l . , 1990), many cells have 
a resistant period in their cell cycle. The radiosensitivity of cells differs in different phases of 
the cell cycle. Cells in late S phase have the highest probability of survival after radiation, 
while cells in the G2/M phase are the most sensitive to damage by radiation (Iliakis and 
Okayasu, 1990; Northdurft e t  a l . , 1992; Quiet e t  a l . , 1991).
Radiation also exerts its toxicity on cells by the generation of oxygen radicals. 
Cells irradiated in the presence of oxygen are more sensitive to radiation than cells irradiated 
under conditions of severe hypoxia. Therefore, tumours may also exert a form of resistance 
by their physical location. Cells located at the centre of a tumour mass are generally oxygen 
deprived and so may be more resistant to radiation.
Cells with altered levels of GST may also exhibit altered sensitivity, as those 
enzymes are known to be involved in protecting cells from the detrimental effects of free- 
radicals, formed following cell irradiation. When Louie e t  a l .  (1985) characterised the 
radioresistance of sublines of the human ovarian cancer cell line A2780 (generated by incubation 
with stepwise increasing concentrations of either adriamycin (to a final resistance level of 100- 
fold for adriamycin), malphalan (10-fold resistant) or cisplatin (10-fold resistant)) and two 
additional cell lines which were established from drug-refractory patients, the melphalan- 
resistant, cisplatin-resistant and two drug-refractory cell lines were found to exhibit cross­
resistance to radiation. These cells also had elevated glutathione levels with respect to the 
parental cell line. The adriamycin-resistant cells, which remained sensitive to radiation, had 
glutathione levels which were only marginally higher than those of the parental cell line.
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Buthionine sulfoximine (which depleted glutathione), significantly, but not completely, increased 
the radiation sensitivity of the malphalan- and cisplatin-selected cell lines, suggesting glutathione 
levels play an important role in the radiation response, but not an absolute one. Twentyman 
e t  a l .  (1991) compared the radiation resistance of three human lung cancer cell lines (a small 
cell, a large cell and an adenocarcinoma) adapted to be cisplatin-resistant (3-fold to 5-fold). The 
cell lines were all melphalan-resistant. The parent lines show a wide range of glutathione 
content per cell, with the cell line with the highest glutathione content showing the greatest 
inherent resistance to cisplatin, melphalan and radiation. Although there was a correlation 
between glutathione content and radiosensitivity of the parent cell lines, acquired resistance to 
cisplatin was not accompanied by increased glutathione content, yet two of the three cisplatin 
resistant lines (the small cell and large cell carcinomas) showed significantly increased 
radioresistance. However, when Miura and Sasaki (1991) investigated the mechanism of 
radioresistance in a subclone of a murine squamous cell carcinoma, the radioresistance of the 
cells appeared to be mediated by a mechanism other than glutathione. Saito e t  a l .  (1991) also 
noted that glutathione levels alone could not act as an indicator of radiosensitivity in rat glioma 
cells.
A correlation exists between the clinical responses of small cell lung cancer 
tumours and the i n  v i t r o  chemosensitivity and radiosensitivity of the respective cell lines (Tanio 
e t  a l ,  1990). Therefore mechanisms associated with conferring chemoresistance to cells may 
also function in altering their radiosensitivity.
Alterations in the expression of the two main markers for chemoresistance in 
lung carcinomas, P-glycoprotein and topoisomerase II, may also affect the sensitivity of the cells 
to radiation. Topoisomerase II is an enzyme involved in regulating DNA topology, and 
quantitative and qualitative changes in the presence of the enzyme in cells may result in cells 
exhibiting resistance to radiation. Cunningham e t  a l .  (1991) found good correlation between 
the reduction in topoisomerase II activity in transfected murine cells and their radioresistance. 
Lynch e t  a l .  (1991) observed increased DNA relaxation in radioresponsive bladder carcinomas 
while Giocanti e l  a l .  (1993) observed that cells arrested in the G2 phase of the cell cycle, 
following cell irradiation, proved to be hypersensitive to the topoisomerase II poison, VP-16.
Conflicting correlations between the expression of P-glycoprotein and 
radiosensitivity have been reported in the literature. Cases have been cited where cells, 
overexpressing P-glycoprotein following exposure to chemotherapeutic drugs, exhibit resistance 
to radiation (Shimm e t  a l . ,  1988; Zijlstra e t  a l . ,  1987). However, P-glycoprotein-expressing 
cells are also found to have unaltered radioresistance, by comparison with non-P-glycoprotein 
expressing parental cells (Glisson and Alpeter, 1992). The literature has also revealed cell lines 
selected following drug exposure, which do not express P-glycoprotein and which exhibit altered
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radiosensitivity (Miller e t  a l . ,  1992). Some radiation-exposed cell lines have been cited as 
exhibiting altered P-glycoprotein expression and chemosensitivity, with other radiation-exposed 
cells have been found to exhibit unaltered chemosensitivity (Mattern e t  a l . ,  1991; Hill, 1993). 
In cases where P-glycoprotein overexpression was induced by radiation treatment, the resulting 
drug resistance profile was generally different from the resistance profile induced by 
chemotherapy treatment.
Shimm e t  a l .  (1988) reported an MDR human lymphoblastic cell line, selected 
for resistance to vincristine and overexpressing P-glycoprotein, which exhibited resistance to 
radiation. However, a cell line derived from a mouse tumour, generated by inoculating with 
the MDR cell line, showed loss of gene amplification (which mediated P-glycoprotein 
overexpression) but did not lose all its radiation resistance, suggesting radiation resistance was 
not totally due to P-glycoprotein expression. An adriamycin-selected MDR small cell lung cell 
line which overexpressed P-glycoprotein and exhibited resistance to radiation has also been 
described by Zijlstra e t  a l .  (1987). In contrast, a VP-16-selected MDR variant of a small cell 
lung cell line described by Glisson and Alpeter, (1992) overexpressed P-glycoprotein but 
exhibited unaltered sensitivity to radiation. Miller e t  a l .  (1992) found that an adriamycin- 
resistant human fibrosarcoma subline (HT1080/DR4), which was 222-fold resistant to 
doxorubicin and expressed a multidrug resistant profile by a mechanism independent of P- 
glycoprotein, exhibited cross-resistance to radiation.
Mattern e t  a l .  (1991) have reported a human epidermoid lung carcinoma cell 
line which acquired a P-glycoprotein overexpressing, drug-resistant profile, following radiation 
treatment. Nonetheless, in general, cell lines which acquire a drug-resistant profile due to 
radiation treatment exhibit an altered profile of cross resistance, in that they are not resistant 
to adriamycin but exhibit resistance to vincristine and VP-16. Hill e t  a l .  (1990a) reported such 
a profile in a range of radiation-treated cell fines, which did not overexpress P-glycoprotein. 
However, the MDR variant of the Chinese hamster cell line isolated by McClean and Hill
(1994) overexpressed P-glycoprotein, but exhibited a similar drug-resistance profile as the non- 
P-glycoprotein expressing cells described by Hill e t  a l .  (1990a).
27
1.6 MDR lung cell lines
An analysis of the mechanisms of resistance in drug-selected and inherently- 
resistant MDR human lung cell lines may enable a better understanding of resistance in lung 
tumours. The first striking conclusion obtained from the information pertaining to MDR lung 
cell lines is that a range of mechanisms exists in the cells and the combination of resistance 
mechanisms displayed by the cells varies between different cell lines selected by exposure to 
the same drug, between the same cell lines selected with different drugs and even between two 
independent selections of the same cell line with the same drug. However, in general, all MDR 
variants of lung cell lines exhibit cross-resistance to the same range of chemotherapeutic drugs.
Twentyman e t  a l .  (1986a) and Mirski e t  a l .  (1987) established adriamycin- 
resistant variants of the small cell lung carcinoma, NCI H69, which exhibited similar cross­
resistance profiles. However, their underlying mechanisms of resistance varied. The cell line 
described by Twentyman e t  a l .  (1986a) overexpressed P-glycoprotein and exhibited decreased 
drug accumulation (Twentyman e t  a l . ,  1986a). The MDR variant selected by Mirski e t  a l .  
(1987), H69AR, possessed decreased topoisomerase II levels, with no alteration in its P- 
glycoprotein or drug accumulation levels. H69AR cells also overexpressed a range of 
membrane-associated and non-membrane-associated proteins not detectable in the sensitive 
parental cells (Mirski and Cole, 1989). These include a calcium- and phospholipid-binding 
protein (Cole e t  a l . , 1992a) and MRP (Cole e t  a l . ,  1992b). The implications of the expression 
of these proteins, or of the altered topoisomerase II levels, on the resistance profile of the cell 
variant described by Twentyman e t  a l .  (1986a) are unknown, due to lack of information 
pertaining to their expression in the cell line. A P-glycoprotein-negative MDR human small cell 
lung cancer cell line, GLC4/ADR (Zijlstra e t  a l . ,  1987), possessed decreased topoisomerase II 
activity by comparison with drug sensitive parental cells. However, the cells additionally 
exhibited decreased drug accumulation and rapid drug efflux, obviously mediated by an as yet 
unidentified transport protein. Furthermore, these cells possessed reduced glutathione levels 
(which were restored when the cells were grown in the absence of drug) and were cross- 
resistant to radiation (Zijlstra e t  a l . ,  1987; Meijer e t  a l . ,  1987; de Jong e t  a l ,  1990, 1993).
Nygren e t  a l .  (1991) and Twentyman e t  a l .  (1986a) have described MDR 
variants of small cell lung carcinomas (U1650/150, U1285/250) and a large cell lung cell line 
(COR L23/R), respectively. Although none of the cell lines overexpress P-glycoprotein, all 
possess reduced drug accumulation, which in the case of COR L23/R cells was accompanied 
by a reduction in the nuclear localisation of the drug (Coley e t  a l . , 1993). The cytoplasmic free 
Ca2+ concentration was elevated in U1690/150 and U1285/250 cells (Nygren e t  a l . ,  1991),
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while the COR L23/R cells exhibited reduced EGF receptor levels (Reeve e t  a l . , 1990).
VP-16-selected MDR variants of the small cell lung cell line, NCI H69, have 
been established by Glisson and Alpeter, (1992) and Jensen e t  a l .  (1992). The HCI H69/VP 
cell line described by Jensen e t  a l .  (1992) exhibits an energy-dependent decrease in drug 
accumulation, implying the presence of an active efflux pump (possibly P-glycoprotein, but this 
has not been confirmed). The H69/VPR-2 cells established by Glisson and Alpeter, (1992) 
overexpressed mdrl mRNA and, although no alteration in topoisomerase II activity was 
observed, the cells exhibited a decrease in the capacity of VP-16 to induce DNA strand breaks 
(which is a function associated with topoisomerase II activity). The VP-16-selected lung cells, 
SBC-3/ETP (a small cell lung carcinoma derived by Takigawa e t  a l .  (1992)), A549(VP)28 (a 
lung adenocarcinoma derived by Long e t  a l .  (1991)) and OC-NYH/VP (a small cell lung 
carcinoma derived by Jensen e t  a l .  (1991)) also exhibited individual mechanisms of resistance. 
The resistance profile of the SBC-3/ETP cells was mediated v i a  overexpression of P- 
glycoprotein (resulting in decreased drug accumulation), reduction in topoisomerase II and 
topoisomerase I activity and an elevation in the cells’ GST-7T levels (Takigawa e t  a l . ,  1992). 
However, resistance in the other cell lines appeared to be as a result of P-glycoprotein- 
independent modifications. While direct evidence of unaltered mdrl expression was presented 
for A569(VP)28 cells (Long e t  a l . ,  1991), the unaltered drug accumulation exhibited by OC- 
NYH/VM cells (Jensen e t  a l . ,  1991) also implies unaltered mdrl expression.
When a cisplatin-resistant variant of NCI H69 cells was characterised, the cell 
line’s MDR profile appeared to be supported, exclusively, by an increase in GST and 
metallothionine II levels (no changes in P-glycoprotein, drug accumulation or topoisomerase II 
were detected) (Hong e t  a l . ,  1988; Kasahara e t  a l . ,  1991). In contrast, the MDR profile of a 
small cell lung carcinoma, established from a patient following combination chemotherapy and 
radiotherapy, appeared to be supported not only by increased GST-ir and glutathione levels, but 
by the overexpression of P-glycoprotein and reduced drug accumulation (Berendsen e t  a l . , 1988; 
de Vries e t  a l . , 1989). However, levels of drug accumulation by the cells did not correlate to 
their P-glycoprotein levels.
The multiple mechanisms of resistance exhibited by MDR lung cell lines are 
clearly demonstrated by MDR variants of a human squamous lung carcinoma, SW-1570, 
established by exposure to varying concentrations of adriamycin (Keizer e t  a l . ,  1989a). All 
variants exhibited an MDR profile to the same range of drugs, with the levels of cross- 
resistance a function of the concentration of adriamycin to which the cells were selected. 
However, the underlying mechanism of resistance varied. The cells resistant to lower levels 
of drug overexpressed neither mdrl mRNA nor P-glycoprotein, whereas cells resistant to higher 
levels of drug overexpressed both (Baas e t  a l ,  1990). Decreased drug accumulation, altered
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intracellular localisation of the drug (the shift from nuclear to cytoplasmic localisation of the 
drug was dependent on the level of resistance exhibited by the cells) and increased cytosolic pH 
were also detailed mechanisms of resistance pertaining to these cells (Keizer e t  a l . ,  1989a; 
Schuurhuis e t  a l . ,  1991; Keizer and Joenje, 1989). The non-P-glycoprotein-expressing MDR 
variants also possessed lower levels of topoisomerase II than the parental cells (Eijdems e t  a l . ,  
1992) and overexpressed a 110 kDa. vesicular protein (Scheper e t  a l . ,  1993). Varying 
cytogenetic aberrations were also observed and were dependent on whether the cells exhibited 
a P-glycoprotein- or a non-P-glycoprotein-mediated mechanism of resistance.
In conclusion, an analysis of the literature pertaining to drug-resistance in lung 
cell lines reveals that MDR can not be correlated to one specific mechanism. Different 
resistance mechanisms are equally important in various cell lines, either in isolation or in 
combination with other mechanisms. Although similar toxicity profiles are exhibited, in 
general, by MDR lung cell lines, the underlying mechanisms of resistance may not be inferred 
from this knowledge.
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1.7 MDR in lung tumours
The correlation of the mechanisms of drug-resistance observed in lung cell lines 
to resistance observed in clinical samples is distorted by the lack of analysis of the full range 
of genetic and biochemical alterations in tumour samples. Predominantly, the genetic alterations 
examined in lung tumours are confined to P-glycoprotein, topoisomerase II and GST-ir. The 
results of these investigations show variations in terms of the correlation between their level of 
expression and the sensitivity of the tumour to chemotherapy.
An investigation into mdrl gene alterations, by DNA slot blot analysis, in 23 
untreated non-small cell lung carcinomas by comparison with 14 adjacent normal lung samples 
showed low levels of DNA amplification in only one adenocarcinoma and two squamous cell 
carcinomas (Shin e t  a l . ,  1992). A concurrent investigation into mRNA overexpression (by 
RNA slot blot analysis) revealed only low mRNA expression in the six tumour samples tested. 
PCR analysis of mdrl mRNA expression in 32 lung carcinomas, prior to and following 
chemotherapy, was detailed by Holzmayer e t  a l .  (1992). In the untreated tumours, 4 of 8 small 
cell lung carcinomas, 13 of 16 adenocarcinomas and 3 of 4 unclassified lung tumours had 
detectable levels of mdrl mRNA. Analysis of lung tumours, following treatment with a range 
of MDR-associated drugs, revealed mdrl mRNA expression in all cases studied (one small cell 
lung carcinoma, one adenocarcinoma and two unclassified lung tumours).
Volm e t  a l .  (1992a) investigated the association between the proliferation rate 
of 36 untreated non-small cell lung tumours, the expression of P-glycoprotein and GST-7T and 
their sensitivity to adriamycin. No correlation between the proliferation rate of the samples and 
GST-7T expression was observed. However, a link between GST-7T and P-glycoprotein 
expression and a correlation between the resistance of the tumours to adriamycin and P- 
glycoprotein or GST-7T expression was noted. Volm e t  a l .  (1992(a, b)) also correlated cells’ 
resistance to chemotherapeutic drugs (measured i n  v i t r o ) ,  overexpression of P-glycoprotein or 
GST-7T and down-regulation of topoisomerase II, in 94 non-small cell lung carcinomas and 
Volm e t  a l .  (1991) established a correlation between the expression of P-glycoprotein, GST-7T, 
smoking history and adriamycin sensitivity for non-small cell lung cancers. However, no 
correlation with topoisomerase II expression was observed. In addition, seven small cell lung 
cell lines, established from biopsy samples, did not overexpress P-glycoprotein, even though 
three of the cell lines were established from patients following chemotherapy with MDR 
associated drugs (Milroy e t  a l . ,  1992).
An analysis of 86 untreated non-small cell lung carcinomas by Scagliotti e t  a l .
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(1991) also revealed that the hing tumour samples expressed P-glycoprotein. Fifteen of the 
samples had more than one in four cells stain positive for P-glycoprotein. However, 
heterogeneity in the level of staining was observed. While some tumour samples possessed a 
few cells that stained positive for P-glycoprotein, others were composed of nearly all P- 
glycoprotein-positive cells, revealing heterogeneity within tumours in relation to the expression 
of MDR-associated proteins.
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1.8 Clonal variation in tumour cell lines.
It is generally assumed that most, if not all, tumours begin from a single mutant 
cell. However, the constantly expanding supply of literature on inter- and intra-tumoural 
heterogeneity has led to the observation that cancers are composed of complex subpopulations 
of cells. Tumours are heterogeneous in several ways. There is the heterogeneity among 
cancers in different individuals who nominally have the same type of disease. A second type 
is that seen within the same patient over the course of time, as the tumour progresses. 
Heterogeneity is also seen within a single tumour at any given time. Therefore, it must be 
assumed that mechanisms of the origin of tumour heterogeneity also include the generation of 
diverse subpopulations from a single clone, a process which may be due to random genetic 
mutation and/or production of cellular variants, as in normal tissue differentiation.
At any given time inter-tumour and intra-tumour heterogeneity may be occurring 
concurrently. When Wilson e t  a l .  (1993) investigated heterogeneity in the potential doubling 
time of 30 colorectal carcinomas, by assaying multiple biopsies from each tumour sample, both 
inter- and intra-tumour variations were observed. Von Hoff e t  a l .  (1986) analyzed the drug 
sensitivity profiles of 99 pairs of tumour samples. Though the sensitivity profiles generated by 
the two different samples of the same primary tumour were quite similar, tumour heterogeneity 
was observed when primary tumours and their metastases were tested. The agreement between 
the drug sensitivity profiles of different metastases was also poor. Nyugen e t  a l .  (1993) noted 
that tumour heterogeneity appeared to be a common characteristic of early cervical carcinomas, 
when the carcinomas were analyzed in terms of their DNA index. Tumour heterogeneity was 
observed in primary and metastatic tumours and, using DNA index to determine tumour origin, 
60% of the metastases could not be traced to their primary origin.
Histological examination of tumour samples often reveals considerable 
differences in the morphology of cancer cells. The co-existence of multiple subpopulations of 
cells within a single tumour has been repeatedly demonstrated in diverse types of tumours. 
These include melanoma (Tsuruo and Fidler, 1981; Jelinek e t  a l . ,  1993), lymphoma-leukaemia 
(Okamura e t  a l . , 1981), sarcoma (Okabe e t  a l . , 1983) and carcinomas (Vindelov e t  a l . ,  1980; 
Worsham e t  a l . , 1993; Nyugen e t  a l . , 1992). Tumour heterogeneity is manifested by a variety 
of phenotypic differences, including differences in cellular morphology and tumour 
histopathology (Okabe e t  a l . ,  1983; Maekawa e t  a l . ,  1993; Bronson e t  a l . ,  1980), growth 
properties (Fried e t  a l . ,  1993), antigenic properties (Fried e t  a l . ,  1993; Shapiro e t  a l . ,  1981), 
the ability to metastasise (Maekawa e t  a l . , 1993), karyotypic differences (Worsham e t  a l . , 1993; 
Berens e t  a l . , 1993) and sensitivity to chemotherapeutic drugs (Dolfini e t  a l . , 1993; Tsuruo and 
Fidler, 1981; Allalunis-Turner e t  a l . ,  1993) and radiation (Powell and McMillan, 1991;
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Allalunis-Turner e t  a l . ,  1993; Allam e t  a l ,  1993).
Formal proof of the existence of tumour subpopulations requires their isolation 
and characterisation. This has now been accomplished with a growing list of cancers from a 
broad range of organs, using cell cultures which have been maintained and passaged i n  v i t r o  
prior to cloning. Maekawa e t  a l .  (1993) established two highly metastatic tumour clones, D-l 
and F-3, from a single murine skin squamous cell carcinoma, both of which had distinct 
morphology and features undergoing pulmonary metastases. Fried e t  a l .  (1993) characterised 
five osteogenic cell subpopulations of the bone marrow stroma cell line, MBA-15. The clones 
differed in their morphology, proliferation rate, quantities and distribution of extracellular 
matrix protein, levels of alkaline phosphatase activity and activation of adenylate cyclase by 
parathyroid hormone and/or prostaglandin E. Berens e t  a l .  (1993) isolated three clonal cell 
lines from the canine astrocytoma cell line DL3580, which exhibited varying chromosome 
modal number. Bronson e t  a l .  (1980) characterised a cell line, that had been established from 
a metastasis of a human testicular germ cell tumour, that consisted of four histological types of 
tumour cells. Okabe e t  a l .  (1983) isolated 25 clonal strains from a single human sarcoma of 
the stomach and two different types of clones have been identified by their morphology and 
behaviour i n  v i t r o .  One set of clones produced tumours in mice while the other did not.
Only rarely have the subpopulations been obtained directly from the patient. 
This raised the possibility that the production of heterogeneous variants was a consequence of 
the i n  v i t r o  environment and occurred sometime after removal of the tumour from the patient. 
However, a number of published results have shown that heterogeneity is a characteristic of 
tumours i n  v i v o .  Shapiro e t  a l .  (1981) karyotyped tumour cells from fresh samples of human 
gliomas within 6-72h. after surgery. An array of unique karyotypes was found in each tumour. 
Simultaneously, dissociated tumour cells were cloned by limiting dilution plating of the cells 
and the clones were karyotyped. By matching karyotypes of the clones with those in the fresh 
samples, it was possible to show that the clones were present in the tumour at the time of 
surgery. In this way, eight gliomas were each shown to contain between 3 and 21 
subpopulations. The different clones from the same tumour also differed in morphology and 
growth kinetics; in addition, antigenic heterogeneity has also been reported in clones derived 
from one of the glioma tumours. Therefore, heterogeneity is a phenomenon detectable in 
tumour samples and is not purely a characteristic of cells in culture. Mehle e t  a l .  (1993) 
investigated tumour heterogeneity in renal carcinomas in ten patients, by DNA fingerprint 
analysis. Two tumour samples were taken from four patients and three samples from six 
patients. DNA fingerprinting of the samples revealed variation in the fingerprint patterns 
between samples from different parts of the same tumour, where up to three different cell clones 
were detected in some tumours.
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It is often assumed that long term culture of cell lines results in a decrease in 
heterogeneity, due to the selection of one population, by the culturing conditions. The presence 
of distinct subpopulations in established cell lines argues against this hypothesis. Worsham e t  
a l .  (1993) observed heterogeneity in a cell culture established from skin; Fried e t  a l .  (1993) 
demonstrated heterogeneity in a bone marrow stroma cell line; Vindelov e t  a l .  (1980) have 
shown that clonal variation existed in lung cultures; Bronson e t  a l  (1980) investigated tumour 
heterogeneity in testicular cancer; Fey e t  a l .  (1993) observed variation in gastric cell lines; 
Zangwill e t  a l .  (1993) have shown that heterogeneity is a characteristic of an ovarian carcinoma 
in culture; Dolfini e t  a l .  (1993) have isolated clones from a colon carcinoma cell line which 
exhibited variations in their sensitivity to chemotherapeutic drugs.
Additional evidence that human cancers contain tumour cell subpopulations 
comes from comparison between primary tumours and metastases. Tanigawa e t  a l .  (1984) 
observed variability in the chemosensitivity of different parts of the same tumour and between 
primary and metastases, although a strong correlation was observed between the 
chemosensitivity of metastases from different sites. Schlag and Schremi (1982) also observed 
considerable differences in primary tumours and their metastases, taken simultaneously from 
the same patient, with respect to their sensitivity to a range of chemotherapeutic agents. Evans 
e t  a l .  (1986) examined the adriamycin-sensitivity of two tumour cell subpopulations derived 
from a primary 13762 rat mammary adenocarcinoma, clone MTC, and a lung metastasis in the 
same animal, clone MTLn3. The MTC cells were significantly more resistant to adriamycin 
than the MTLn3 cells.
Heterogeneity in the metastatic phenotype may result from the metastatic 
tumours being composed of cell populations which only consist of a small percentage of the 
primary tumour. Subpopulations never existing in the primary tumour may exist in the 
metastasis, due to spontaneous genetic variation or induction by the primary treatment. 
Therefore, different characteristics, such as sensitivity to chemotherapeutic drugs or radiation, 
may exist in different metastases arising from a single primary tumour. As the metastases may 
bear little resemblance to the primary tumour in terms of chemosensitivity, treatments used in 
the eradication of the primary tumour may be ineffective in the treatment of the metastases.
The observation that tumours are made up of subpopulations of varying 
characteristics poses a problem for the development of effective therapy. Tumour 
subpopulations differing in susceptibility to both chemotherapy and radiotherapy have been 
characterised. The existence of resistant variants within primary cell lines, and presumably 
tumours, may have serious implications for therapy, since the existence of even one cancer cell 
at the end of treatment could result in a regeneration of the tumour. If this cancer cell possesses 
an altered, more aggressive, phenotype, it would result in a poor prognosis for future therapy.
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AUalunis-Turner e t  a l .  (1993) concurrently established two aneuploid cell lines which differ in 
their inherent sensitivity to ionising radiation and chemotherapeutic agents, from a single 
specimen obtained from a patient with glioblastoma. M059J cells were approximately 30-fold 
more sensitive to radiation than were M059K cells and M059J cells were also more sensitive 
to bleomycin, nitrogen mustard and N,N-bis(2-chloroethyl)-N-nitrosourea. Tsuruo and Fidler 
(1981) demonstrated that differences in drug response exist among cells populating parental 
tumours; the tumours investigated were of three murine tumours, the B16 melanoma, the K- 
1735 melanoma and the UV-2237 fibrosarcoma and the A-375 human melanoma. Allam e t  a l .
(1993) observed significant intra-tumoural heterogeneity of radiation sensitivity in some 
malignant gliomas, by comparing the intrinsic radiation sensitivity of different glioma sublines 
derived from the same tumour. Powell and McMillan (1991) also observed clonal heterogeneity 
in response to ionising radiation in a human glioma cell line, IN859. Significant differences 
in DNA repair fidelity occurred between the most radioresistant and sensitive clones, and 
between the sensitive clone and the parental cell line. Dolfini e t  a l .  (1993) isolated two cellular 
clones of LoVo colon adenocarcinoma cells. LoVo C l.7 was intrinsically resistant to 
adriamycin while LoVo C l.5 showed the same resistance index as the mixed parental 
population. Therefore, the phenotype of the cell line is not dictated by the most aggressive 
subpopulation, but is modulated by the presence of other cells with differing characteristics. 
The behaviour of a cancer is the result of all the subpopulations within it. Knowledge of the 
characteristics of the individual subpopulations is insufficient to predict the behaviour of the 
whole cancer. The fact that one can characterise individual subpopulations from cancers is 
meaningless unless knowledge of how these characteristics may be modified by neighbouring 
cells and/or how these cells may in turn modify the characteristics of the surrounding cells.
The problem of selecting effective therapy for heterogeneous tumours may be 
further complicated by the observation that tumour heterogeneity is a dynamic process. 
Evidence shows that individual subpopulations from tumours are heterogeneous in their stability. 
Chambers e t  a l .  (1981) observed variations in the stability of the metastatic phenotype in clones 
of the murine KHT sarcoma cells. Therefore, heterogeneity in the stability of the phenotype 
of a cell line or tumour sample may give rise to new variants with altered properties. This may 
explain, at least partially, the variation observed between primary tumours and their metastases 
in such properties as chemosensitivity (Tanigawa e t  a l . ,  1984; Schlag and Schremi, 1982). 
Tumour cell heterogeneity provides a mechanistic basis for the concept of neoplastic 
progression, that is, the acquisition by tumours of new characteristics during tumour 
development. Changes in cancer behaviour could be ascribed to progressive selections of 
different clones resulting in shifts in the predominant cell subpopulations and, therefore, altering 
any cell interactions that may be occurring. Poste e t  a l .  (1981) also showed that instability in
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the metastatic phenotype of B16 melanoma cells became evident after cloning, whereas 
individual clones growing together as mixed cell populations retain their characteristic degree 
of metastatic ability. Therefore, tumour cell interactions can influence subpopulation behaviour 
and the characteristics of the tumour may be defined by more than the individual properties of 
its subpopulations. The demonstration of tumour cell heterogeneity focuses on differences 
among multiple cell populations and these differences are shown most convincingly when the 
subpopulations are grown and compared in isolation. Tumour cells and cell subpopulations do 
not, however, exist independently of each other, but rather as part of a mixed cell population. 
The existence of interactions between the tumour cells is, therefore, not unexpected and the 
interactions may either enhance or diminish a characteristic of the surrounding cells.
There are many ways that tumour subpopulations can influence each other’s 
growth and behaviour. Host and/or tumour cell factors may be involved. Some interactions 
require cell contact while others act systemically. Miller e t  a l .  (1989) observed that when 
subpopulations of a murine mammary tumour, with varying intrinsic sensitivity to methotrexate 
were mixed the resulting tumours exhibited altered sensitivity to methotrexate. The cell line 
consisting of a mixture of cell lines 66 and 4T07 tended to be as responsive to methotrexate 
toxicity as 4T07 alone, the most sensitive clone, whereas line 168 plus 4T07 tended to be less 
responsive than line 4T07 alone. The tumour arising after exposure to methotrexate tended to 
contain more cell line 66 or 168 than untreated mixed tumours. In another experiment (Miller 
e t  a l . , 1981b), the sensitivity of cells to methotrexate i n  v i t r o  was altered when cells of differing 
sensitivity were grown in contact. In the presence of the methotrexate-sensitive subpopulation 
of the murine mammary tumour, 410.4, the sensitivity of lines 168 and 67 was increased, but 
the sensitivity of the relatively resistant cell line, T68H clone 8, was not affected. Miller e t  a l .  
(1991) also found that when the melphalan-sensitive cell line 4T07 was grown mixed with the 
less sensitive cell line 66, in tumours in mice, line 66 was more sensitive than when grown 
alone. The melphalan-sensitivity of tumours derived from cell line 66, grown on the opposite 
side of mice bearing 4T07 tumours, was not altered by comparison with the sensitivity of line 
66 tumours when grown alone. Furthermore, line 66 was not more sensitive when grown 
mixed with 168TFAR, a melphalan-sensitive subpopulation, than when grown alone. Miller 
e t  a l .  (1981b) also observed that individual tumour subpopulations which differ in sensitivity 
to chemotherapeutic drugs can influence each other’s drug sensitivity, even when they are not 
in physical contact. When mice were injected with cyclophosphamide sensitive cells, 168, and 
resistant cells, 410, on opposite flanks, the sensitivity of line 168 was not affected by 410 cells 
but the sensitivity of 410 was increased by the presence of 168 cells. Injections of line 168 or 
410 alone on opposite flanks, did not alter the cells sensitivity. Therefore, interactions can 
occur between cell subpopulations which are not in physical contact and the consequence of the
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interaction may be uni-directional. Miller e t  a l .  (1988) also noted that line 4T07 suppressed 
the growth of line 168 when grown in contact. Line 168 in the absence of cell line 4T07 had 
a doubling time one half that of 4T07 cells, yet when a ratio of even 100:1, in favour of the 
cell line 168, was injected into nude mice, the resulting tumour consisted primarily of 4T07 
cells. The suppression did not occur when the two cell lines were injected simultaneously at 
different subcutaneous sites, nor did it occur when line 168 was injected in mixtures with 
lethally irradiated cell line 4T07, implying cell contact was necessary for interactions resulting 
in the modification of growth in the cell lines. Intercellular interactions among two 
subpopulations of an Ehrlich ascites carcinoma were noted during i n  v i v o  cell growth, as 
tumours, in nude mice (Aabo e t  a l . , 1987). A growth inhibitory interaction by a slow growing 
subpopulation (El. 15) on a fast growing subpopulation (E l.95) was observed, but only when 
the cells were growing in contact, as tumours. Ascites from the slow growing E l. 15 cells 
exhibited no inhibitory effect on E l.95 cells.
Leith e t  a l .  (1987) noted that growth kinetics of various artificial heterogeneous 
tumours, composed of mixtures of the two subpopulations of the human colon adenocarcinoma 
DLD-1, clone A and D, could not be predicted from knowledge of the growth parameters of 
the pure tumour cell lines, grown as xenograft tumours. It was found that mixed tumours 
became zonal in composition, as a function of time, and that mixtures of extreme composition, 
9% A and 91% D or 91% A and 9% D, remained stable while those of intermediate 
composition, 50% A and 50% D, did not. Given the clonal nature of cellular propagation and 
the limited mobility of cells in solid tissue or in culture on a solid support, subpopulations 
which may be in competition for limited space or resources would be expected to be arranged 
in zones rather than completely mixed together. Michelson e t  a l .  (1987) also observed that 
when neoplasms were grown i n  v i v o  as xenografts made from varying proportions of the two 
clonal subpopulations of DLD-1, regions composed primarily of single subpopulations emerged 
in all cases.
Although tumours are mixed populations of cells, knowledge of the 
characteristics of individual components is not sufficient to predict the behaviour of the whole. 
Individual cancer subpopulations can interact to affect each others’ growth, immunogenicity, 
ability to metastasise, sensitivity to drugs and clonal stability. However, cancer cell 
subpopulations can exist within a tumour and/or cell line without altering each other’s phenotype 
or modifying their response to external stimuli. Barranco e t  a l .  (1988) observed that when two 
clones of a human astrocytoma cell line were mixed 1:1, one sensitive and one resistant to l-(2- 
chloroethyl)-3-(4-methylcyclohexyl)-l-l-nitrosourea, where both cell lines had similar doubling 
times, cell cycle distribution and colony forming efficiency, exposure of the cell mix to three 
weekly treatments of the drug resulted in the generation of a population consisting of the
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resistant subclone. Leith e t  a l .  (1988) constructed artificial heterogeneous tumours using two 
clonal cell lines, A and D, originally isolated from the heterogeneous DLD-1 human colon 
adenocarcinoma, mixed at the ratio 1:9 and 9:1, respectively. Mitomycin C killed A cells more 
efficiently than D cells, by a factor of about 2.3. After treatment of mixes with mitomycin C, 
the tumours reached stable, albeit altered (based on the individual survival of A and D cells 
from pure cultures) percentage mixtures of subpopulations.
However, exposure of mixed cell populations to external stimuli may also alter 
the tumour composition. Leith e t  a l .  (1988) observed that the artificial heterogeneous xenograft 
tumours produced by injecting mixtures of the two clonal cell lines A and D isolated from the 
DLD-1 human colon adenocarcinoma, at a ratio of 9:1 and 1:9, showed a significant change 
in the percentage composition of the tumour following radiation treatment. Both mixtures 
became significantly enriched in the subpopulation that was originally predominant, whereas the 
composition of untreated mixtures remained constant.
In itself, tumour heterogeneity provides a rationale for combination therapy 
since subpopulations resistant to one treatment might be sensitive to another. However, the 
major problem of combination chemotherapy is the ability of cells to be either inherently 
resistant, or to acquire resistance, to the chemotherapeutic drugs. As tumour cells are 
heterogeneous in relation to the susceptibility to chemotherapeutic drugs, it follows that drug- 
resistant tumour cells may also exhibit variations in their sensitivity. Heterogeneity within drug- 
resistant cells may occur by selection of the more resistant variants of the primary cells, in cases 
where resistance is observed to occur following primary therapy, or by inducing new drug- 
resistant variants in the cells by mutagenistic effects of the chemotherapeutic drugs. 
Heterogeneity within MDR cell lines is implied in cases where exposure of cell lines by 
different research groups to the same chemotherapeutic drug has resulted in the generation of 
MDR cell lines of differing resistance profiles and mechanisms.
Numerous MDR variants of the small cell lung carcinoma, NCI-H69, have been 
established. Twentyman e t  a l .  (1986), Mirski e t  a l .  (1987) and Jensen e t  a l .  (1989) have all 
described MDR cell lines selected by exposure of the HCI-H69 cells to adriamycin. 
Twentyman e t  a l .  (1986) adapted the NCI-H69 cells to grow in 0.4/xg/ml adriamycin, over a
7 month period. Mirski e t  a l .  (1987) cultured the cells in gradually increasing concentrations 
of adriamycin up to 0.8/xM, over 14 months. Jensen e t  a l .  (1989) passaged the NCI-H69 cell 
line three times in 0 .1/xg/ml adriamycin and then maintained the cells in drug-free medium for
8 weeks prior to characterisation. All three cell lines exhibited the MDR phenotype of cross 
resistance to a range of structurally unrelated drugs, but while the cell lines established by 
Twentyman e t  a l .  (1986) and Jensen e t  a l .  (1989) overexpressed P-glycoprotein, the MDR 
variants isolated by Mirski e t  a l  (1987) did not. When Yang and Trujillo (1990) established
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two independently-derived MDR sublines of the human colon carcinoma LoVo, the phenotype 
of the resistant cells varied. AdRl .2 was developed by exposing the cells to stepwise increasing 
concentrations of adriamycin, from 0.01/xg/ml to 1.2/xg/ml, over 16 months, and was then 
maintained in the absence of drug. SRA1.2 cells were selected by exposing the LoVo cells to 
9 one-hour drug exposures, with 1.2/xg/ml of adriamycin, allowing the cells time to recover 
between each treatment. The AdRl.2 cells were approximately 40-fold more resistant to 
adriamycin than SRA1.2 cells, yet both exhibited cross-resistance and collateral sensitivity to 
the same chemotherapeutic drugs. Both drug-resistant cell lines exhibited overexpression of a 
130 kDa. membrane protein, which does not cross-react with an anti-P-glycoprotein monoclonal 
antibody, but only AdRl.2 cells showed over-production of a 150 kDa. membrane bound 
protein which cross-reacted with C219 antibody. AdRl .2 cells also possessed an activated drug 
efflux pump, overexpression of GST-7T and decreased nuclear-bound drug, whereas SRA1.2 
cells only exhibited the decrease in the nuclear location of the drug. However, it cannot be 
confirmed whether the altered phenotypes are a result of selecting out different clonal cell lines 
from a heterogeneous parental population (Dolfmi e t  a l .  (1993) have isolated clones of the LoVo 
cell line which exhibited altered adriamycin sensitivity) or whether the MDR cell lines are 
themselves heterogeneous.
In order to confirm clonal variation within an MDR cell line, the individual 
variants must be isolated and characterised. This has been carried out by Yang e t  a l .  (1993). 
A drug-resistant variant of the human colon carcinoma cell line, LoVo, was established by 
exposing the cells to stepwise increasing concentrations of cisplatin, from 0.005 to 2.0/ig/ml, 
over 20 months. Morphologically distinct subpopulations were observed in the resistant cells 
and 22 clones were selected by limiting dilution. All clones had one of two distinct 
morphologies, designated CP2.0 and RT, and these two cisplatin-resistant clones also exhibited 
differing drug-resistant phenotypes. CP2.0 cells were spindle-like in shape and were resistant 
to cisplatin, mustargen, VP-16, 5-fluorouracil, adriamycin and vincristine to a fold resistance 
of 6.4, 2.3, 1.1, 2.6, 2.6 and 7.8, respectively, relative to LoVo cells. The RT cells appeared 
rounded, with vacuoles, and possessed a level of fold resistance to the above mentioned drugs, 
of 2.1, 1.9, 1.0, 1.6, 0.6 and 0.3, respectively. CP2.0 cells also overexpressed P-glycoprotein 
and accumulated less adriamycin, relative to LoVo cells. RT cells, on the other hand, did not 
overexpress P-glycoprotein and accumulated higher levels of adriamycin, by comparison with 
LoVo cells. Therefore, intercellular heterogeneity in the expression of MDR-associated 
mechanisms of resistance and any cell-cell interactions which may be occurring between 
subpopulations of the cell line, may result in a modification of the cells’ resistance and may be 
of importance in analysing the overall resistance of the MDR cells. However, the literature 
details only a few comprehensive studies on heterogeneity in cells’ sensitivity to 
chemotherapeutic drugs and interactions which may modify that sensitivity.
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1.9 Aims of this thesis
Following the observations in the literature that heterogeneity is a property of 
many cancers and cell lines and that few studies pertaining to heterogeneity within MDR cell 
lines have been documented, an analysis of heterogeneity within an MDR variant of a lung cell 
line was undertaken. Therefore, the aims of this thesis were to determine if heterogeneous 
subpopulations exist within an adriamycin-selected MDR variant of the human squamous lung 
carcinoma, DLKP-A, and to characterise these subpopulations, in terms of their MDR profile, 
their sensitivity to radiation and the biochemical and genetic alterations pertaining to drug 
resistance, exhibited by these variants. The mechanisms by which the subpopulations survive 
and interact, within the heterogeneous population was to be elucidated. Finally, the 
characteristics exhibited by the adriamycin-selected MDR cell line were to be compared with 
a VP-16-selected MDR variant of the same cell line. This was to determine if MDR variants 
of the same cell, derived by exposure to different chemotherapeutic drugs, resulted in similar 
MDR cell lines and if similar biochemical and genetic mechanisms supported the MDR profiles.
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Materials and Methods
2.1 Water
A Millipore Milli-RO 10 Plus system, fed to an Elga Elgastat UHP was used 
to produce ultra-high quality water for use in the production of all media and solutions. This 
consisted of a pre-treatment which utilised activated carbon, pre-filtration and anti-scaling, prior 
to a reverse osmosis step. This was followed by organic adsorption, ion exchange, ultra­
microfiltration, photo-oxidation and ultrafiltration. The quality of the water was monitored on­
line, with a specification of 18 megaohms/cm resistivity at 25°C.
2.2 Glassware
All glassware and bottle-caps which came in contact with medium or reagents 
were soaked in a 2% (v/v) solution of RBS-25 (AGB Scientific; RBS-25) in warm water for 1 - 
2h. The bottles were then scrubbed, rinsed in warm water, and washed by machine using 
Neodiser detergent. The glassware and bottle-caps were then rinsed twice with distilled water 
and once with ultrapure water.
2.3 Sterilisation
Glassware, water and all thermostable compounds were sterilised by autoclaving 
at 120°C for 20 min. at 15 p.s.i. pressure. Temperature labile compounds were filtered 
through a 0.22¡ i m  sterile filter (Millipore; millex-gv).
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2.4 Medium preparation
Growth medium was prepared as outlined in Table 2.1, the pH adjusted to pH 
7.45-7.55 by the addition of sterile 1.5M NaOH, and the volume adjusted to 5L. The medium 
was then filtered through a sterile 0.22/m bell filter (Gelman; G.1423S) into sterile 500ml 
bottles and stored at 4°C, Sterility checks were carried out on the medium, which included 
performing turbidity checks and setting up Columbia (Oxoid; CM331) blood agar plates and 
Sabauraud (Oxoid; CM 217) dextrose and Thioglycollate (Oxoid; CM173) broths. ATCC 
medium was made by mixing Dulbecco’s Modified Eagles medium (DMEM) and Hams F12 
in a ratio of 1:1. All medium was supplemented with 2mM L-glutamine (Gibco; 043-05030) 
and 5 %  foetal calf serum (FCS) (Seralab; 101024), prior to use. Minimum essential medium 
Eagle (MEM) was also supplemented with 1 %  MEM non-essential amino acid solution (Sigma; 
M7154)
Table 2.1 : Preparation o f growth medium
DMEM MEM HamsF12
10X Medium 500ml 10X DMEM 
Gibco 042-02501M
500ml 10X MEM 
Gibco 042-01430M
HamsF12 powder 
Gibco 074-01700N
Ultrapure H20 4300ml 4300ml 4700ml
1M Hepes (pH 7.5)* 
Sigma H9136
100ml 100ml 100ml
7.5% NaHC03 
BDH 30151
45ml 45ml 45ml
* The weight equivalent o f 1M N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfomc acid) (Hepes) was 
dissolved in an 80% volume o f ultra-pure water and autoclaved. The pH was then adjusted to 7.5 with 
a 5M NaOH solution.
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2.5.1 Cell lines
All cell culture work was carried out in a class II down-flow re-circulating 
laminar flow cabinet (Holton or Gelman Cytoguard) and strict aseptic technique was adhered 
to at all times. All cell lines which were routinely used throughtthis research work are outlined 
in Table 2.2. and are anchorage dependent. Cells were grown in 25cm2 flasks (Costar; 3050) 
or 75cm2 flasks (Costar; 3075). Cells were grown at 37°C in the presence of 5% C02 and fed 
every two to three days or when a medium pH change was observed (as determined by a change 
in the colour of the medium due to the presence of a phenol red indicator).
Table 2.2 : Cell lines used in  the course o f this research work.
Cell Line Growth Medium Detail of cell type Source
DLKP ATCC Human Lung Squamous Cell 
Carcinoma
G. Grant 
NCTCC
DLKPA ATCC DLKP adapted to multidrug 
resistance by increasing stepwise 
exposure to Adriamycin (Farmatalia)
A. Redmond 
NCTCC
T24 MEM Human Bladder Carcinoma ATCC
SKMES1 ATCC Human Squamous Lung Carcinoma ATCC
HT29 MEM Human Colon Carcinoma ATCC
OAW-42 ATCC Human Ovarian Carcinoma ATCC
Hep-2 ATCC Human Epidermoid Carcinoma o f the 
Larynx (HeLa markers)
ATCC
Hep-2A ATCC Hep-2 adapted to multidrug resistance 
by increasing stepwise exposure to 
Adriamycin (Farmitalia)
A. Redmond 
NCTCC
45
2.5.2 Sub-culture of cell lines
On reaching confluency, or when required for use in assays, the cells were sub­
cultured by enzymatic detachment. Waste medium was poured from the cells and the cells were 
rinsed with 2ml of trypsin/EDTA (0.25% trypsin (Gibco; 043-05090), 0.01% EDTA (Sigma; 
EDS) solution in PBS (Oxoid; BR14a)), which had been preincubated at 37°C for 15 min. The 
cells were then incubated with a further 2ml of the trypsin/EDTA solution for 10-15 min. or 
until a single-cell suspension was obtained. An equal volume of medium, containing foetal calf 
serum, was added. The cell suspension was transferred to a 30ml sterile universal (Sterilin; 
128a) and centrifuged at 120 g. for 5 min. The medium was poured from the universal and the 
cell pellet was resuspended in 5ml of growth medium. A cell count was performed, as outlined 
in Section 2.5.3. Approximately 2xl04 or 105 cells were added to 10ml of medium in a 25cm2 
flask or 20ml of medium in a 75cm2 flask, respectively. These were then incubated at 37°C 
in 5% C02.
2.5.3 Cell counting
A sample of a single cell suspension was mixed in a ratio of 4:1 with trypan 
blue dye (Gibco; 525). Following a 2 min. incubation at room temperature, a sample of the 
cell mixture was applied to a haemocytometer, such that it was held in the areas between the 
haemocytometer and coverslip. Cells in the 16 squares of the four outer corner grids were 
counted, and the average of the four squares was multiplied by 10*, to determine the cell 
number per ml. Cells which stained blue were non-viable and those which remained unstained 
were viable.
2.5.4 Large-scale cell culture
Cells required in large numbers were cultivated in roller bottles. Approximately 
100ml of growth medium was allowed to equilibrate in the roller bottle at 37°C for 30 min., 
prior to the addition of a single cell suspension (approximately 2xl07 cells in total). The roller 
bottle was incubated at 0.25 r.p.m. overnight, then the rotor speed increased to 0.50 r.p.m. 
The cells in the roller bottle were fed every 3-4 days until the reached 80% confluency, at 
which stage they could be used where large cell numbers were required.
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2.6 Mycoplasma detection
To establish that M y c o p l a s m a  infection of cell lines was not occurring, the cells 
were examined using the Hoechst 33258 indirect staining method and the mycoplasma culture 
method of M y c o p l a s m a  detection. The cell lines which were being tested were grown, for a 
minimum of three passages following thawing, in an antibiotic- and drug-free medium. Medium 
was exposed to a flask of nearly-confluent cells for three days. The medium was then 
asceptically collected and used for the detection of M y c o p l a s m a  contamination of the cell line.
2.6.1 Hoechst 33258 indirect stain
NRK cells (2 x 103) were grown overnight at 37 °C in 5% C02 on sterile 
coverslips in 1ml of DMEM supplemented with 5 % FCS and 2mM L-glutamine, in individual 
sterile dishes. One ml of the collected sample medium was added to duplicate coverslips of 
NRK cells and incubated for 5 days (the cells should have reached approximately 50% 
confluency at this stage). The medium was removed from the coverslips. The coverslips were 
then washed twice with PBS, washed once with a 1:1 solution of ice-cold PBS : Carnoy’s 
fixative (this was a freshly prepared 1:3 solution of glacial acetic acid (Sigma; A0808) : 
methanol (BDH; 101584W) which had been stored at -20°C for 30 min.), and fixed for 10 min. 
in Cornoy’s fixative. The coverslips were then allowed to air dry and 2ml of Hoechst 33258 
stain (Sigma; B2883) at 50/zg/ml in PBS was added to each coverslip and incubated in darkness 
for 10 min. The coverslip was then washed with water and mounted onto a glass slide, using 
50% glycerol (BDH; 101184K) in 0.1M citric acid, 0.2M disodium phosphate, pH 5.5 as the 
mounting solution. The slides were then examined for M y c o p l a s m a  contamination under oil 
immersion using a mercury fluorescent lamp. Nucleic acid is stained by the Hoechst 33258 
stain. Therefore, the NRK cell nucleus stains brightly and any extra-nuclear stain is an 
indication of the presence of M y c o p l a s m a .  Appropriate controls (medium not exposed to cells 
as the negative control and a sample of known M y c o p l a s m a  contaminated medium as the 
positive control) were included in the procedure.
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2.6.2 M ycoplasma culture method
Ninety mis. of M y c o p l a s m a  agar (Oxoid; CM401) and M y c o p l a s m a  broth 
(Oxoid; CM403) bases were supplemented with 16.33% FCS, 0.002% DNA (BDH; 42026), 
2/xg/ml fungizone (Gibco; 05290), 2xl03 units penicillin (Sigma; Pen-3) and 10ml of a 25% 
(w/v) yeast extract solution (which had been boiled for 5 min. and filtered through a 0.2^un 
filter). Sample medium (0.5ml) from the cell line being tested was incubated with 3ml of the 
broth, for 48h. at 37°C. A streak from the broth was then innoculated onto 10ml agar plates 
and incubated for up to 3 weeks at 37° C in a C02 environment, with constant microscopic 
analysis for colony formation. The presence of ‘fried egg’ type colonies indicated the existence 
of M y c o p l a s m a  contamination of the cell Une.
2.7.1 Long Term Storage of Animal Cells
For cryo-preservation, a single ceU suspension was prepared (Section 2.5.2) 
from a sub-confluent large-scale culture of ceUs (Section 2.5.4). The ceU peUet was 
resuspended in FCS. An equal volume of 10% (v/v) DMSO (Sigma; D5879) in FCS was added 
dropwise, with constant mixing, to the cell suspension, to give a final cell concentration of 107 
cells/ml The cell suspension was then added, in 1.5ml volumes, to cryovials (Greiner; 122 278) 
which were placed in the vapour phase of liquid nitrogen for 2.5h. They were then stored in 
the Uquid phase until required.
2.7.2 Recovery of Frozen Stocks
A frozen vial of ceUs was removed from Uquid nitrogen storage and thawed 
rapidly in a 37° C water bath. The thawed cell suspension was transferred to a sterile universal 
with 5ml of medium containing 5 % FCS and 2mM L-glutamine and was centrifuged for 5 min. 
at 120 g. The medium was gently removed and the cell peUet resuspended in 2ml of the 
medium. The cells were then transferred to a 25cm2 flask with 10ml of medium and the cells 
were incubated for 24h. to aUow ceU attachment. FoUowing ceU attachment, the ceUs were re­
fed with fresh medium.
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2.8 Safe Handling of Cytotoxic Drugs.
Due to the serious potential risks incurred from the handling of 
chemotherapeutic agents, extreme care was exercised in their handling and disposal. All work 
with cytotoxic drugs was carried out in Gelman ‘Cytoguard’ laminar air flow cabinets (CG 
Series). Face masks and double gloves were worn when dealing with concentrate solution and 
all drugs were stored and disposed as outlined in Table 2.2.
Table 2.2 : Chemotherapeutic drugs used in  the research work
CYTOTOXIC DRUG SUPPLIER DISPOSAL STORAGE
DOXORUBICIN
2mg/ml
Farmitalia Inactivate with 1 % 
hyperclorite solution 
and dispose with 
excess water.
Stock @ 4°C, in 
darkness
VP-16 (etoposide) 
20mg/ml
Bristol Myers 
Pharmaceuticals
Incineration Store @ room 
temp. Working 
stock @ -20 °C, in 
darkness
VINCRISTINE 
1 mg/ml
David Bull 
Laboratories Ltd.
Inactivate by 
autoclaving and 
dispose with excess 
water.
Store @ 4°C in 
darkness
5-FLU OROURACIL 
25mg/ml
Farmitalia Inactivate by addition 
of equal volume of 
5M NaOH and 
dispose with excess 
water.
Store @ room 
temp, in darkness
CIS-PLATIN
lmg/ml
Lederle Incineration Store @ room 
temp, in darkness
2.9 Conditioned Medium
DLKP-A cells were grown, as outlined in Section 2.5.4, for large-scale cell 
culture. When cells were approximately 80% confluent, the medium was removed and replaced 
with 100ml of fresh medium, which was again incubated overnight. This medium was 
collected, spun at 120 g. for 5 min. to pellet any cells and filtered through a 0.22/im gelman 
filter. The conditioned medium was stored at 4°C.
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2 .10 Isolation of variants of DLKP
2.10.1 Adaption of MDR variants
The cell lines being adapted to drug resistance were grown in the selective drug, 
VP-16, at a concentration which gave 10% survival as determined by miniaturised toxicity 
assays (Section 2.11.1). Cells were grown at this concentration until they appeared healthy by 
microscopic examination and had attained high numbers. The drug concentration to which the 
cells were exposed was then doubled. This process was repeated until good cell growth was 
obtained in the desired concentration of VP-16. Overall, the DLKP cell line was selected for 
drug resistance by exposing the cells to increasing concentrations of VP-16, from an initial 
concentration of 0.3/i.g/ml VP-16 to final concentrations of 3.0/xg/ml (in the case of the cell line 
DLKP/VP3) and 8.0/tg/ml (in the case of the cell line DLKP/VP8).
2.10.2 Selection of MDR Clones
The DLKP-A cell line was sub-cultured, a cell count was performed and the 
cells were plated at 50 cells per 35mm tissue culture petri-dish (Greiner; 627160), in 2ml of 
medium (Section 2.10) supplemented with 10% FCS and 1% L-glutamine. The cells were 
grown for 24h. in 5% C02 at 37"C to allow cell attachment. The plates were microscopically 
examined to ensure cells adhered singularly and in a dispersed manner. The cells were grown, 
with constant monitoring and feeding with a 1:1 mixture of medium to conditioned medium, 
until individual cells had formed single colonies of approximately 50 cells. The colonies were 
individually sub-cultured. Cloning rings (stainless steel rings, with an inner diameter of 8mm) 
were used to form individual trypsination chambers. This involved removing the medium from 
each petri-dish and washing the cells with sterile PBS. The PBS was removed from the plate 
and a sterile cloning ring, with its end covered in siliconised grease, was placed around an 
individual colony, isolating it from other colonies on the plate and forming a separate sub- 
culturing chamber. Trypsin/EDTA (Section 2.5.2)(100^1) was added to the colony and the cells 
incubated at room temperature for 5 min. The trypsin/EDTA was then repeatedly pipetted up 
and down, using a Gilson micropipette, to ensure all cells had detached. The cells were 
transferred to a single well of a 96-well plate (Costar; 3599). Medium (100/xl) was added to 
the well, and the cells were allowed to attach overnight at 37°C in 5% C02. Following
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attachment, the medium was removed from the well and 200//.1 of fresh medium added. When 
the cells had reached approximately 90% confluency, they were sub-cultured into a single well 
of a 48-well plate (Costar; 3548). This procedure was followed to repeatedly transfer the cells 
into a 24-well plate (Costar; 3424), 6-well plate (Costar; 3406), 25 cm2 flask (Costar; 3050) and 
75 cm2 flask (Costar; 3075). Stocks of the randomly selected clones were maintained frozen 
(Section 2.7.1) and all clones were routinely maintained in the absence of adriamycin, when in 
culture. All assays were carried out within a ten passage span following revival of the cells 
from cryo-preservation.
2.10.3 Irradiation of DLKP cells
Cells to be exposed to radiation were subcultured into a 75 cm2 tissue culture 
flask at a density of 5 x 10s cells/flask and allowed to attach overnight. Following a 24h. 
incubation the growth medium was replaced with fresh medium and the flask of cells was 
irradiated, at room temperature, with a single defined radiation dose from a linear accelerator 
at a dose rate of 2.5-2.6 Gray (Gy.)/min. One cm of tissue equivalent bolus was placed on top 
of the plate during irradiation, to ensure electronic equilibrium. Following irradiation, the cells 
were maintained at 37°C in 5 % C02 overnight. The next morning the medium in the flask was 
replaced with fresh medium. The cells were allowed to grow until they appeared healthy and 
had attained high numbers, at which stage they were again exposed to another dose of radiation. 
The radiation doses to which the cells were exposed is outlined in Table 2.10.3 and the cell line 
which resulted from the radiation treatment was designated DLKP/RAD.
Day Radiation Dose Passage Number
1 150 cGy 17
15 600 cGy 18
21 900 cGy 19
28 900 cGy 19
48 1200 cGy 19
77 1200 cGy 20
83 1200 cGy 20
Table 2.10.3 : The radiation treatment profile used in the generation o f the cell line DLKP/RAD, from 
the parental cell line, DLKP.
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2.11 Miniaturised assays
In all assays, cells were pre-treated in a similar manner to ensure that the cells 
were healthy and in a logarithmic phase of growth prior to analysis. Two days prior to the 
assay, the cells were subcultured into 75cm2 flasks at a density of 2 x 105 cells/flask. The cells 
were allowed to attach overnight and the next day the cells were fed with fresh medium. On 
the day the assay was set up, the cells were sub-cultured and a single cell suspension obtained 
as described in Section 2.5.2.
2.11.1 Toxicity Assays : 96 Well Plate
Cells were plated, from a single cell suspension, into a 96 well plate (Costar; 
3599) at a cell density of 103 cells/well in 100/xl of medium. The first column of the plate was 
used as the plate control and contained only medium. Cells were allowed to attach for 24h. at 
37 °C in 5% C02, then 100/¿I of the required drug dilution (which was diluted to 2X the final 
concentration required in the assay) was added to each well, in replicas of eight. Drug 
concentrations used in each assay ranged from 0.0M to a concentration which achieved 
approximately 100% cell kill. The plates were then incubated for a further 6 days at 5% C 02 
and 37°C, or until control wells (no drug added) reached 80% confluency. Drug toxicity was 
then determined by acid phosphatase analysis (Connolly e t  a l ., 1986; Martin and Clynes, 1991). 
Medium was removed and the assay plates rinsed twice with PBS. Then 100/xl of assay 
substrate, lOmM p-nitrophenyl phosphate (Sigma; 104-0) in 0.1M sodium acetate, 0.1% triton 
X-100 (Sigma; X100), pH 5.5 was then added to each well and the plate incubated at 37°C for 
2h. in darkness. The enzyme reaction was then stopped by the addition of 50/xl of 1.0M NaOH 
and the plate read in a dual beam plate reader at 405nm (reference wavelength 620nm.).
2.11.2 Radiation Assay : 24 Well Plate
Cells were plated from a single cell suspension into 24 well plates (Costar; 
3424), in replicas of six, at a cell density of 400 cells/well, in 500/xl of complete medium. As 
the complete assay plate was exposed to one dose of radiation, a separate plate was set up for 
each radiation dose. The plates were incubated overnight at 37°C in 5% C02 to allow cell
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attachment. The plates were then individually irradiated, at room temperature, with a single 
defined radiation dose from a linear accelerator, at a dose rate of 2.5 - 2.6 Gy./min. One cm. 
of tissue-equivalent bolus was placed on top of the plate during irradiation, to ensure electronic 
equilibrium. Following radiation exposure, the cells were maintained at 37°C in 5% C 02 
overnight. The medium was then replaced with fresh medium, and the cells maintained, with 
constant medium replacement every 4-5 days, until the control plate (which was not irradiated) 
had reached approximately 80% confluency. The medium was then removed, the plate washed 
twice with PBS and the cells fixed with 10% formalin (Sigma; F1635) for 10 min. The 
formalin was removed and the plate allowed to dry. The cells were stained with 0.025% crystal 
violet (Sigma; C3886) for 10 min. The plate was then washed to remove excess stain and again 
allowed to air dry. The stain was eluted with 300/xl of 33.3% glacial acetic acid and 200/d of 
this was then transferred to a 96 well plate. The plate was read in a dual beam plate reader at 
570nm (reference wavelength 620nm.).
2.11.3 Plating density assay : 24 Well Plate
Cells were plated from the single cell suspension into 24 well plates at a cell 
density of 200 cells/well, in 500/d of complete medium. The plates were incubated overnight 
at 37°C in 5% C02 to allow cell attachment. Control plates, containing 2000 cells/well were 
set up in parallel. Then, 500/xl of a 2X drug dilution was added to each well, in replicas of 
three. Plates were incubated at 37°C in 5 % C02 until the control wells (no drug added) reached 
80% confluency. The medium was then removed, the plate washed twice with PBS and the 
cells fixed with 10% formalin for 10 min. The formalin was removed and the plate allowed 
to dry. The cells were then stained with 0.025% crystal violet for 10 min. The plates were 
washed to remove excess stain and allowed to air dry. The stain was then eluted with 300/d 
of 33.3 % glacial acetic acid and 200/d of this was then transferred to a 96 well plate. The plate 
was read in a dual beam plate reader at 570nm (reference wavelength 620nm).
2.11.4 Drug Replacement Assay : 24 well plate
Triplicate plates of cells were plated from a single cell suspension into 24 well 
plates at a cell density of 200 cells/well, in 500/d of medium. The plates were incubated
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overnight at 37°C in 5 %  C 0 2  to allow cell attachment, Triplicate control plates, containing 
2000 cells/well were set up in parallel. Then, 500/d of a 2X drug dilution was added to each 
well, in replicas of three. Plates were incubated at 37°C in 5% C02. Fresh concentrate drug 
was added to one of the triplicates every 48h., to replace the drug which was inactivated 
(adriamycin has a half-life of 29h. at 37°C in growth medium (Hilderbrand-Zanki and Kern, 
1986)). A complete drug and medium change was given to a second of the triplicate plates 
every 48h. The drug in the third of the triplicate plates was neither supplemented with 
additional drug nor replaced with fresh drug and medium. Plates were maintained at 37°C in 
5% C02 until the control wells (no drug added) reached 80% confluency. The medium was 
then removed, the plate washed twice with PBS and the cells fixed with 10% formalin for 10 
min. The formalin was removed and the plate allowed to dry. The cells were then stained with 
0.025% crystal violet for 10 min. The plate was washed to remove excess stain and allowed 
to air dry. The stain was eluted with 300/d of 33.3% glacial acetic acid and 200/d of this was 
then transferred to a 96 well plate. The plate was then read in a dual beam plate reader at 
570nm (reference wavelength 620nm).
2.11.5 Circumvention Assay : 96 Well Plate
Cells were plated, from single cell suspension, into a 96 well plate at a cell 
density of 103 cells/well in 100/d of complete medium. The first column acted as a plate control 
and contained only medium. Cells were allowed to attach for 24h. at 37°C in 5% C02. Then 
50/d of a 4X concentration of the required drug and/or circumventing agents (verapamil (Sigma; 
Y4629) and cyclosporin A (Sandoz; Sandimmune)) was added to the appropriate wells, in 
replicas of eight. Medium was added to wells which required a volume adjustment in order to 
bring the final volume to 200/d/well. The plates were incubated for a further 6 days at 5 % C02 
and 37 °C, or until the control wells (no drug or circumvention agent added) reached 80% 
confluency. Drug-induced cell kill was then determined by acid phosphatase analysis. Medium 
was removed and the assay plates rinsed twice with PBS. Then 100/d of lOmM /?-nitrophenyl 
phosphate in 0 .1M sodium acetate, 0.1% triton-X-100, pH 5.5 was added to each well and the 
plate incubated at 37°C for 2h. in darkness. The enzyme reaction was stopped by the addition 
of 50/d of 1.0M NaOH and the plate read in a dual beam plate reader at 405nm (reference 
wavelength 620nm).
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2.12 Protein Analysis
2.12.1 Topoisomerase II isolation
All cells used in the determination of the cellular content of topoisomerase II 
were in the exponential phase of cell growth when the protein was extracted. To prevent 
proteolytic degradation of the topoisomerase II during the isolation procedure, all solutions used 
to prepare the samples for electrophoresis contained the following freshly prepared cocktail and 
unless otherwise stated, all procedures were carried out on ice or at 4°C : Phenylmethylsulfonyl 
fluoride (PMSF) (Sigma; P7626) (ImM); benzamidine (Sigma; B6506) (ImM); Soybean trypsin 
inhibitor (Sigma; T9003) (lmg/ml); leupeptin (Sigma; L2884) (50/xg/ml); pepstatin A (Sigma; 
P6425) (1/ig/ml) and aprotinin (Sigma; A1153) (20/xg/ml).
2.12.1.1 Nuclear extraction
This protocol has been adapted from the protocol by Danks e t  a l .  (1988). 
Exponentially growing cells (10*) were trypsinised from a large cell culture (as outlined in 
Section 2.5.2) and permeablised by resuspending the PBS-washed cell pellet in 1.75ml of 
hypotonic buffer (5mM KH2P04, 2mM MgCl2, 4mM DTT, O.lmM NaJiDTA, pH 7.0) and 
incubating for approximately 20 min. When approximately 90% of the cells stained with trypan 
blue, they were centrifuged at 400g for 5 min. The cells were resuspended in hypotonic buffer 
containing 0.25M Sucrose at a cell density of 5xl0acells/8ml. Each 8ml aliquot was layered 
over 3ml of hypotonic buffer containing 0.3M Sucrose and centrifuged at 2000g for 20 min. 
The supernatant was removed and the pellet volume determined. The pellet was resuspended 
in a half volume of lysis buffer (5mM KH2P 04, 4mM DTT, ImM NaaEDTA, pH 7.0) and 
incubated for 15 min. Nuclear topoisomerase II was then extracted by adding half the pellet 
volume of a 1.0M salt extraction buffer (40mM Tris, 2.0M NaCl, 4mM DTT, 20% glycerol, 
pH 7.5). The solutions were vortexed and incubated for 30 min, followed by a 100,000g 
centrifugation for lh. The clear supernatant was then removed and the pellet re-centrifuged. 
The second supernatant was pooled with the first and either used immediately or stored at - 
170°C until required for the determination of topoisomerase II content in the cells. If stored, 
the extract was used within three days.
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2.12.1.2 Total cell extraction
Cells used for the determination of the topoisomerase II content in total cell 
extract were grown until approximately 107 cells were obtained. These cells were trypsinised 
and centrifuged at 120 g. for 5 min. The cell pellet was washed with PBS and recentrifuged. 
The resulting cell pellet was resuspended in 0.2ml of DNase 1 buffer (lOmM Tris, ImM 
MgClj, 0. ImM CaCl and ImM DTT, pH 7.8). The cells were incubated on ice for 15-20 min. 
and were then checked for cell lysis (by trypan blue staining). If the cells did not lyse within 
20 min., the cell density was too high and more DNase 1 buffer was added. When cell lysis 
was achieved, 120 units of DNase 1 enzyme (Promega; RQ1 RNase-free DNase) was added and 
the cells were incubated for 20 min. in a 37°C waterbath. The sample was used immediately 
or stored at -170°C until required for the determination of topoisomerase II content in the cells. 
If stored, the extract was used within three days.
2.12.2 Cell membrane preparations
Membrane preparations for Western blot analysis were prepared from 2 x 107 
cells which were in the exponential growth phase. Following trypsinisation the cells were 
washed three times in PBS. All the following steps in the procedure were performed while the 
cells were kept on ice. The cell pellet was resuspended in 5ml of ice-cold lysis buffer (lOmM 
KC1, 1.5mM MgCl2, lOmM Tris, pH 7.4 and 2mM PMSF was added immediately prior to 
use). The cells were sonicated until lysis was observed by microscopical analysis. The lysed 
cells were then centrifuged at 100,000 g. for lh  at 4°C. The pellet obtained was resuspended 
in 500/d of lysis buffer. An aliquot was removed for protein quantification and the remainder 
was divided into 100/d aliquots and lyophilised overnight. The lyophilised samples were stored 
at -80°C until required for Western blot analysis.
2.12.3 Quantification of protein
The protein levels were determined using the Bio-Rad protein assay kit (Bio- 
Rad; 500-0006) and by using several concentrations of bovine serum albumin (BSA) (Sigma; 
A9543) as standards. The dye reagent was provided as a 5-fold concentrate. The appropriate 
standards (0.1ml) and test samples (0.1ml) were placed in clean, dry test tubes. The diluted 
dye reagent (5ml) was added and the mixture vortexed. After a period of 5 min.
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to lh ., the OD595 was measured, against a reagent blank. From the plot of the OD595 of the 
standards versus their concentrations, the concentration of protein in the test samples was 
determined.
2.12.4 Gel electrophoresis
The protein present in the cell preparations were separated on a size basis using 
a 7.5% SDS polyacrylamide gel. The resolving gel was made by mixing 3.8ml of an 
acrylamide stock (29. lg acrylamide (Sigma; A8887) and 0.9g NN-methylene bis-acrylamide 
(Sigma; N7256) made up to 100ml with water), 8.0ml of water and 3.0ml of 1.875M Tris-HCl, 
pH 8.8. To this solution, 150/il of 10% SDS (Sigma; L4509), 50/xl of 10% ammonium 
persulphate (Sigma; A1433) and 7.5/xl of TEMED (Sigma; T8133) were added. The gel was 
immediately poured into two clean 10cm x 8cm gel cassettes. Each gel cassette comprised of 
a glass and aluminium plate separated by two 0.75cm plastic spacers, one on either outer edge.
The gel was overlayed by saturated butanol and allowed to set. Once set, the saturated butanol 
was removed, the gel tops washed with water and the stacking gels poured. The stacking gels 
comprised of 0.8ml of the acrylamide stock mixed with 3.6ml of water and 0.5ml of 1.25M 
Tris-HCl, pH 6.8. To this solution 50/d of 10% SDS, 17/xI of 10% ammonium persulphate and 
5/xl of TEMED were added, the solution mixed and poured onto the resolving gels. A comb 
of the appropriate thickness and well size was immediately inserted and the gel allowed to set. 
When the wells had formed, the gel combs were removed and the gels transferred to a mini­
electrophoresis apparatus. The gels were flooded with running buffer (1.9M glycine (Sigma; 
G6761), 0.25M Tris, 0.1% SDS. The pH of the buffer should be 8.3 without adjustment).
Protein samples were loaded into the wells, based on equal protein loading. The 
samples to be loaded were diluted 1:1 with loading buffer (50mM Tris-HCl, pH 6.8, 1 % SDS, 
5% 2-mercaptoethanol (Sigma; M6250), 5% glycerol and 0.1% bromophenol blue) and boiled 
for 2 min. They were then loaded onto the gel, as were appropriate molecular weight markers. 
The gels were run for approximately 1.5h. with voltage set at 250V and current set at 45mA.
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2.12.5 Western blotting procedure
Following electrophoresis, the acrylamide gels were equilibrated in transfer 
buffer (25mM Tris, 192mM Glycine: the pH should be 8.3-8.5 without adjustment). 
Nitrocellulose filter (Amersham; Hybond-C), which was cut to the same size as the gel, was 
soaked in transfer buffer for 5 min. Four stacked sheets of Whatman 3mm filter paper (again, 
cut to the size of the gel) were soaked in transfer buffer and placed on the cathode plate of a 
semi-dry blotting apparatus. Excess air was removed from between the filters by sliding a 
pipette over and back on the filter paper. The nitrocellulose was placed over the filter paper, 
again ensuring no air bubbles became trapped. The acrylamide gel was placed on the 
nitrocellulose and the nitrocellulose was marked at the sites of the gel lanes and size markers. 
Four more sheets of pre-soaked filter paper were placed on top of the gel (ensuring no air was 
trapped) and the protein was transferred from the gel to the nitrocellulose at a current of 
0.34mA/0.15V for 30 min. The nitrocellulose was then placed in blocking buffer and the 
nitrocellulose blocked and exposed to specific antibodies. In all cases, a concurrent negative 
blot was performed, whereby the primary antibody was replaced with antibody diluent or pre- 
immune serum where available.
2.12.5.1 P-glycoprotein
Following transfer of the protein to the nitrocellulose, the nitrocellulose was 
blocked for 2h. at room temperature in TBS (500mM NaCl, 20mM Tris, pH 7.5) containing 
0.5% non-fat dried milk (Cadbury; Marvel skimmed milk). The nitrocellulose was rinsed twice 
with TBS and was exposed to the primary antibody (0.25/xg/ml C219 antibody (Centicor
Diagnostics) in 10ml TBS, 0.1% Tween-20) at 4°C overnight. The nitrocellulose was washed
three times in TBS containing 0.5% Tween-20 (Sigma; P1379). The nitrocellulose was exposed 
to the secondary antibody (a 1/9,500 dilution of rabbit anti-mouse IgG (Sigma; A-1902) in TBS, 
0.1% Tween-20) for 1.5h. at room temperature. The nitrocellulose was again washed three 
times in TBS and was developed as outlined in Section 2.12.6.
2.12.5.2 Topoisomerase II
Following transfer of the protein to the nitrocellulose, the nitrocellulose was 
blocked at 4°C overnight in blocking solution (lOmM Tris-HCl, pH 7.4, 140mM NaCl, 5%
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non-fat dried milk, 3% BSA, 0.2% Tween-20). The primary antibodies (a polyclonal rabbit 
serum that recognises topoisomerase II and pre-immune rabbit serum (as a negative control), 
which were gifts from Dr. W.T. Beck and decribed by Friche e t  a l .  (1991)) were diluted 1/700 
with blocking solution. The nitrocellulose was incubated with the primary antibody for 48h. 
at 4°C. The nitrocellulose was then washed three times with lOmM Tris, 140mM NaCl, pH
7.4 and incubated with the secondary antibody (a 1/13,000 dilution of goat anti-rabbit IgG 
(Sigma; A-8025) in blocking solution) at room temperature for 2h. The nitrocellulose was again 
washed three times with lOmM Tris, 140mM NaCl, pH 7.4 and was developed as outlined in 
Section 2.12.6.
2.12.5.3 Topoisomerase II-a and Topoisomerase II-B
Following transfer of the protein to the nitrocellulose, the nitrocellulose was 
blocked at 4°C overnight in blocking solution (PBS containing 3% BSA). The primary 
antibodies (monoclonal antibodies 6G2 and 8F8 which recognise topoisomerase II-a and 
topoisomerase II-B, respectively, were gifts from Dr. G. Astaldi-Ricotti and decribed by Negri 
e t  a l .  (1992)) were diluted 1/50 (6G2) and 1/300 (8F8) with PBS containing 0.1% BSA. The 
nitrocellulose was incubated with the primary antibody overnight at 4°C. The nitrocellulose was 
then washed three times with PBS containing 0.1% Tween-20 and incubated with the secondary 
antibody (a 1/9,500 dilution of rabbit anti-mouse IgG (Sigma; A-1902) in PBS, containing 0.1% 
BSA, 0.1% Tween-20) at room temperature for 2h. The nitrocellulose was again washed three 
times with PBS, containing 0.1% Tween-20 and was developed as outlined in Section 3.12.6.
2.12.6 Developing blots
The blots were developed by incubating the blots in a developing substrate until bands 
and/or background colour appeared. The developing substrate consisted of a mixture of 2.5ml 
of solution A and 1ml of solution B in 22.5ml of a solution consisting of 0.5M Tris-HCl, pH 
8.9 containing 0.1ml of 1.0M MgCl2. Solution A consisted of 0.1% Nitroblue tetrazolium 
(Sigma; H-5514) in 10ml Tris-HCl, pH 8.9. SolutionB consisted of 5mg/ml 5-bromo-4-chloro- 
3-indolylphosphate (Sigma; B-0274) in Dimethyl formamide (Sigma; D-8654). Once the blots 
had developed, they were washed in water at room temperature and allowed to dry. They were 
then stored in the dark.
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2.13 RNA Analysis
All steps in the RNA analysis protocol were carried out in sterile conditions, 
where possible. The cell were grown on 135nnn-diameter petri-dishes until they reached 80% 
confluency. The medium was then removed and the cells rinsed twice with PBS. The cells on 
five replica plates were lysed by the addition of 5ml of a 4M guanidinium thiocyanate (GnSCn) 
solution. The 4M GnSCn consisted of 50g of guanidinium thiocyanate (Sigma; G6639), 0.5g 
of N lauroyl sarcosine (Sigma; L5125) and 5ml of 1M Na citrate (RDH; 32320), pH 7.0. The 
solution was brought to 100ml with water and filtered through a 0.45/xm filter. The solution 
was stored at room temperature in the dark, until required. Immediately before use, 
700/xl/100ml of G-mercaptoethanol and 330/d/100ml of antifoam A (Sigma; A5758) were added.
The cell lysate solution was then centrifuged at 120 g. for 5 min. and the 
solution layered over 5.5ml of a 5.7M cesium chloride cushion in ultracentrifuge tubes. The 
5.7M cesium chloride solution consisted of 95.8g of CsCl (Sigma; C3032) and 2.5ml of 1M 
sodium citrate, pH 7.0 per 100ml of water. The solution was filter sterilised and 100/d of 
diethyl procarbonate (DEPC) (Sigma; D5758) was added, the mixture left at room temperature 
for 2h. and the solution was then autoclaved.
The cell extract was then centrifuged at 100,000 g. for 21-24h. at 15°C. in a 
swinging bucket centrifuge. The guanidinium thiocyanate and the "jelly-like" layer below the 
GnSCn/CsCl interface were removed by aspiration. The cesium chloride was then removed to 
the last 1ml The tubes were inverted and the bottom, containing the RNA pellet, cut from the 
rest of the tube using a heated scalpel blade. The pellet was washed with 95 % ethanol at room 
temperature and resuspended in 200/d of DEPC-treated water, by pipetting up and down, on 
ice. The resuspended pellet was transferred into eppendorf tubes and the pellet remains were 
rinsed into the eppendorf tube with a further 200/xl The RNA was precipitated by the addition 
of 3M sodium acetate (to a final concentration of 0.3M) and two volumes of absolute ethanol 
and incubation at -20°C or -80°C overnight. The RNA was pelleted by spinning at 4°C in a 
microfuge at maximum speed. The pellet was washed with 70% ethanol and resuspended in 
100/d of DEPC-treated water. The RNA was stored at -80°C.
2.13.1 Total RNA extraction
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2.13.2 Quantification of RNA
The RNA was quantified spectrophotometrically at 260nm and 280nm. An 
optical density of 1 at 260nm is equivalent to 40mg/ml RNA. A ratio of Ajft)/A280 of 2 is 
indicative of pure RNA.
2.13.3 Reverse transcriptase reaction
The cDNA was formed on the RNA template by the following reactions, which 
were incubated on ice unless otherwise stated. One /x] of Oligo(dT) 12-18 primers (l/xg//d), 
1/xl of total RNA (1/xg/ t^l) and 3/xl of water were mixed, heated to 70°C for 10 min. and then 
chilled on ice. To this solution the following components were added: 4/xl of a 250mM Tris- 
HC1 pH 8.3, 375mM KC1 and 15mM MgCl2 buffer, 2/xl of DTT (lOOmM), 1/d of RNasin 
(40U.//xl), 1/xl of dNTPs (lOmM each), 6/xl of water and 1/d of Moloney murine leukemia 
virus-reverse transcriptase (200U.//d). The reaction mixture was incubated at 37°C for lh. 
followed by 2 min. at 95°C.
2.13.4. Polymerase chain reaction (PCR)
Five /xl of cDNA was incubated with relevant primers in the PCR for 30 cycles. 
The resulting product was analysed by gel electrophoresis and densitometry. Water (24.5/d) 
was mixed with 5/xl of a lOOmM Tris-HCl pH 9.0 at 25°C, 50mM KC1, 1 % Triton X-100, 3/xl 
of 25mM MgCl2, 8/xl of 1.25mM dNTP, 1/xl of 250/xg/ml first strand target primer, 1/xl of 
250/xg/ml second strand target primer, 1/d of 250/xg/ml B-actin first strand primer, 1/xl of 
250/tg/ml B-actin second strand primer, 0.5/xl of 5U.//xl T a q  DNA polymerase enzyme and 5/xl 
of cDNA from the reverse transcriptase reaction (which had been heated to 95°C. for 3 min., 
followed by cooling on ice). A drop of mineral oil was added to each reaction tube and the 
cDNA amplified by the following procedure: 95°C for 1.5 min., 30 cycles of 95°C for 1.5 
min., 55°C for 1 min. and 72°C for 3 min., 72°C for 7 min. and then held at 4°C. Ten /xl of 
gel loading buffer was added to each tube and 10/xl of the cDNA solution was then separated 
by electrophoresis for 4h. at 100V on a 4% agarose (Nusieve agarose) gel containing ethidium 
bromide with TBE (22.5mM Tris, 22.5M boric acid (Sigma; B7901), 0.5mM EDTA, pH 8.0) 
as the running buffer.
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2.14 Gap junctional intercellular communication
2.14.1 Detection of functional gap junctions in cells
The presence of functional gap junctions in variants of the DLKP cell line was 
determined using the lucifer yellow scrape loading method of analysis (El-Fouly e t  a l .  ,1987). 
The cells were plated onto a sterile coverslip in individual sterile dishes, in 1 ml of medium, 
at a cell density of approximately 5 x 104 cells. The coverslip was incubated at 37°C in 5% 
C02 until the cells reached confluency. The medium was then removed from the cells and the 
cells rinsed twice, for 2 min. each time, in assay buffer (130mM NaCl, 2.8mM KC1, 2mM 
MgCl2, lOmM Hepes, pH 7.2). Lucifer yellow (Sigma; L0144) (0.5mg/ml) in assay buffer was 
added to the cells and a blade was used to score the cells, at a central location on the coverslip. 
The cells were incubated in this solution for 2 min. at 37°C in 5 % C02 in darkness. The lucifer 
yellow solution was then removed and the cells washed twice with 2 ml of the assay buffer 
containing ImM CaCl2. The cells were then viewed under a fluorescent microscope.
In cases where gap junctional-intercellular communication was being inhibited 
with heptanol (Sigma; H6129), the procedure was carried out as outlined above, with the 
following modifications. The cells were pre-incubated in assay buffer containing 1.5mM 
heptanol for 1.5 h. prior to scrape loading the lucifer yellow into the cells. The scrape loading 
section of the assay was also carried out in heptanol containing buffer. However, heptanol was 
omitted from the final wash buffer.
The ability of adriamycin to be transported intercellularly v i a  gap junctions was 
also investigated. The procedure used for this experiment was the same as that used in the 
investigation of the intercellular transfer of lucifer yellow, except that the lucifer yellow was 
replaced by 100/xM adriamycin and the cells were exposed to the adriamycin-containing solution 
for 5 min. following the scoring of the cells. The effect of cyclosporin A on adriamycin 
transfer by gap junctions was investigated by adding 30/xg/ml cyclosporin A to all solutions 
containing adriamycin.
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2.14.2 Investigation of gap junctional-mediated adriamycin toxicity
The effect of the blocking of gap junctional-communication on adriamycin 
toxicity to variants of DLKP was investigated in a miniaturised assay. The cells were set up 
in four 24 well plates; one plate at 200 cells/well, one at 2000 cells/well, one at 400 cells/well 
and the final plate at 4000 cells/well, in a volume of 500/d/well. The cells were allowed to 
attach overnight at 37°C in 5% C 0 2 . Following cell attachment, 250/xl of 6mM heptanol (the 
heptanol was originally dissolved in DMSO and then diluted with medium) was added to the 
plates containing 400 cells/well and 4000 cells/well. An equal volume of medium, containing 
the same concentration of DMSO as was used to dissolve the heptanol, was added to the two 
remaining plates. A concentration of heptanol of 1.5mM had resulted in 50% cell kill, by 
comparison with a DMSO control, when cells were exposed to the chemical in a preliminary 
assay (carried out as in Section 2.11.1). The cells were incubated for a further 24h. at 37°C 
in 5% C02. Adriamycin (250/d of a 4X final concentration) was then added to the plate in 
replicas of three and the plates incubated until the control wells reached approximately 80% 
confluency. Cell growth was then measured by analysing the intensity of crystal dye staining, 
as performed in the plating density assay (Section 2.11.3).
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2.15 Adriamycin accumulation
Cells were plated, from a single cell suspension, into a 6 well plate at a cell 
density of 5 x 105 cells/well in 5ml of growth medium. The cells were incubated at 37°C in 5 % 
C02 for 48h. The medium was then removed from the cells and 4ml of fresh medium 
containing 10/xM adriamycin (and an appropriate concentration of circumventing agent, if 
required in the assay) was added to duplicate wells. Control wells were set up containing 
adriamycin-free medium. The cells were incubated at 37°C in 5 %  C 0 2 . At specific time 
intervals, the medium was removed from the cells and the cells washed twice with ice-cold PBS. 
Ice cold water (2ml) was added to each well and left for approximately 5 min. or until cell lysis 
was observed, as determined by microscopical analysis. Two mis of an ice-cold 0.6M HC1 
solution in methanol was added to each well and the plates further incubated for 3 min. The 
solution was then centrifuged at 4000g for 10 min. The fluorescence of the supernatant was 
measured, against the control blanks, at an excitation range of 470nm and an emission of 
585nm, using a Perkin Elmer LC50 luminescence spectrometer. The concentration of 
adriamycin in the supernatant was determined from a Unear standard curve, prepared from the 
fluorescence of known concentrations of adriamycin.
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2 . 1 6 Conditioned medium assay
The effect that conditioned medium from one cell line, generated in the presence 
and absence of adriamycin, exerted on the drug sensitivity of another cell line was investigated. 
Four 75cm2 flasks of DLKPA2B and DLKPA5F cells were set up at 10s cells per flask. The 
cells were allowed to attach overnight at 37°C in 5 % C02. The medium was removed from the 
cells and two flasks of each cell line were re-fed with 30ml of fresh medium. The remaining 
two flasks of each cell line were re-fed with 30ml of fresh medium containing 2.5/ig/ml 
adriamycin. The flasks were incubated for a further 24h. at which time the conditioned medium 
was collected from each flask and the media from replica flasks were pooled. The conditioned 
media was centrifuged at 120 g. and the supernatant filtered through a 2/im low protein-binding 
filter. The adriamycin content of the conditioned media was determined from their level of 
fluorescence (as determined using a Perkin Elmer LC50 luminescence spectrometer, with an 
excitation of 470nm and an emission of 585nm) as compared to freshly diluted adriamycin 
standards. In each case the conditioned medium from a cell line was analysed using the 
appropriate adriamycin-free conditioned medium produced by the same cell line as a blank. 
Fresh adriamycin was added to a sample of the conditioned medium, generated by the four 
individual procedures, re-adjusting the adriamycin concentration to 2.5/xg/ml. Adriamycin was 
also added to fresh medium, to a final concentration of 2.5/ig/ml (Table 2.16).
Simultaneously, DLKPA2B cells were set up as for a plating density assay 
(Section 2.11.3), such that by this stage of the production of adriamycin- containing conditioned 
media, the cells had been allowed to attach overnight. The adriamycin-containing conditioned 
media were now diluted, using the appropriate adriamycin-free medium, and 500/d of these 
adriamycin dilutions were added to triplicate wells of the 24 well plate. The control in each 
case was the adriamycin-free medium, produced by that cell line. The plates were incubated 
in 5% C02 at 37°C until the control wells were approximately 80% confluent, at which stage 
the level of cell growth was ascertained using crystal violet staining, as outlined in Section 
2.11.3.
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Exposure of cells to 
adriamycin.
Determination of
adriamycin
concentration.
Adjustment of
adriamycin
concentration.
Dilution of 
adriamycin- 
containing 
medium.
Use of the
conditioned
medium.
Adriamycin was added to 
fresh ATCC medium, to a 
final concentration of 
2.5/ig/ml.
Serial dilutions of 
the drug-containing 
medium were 
performed, using 
fresh ATCC 
medium.
The medium 
was added to 
the DLKPA2B 
cells in a 24 
well assay.
ATCC medium, 
containing 2.5/ig/ml 
adriamycin, was exposed 
to DLKPA2B for 24h. at 
37°C. The conditioned 
medium was collected, 
centrifuged and filtered 
through a low protein- 
binding 0.22/xm filter.
The concentration 
of adriamycin 
present in the 
conditioned 
medium was 
determined by its 
fluorescence.
Fresh
adriamycin was 
then added to an 
aliquot of the 
conditioned 
medium, to a 
final
concentration of 
2.5/ig/ml.
This drug-
containing
conditioned
medium was diluted
with drug-free
conditioned
medium.
The
conditioned 
medium was 
added to the 
DLKPA2B 
cells in a 24 
well assay.
ATCC medium, 
containing 2.5/ig/ml 
adriamycin, was exposed 
to DLKPA5F for 24h. at 
37°C. The conditioned 
medium was collected, 
centrifuged and filtered 
through a low protein- 
binding 0.22/im filter.
The concentration 
of adriamycin 
present in the 
conditioned 
medium was 
determined by its 
fluorescence.
Fresh
adriamycin was 
then added to an 
aliquot of the 
conditioned 
medium, to a 
final
concentration of 
2.5/tg/ml.
This drug-
containing
conditioned
medium was diluted
with drug-free
conditioned
medium.
The
conditioned 
medium was 
added to the 
DLKPA2B 
cells in a 24 
well assay.
Fresh ATCC medium was 
exposed to DLKPA2B 
cells for 24h. at 37°C.
The conditioned medium 
was then collected, 
centrifuged and filtered 
through a low protein- 
binding 0.22/im filter.
Adriamycin was 
then added to an 
aliquot of the 
conditioned 
medium, to a 
final
concentration of 
2.5/tg/ml.
Serial dilutions 
were performed on 
the drug-containing 
conditioned 
medium, using the 
drug-free 
conditioned 
medium.
The
conditioned 
medium was 
added to the 
DLKPA2B 
cells in a 24 
well assay.
Fresh ATCC medium was 
exposed to DLKPA5F 
cells for 24h. at 37°C.
The conditioned medium 
was then collected, 
centrifuged and filtered 
through a low protein- 
binding 0.22/im filter.
Adriamycin was 
then added to an 
aliquot of the 
conditioned 
medium, to a 
final
concentration of 
2.5/ig/ml.
Serial dilutions 
were performed on 
the drug-containing 
conditioned 
medium, using the 
drug-free 
conditioned 
medium.
The
conditioned 
medium was 
added to the 
DLKPA2B 
cells in a 24 
well assay.
Table 2.16 : Protocol followed in  the generation o f adriamycin-free and adriamycin-containing 
conditioned media.
Results
3.1 Establishment of novel MDR cell lines
3.1.1 Establishment of DLKP/VP-3 and DLKP/VP-8
Two new multidrug resistant variants of the human squamous cell carcinoma 
cell line DLKP (Law e t  a l . ,  1992) were established, as outlined in Section 2.9. DLKP adapted 
readily to continuous growth in VP-16. The initial selective pressure to which the cell line was 
exposed was 0.3/xg/ml VP-16. The cell line adjusted to growth in 3.0/xg/ml VP-16 within six 
months and to a final concentration of 8.0/tg/ml VP-16 within an additional three months. The 
cell lines selected to and maintained in a concentration of 3.0/ig/ml VP-16 and 8.0/xg/ml VP-16 
were designated DLKP/VP-3 and DLKP/VP-8, respectively.
3.1.2 Cross-resistance patterns of DLKP/VP-3 and DLKP/VP-8
To ensure that the VP-16 selected cells possessed the multidrug resistance 
characteristic of exhibiting cross-resistance to a range of structurally unrelated chemotherapeutic 
drugs, their sensitivities to five such drugs were determined. These drugs included: the 
selective agent, VP-16; the anthracycline, adriamycin; the alkylating agent, cisplatin; the vinca 
alkaloid, vincristine and the anti-metabolite, 5-fluorouracil. The sensitivity of DLKP/VP-3 and 
VP-8 cells to the chemotherapeutic agents were tested a minimum of three times with eight 
replicas performed in each assay. Table 3.1.2.1 presents the average IC50 values for the 
chemotherapeutic agents acting on the parental cell line, DLKP and the two VP-16 selected 
variants obtained from their toxicity profiles, as described in Section 2.12.1, with the IC50 
values determined as outlined in Appendix A. Table 3.1.2.2 represents the fold increase in the 
IC50 values of the variants with respect to the parental cells.
DLKP/VP-3 and DLKP/VP-8 both possessed multidrug resistance phenotypes 
and exhibited cross-resistance and hyper-sensitivity to a similar range of drugs. They were 
resistant to their selective agent VP-16 and cross-resistant to adriamycin and vincristine. They 
exhibited collateral sensitivity to cisplatin and no significant alteration in their sensitivity to 5- 
fluorouracil (Table 3.1.2.1).
In terms of fold resistance, both selected cell lines were most resistant, not to 
their selective agent, but to vincristine (approximately 1700- and 1000-fold resistant, 
respectively), next to adriamycin (270- and 90-fold, respectively), with the least fold increase 
in relation to VP-16 (approximately 100- and 60-fold, respectively). The increase in their
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resistance to vincristine was approximately one order of magnitude greater than their resistance 
to adriamycin or VP-16 (Table 3.1.2.2). The fold resistance ratio displayed by bothDLKP/VP- 
3 and DLKP/VP-8 with respect to vincristine and VP-16 was approximately constant, i .  e .  when 
the resistance to one drug was doubled, both doubled. However, DLKP/VP-8 was three times 
more resistant to adriamycin than DLKP/VP-3. Cell lines DLKP/VP-3 and DLKP/VP-8 were 
approximately 3- and 4-fold, respectively, more sensitive to cisplatin than the parental cell line, 
DLKP.
i c 50 (nM) DLKP DLKP/VP-3 DLKP/VP-8
Adriamycin 24.83 +  14.48 2237.07 +  328.79* 6764.31 +  945.35*
Cisplatin 873.00 ±  387.33 281.67 +  149.00* 191.67 + 50.33*
Vincristine 1.21 + 0.30 1317.66 + 194.91* 2102.28 + 420.59*
VP-16 146.45 + 68.81 8527.35 + 338.60* 14826.71 ±  958.21*
5-Fluorouracil 9551.11 + 6255.96 4448.12 ±  3631.82 8621.06 + 4067.64
Table 3 .1 .2 .1  : IC30 values for a range o f chemotherapeutic drugs acting on the cell lines DLKP, 
DLKP/VP-3 and DLKP/VP-8 . The values are given as the average IC50 value ±  the standard deviation, 
on a minimum of three repeats. The IC50 values were determined as outlined in Appendix A.
* The values are significantly different from the corresponding DLKP values.
FOLD RESISTANCE DLKP/VP-3 DLKP/VP-8
Adriamycin 90.10 + 13.24 272.42 + 38.07
Cisplatin 0.32 + 0.17 0.22 + 0.06
Vincristine 1088.98 + 161.08 1737.42 + 347.60
VP-16 58.23 + 2.31 101.24 + 6.54
5-Fluorouracil 0.47 ± 0.38 0.90 ± 0.43
Table 3 .1 .2 .2  : The fold increase in  resistance to chemotherapeutic drugs in DLKP/VP-3 and DLKP/VP- 
8 with respect to DLKP, as determined by comparing their ICJ0 values.
3.2 Establishment of clones of an MDR cell line
3.2.1 Establishment of Clones
To study the heterogenous nature of the DLKP-A cell line and to determine if 
different sub-populations within the cell line were responsible for various characteristics of the 
overall population, nine clones of the MDR cell line were established as outlined in section 
2.10. During the initial stages of isolating clones of DLKP-A, poor growth was observed when 
the DLKP-A cells were plated at the low densities necessary to ensure that all colonies arose 
from single, well-dispersed cells. When conditioned medium (Section 2.10) from the DLKP-A 
cell line was used to partially feed the cells at this stage of the isolation procedure (at a 1 :1  
dilution with fresh medium), it appeared to stimulate the cells to grow, in comparison with the 
growth observed when only fresh medium was used. The clones of DLKP-A were maintained 
as individual cell lines without selective pressure and randomly designated DLKPA2B, 
DLKPA6B, DLKPA9B, DLKPA11B, DLKPA3C, DLKPA10C, DLKPA2D, DLKPA5D and 
DLKPA5F.
3.2.2 Cross-resistance profiles of DLKP-A Clones
To determine if the clonal populations present in the DLKP-A cell line were 
multidrug resistant, or whether specific clones were resistant to certain drugs and the 
combination of clones was responsible for the overall MDR profile, the sensitivities of the 
clones to a variety of chemotherapeutic compounds were investigated. These agents included 
adriamycin, VP-16, vincristine, cisplatin and 5-fluorouracil. Table 3.2.2.1 presents the IC50 
values obtained for the parental cell line DLKP, its MDR adapted variant DLKP-A and the nine 
clones established from the MDR variant. The sensitivity of all cell lines to the different 
chemotherapeutic agents was tested a minimum of three times, with eight replicas performed 
in each assay. The ICJ0 values were evaluated as outlined in Appendix A. Table 3.2.2.2 
presents the fold increase in the IC^ values of the MDR variant, DLKP-A, and its clones, with 
respect to the drug sensitive parental cell line, DLKP.
DLKP-A, as previously described by Clynes e t  a l . , (1992), exhibited an MDR 
profile. Under the experimental conditions used in this study, DLKP-A was found to be 
resistant, not only to its selective agent, adriamycin (250-fold resistant), but also highly cross- 
resistant to vincristine (1500-fold resistant) and resistant to a lesser extent to VP-16 (60-fold 
resistant). It showed neither significant cross-resistance nor collateral sensitivity to cisplatin 
(1.46-fold resistant) or 5-fluorouracil (1.75-fold resistant). The cell line exhibited a high level 
of deviation in its toxicity profile with respect to all drugs examined.
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ICS„ (nM) Adriamycin Cisplatin Vincristine VP-16 5-Fluorouracil
DLKP 24.83 ± 14.48* 873.00 + 387.33 1.21 + 0.30* 146.45 + 68.81* 9551.11 + 6255.96
DLKPA 6310.34 + 2965.52* 1277.33 + 364.00 1820.15 ± 855.90* 8885.49 + 1172.27* 16679.48 ± 7071.48
DLKPA2B 913.79 ± 396.55*-* 500.00 ± 63.33* 276.27 + 85.59*-* 2660.55 + 1219.84*-* 12259.80 ± 7355.88
DLKPA6B 2348.28 + 810.34*-* 616.67 + 66.67* 444.20 + 198.27*-* 4359.50 + 1862.05*-* 7363.57 ± 3120.68
DLKPA11B 2082.76 + 310.34*-* 543.33 + 233.33* 397.62 + 196.10» 3688.41 ± 287.12*-* 5149.88 ± 953.11*
DLKPA5F 8208.62 + 1701.73* 1213.33 + 23.33 1542.80 + 756.23* 7410.81 ± 1182.47* 9362.03 ± 4481.17
DLKPA9B 6087.24 + 1194.83* 796.67 ± 100.00 2171.72 + 200.00* 8961.94 + 1979.27* 10591.85 + 53.80
DLKPA3C 8136.21 ± 1218.97* 953.33 ± 123.33 2401.95 ± 410.62* 5176.69 + 62.86*-* 8554.96 + 3382.01
DLKPA10C 2206.90 + 1908.62* 825.00 + 73.00 1178.76 ± 98.59* 3380.90 + 1868.84*-* 9362.03 ± 1691.01
DLKPA2D 4109.48 + 305.17# 1461.67 + 73.00* 2154.93 ± 49.84* 6223.24 ± 2891.61* 13912.38 ± 1929.29
DLKPA5D 5294.83 ± 879.31* 1701.67 + 73.00** 907.91 + 191.77* 14085.97 + 506.29* 9684.86 + 3697.16
Table 3.2.2.1: IC^ values obtained for a range of chemotherapeutic drugs towards DLKP, DLKP-A and its clones. The values given are the mean 
IC^ value + the standard deviation. The average IC^ values was calculated as outlined in Appendix A and the standard deviation was determined 
using a m inim um  of triplicate repeat assays, in all cases.
* The value is significandy different from the corresponding DLKP-A value.
* the value is significandy different from the corresponding DLKP value.
FOLD
RESISTANCE
Adriamycin Cisplatin Vmcristine VP-16 5-Fluorouracil
DLKPA 254.14 ± 119.43 1.46 ± 0.42 1504.26 ± 707.36 60.67 ± 8.00 1.75 + 0.74
DLKPA2B 36.80 ± 15.97 0.57 ± 0.07 228.32 ± 70.74 18.17 + 8.33 1.28 + 0.77
DLKPA6B 94.59 ± 32.64 0.71 ± 0.08 367.11 ± 163.86 29.77 ± 12.71 0.77 ± 0.33
DLKPA11B 83.88 ± 12.50 0.62 + 0.27 328.61 + 162.07 25.19 + 1.96 0.54 ± 0.10
DLKPA5F 330.59 + 68.53 1.39 ± 0.03 1275.04 ± 624.98 50.60 ± 8.07 0.98 + 0.47
DLKPA9B 245.16 ± 48.12 0.91 + 0.11 1794.81 + 165.29 61.19 ± 13.51 1 .1 1  ± 0.06
DLKPA3C 327.68 ±  49.09 1.09 ± 0.14 1985.08 ± 339.36 35.35 + 0.43 0.90 ± 0.35
DLKPA10C 88.88 + 76.87 0.95 ± 0.08 974.18 + 81.48 23.09 ± 12.76 0.98 ± 0.18
DLKPA2D 165.50 + 12.29 1.62 + 0.08 1780.93 ±41.19 42.49 + 19.74 1.46 ± 0.20
DLKPA5D 213.21 ± 35.41 1.95 ± 0.08 750.34 ± 158.49 96.18 + 3.46 1.01 ± 0.39
Table 3 . 2 . 2 . 2  : Fold increase in resistance towards chemotherapeutic drugs of DLKP-A and its clones, with respect to DLKP. The fold resistance 
was determined by dividing the average IC50 value for the cell line of interest by the corresponding average ICW value for DLKP.
All clones exhibited similar cross-resistance profiles to that of DLKP-A, in that 
they were highly resistant to the MDR-associated drugs, adriamycin, vincristine and VP-16. 
As was observed with the DLKP-A cells, high levels of deviation existed within the IC*, values 
determined, especially in respect to vincristine resistance where up to 50% standard deviation 
was noted e . g .  the standard deviation on the average IC^ value of vincristine toxicity to 
DLKPA5F was 49%. The high inter-assay variability means that an exceedingly large 
difference must exist between two cell populations, with respect to their sensitivity to a 
chemotherapeutic drug, before a significant difference is noted.
As was found for DLKP-A, all the clones exhibited the same rank order of 
resistance, i .  e .  significantly more resistant to vincristine than to adriamycin and less resistant 
to VP-16. Very low levels of resistance or sensitivity to cisplatin or 5-fluorouracil were 
exhibited by some clones. Within the clonal sub-populations, there was a 9-fold variation in 
resistance levels to adriamycin. This variation ranged from a 37-fold resistance in DLKPA2B 
to 331-fold resistance in DLKPA5F. There was an 8-fold variation in resistance levels to 
vincristine (228-fold resistance level in DLKPA2B and 1985-fold resistance in DLKPA3C). 
With respect to VP-16, there was a 5-fold variation within the clonal population; DLKPA2B 
was 18-fold resistant whereas DLKPA5D was 96-fold resistant. The cloned cell line most 
resistant to one specific MDR associated drug was not most resistant to all MDR drugs, but 
DLKPA2B was the least resistant clone with regard to resistance to the typical MDR drugs. 
With respect to DLKP-A, the clonal cell lines DLKPA2B, DLKPA6B and DLKPA1 IB exhibited 
collateral sensitivity to cisplatin (with a fold resistance of 0.57 ± 0.07, 0.71 ± 0.08 and 0.62 
±  0.27 respectively), but not by comparison with the cisplatin sensitivity of the parental DLKP 
cell line (an IC50 of 873.00 ±  387.33 nM was detected for DLKP while the IC50 values for 
DLKPA2B, DLKPA6B and DLKPAIIB were 500.00 ±  63.33 nM, 616.67 ± 66.67 nM and 
543.33 ± 233.33 nM, respectively). DLKPAIIB also exhibited sensitivity to 5-fluorouracil 
(fold resistance of 0.54 ± 0.10), in comparison to the level of sensitivity noted in DLKP-A 
(fold resistance of 1.75 ±  0.74). DLKPA5D showed a slight increase in resistance with respect 
to DLKP-A in terms of cisplatin toxicity (fold resistance of 1.95 ± 0.08).
The relative resistance levels exhibited to the five chemotherapeutic drugs varied 
for each clone. Table 3.2.2.3 presents the relative fold resistance ratio of adriamycin, 
vincristine and VP-16, for DLKP-A and the nine clonal sub-populations. The fold resistance 
to adriamycin, for each cell line, was taken as the unit fold resistance and the cells resistance 
to vincristine and VP-16 normalised to this. DLKP-A possessed a cross-resistance profile of 
1:5.92:0.64 in relation to adriamycin, vincristine and VP-16, respectively. Although all clonal 
cell lines of DLKP-A retained the property of most resistance to vincristine, less to adriamycin 
and least resistant to VP-16, no clone had a similar ratio of fold resistance to the three drugs
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as that observed in DLKP-A. DLKPA9B exhibited a fold resistance ratio most like that of 
DLKP-A. It possessed a fold resistance ratio of 1:7.32:0.25 with respect to resistance to 
adriamycin, vincristine and VP-16. The relative ratio of fold resistance to adriamycin and VP- 
16 was similar for both the DLKP-A and DLKPA9B cells, but DLKPA9B exhibited a higher 
fold resistance to vincristine, when normalised to adriamycin resistance, than that observed for 
DLKP-A. DLKP-A and DLKPA3C also showed similar fold resistance ratios to adriamycin 
and vincristine (1:5.92 for DLKP-A and 1: 6.06 for DLKPA3C) but the ratios of adriamycin 
to VP-16 fold resistance for both cell lines were significantly different (1:0.24 for DLKP-A and 
1:0.11 for DLKPA3C).
The cell clones DLKPA10C and DLKPA2D exhibited similar fold resistance 
ratios. DLKPA10C possessed a ratio of 1:10.96:0.26 while DLKPA2D possessed a ratio of 
1:10.61:0.26, with respect to adriamycin, vincristine and VP-16 fold resistance. However, the 
DLKPA2D cells were twice as resistant to the drugs as the DLKPA10C cells (165.50 ±  12.29 
and 88.88 ± 76.87 fold resistance, respectively). Although both cell lines exhibited a ratio of 
adriamycin to VP-16 resistance similar to DLKP-A cells, the relative ratio of adriamycin to 
vincristine resistance was twice that noted for DLKP-A. The cell lines DLKPA6B and 
DLKPA11B also possessed similar fold resistance ratios DLKPA6B exhibited a ratio of 
adriamycin, vincristine and VP-16 resistance of 1:3.88:0.31, while that of DLKPA11B was 
1:3.92:0.30. Both cell lines were also resistant to adriamycin to a similar level (the ICS0 of 
adriamycin toxicity to DLKPA6B was 2348.20 ± 810.34 nM, while that of DLKPA11B was 
2082.76 ±  310.34 nM). Although the relative fold resistance ratio of adriamycin resistance to 
vincristine resistance was similar for DLKPA5F (1:3.86) as that detected for DLKPA6B 
(1:3.88) and DLKPA11B (1:3.92), the fold resistance ratio of adriamycin to VP-16 in 
DLKPA5F (1:0.15) was half that observed for DLKPA6B (1:0.31) and DLKPA11B (1:0.30). 
DLKPA5F cells were also 4-fold more resistant to adriamycin and vincristine than DLKPA6B 
and DLKPA11B (Table 3.2.2.2).
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CELL LINE/CLONE Adriamycin Vincristine VP-16
DLKP-A 1 5.92 0.24
DLKPA2B 1 6.20 0.49
DLKPA6B 1 3.88 0.31
DLKPA11B 1 3.92 0.30
DLKPA5F 1 3.86 0.15
DLKPA9B I 1 7.32 0.25
DLKPA3C 1 6.06 0.11
DLKPA10C 1 10.96 0.26
DLKPA2D 1 10.61 0.26
DLKPA5D 1 3.52 0.45
Table 3.2.2.3 : The ratio of the relative fold resistance of the MDR cell lines to adriamycin, vincristine 
and VP-16. The fold resistance level to adriamycin in each cell line is given as a unit resistance and the 
fold resistance to vincristine and VP-16 was normalised to the adriamycin resistance.
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3.3 DNA fingerprint analysis of the drug resistant variants
DNA fingerprint analysis was carried out to ensure that the VP-16-selected 
MDR cell lines were variants of DLKP and that the clones DLKPA2B, DLKPA6B, DLKPA1 IB 
and DLKPA5F were variants of DLKP-A. DNA was extracted from the cell lines by Cellmark 
Diagnostics and DNA fingerprints were produced with the multi locus probes, 33.15 and 33.6 
(Case Number R932939). As may be observed from Figures 3.3, the DNA fingerprints of all 
DLKP variants had 56 identical bands and so share approximately 99% homology. Hence, all 
cell lines must have originated from a common source. DLKP, DLKP-A and DLKPA6B had 
one additional band each, at different positions, within their fingerprint. DLKP/VP-3 and 
DLKPA1 IB had two additional bands each within their fingerprints, one of which was present 
in both cell lines.
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Figure 3.3 : DNA fingerprint analysis of DLKP variants, produced with the multi locus probes 33.15 
(a) and 33.6 (b).
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3.4 Stability of the toxicity profiles of drug resistant variants of DLKP
3.4.1 Stability of VP-16 toxicity profiles of VP-16-selected MDR variants of DLKP
The stability of the drug resistant phenotype was studied by maintaining the 
MDR cells in the absence of VP-16 for up to three months. As can be determined from Figures
3.4.1.1 and 3.4.1.2, the toxicity profile of the cell lines, DLKP/VP-3 and DLKP/VP-8, with 
respect to VP-16, were maintained for up to three months with little deviation. These lines 
were therefore characterised as being stable cell lines, with respect to their level of resistance 
to VP-16.
3.4.2 Stability of adriamycin toxicity profiles of DLKP, DLKP-A and DLKPA5F
To ensure that the level of resistance to adriamycin observed in the clones was 
a real and stably expressed characteristic, the stability of their adriamycin toxicity profiles was 
investigated.
DLKP cells were sensitive to adriamycin and the level of adriamycin toxicity 
remained stable when thawed and passaged (Figure 3.4.2.1(a)). The adriamycin resistance of 
DLKP-A cells remained stable when the cells were cultured in the absence of selective pressure 
for three months (Clynes e t  a l . ,  1992). The stability of the adriamycin toxicity profile when 
the cells were repeatedly frozen and thawed and/or subcultured was confirmed (Figure 
3.4.2.1(b)). The effect of cryopreservation and subculturing on the adriamycin toxicity profile 
of DLKPA5F, as a representive of a clone of DLKP-A, was also examined. Though the clone 
was maintained in the absence of any selective pressure, the adriamycin toxicity profile was 
stable following continuous freeze/thawing and subculturing (Figure 3.4.2.2). Any deviation 
in the toxicity profile appeared to be due to inter-assay variability.
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VP-16 conc. (jig/ml)
Figure 3.4.1.1 : Stability 
of the VP-16 toxicity 
profile of DLKP/VP-3 
when maintained in drug- 
free medium, for up to 
three months. The error 
bars represent the standard 
deviation on the mean of 
eight replicas.
Figure 3.4.1.2 : Stability 
of the VP-16 toxicity 
profile of DLKP/VP-8 
when maintained in a drug- 
free medium, for up to 
three months. The error 
bars represent the standard 
deviation on the mean of 
eight replicas.
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Figure 3.4.2.1 : Stability of the adriamycin toxicity profiles of DLKP (a) and DLKP-A (b), following 
thawing and passaging in the absence of adriamycin. The error bars represent the standard deviation on 
the mean of eight replicas.
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Figure 3 . 4 . 2 . 1  : Stability of the adriamycin 
toxicity profile of DLKPA5F, following thawing 
and passaging in the absence of adriamycin. 
Figure 3.4.2.2(a) presents the adriamycin 
toxicity profiles of DLKPA5F when thawed at 
P56 and its profile at subsequent passage 
numbers. Figure 3.4.2.2(b) presents the 
adriamycin toxicity profiles of DLKPA5F at 
P58, immediately prior to and after thawing and 
its profile at subsequent passage numbers. The 
cells at P58 prior to freezing are the same cells 
as DLKPA5F thawed at P56 and passaged twice, 
as in Figure 3.4.2.2(a). Figure 3.4.2.2(c) 
presents the adriamycin toxicity profile of 
DLKPA5F at P60, immediately following cell 
thawing and after passaging the cell line.
The error bars represent the standard deviation 
on the mean of eight replicas.
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3.5 Radiation studies
Exposure of cells to chemotherapeutic drugs has, in some cases, been associated 
with conferring cross-resistance to radiation on these cells, with the converse also found 
(Mattern e t  a l . ,  1991; Hill e t  a l . ,  1990b; Tanio e t  a l . ,  1990). In order to investigate if this 
were true for the MDR variant of the squamous cell carcinoma cell line, DLKP-A and its clonal 
cell lines, their toxicity profiles with respect to radiation were examined and compared to that 
found in DLKP. To determine if resistance to radiation leads to drug cross-resistance for this 
cell line, DLKP was exposed to varying increasing doses of radiation and studied to detect any 
alterations in its toxicity profile with respect to a range of clinically used drugs.
3.5.1 Toxicity of chemotherapeutic drugs to radiation treated cells
Following exposure of DLKP to increasing doses of radiation, allowing time 
for the cells to recover between each exposure (as outlined in Table 3.5.1), DLKP did not 
exhibit an MDR profile, i .  e .  it showed no significant alteration in its level of sensitivity to any 
of the five chemotherapeutic agents tested (Table 3.5.2). The toxicity profile, as deduced by 
ICso values, was unaltered with respect to vincristine and VP-16 and is decreased, but not by 
a significant amount, in terms of adriamycin, cisplatin and 5-fluorouracil.
Day Radiation Dose Passage Number
1 150 cGy 17
15 600 cGy 18
21 900 cGy 19
28 900 cGy 19
48 1200 cGy 19
77 1200 cGy 20
83 1200 cGy 20
Table 3.5.1 : The radiation treatment profile used in  the generation of the cell line DLKP/RAD, from 
the parental cell line, DLKP.
ICS0 (nM) DLKP DLKP/RAD
Adriamycin 24.80 ± 14.48 13.02 + 0.36
Cisplatin 873.00 ± 387.33 500.00 ± 13.00
Vincristine 1.21 ± 0.30 1.20 ± 0.60
VP-16 146.45 ± 68.81 158.00 ± 15.80
5-FluorouraciI 9551.11 + 6255.96 3239.82 + 1191.39
Table 3.5.2 : IC50 values of a range of chemotherapeutic drugs to DLKP and DLKP/RAD. The ICjq 
value presented is the mean value calculated from triplicate repeat assays. It is presented as the average 
ICJ0 +  standard deviation and is calculated as outlined in  Appendix A.
3.5.2 Toxicity of radiation to MDR Cells
Exposure of a squamous cell carcinoma to a chemotherapeutic drug, such that 
it acquired an MDR phenotype of cross-resistance to a range of structurally unrelated drugs, as 
in the case of DLKP-A, resulted in no notable alteration in the cells’ susceptibility to cell kill 
by radiation. The radiation toxicity was determined by the cells’ IC50 value, the quasi-threshold 
value, Dq (which represents the size of the shoulder on the curve and reflects the cells ability 
to accumulate and repair irradiation damage) and D0 (which represents the slope of the straight 
line part of the curve) (see Appendix B). The MDR cell line DLKP-A, exhibited a slight 
increase in its IC50 value, extrapolation number and D0, indicating a slight increase in the cell 
line’s resistance to radiation, with respect to DLKP (Table 3.5.2). The level of radiation 
sensitivity observed in the DLKP-A clones ranged from more sensitive than the parental cell line 
(DLKP), to more resistant than the DLKP-A cell line.
The clonal cell lines of DLKP-A exhibited variation with respect to their 
radiation profile. DLKPA2B, DLKPA6B, DLKPA3C, DLKPA10C and DLKPA2D all 
possessed IC50 values within the range of DLKP-A (242 ± 32 cGy). However, DLKPA6B was 
the only one of these clones which also possessed an extrapolation number similar to DLKP-A. 
DLKPA2B and DLKPA3C had lower Dq values and slightly higher D0 values, with respect to 
DLKP-A. DLKPA10C and DLKPA2D had both slightly lower Dq and D0 values. DLKPA5F 
was notably more resistant to radiation than DLKP-A, as determined from its higher IC50 and 
Dq values. Both cell lines had similar D0 values, but DLKPA5F had an IC50 and Dq value of 
303 ±  35 cGy and 177.05 cGy, respectively, as compared to the values obtained for DLKP-A 
of 242 ± 32 cGy and 130.43 cGy, respectively. In comparison with DLKP-A, DLKPA11B 
and DLKPA5D were more sensitive to cell kill by radiation.
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Cell line Radiation Data
D0 (cGy) Dq (cGy) IC50 (cGy)
DLKP 115.17 88.13 193 ± 83
DLKPA 167.39 130.43 242 ± 32
DLKPA2B 214.41 68.58 215 + 83
DLKPA6B 120.63 125.40 215 + 15
DLKPA11B 188.48 62.83 134 + 30
DLKPA5F 164.77 177.05 303 ± 35
DLKPA9B 163.35 109.95 165 ± 65
DLKP A3 C 191.75 72.68 208 + 47
DLKPA10C 128.76 98.15 191 ± 52
DLKPA2D 122.11 90.53 194 ± 60
DLKPA5D 230.77 27.69 124 ± 21
Table 3.5.2 : Toxicity of ionising radiation to DLKP variants, as determinable from the IC*, of radiation 
to the cells, the quasi-threshold dose, Dq and D0. The IC50 value shown is the mean of the values 
obtained from duplicate assays. The IC50 value was calculated as outlined in Appendix A and the D0 and 
Dq values were determined as shown in Appendix B.
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3.6 Doubling time of cell lines
The doubling time, calculated during the exponential phase of cell growth, was 
determined for variants of DLKP, while growing in ATCC medium supplemented with 1 %  L- 
glutamine and 5 %  foetal calf serum (Sera Lab : Batch number 101024) and the results are 
presented in Table 3.6.1. The doubling time was determined from a single experiment which 
contained eight internal replicas.
DLKP had a doubling time of 36.19h., while the doubling time observed in its 
MDR variant, DLKP-A, was reduced to 31.72h. The VP-16-selected MDR cell lines also had 
reduced doubling times with respect to DLKP. DLKP/VP-8 had a doubling time of 33.38h., 
while DLKP/VP-3 had a greatly reduced doubling time of 19.77h. All DLKP-A clones isolated 
had their own unique doubling times, ranging from 15.60h. for DLKPA2D to 32.86h. for 
DLKPA5F.
Cell line Doubling time (hours)
DLKP 36.19
DLKPA 31.72
DLKPA2B 31.74
DLKPA6B 32.91
DLKPA11B 24.01
DLKPA5F 32.86
DLKPA9B 19.78
DLKPA3C 20.63
DLKPA10C 16.80
DLKPA2D 15.60
DLKPA5D 20.59
DLKP/VP-3 19.77
DLKP/VP-8 33.38
Table 3.6.1: Doubling times of variants of the DLKP cell line, determined during the exponential phase 
of cell growth.
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3.7 Regeneration of DLKP-A-like population
All clones isolated from DLKP-A possessed the MDR phenotype of cross­
resistance to a range of structurally unrelated chemotherapeutic drugs (Section 3.2.2). 
However, no clone had an identical toxicity profile to that observed in DLKP-A. To determine 
if a DLKP-A-like cell population could be regenerated, the four clones DLKPA2B, DLKPA6B, 
DLKPA1 IB and DLKPA5F were mixed at varying ratios, to establish a population similar to 
DLKP-A, as determined by its toxicity to adriamycin. As can be seen from Figure 3.7.1, a 
mixture of DLKPA5F, DLKPA2B, DLKPA6B and DLKPA11B in the ratio 2:1:1:1, 
respectively, generated a cell line with a toxicity profile most like that of DLKP-A. Most 
deviation between DLKP-A and the mixed populations occurred at low drug concentrations. 
While 1/ig/ml adriamycin resulted in negligible cell kill in DLKP-A, 10% kill was observed in 
the regenerated cell line most like DLKP-A and 20-35 % kill was noted in all other regenerated 
cell lines at this concentration of adriamycin. Therefore, a factor(s) present in the DLKP-A cell 
line, which contributed to its adriamycin-resistance, was missing from the mixed clones, or if 
present, its effect was masked.
The regenerated cell line most like DLKP-A with respect to adriamycin toxicity, 
was examined to determine if it also had similar VP-16 and vincristine toxicity profiles. The 
resulting toxicity profiles, generated from performing concurrent toxicity assays on the mixed 
population of clones and the DLKP-A cell line (in duplicate), showed that the mixed cell line 
also exhibited similar levels of resistance to vincristine and VP-16 to that observed in DLKP-A 
(Figure 3.7.2).
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Figure 3.7.1: Toxicity profile of DLKP-A and mixed cell lines, consisting of various ratios 
of DLKPA5F, DLKPA2B, DLKPA6B and DLKPA11B, to adriamycin. The error bars 
represent the standard deviation on eight replicas.
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Figure 3 .7 .2  : Toxicity profile o f DLKP-A and the mixed clones, in  the 
ratio 2:1:1:1 o f DLKPA5F, DLKPA2B, DLKPA6B and DLKPA11B, 
respectively, to vincristine (a) and VP-16 (b). The error bars represent
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3.8 mRNA analysis
Alterations in the expression of proteins involved in conferring an MDR profile 
on cells, were investigated at the mRNA level in DLKP, its VP-16 and adriamycin selected 
MDR variants and four clones of DLKP-A, DLKPA2B, DLKPA6B, DLKPA11B and 
DLKPA5F. The level of gene transcripts, corresponding to mdrl, topoisomerase II, 
topoisomerase II-a and topoisomerase II-B, were examined by RT-PCR analysis. The analysis 
was performed on one RNA extraction from each cell line. Duplicate batches of cDNA were 
generated, using the Moloney murine leukaemia virus reverse transcriptase enzymes. The 
duplicate cDNA aliquots were used to individually assess the mRNA levels of interest in the 
original sample, by PCR amplification of sequences specific to each RNA. The level of 
transcript of interest in each cell line was normalised to the level of the ubiquitously expressed 
B-actin mRNA and so corrected for inter-reaction variations in the amplification efficiency. The 
primers used to specifically amplify B-actin mRNA are detailed by O’Driscoll e t  a l .  (1993) and 
amplify a 383bp stretch of B-actin cDNA. In each case, 30 cycles of amplification of the 
mRNA of interest were performed. The PCR product concentration is proportional to the 
starting target DNA only as long as the product accumulation remains exponential. As the point 
at which the exponential accumulation plateaus was not assessed prior to analysis, the 
determination of the mRNA levels in these experiments was only semi-quantitative.
3.8.1 Analysis of mdrl transcripts.
The mdrl-specific primers used in this study have been previously detailed by 
Noonan e t  a l .  (1990). They amplify a 157bp region of the mdrl cDNA, from position 2596 
to 2752 on the mdrl cDNA sequence. The primers flank a sequence that crosses an intron, so 
contaminating DNA can be detected by the production of a 1257bp band. When these primers 
were used to detect mdrl mRNA levels in variants of DLKP, the level of the mdrl transcripts 
was increased in all the MDR cell lines by comparison with DLKP, which expressed no 
detectable levels of mdrl mRNA (Figure 3.8.1). The only significant difference in mdrl 
mRNA levels detected were those noted when any of the MDR cell lines were compared with 
DLKP. When compared to each other, the relative differences in the intensity of the bands 
resulting when mdrl mRNA levels were examined in all the MDR cell fines was minimal. In 
the VP-16-selected cell lines, DLKP/VP-3 appeared to possess slightly higher levels of mdrl 
mRNA than the more resistant cell line, DLKP/VP-8 (Table 3.8.1), but the differences in their 
mRNA levels was not significant. DLKP/VP-8 exhibited an equal level of the mdrl transcript
to that noted in DLKP-A. All clones of DLKP-A appeared to express less mdrl mRNA than 
that detected in DLKP-A. Levels detected in DLKPA5F were slightly lower than those found 
in DLKP-A. The cell lines, DLKPA2B and DLKPA11B had equal, but lower, levels of mdrl 
mRNA than DLKPA5F. The mdrl mRNA level detected in DLKPA6B was significantly 
different from that noted in DLKP-A. DLKPA6B possessed approximately half the amount of 
mdrl mRNA observed in DLKP-A.
3.8.2 Analysis of topoisomerase II mRNA transcripts
The primers used to determine the levels of topoisomerase II mRNA in the cell 
lines, allowed the detection of topoisomerase II in general, by amplifying a region that is 
common to both the a  and fl isoforms of the enzyme. The primers, detailed by O’Driscoll e t  
a l .  (1993), amplify a 216bp region homologous to the region spanning base pairs 1395 to 1610 
of topoisomerase II, as described by Tsai-Pflugfelder e t  a l .  (1988). Analysis of topoisomerase 
II mRNA levels in the cell lines revealed only a slight reduction in the levels of the mRNA in 
the DLKP/VP-3 and DLKP/VP-8 cell lines by comparison with the levels noted in DLKP 
(Figure 3.8.1). Although no significant alterations in mRNA levels were observed in DLKP-A 
compared to DLKP, a reduction in transcript levels was noted in the DLKP-A clones. 
However, the level of topoisomerase II mRNA expression was similar in all clones.
3.8.3 Analysis of topoisomerase II-a mRNA transcripts
Analysis of mRNA levels which code for the a  subunit of the topoisomerase II 
enzyme revealed no significant alteration in the MDR cell lines examined (Figure 3.8.1). All 
cell lines expressed detectable levels of topoisomerase II-a. A 139bp region, from base 4052 
to 4190, of the topoisomerase II-a sequence published by Tsai-Pflugfelder e t  a l .  (1988) was 
detected in this case. Although the region amplified was slightly homologous to topoisomerase 
Il-fl, the primers were specific for topoisomerase II-a (O’Driscoll e t  a l . ,  1993).
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3.8.4 Analysis of topoisomerase Il-fl mRNA transcripts
RT-PCR analysis of mRNA levels coding for topoisomerase Il-fl was carried 
out using primers to bases 4335-4364 and 4425-4452 of the topoisomerase Il-fl cDNA described 
by Jenkins e t  a l .  (1992). These primers amplified a 118bp region unique to topoisomerase Il-fl 
(O’Driscoll e t  a l . , 1993). RT-PCR analysis revealed that all the cell lines expressed detectable, 
but low levels of the mRNA (Figure 3.8.1). The intensity of the topoisomerase Il-fl homologous 
band, relative to the intensity of the fl-actin band, was approximately one fifth of that observed 
for the other transcripts. Once again, any alterations observed in the topoisomerase Il-fl mRNA 
levels in the cell lines were not significant by comparison with the levels detected in DLKP.
CELL LINE/ 
CLONE
mdrl Topo n Topo II-a Topo D-6
DLKP/VP-8 1 0.583, 0.688 0.636, 0.545 0.455, 0.500 0.048, 0.050
DLKP/VP-3 1 0.737, 0.750 0.520, 0.625 0.555, 0.500 0.039, 0.050
DLKP 0.000*, 0.000* 0.625, 0.647 0.555, 0.555 0.120, 0.091
DLKPA 0.647, 0.688 0.667 , 0.533 0.500, 0.211 0.100, 0.100
DLKPA2B 0.500, 0.500 0.400, 0.368 0.571, 0.555 0.130, 0.050
DLKPA6B 0.333, 0.100 0.364, 0.458 0.500, 0.600 0.053, 0.063
DLKPA11B 0.500, 0.500 0.263, 0.478 0.444, 0.429 0.091, 0.0*
DLKPA5F 0.563, 0.579 0.316, 0.389 0.500, 0.500 0.091, 0.053
Table 3 .8 .1  : Densitometrical analysis o f mRNA levels o f m drl, topoisomerase II, topoisomerase 
II-a and topoisomerase II-i5, as determined by RT-PCR. The densitometer readings were normalised 
to the level o f the iJ-actin transcript present in  each cell line, which was co-amplified with the 
transcript o f  interest, by PCR.
’ The transcript o f  interest was not detectable by densitometrical analysis in this case, but a band 
corresponding to fl-actin was observed.
3.8.5 Conclusions
The mRNA levels of genes associated with MDR were altered in all drug 
resistant cell lines examined, as determined by RT-PCR analysis. All the resistant cell lines 
over-expressed mdrl mRNA, by comparison with the drug-sensitive parental cells. 
However, any alterations in the mRNA levels of topoisomerase II, or its a  and fl isoforms, 
in DLKP-A, DLKP/VP-3 and DLKP/VP-8 was not significant. A small reduction in the 
topoisomerase II mRNA levels in the four clones of DLKP-A, was observed.
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Figure 3.8 : Gel electrophoresis of the products of RT-PCR analysis of the mRNA levels of mdrl (a), topoisomerase II (b), 
topoisomerase II-a (c) and topoisomerase II-J3 (d) in DLKP variants. The left-hand lane contains the DNA molecular weight 
marker,which contains 22 fragments with the following number of base pairs; 587, 540, 504, 458, 434, 267,234, 213,192, 
184, 124, 123, 104, 89, 80, 64, 57, 51, 21, 18, 11 and 8. The right hand, last two lanes contain water controls, where 
cDNA was not added to the PCR reaction, but was replaced by an equal volume of -ultra-pure water. This acted as the 
negative control for the PCR reaction. The central lanes contain the products of the RT-PCR analysis on the cell lines of 
interest, in duplicate. Two bands were produced in these cases, the upper band by the Ji -actin primers and the lower band 
by the primers to either mdrl (a), topoisomerase II (b), topoisomerase II-a (c) or topoisomerase II-B (d). The B-actin band 
acted as an internal positive control and as a means to normalise the intensity of the bands of interest.
* RT-PCR analysis on these cell lines was originally performed by Ms. Lorraine O’Driscoll, M.Sc. and was repeated here 
to enable comparisons between their mRNA levels and those of other DLKP variants.
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3.9 Protein analysis
Alterations in the expression of proteins associated with MDR was 
investigated by Western blot analysis. Over-expression of P-glycoprotein and alterations 
in the levels of topoisomerase II a  and 15 subunits were examined in the VP-16-selected 
MDR cells and the clones isolated from DLKP-A. Comparisons were made with the levels 
observed in the DLKP and DLKP-A cell lines.
3.9.1 Western blot analysis of topoisomerase II levels.
3.9.1.1 Topoisomerase II levels in total cell extract.
Topoisomerase II levels, as determined by Western blot analysis of total cell 
extract, with a polyclonal antibody to topoisomerase II (Fernandes e t  a l . , 1990) showed that 
all cell lines possessed immunologically reactive topoisomerase II (Figure 3.9.1.1.1). The 
antibody detected a 170 kDa. (topoisomerase Il-or) and 180 kDa. (topoisomerase II-B) 
isoform of the enzyme, in all cell extracts. Western blot analysis with pre-immune rabbit 
serum revealed no detectable immunologically reactive compounds (Figure 3.9.1.1.1). The 
band intensity in all cases was analyzed by densitometrical means and the results detailed 
in Table 3.9.1.1. Topoisomerase II levels were determined in two separate cell extractions 
and the results were found to correlate.
Topoisomerase II levels varied for each cell line studied. DLKP, the 
parental cell line, possessed the highest levels of immunologically detectable topoisomerase 
II while a stronger band was noted for the 180 kDa. form than the 170 kDa. form. 
Topoisomerase II levels were reduced in DLKP-A, in comparison with DLKP and again the 
180 kDa. band appeared to be the stronger of the two bands detected. Detectable levels of 
topoisomerase II in the VP-16-selected cell lines varied. The level of topoisomerase II in 
DLKP/VP-3 was increased slightly over that observed in DLKP. This increase was 
reflected by an increase in band intensity of both the 170 kDa. and 180 kDa. form, with the 
180 kDa. band staining strongest. The overall topoisomerase II level in DLKP/VP-8 was 
reduced by comparison with DLKP and the band corresponding to the 180 kDa. form was 
the stronger of the two bands. The relative intensity of the 180 kDa. to the 170 kDa. bands 
for each cell line described above, remained constant.
Topoisomerase II levels in total cell extracts from four clones of DLKP-A
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were examined. Both the 170 kDa. and 180 kDa. form were detected with the polyclonal 
antibody. DLKPA2B, the most adriamycin-sensitive clone, had a topoisomerase n  level 
similar to the drug sensitive parental cells, DLKP, and the relative intensity of the 170 kDa. 
to 180 kDa. band was constant, in comparison with the levels observed in DLKP. 
DLKPA6B, which was 95-fold resistant to adriamycin relative to DLKP, had decreased 
levels of detectable topoisomerase II, when compared to DLKP and possessed approximately
1.5 times the level detected in DLKP-A. The relative level of the two isoforms was altered 
in this cell extract, by comparison with the levels detected in DLKP. The detected 170 
kDa. band was more intense than the 180 kDa. band. DLKPA11B, which was 85-fold 
resistant to adriamycin, also possessed more immunologically detectable topoisomerase II 
than DLKP and in this case the intensity of both enzyme isoforms were equal. DLKPA5F, 
the most resistant clone, had an overall topoisomerase II level similar to DLKP and to the 
most drug sensitive clone, DLKPA2B. In contrast to both these cell lines, total cell extract 
from DLKPA5F contained equal levels of detectable 170 kDa. and 180 kDa. forms of the 
protein.
The levels of the a  and fi subunits of topoisomerase II were individually 
examined by Western blot analysis of the total cell extract with monoclonal antibodies which 
individually identify the a  and fi subunits (Figure 3.9.1.1.2). The topoisomerase II-a 
isoform detected was a 170 kDa. protein. The topoisomerase Il-ft form banded at 150 kDa. 
and 180 kDa. The 150 kDa. product has been characterised as a possible breakdown 
product of the 180 kDa. topoisomerase Il-fl subunit (Negri e t  a l . ,  1992).
All cell lines tested contained detectable levels of both a  and B 
topoisomerase II subunits (Figure 3.9.1.1.2). DLKP had the highest levels of topoisomerase 
Il-ct detected in total cell extract. The VP-16-selected MDR cells exhibited reduced levels 
of the a  subunit. DLKP/VP-3 showed only a slight reduction in the level of the protein, 
while the level of the immunoreactive protein was decreased 3-fold in DLKP/VP-8. DLKP- 
A possessed a similar level of topoisomerase II-a to that observed in DLKP/VP-8. All 
DLKP-A clones had reduced levels of detected topoisomerase II-a, by comparison with 
DLKP, but had slightly higher levels than those noted in DLKP-A. Of the four clones, the 
levels of topoisomerase II-a were greatest in DLKPA11B, DLKPA2B had slightly lower 
amounts and DLKPA5F and DLKPA6B had the lowest, but relatively equal amounts of 
topoisomerase II-a.
DLKP and its MDR variants DLKP-A, DLKP/VP-3 and DLKP/VP-8 all 
possessed a form of topoisomerase II-B that banded at 150 kDa., with very low levels of the 
180 kDa. form observed. DLKP again possessed highest levels of the immunologically 
reactive enzyme. By comparison with DLKP, DLKP-A and DLKP/VP-3 had equal and
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slightly lower levels of the enzyme, with DLKP/VP-8 having lowest levels of the protein. 
The relative difference in topoisomerase 11-15 levels between the cell lines was small in 
comparison with the relative differences observed for topoisomerase II or its a  subunit.
Western blotting analysis on DLKP-A clones resulted in the detection of 
only a 150 kDa. form of topoisomerase II-J3. DLKPA5F and DLKPA1 IB had protein levels 
similar to that noted in DLKP. DLKPA2B and DLKPA6B had equal but greatly reduced 
levels, when compared to the amount detected in DLKP.
3.9.1.2 Topoisomerase II levels in nuclear extract.
Topoisomerase II levels in cell nuclear extracts from variants of the DLKP 
cell line were examined with duplicate nuclear extractions from each cell line. The level 
of the enzyme detected differed for each variant. The polyclonal antibody to topoisomerase 
II detected a nuclear protein of 170-180 kDa. (Figure 3.9.1.2.1), with highest levels of the 
immunologically reactive protein present in DLKP. The VP-16-selected MDR cell lines 
exhibited decreased levels of the protein, with the level of protein inversely proportional to 
their level of selection to VP-16. The level of detectable protein was greatly decreased in 
nuclear extracts from DLKP-A, which had less immuno-detectable protein than DLKP/VP- 
8, though both cell lines exhibited similar resistance profiles. Examination of topoisomerase 
II levels in nuclear extracts from DLKP-A clones revealed that both DLKPA5F and 
DLKPA2B, the most and least adriamycin-resistant clones respectively, had approximately 
equal levels of the protein, which was comparable with the level noted in DLKP-A. 
DLKPA11B and DLKPA6B had comparable levels of topoisomerase II and an 
approximately 3-fold increase in their enzyme levels, when compared with DLKP-A.
Analysis of topoisomerase H-a levels in nuclear extracts from the cell lines, 
revealed the presence of an immunoreactive protein that banded at 170 kDa. (Figure
3.9.1.2.2). VP-16-selected MDR cells had decreased levels of the a  subunit in comparison 
with DLKP, with the greatest decrease noted in the cell line with highest resistance. 
Topoisomerase II-a levels were also decreased in DLKP-A. The protein level in clones of 
DLKP-A was substantially higher than that observed in DLKP-A, but remained less than 
that noted in DLKP. DLKPA5F had topoisomerase II-a levels slightly lower than that 
observed in DLKP, while the topoisomerase II-a levels in DLKPA6B cells were marginally 
less than that noted in DLKPA5F. DLKPA1 IB and DLKPA2B had approximately a 4-fold 
and 8-fold decrease, respectively, in the level of their a  subunit when compared to DLKP.
Analysis of immunologically detectable topoisomerase II-J5 levels in cell
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nuclear extracts revealed the presence of only the 180 kDa. form of the topoisomerase Il-fl 
enzyme in all cell lines (Figure 3.9.1.2.2). No 150 kDa. form of the enzyme, which was 
observed when the total cell lysate was examined, was detected. The level of the protein 
was approximately equal in all nuclear extracts, with only slight decreases observed in 
DLKP and DLKPA2B.
CELL LINE/ 
CLONE
Topo n Topo Ha Topo I IB Topo n Topo Ha Topo H6
Total cell lysate Nuclear extract
DLKP/VP-8 0.61 0.18 0.08 1.22 0.31 1.93
DLKP/VP-3 1.27 0.51 0.11 2.09 0.49 2.35
DLKP 1.14 0.54 0.17 3.47 0.93 1.44
DLKPA 0.44 0.19 0.11 0.72 0.05 1.68
DLKPA2B 1.12 0.27 0.02 0.80 0.11 1.44
DLKPA6B 0.67 0.20 0.02 2.40 0.60 2.10
DLKPA11B 1.41 0.33 0.15 2.24 0.22 2.65
DLKPA5F 1.14 0.21 0.16 0.96 0.84 2.17
Table 3 .9 .1 .1  : Densitometrical analysis of topoisomerase II detection by Western blotting.
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Figure 3.9.1.1.1 : Western blot detection o f topoisomerase II protein in  total cell 
extracts, isolated from DLKP variants. The protein was detected using a polyclonal 
antibody directed against topoisomerase II (a), with the pre-immune serum acting as 
the negative control (b). In all cases, 45/ig o f  protein was loaded per lane. The left 
and right lanes contained molecular weight markers.
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topoisomerase II-E (b) in  total cell extract from DLKP variants. The proteins were 
detected by monoclonal antibodies directed against the specific forms o f  the enzyme. 
A  total of 45/xg of protein was loaded per lane. The left and right lanes contained 
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3.9.2 Western blot analysis of p-glycoprotein levels.
P-glycoprotein, as determined by Western blot analysis on membrane 
preparations, was over-expressed in all MDR cell lines (Figure 3.9.2.1). The analysis was 
performed in duplicate from a single cell preparation, and the results obtained were correlated. 
10/ig of protein was separated by gel electrophoresis and checked for cross-reactivity with the 
anti-P-glycoprotein antibody, C219, a 170 kDa. protein was seen to be elevated in the VP-16- 
selected MDR cells. DLKP/VP-3, the less resistant variant, expressed higher levels of the 
protein than the more resistant DLKP/VP-8 cell line, as was confirmed by densitometrical 
analysis (Table 3.9.2.1). All clones of DLKP-A over-expressed P-glycoprotein to greater levels 
than DLKP-A, which has been previously characterised (Clynes e t  a l . , 1992). When the clones 
were compared, it was noted that the most resistant clone, DLKPA5F, expressed the lowest 
levels of immunodetectable P-glycoprotein while the remaining clones expressed approximately 
equal levels of the protein. However, the variation in P-glycoprotein expression between the 
clones was slight.
CELL LINE/ 
CLONE
P-Glycoprotein
DLKP/VP-8 3.97
DLKP/VP-3 4.17
DLKP 0.00
DLKPA 0.03
DLKPA2B 0.68
DLKPA6B 0.75
DLKPA11B 0.76
DLKPA5F 0.59
Table 3 .9 .2 .1 . : Densitometrical analysis o f P-glycoprotein levels detected by Western blotting.
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Figure 3.9 .2 .1  : Western blot detection o f cell membrane preparations from DLKP 
variants with the monoclonal antibody, C219, directed against p-glycoprotein (a). 
The negative control is shown in figure b, where the primary antibody, C219, was 
replaced by an equal volume o f antibody diluent, with the remainder o f the blotting 
procedure carried out as for the positive blot. In all cases lOjtg o f protein was 
loaded per lane. The left and right lanes contained molecular weight markers.
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3.9.3 Conclusions
Protein analysis of the levels of topoisomerase II, its a  and B subunits and 
P-glycoprotein present in the cell lines studied in this research work revealed that they were 
altered in the MDR cell lines by comparison with the parental cell line, DLKP. P- 
glycoprotein was over-expressed in all the drug-resistant cells and to highest levels in the 
VP-16-selected variants of DLKP. In general, the levels of topoisomerase II and its a  
subunit were reduced in the drug-resistant cells, by comparison with DLKP cells. However 
enzyme levels varied in the cell lines, depending on whether the levels of enzyme present 
in the isolated nucleus or total cell extract were determined. The levels of topoisomerase 
II-B did not vary as significantly, between drug resistant and sensitive cell lines. The anti- 
topoisomerase II-B monoclonal antibody detected two homologous proteins, with respect 
to their immunological reactivity, a 180 kDa. protein and a smaller 150 kDa. protein.
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The level of adriamycin accumulated by VP-16-selected MDR cells was 
measured and compared to that accumulated by the drug-sensitive parental cell line. The 
effect of a calcium channel antagonist, verapamil and an immunosuppressive agent, 
cyclosporin A, on the level of adriamycin accumulation by the cells, was examined.
Adriamycin accumulation was reduced in the MDR cells selected by 
exposure to increasing concentrations of VP-16, in comparison to the level of drug 
accumulated by the parental cell line (Figure 3.10.1(a), 3.10.3(a)). DLKP accumulated 
approximately 1 nanomole of adriamycin per 106 cells within 4 hours. DLKP/VP-3 
accumulated 100 - 200 picomoles of adriamycin per 106 cells in the same time period. 
DLKP/VP-8 accumulated slightly more adriamycin than DLKP/VP-3, within the 4 hours. 
These levels were the maximum accumulated by each cell Une under the experimental 
conditions.
When the level of adriamycin accumulated by DLKP in the presence of 
cyclosporin A (10/xg/ml and 30/xg/ml) was studied, only slight changes in either the 
accumulation rate or the maximum level of adriamycin accumulated by the cells was 
observed (Figure 3.10.1(b)). The addition of cyclosporin A altered both the accumulation 
rate and the final level of adriamycin accumulated by DLKP/VP-3 and DLKP/VP-8 (Figure
3.10.2). In the presence of both 10/xg/ml and 30/xg/ml cyclosporin A, the level of 
adriamycin uptake by both cell lines reverted to that observed in the DLKP cell Une under 
similar experimental conditions.
Verapamil also enhanced the accumulation of adriamycin by the drug 
resistant cells (Figure 3.10.4). Verapamil, at 10/xg/ml and 30/xg/ml, altered neither the 
accumulation rate of adriamycin by DLKP nor the maximum level accumulated (Figure
3.10.3). However, the presence of verapamil at both concentrations, resulted in an increase 
in adriamycin accumulation in DLKP/VP-3 cells, to levels comparable with the parental cell 
line (Figure 3.10.4(a)). With respect to DLKP/VP-8, exposing the cells to verapamil at 
10/tg/ml, resulted in intercellular adriamycin levels comparable with DLKP. However, 
when the ceUs were exposed to 30/xg/ml verapamü, the adriamycin was accumulated to a 
level greater than that observed in the parental ceü Une (approximately 1.4 nanomoles of 
adriamycin accumulated in DLKP/VP-8, in comparison to 1.2 nanomoles in DLKP, under 
simUar conditions) (Figure 3.10.4(b)).
3.10 Adriamycin accumulation by VP-16-selected MDR cell lines
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Figure 3 .10.1 : Adriamycin accumulation in DLKP, DLKP/VP-3 and 
DLKP/VP-8 over a 4h. time period (a) and the effect of cyclosporin A, 
at 10/*g/ml and 30/tg/ml, on adriamycin accumulation by DLKP over the 
same time period (b).
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Figure 3.10.2 : The effect o f cyclosporin A, at 10/xg/ml and 30/ig/ml, on 
adrianiycin accumulation by DLKP/VP-3 (a) and DLKP/VP-8 (b) over a 
4h. time period.
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Figure 3.10.3 : Adriamycin accumulation in  DLKP, DLKP/VP-3 and 
DLKP/VP-8 over a 4h. time period (a) and the effect o f  verapamil, at 
10^g/ml and 30/xg/ml, on adriamycin accumulation by DLKP over the 
same time period (b).
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Figure 3.10.4 : The effect of verapamil, at 10/ig/ml and 30/xg/ml, on 
adiiamycin accumulation by DLKP/VP-3 (a) and DLKP/VP-8 (b) over a 
4h. time period.
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3.11 Circumvention of DLKP variants
The ability of the calcium channel antagonist, verapamil and the 
immunosuppressive agent cyclosporin A, to overcome drug-resistance, either partially or 
completely, when used in combination with chemotherapeutic drugs, was investigated in 
relation to variants of the cell line DLKP. The toxic effects of both cyclosporin A and 
verapamil to the cell lines, at the concentrations used in these assays, are summarised in 
Table 3.11.1. Summary tables are also given of the ability of the circumventing agents to 
enhance the toxicity of adriamycin (Table 3.11.6.2), vincristine (Table 3.11.6.3) and VP-16 
(Table 3.11.6.4).
3.11.1 Toxicity of the circumventing agents to variants of DLKP
The circumventing agents, cyclosporin A and verapamil, proved to be least 
toxic to DLKP in comparison to its MDR variants. When DLKP was exposed to up to 
3.0/ig/ml verapamil, under the assay conditions outlined in Section 2.12.5, it proved non­
toxic to DLKP cells (102.69 ± 3.23% survival). Cyclosporin A, at concentrations of up 
to a maximum of 2.0/xg/ml, also exhibited little toxicity on DLKP (92.61 ± 8.01% 
survival). However, both circumventing agents proved to be toxic to all the MDR variants 
of DLKP. This was most notable in the case of the VP-16-selected MDR cells, DLKP/VP- 
3 and DLKP/VP-8. When the cells were incubated with 3.0/xg/ml verapamil, under assay 
conditions, only 48.11 ± 7.98% and 30.20 ± 7.48% cell growth was noted, respectively.
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CELL LINES Cyclosporin A Verapamil
0.2/tg/ml 1.0/xg/ml 2.0/xg/ml 0.2/ig/m l 1.0/tg/ml 3.0/tg/m l
DLKP 95.23 93.38 92.61 101.34 101.23 102.69
(4.42) (8.05) (8.01) (3.66) (5.71) (3.23)
DLKP/VP-3 95.34 91.58 84.02 102.71 67.64 48.11
(6.82) (9.03) (15.14) (15.24) (7.27) (7.98)
DLKP/VP-8 96.96 92.84 90.71 93.75 51.71 30.20
(16.03) (14.74) (10.32) (7.47) (10.41) (7.48)
DLKP-A 103.18 98.45 70.15 92.58 73.37 50.34
(7.27) (8.95) (13.81) (13.31) (16.35) (19.11)
DLKPA5F 97.14 85.75 68.60 97.98 81.41 65.98
(5.85) (13.12) (5.02) (15.36) (20.15) (19.44)
DLKPA11B 88.23 76.37 77.83 99.94 97.87 88.56
(6.50) (8.45) (12.60) (5.99) (8.46) (3.45)
DLKPA6B 93.63 81.82 61.40 99.20 91.89 86.30
(3.73) (5.04) (9.23) (11.38) (11.13) (11.24)
DLKPA2B 93.93 83.88 66.41 1 89.22 79.36 63.90
(3.34) (7.95) (8.02) (10.16) (12.96) (16.09)
Table 3 .1 1 .1 :  The toxicity o f cyclosporin A and verapamil, at varying concentrations, to the DLKP 
variants. The data presented in  this table is a summary of the data in  Tables 3.11.1.1 - 3 .11.4.20. 
The percentage growth in  the absence o f cyclosporin A  and verapamil is taken as 100% survival. 
Growth in  the presence of varying concentrations o f the circumvention agents is presented as the 
percentage growth relative to that observed in the 100% controls. The values in  brackets are the 
standard deviations on the percentage survival values.
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3.11.2 Circumvention of DLKP
Cyclosporin A was relatively non-toxic to the cell line DLKP, with greater than 
90% growth observed, at a concentration of up to 2 .0/xg/ml (Table 3.11.2.1). A t all 
concentrations up to 2 .0/xg/ml, cyclosporin A enhanced the toxicity of adriamycin, vincristine 
and VP-16. Although 45.06 ±  3.34% cell growth occurred in the presence of 0.02/xg/ml 
adriamycin, only 27.52 ±  7.21% growth occurred when 0.2/xg/ml cyclosporin A  was also 
present. Growth was further reduced, to 13.03 ±  1.41%, when the concentration of the 
circumventing agent was increased to 2 .0/xg/ml. Cyclosporin A  was a more potent enhancer 
of vincristine toxicity than adriamycin toxicity. The presence of 0.001 /xg/ml vincristine resulted 
in 98.44 ±  5.66% cell growth with respect to the drug-free control, but with the combined 
presence of 0.001/xg/ml vincristine and 2 .0/xg/ml cyclosporin A (which was non-toxic and 
resulted in 99.77 ±  3.79% cell growth) only 3.63 ±  0.47% cell survival was observed. The 
toxicity of VP-16 to DLKP was also enhanced by cyclosporin A. Cell growth in 0.075/xg/ml 
VP-16 resulted in 91.69 ±  2.91% cell survival, while its combination with 2 .0/xg/ml 
cyclosporin A  resulted in only 50.04 ±  3.43% cell survival (cell survival in  2 .0/xg/ml 
cyclosporin A alone was 97.09%).
Verapamil was also an effective circumventing agent, when used in combination 
with adriamycin, vincristine or V P-16 to enhance their toxicity to the DLKP cell line (Table
3.11.2.2), but overall it appeared to be less potent than cyclosporin A. Verapamil was non­
toxic to DLKP up to a concentration of 3.0/xg/ml (108.14 +  4.03% growth). The presence of 
3 .0/xg/ml verapamil in combination with 0.02/xg/ml adriamycin enhanced its toxicity, decreasing 
the percentage survival from 41.98 ±  7.12% to 24.94 ±  2.49% . As was observed with 
cyclosporin A, the combination of the circumventing agent, verapamil, with vincristine, 
appeared to be the most potent combination for DLKP toxicity. The addition of 3 .0/xg/ml 
verapamil decreased the percentage survival from 94.12 ±  5.72% cell survival in the presence 
of 0.001/xg/ml vincristine alone to only 51.18 ±  4.97% in the presence of the combination. 
The toxicity of V P-16 to DLKP was less notably amplified by the addition of verapamil. The 
addition of 3 .0/xg/ml verapamil reduced the survival in the presence of drug from 98.61 ±  
3.02% in the presence of 0.075/xg/ml VP-16 alone to 90.62 ±  4.73% survival for the 
combination.
Il l
% Survival Cyclosporin A
0 /jg/ml 0.2 /j.g/ml 1.0 /jg/ml 1.5 /jg/ml 2.0 /jg/ml
Adriamycin
0.0 /jg/ml 100 97.41 97.56 98.22 97.45
(4.83) (5.80) (3.52) (10.09) (5.26)
0.01 /ig/ml 97.76 96.56 94.28 91.65 85.81
(3.90) (5.88) (4.10) (6.61) (4.72)
0.0 /¿g/ml 100 95.30 87.35 87.65 87.94
(7.60) (6.15) (3.00) (6.44) (3.92)
0.02 /tg/ml 45.06 27.52 14.53 6.93 13.03
(3.34) (7.21) (1.41) (1.84) (1.41)
Vincristine
0.0 /tg/ml 100 99.45 99.41 98.32 99.77
(5.86) (4.84) (7.54) (5.98) (3.79)
0.001 /jg/ml 98.44 86.52 21.52 6.68 3.63
(5.66) (7.03) (2.89) (1.33) (0.47)
0.0 fig/nil 100 87.83 82.33 83.33 80.78
(7.41) (4.85) (4.00) (5.26) (12.96)
0.002 fig/ml 12.01 5.76 1.65 1.50 1.45
(1.40) (0.95) (0.35) (0.30) (0.30)
VP-16
0.0 jug/ml 100 96.14 100.24 97.40 97.09
(2.44) (3.39) (4.96) (3.39) (4.76)
0.075 fig/mi 91.69 86.10 65.35 58.43 50.04
(2.91) (4.69) (5.39) (3.66) (3.43)
Table 3.11.2.1 : Effect of cyclosporin A on adriamycin, vincristine and VP-16 toxicity to DLKP. 
Survival was calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicas. The values in brackets are the standard deviations on the data.
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% Survival Verapamil
0 /tg/ml 0.2 /tg/ml 1.0 /ig/ml 2.0 /ig/ml 3.0 /tg/ml
Adriamycin
0.0 /ig/ml 100 106.48 108.56 111.48 108.14
(11.33) (4.92) (6.14) (9.87) (4.03)
0.01 /tg/ml 101.19 100.34 103.18 109.87 106.82
(8.09) (7.25) (6.36) (14.70) (7.37)
0.0 /ig/ml 100 96.65 99.14 103.90 102.67
(3.46) (7.30) (3.04) (3.81) (2.72)
0.02 /ig/ml 41.98 37.40 35.54 29.42 24.94
(7.12) (6.66) (2.86) (3.40) (2.49)
Vincristine
0.0 /ig/ml 100 99.41 101.82 100.28 102.05
(2.51) (4.10) (5.84) (4.10) (4.14)
0.001 /ig/ml 94.12 94.79 81.53 68.03 51.18
(5.72) (5.72) (6.47) (5.29) (4.97)
0.0 ftg/ml 100 101.71 93.08 100.69 100.60
(4.59) (6.55) (4.66) (6.69) (6.41)
0.002 /ig/ml 14.90 11.99 5.86 4.01 3.27
(1.38) (1.48) (0.92) (0.46) (0.42)
VP-16
0.0 /ig/ml 100 102.43 103.54 102.54 100.00
(3.54) (3.82) (6.28) (4.06) (3.38)
0.075 /ig/ml 98.61 98.81 96.26 94.87 90.62
(3.02) (3.54) (3.42) (3.94) (4.73)
Table 3.11.2.2 : Effect of verapamil on adriamycm, vincristine and VP-16 toxicity to DLKP. Survival 
was calculated as percentage growth relative to that measured in a drug-free control and is the mean of 
eight replicas. The values in brackets are the standard deviations on the data.
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3.11.3 Circumvention of drug resistance in VP-16-selected cell lines
Cyclosporin A and verapamil enhanced the toxicity of chemotherapeutic drugs 
to the VP-16- selected cell lines, DLKP/VP-3 and DLKP/VP-8 (Tables 3.11.3.1 - 3 .11.3.4 and 
summarised in Tables 3.11.6.1 - 3.11.6.4). Cyclosporin A  was relatively non-toxic to 
DLKP/VP-3 and DLKP/VP-8, up to a concentration of 2.0/xg/ml (Tables 3.11.3.1 and 3.11.3.2, 
respectively), but verapamil was toxic at a concentration of 2.0/ig/ml to DLKP/VP-3 (Tables
3.11.3.3 and 3.11.1) and 1.0/tg/ml to DLKP/VP-8 (Tables 3 .11.3.4 and 3.11.1).
In relation to DLKP/VP-3, cyclosporin A  enhanced the toxicity of adriamycin, 
vincristine and VP-16 (Table 3.11.3.1). The presence of 1,5/xg/ml adriamycin resulted in 81.01 
±  19.09% cell survival relative to a drug-free control. However, cell survival was decreased 
to 10.44 +  3.06% in the presence of 2.0/xg/ml cyclosporin A. Likewise, the addition of 
cyclosporin A  decreased the percentage cell survival in the presence of 1.2/xg/ml vincristine 
from 75.91 ±  7.51% to 21.10 ±  2.43% . Cyclosporin A  also enhanced the toxicity of VP-16. 
The presence of 2.0/xg/ml cyclosporin A  decreased the percentage cell survival from  51.60 ±  
6.64% in  the presence of 5.0/xg/ml VP-16 alone, to 8.05 +  2.30% in the presence of the 
combination. A  similar effect was noted for DLKP/VP-8 in relation to the ability of 
cyclosporin A  to enhance the toxicity of cytotoxic drugs (Table 3.11.3.2). The presence of 
2.0/xg/ml cyclosporin A reduced the percentage cell survival from 74.49 +  12.93% to 12.88 
±  2.30% in the presence of 4.0/^g/ml adriamycin, from 48.54 ±  8.44% to 9.27 ±  1.67% in 
the presence of 2.0^g/m l vincristine and from 69.09 ±  3.04% to 26.36 ±  4.55%  in the 
presence of 8.0/xg/ml VP-16. For both DLKP/VP-3 and DLKP/VP-8, cyclosporin A  appeared 
equally effective at enhancing the toxicity of all three chemotherapeutic drugs.
Although verapamil was relative toxic to both DLKP/VP-3 and DLKP/VP-8, 
it still remained a potent enhancer of the toxicity of adriamycin and vincristine for both cell 
lines (Table 3.11.3.3 and 3.11.3.4 respectively). A t a concentration of 3.0/ig/ml, verapamil 
enhanced the toxicity of 2.0/xg/ml adriamycin in DLKP/VP-3 cells. This can be seen from  the 
decrease in  cell survival from 71.16 ±  6.93% in the absence of the circumventing agent to 
12.09 ±  1.45% in its presence, while the toxicity due to verapamil alone was 54.97 ±  5.60% 
(Table 3.11.3.3). The same concentration of verapamil also increased the toxicity of vincristine 
when used in combination. Cell survival dropped from 61.16 +  5.43% in the presence of 
2.0/xg/ml vincristine alone to 11.97 ±  1.58% in the presence of the combination of verapamil 
and vincristine. In respect to DLKP/VP-8, 3.0/xg/ml verapamil enhanced the toxicity of 
4.0/ig/ml adriamycin. The percentage cell survival dropped from 82.74 ±  13.31% for 
adriamycin alone to 6.83 ±  0.53% for the combination, while the percentage cell survival with 
respect to verapamil alone accounting for 27.46 ±  4.30% survival (Table 3.11.3.4). The
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toxicity of vincristine was also intensified by verapamil, with 45.80 ±  7.07%  cell survival 
observed in the presence of 2.0/xg/ml vincristine, while this was decreased to 5 .22 ±  1.45% 
by the addition of 3.0/xg/ml verapamil.
W hen verapamil was added to VP-16-selected cells in the presence of VP-16, 
the combination partially masked their individual toxic effects (Tables 3.11.3.3 and 3.11.3.4). 
Following the addition of verapamil to cells in the presence of VP-16, an increase in the 
percentage cell kill was obtained with regard to that observed for either verapamil or V P-16 
alone. However, the percentage cell kill did not represent the product of the individual cell kill 
for both compounds. The addition of 3.0/xg/ml verapamil to DLKP/VP-3 cells in the presence 
of 5.0/xg/ml VP-16 decreased the percentage cell survival from 50.65 ±  5.44% to only 32.51 
±  3.91% (Table 3.11.3.3), while the percentage cell survival in the presence of 3.0/xg/ml 
verapamil alone was 47.81 ±  11.83%. Likewise, the addition of 3.0/xg/ml verapamil to 
DLKP/VP-8 cells in the presence of 12.0/xg/ml VP-16 decreased the percentage cell survival 
from 37.05 ±  2.88% to 21.57 +  5.09% , but cell survival in the presence o f 3.0/xg/ml 
verapamil alone was only 26.83 ±  4.13% (Table 3.11.3.4). W hen cell kill by VP-16 and 
verapamil in  combination was examined by the Chou and Talalay (1984) method of analysis, 
an antagonistic effect was observed.
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% Survival Cyclosporin A
0 jug/ml 0.2 /ig/ml 1.0 fig/ml 1.5 fig/ml 2.0 fig/mi
Adriamycin
0.0 ¿ig/ml 100 102.11 96.10 97.57 98.95
(13.17) (13.71) (15.93) (15.08) (12.87)
1.5 /jg/ml 81.01 77.95 49.58 25.00 10.44
(19.09) (17.30) (15.72) (5.80) (3.06)
0.0 /ig/ml 100 99.89 97.70 98.98 97.43
(6.35) (4.50) (7.45) (8.57) (8.52)
2.0 ftg/ml 71.40 68.77 38.30 18.00 10.93
(9.59) (6.37) (5.62) (4.28) (0.91)
Vincristine
0.0 fig/ml 100 98.23 98.67 93.48 87.40
(17.08) (9.06) (9.94) (11.27) (12.49)
1.2 itg/ml 75.91 68.95 45.52 32.37 21.10
(7.51) (6.52) (5.75) (4.09) (2.43)
0.0 fig/ml 100 90.52 77.20 73.87 67.89
(15.70) (6.61) (17.86) (10.68) (13.10)
2.0 ftg/ml 53.59 48.13 28.14 15.28 11.89
(4.19) (4.83) (1.55) (3.39) (2.76)
VP-16
0.0 ¿ig/ml 100 85.95 88.25 69.60 68.45
(22.62) (15.45) (16.48) (9.45) (7.54)
5.0 jug/ml 51.60 48.15 24.39 9.83 8.05
(6.64) (4.73) (4.47) (2.04) (2.30)
Table 3.11.3.1 : Effect of cyclosporin A on adriamycin, vincristine and VP-16 toxicity to DLKP/VP-3. 
Survival was calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicas. The values in brackets are the standard deviations on the data.
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% Survival Cyclosporin A
0 /ig/ml 0.2 /ig/ml 1.0 /ig/ml 1.5 /ig/ml 2.0 ng/ml
Adriamycin
0.0 /ig/ml 100 98.75 94.26 92.21 89.42
(7.17) (9.44) (7.24) (10.58) (7.24)
4.0 jig/ml 74.49 69.95 47.53 26.41 12.88
(12.93) (9.79) (7.99) (5.79) (2.30)
0.0 fig/m] 100 70.02 66.48 64.71 76.26
(10.01) (7.91) (6.89) (7.45) (16.20)
5.0 /ig/ml 44.60 35.10 22.53 15.46 13.59
(6.70) (4.56) (3.63) (1.86) (2.05)
Vincristine
0.0 fig/ml 100 106.40 104.36 108.81 105.42
(6.85) (6.54) (5.84) (7.74) (9.64)
2.0 p.g/ml 48.54 48.03 24.11 14.09 9.27
(8.44) (7.97) (5.38) (3.01) (1.67)
0.0 jug/ral 100 91.28 85.93 93.74 91.19
1 (4.37) (5.76) (8.72) (4.94) (5.68)
1.5 /ig/ml 42.47 40.33 27.41 21.65 16.38
(3.62) (3.70) (2.80) (2.39) (0.91)
VP-16
0.0 /tg/ml 100 97.51 101.91 101.66 98.24
(7.10) (8.89) (8.65) (13.83) (4.84)
12.0 jig/ml i 29.16 26.58 15.93 10.31 7.23
(3.91) (3.13) (2.69) (1.86) (1.17)
0.0 /ig/ml 100 117.79 104.12 97.51 83.73
(4.16) (8.03) (4.66) (5.53) (6.51)
8.0 /¿g/ml 69.09 69.67 50.65 36.77 26.36
(3.04) (3.90) (6.07) (2.49) (4.55)
Table 3.11.3.2 : Effect of cyclosporin A on adriamycin, vincristine and VP-16 toxicity to DLKP/VP-8. 
Survival was calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicas. The values in brackets are the standard deviations on the data.
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%  S u rv iv a l V e ra p a m il
0 /ig/ml 0.2 ¿ig/ml 1.0 ¿ig/ml 2.0 /ig/ml 3.0 /tg/ml
Adriamycin
0.0 /ig/ml 100 89.86 54.66 44.52 36.52
(23.86) (10.80) (9.07) (9.40) (7.67)
1.5 fig/ml 80.79 73.87 36.93 18.96 12.45
(19.21) (11.95) (6.84) (3.71) (2.56)
0.0 /jg/m] 100 91.12 70.03 55.92 54.97
(4.07) (7.49) (6.11) (4.97) (5.60)
2.0 ¿tg/ml 71.16 63.35 31.68 16.25 12.09
(6.93) (5.73) (3.27) (2.02) (1.45)
Vincristine
0.0 jig/ml 100 113.51 71.17 58.94 45.11
(10.74) (10.00) (10.85) (8.19) (7.77)
1.2 /ig/ml | 85.00 86.49 41.49 24.57 17.55
(12.45) (9.29) (5.64) (3.40) (2.98)
0.0 jig/ml 100 95.04 71.20 55.49 56.13
(8.08) (5.84) (6.25) (5.32) (94.56)
2.0 ng/ml 61.16 53.27 31.72 17.06 11.97
(5.43) (5.55) (3.27) (2.34) (1.58)
VP-16
0.0 jig/ml 100 124.02 71.12 56.80 47.81
(11.38) (15.27) (10.53) (10.06) (11.83)
5.0 /tg/ml 50.65 48.88 42.49 35.38 32.51
(5.44) (3.91) (6.75) (6.27) (3.91)
Table 3.11.3.3 : Effect of verapamil on adriamycin, vincristine and VP-16 toxicity to DLKP/VP-3. 
Survival was calculated as percentage growtli relative to that measured in a drug-free control and is the 
mean of eight replicas. The values in brackets are the standard deviations on the data.
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% Survival Verapamil
0 /ig/ml 0.2 /ig/ml 1.0 /ig/ml 2.0 /tg/ml 3.0 /ig/ml
Adriamycin
0.0 /ig/ml 100 102.80 50.22 27.64 27.46
(11.22) (6.52) (6.43) (2.80) (4.30)
4.0 /ig/ml 82.74 84.03 28.17 11.80 6.83
(13.31) (18.10) (5.90) (1.15) (0.53)
0.0 ftg/ml 100 86.48 60.14 44.09 41.78
(7.73) (4.15) (4.76) (4.76) (2.61)
5.0 fig!ml 54.22 46.16 28.19 19.05 22.50
(9.83) (3.15) (3.53) (1.15) (8.53)
Vincristine
0.0 jig/ml 100 95.94 31.88 27.19 24.52
(14.60) (11.42) (8.12) (7.42) (5.10)
2.0 /ig/ml 45.80 48.17 11.65 4.00 5.22
(7.07) (11.07) (2.38) (0.52) (1.45)
0.0 /jg/ml 100 83.39 57.18 39.60 37.18
(5.88) (5.97) (1.21) (2.26) (3.06)
1.5 /ig/ml 40.73 36.45 19.92 12.50 10.00
(2.34) (2.50) (1.53) (1.05) (1.29)
VP-16
0.0 /ig/ml 100 99.33 52.44 34.71 26.83
(5.53) (5.21) (11.89) (5.92) (4.13)
12.0 /ig/ml 37.05 43.05 30.52 24.11 21.57
(2.88) (9.39) (8.30) (6.13) (5.09)
0.0 ¿ig/ml 100 94.54 57.41 39.02 23.41
(9.21) (14.05) (12.26) (12.26) (14.72)
8.0 /tg/ml 61.32 59.98 42.25 20.18 16.28
(5.91) (6.69) (7.92) (5.13) (4.46)
Table 3.11.3.4 : Effect of verapamil on adriamycin, vincristine and VP-16 toxicity to DLKP/VP-8. 
Survival was calculated as percentage growth relative to that measured in a drug-free control and is the 
mean of eight replicas. The values in brackets are the standard deviations on the data.
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3.11.4 Circumvention of drug resistance in DLKP-A
The toxicity of adriamycin, vincristine and V P-16 to DLKP-A was enhanced 
by the presence of cyclosporin A and verapamil (Tables 3.11.4.1 - 3.11.4.5 and summarised 
in Tables 3.11.6.1 - 3.11.6.4). As the concentration of circumventing agent was increased the 
synergistic effect was generally enhanced.
Cyclosporin A  was relatively non-toxic to DLKP-A at concentrations below 
1,0/xg/ml. At 2.0/xg/ml approximately 70% cell growth was noted (Table 3.11.4.1 - 3.11.4.3). 
Verapamil was more toxic to DLKP-A. In the presence of 1.0/xg/ml verapamil, approximately 
60 - 70% cell growth was obtained, while at 3.0/xg/ml only approximately 40% growth was 
noted (Table 3.11.4.3 to 3.11.4.5).
Cyclosporin A  was a potent enhancer of adriamycin toxicity towards DLKP-A. 
Adriamycin at 1.0/xg/ml, allowed 100.74 ±  12.08% growth, but when combined with 2.0/xg/ml 
cyclosporin A, only 50.56 ±  4.46% growth relative to DLKP-A, occurred (Table 3.11.4.1). 
W hen the adriamycin concentration was increased to 3.0/xg/ml, resulting in 48.36 ±  12.09% 
growth, the presence of 1.0/xg/ml cyclosporin A reduced the percentage survival to only 13.73 
±  5.43% .
Vincristine’s toxicity to DLKP-A was also enhanced by cyclosporin A. The 
combined effect of 0.5/xg/ml vincristine and 1.0/xg/ml cyclosporin A  resulted in a decrease in 
percentage cell survival, from 102.79 ±  5.43% (for vincristine alone) to 77.98 ±  4.96%. 
However, when the concentration of cyclosporin A was increased to 2.0/xg/ml, only 34.89 ±  
4.34% cell survival was noted. In the presence of 1.0/xg/ml vincristine alone, 85.94 ±  9.50% 
cell survival was observed, but when combined with 1.0/xg/ml cyclosporin A, only 41.65 ±  
10.40% cell survival was noted, although cyclosporin A did not elicit a toxic response when 
used alone (100.72 ±  11.12% cell survival). W hen the vincristine concentration was further 
increased to 3.0/xg/ml, resulting in 31.37 ± 7 .2 1 %  cell survival, only 4.33 ±  1.51% survival 
was noted when 1.0/xg/ml cyclosporin A  was also present.
Cyclosporin A  also enhanced the toxicity of VP-16 with respect to the cell line, 
DLKP-A (Table 3.11.4.3). The addition of 2.0/xg/ml cyclosporin A  to a toxicity assay in  the 
presence of 2.0/xg/ml V P-16 decreased the percentage cell survival from  69.01 ±  1.87% to 
13.45 ±  5.31% , while the percentage survival in the presence of2.0/xg/ml cyclosporinA  alone 
was 66.85 ±  20.58%
Verapamil increased the potency of V P-16, adriamycin and vincristine (Table
3.4.4.3 to 3.11.4.5). W ith respect to DLKP-A, 75.51 ±  4.07% cell growth occurred in  the 
presence of 2.0/xg/ml VP-16. This was reduced in the combined presence of 2.0/xg/ml VP-16 
and increasing concentrations of verapamil, to a minimum cell survival of 29.75 ±  1.05% in
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the presence of VP-16 and 3 .0/xg/ml verapamil. In isolation, this concentration of verapamil 
resulted in  72.13 ±  4.62% cell growth (Table 3.11.4.3).
Table 3.11.4.4 shows the percentage survival for DLKP-A with various 
concentrations of verapamil and adriamycin. Again, the circumventing effect was more potent 
at increased concentrations of verapamil. W hile the presence of 1.0/xg/ml adriamycin resulted 
in 93.54 ± 2 1 .0 4 %  cell survival, the addition of 1.0/xg/ml verapamil reduced this to 45.63 ±  
13.96%. An increase in the concentration of verapamil to 3 .0/xg/ml resulted in a further 
decrease to only 27.71 ±  9.38% cell survival. For verapamil, a concentration of 1.0/xg/ml and 
3.0/xg/ml resulted in 73.54 ±  20.42% and 36.46 ±  18.13% cell survival, respectively. The 
intensity of the circumvention effect was also dependent on the initial cell kill produced by the 
cytotoxic agent. While 1.0/xg/ml verapamil resulted in 68.04 ±  12.55% cell growth of DLKP- 
A  and 0.05/xg/ml adriamycin allowed 109.74 ±  11.32% growth, the combination only resulted 
in 59.24 ±  12.48% cell growth. W hen the concentration of adriamycin was increased to 
1.0/xg/ml (resulting in 96.03 ±  8.32% cell growth), the presence of the same concentration of 
verapamil reduced cell survival to only 47.47 ±  6.28% . Cell growth in the presence of 
3 .0/xg/ml adriamycin was 62.48 ±  12.48% but this was decreased to 14.43 ±  2.81% by the 
addition of 1.0/xg/ml verapamil.
Verapamil also proved an efficient enhancer of vincristine toxicity towards 
DLKP-A (Table 3.11.4.5). Again, the circumventing ability was dependent on the 
concentration of both the cytotoxic drug and the circumvention agent. Vincristine, 0.5/xg/ml, 
resulted in 96.37 ± 4 .8 9 %  cell growth with no significant circumvention noted until the cells 
were exposed to a concentration of 3.0/xg/ml verapamil. The combination of vincristine and 
verapamil resulted in only 26.18 ±  2.52% growth. No notable circumvention was observed 
when a combination of 1.0/xg/ml vincristine and 1.0/xg/ml verapamil was used, but when the 
level of vincristine was increased to 3.0/xg/ml, the percentage survival fell from 18.91 ± 3 .1 5 %  
to 3.30 ±  1.07% in the absence and presence of verapamil, respectively.
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% SURVIVAL CYCLOSPORIN A
0.0 /jg/ml 0.2 /jg/ml 1.0 /jg/ml 1.5 /jg/ml 2.0 /jg/ml
ADRIAMYCIN
0.0 /jg/ml A 100
(7.16)
113.01
(12.45)
104.28
(9.11)
97.56
(9.11)
85.32
(9.29)
B 100
(38.32)
101.13
(24.94)
108.56
(33.50)
0.05 /jg/ml B 104.28
(16.62)
102.52
(28.84)
90.43
(22.80)
1.0 /tg/ml A 100.74
(12.08)
102.60
(10.78)
90.52
(10.04)
75.28
(10.04)
50.56
(4.46)
3.0 /jg/ml B 48.36
(12.09)
13.73
(5.43)
Table 3.11.4.1 : Effect of cyclosporin A on adriamycin toxicity to DLKP-A. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
% SURVIVAL CYCLOSPORIN A
0.0 /jg/ml 0.2 /tg/ml 1.0 /tg/ml 1.5 /jg/ml 2.0 fig/ml
VINCRISTINE
0.0 /tg/ml A 100 103.72 91.94 71.32 58.29
(7.33) (5.89) (9.30) (6.20) (6.82)
B 100 105.17 100.72
(11.48) (11.48) (11.12)
0.5 /jg/ml A 102.79 91.63 77.98 62.79 34.89
(5.43) (5.27) (4.96) (5.43) (4.34)
1.0/jg/ml B 85.94 87.80 41.65
(9.50) (21.69) (10.40)
3.0 /tg/ml B 31.37 4.33
(7.21) (1.51)
Table 3.11.4.2 : Effect of cyclosporin A on vincristine toxicity to DLKP-A. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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% SURVIVAL CYCLOSPORIN A
0 /ig/ml 0.2 /tg/ml 1.0 /ig/ml 1.5 /tg/ml 2.0 /tg/ml
VP-16
0.0 /ig/ml 100 92.87 86.77 57.02 66.85
(3.98) (5.12) (6.38) (4.51) (20.58)
2.0 fig/ml 69.01 67.76 45.66 18.95 13.45
(1.87) (1.39) (2.02) (3.90) (5.31)
% SURVIVAL VERAPAMIL
0.0 /ig/ml 0.2 /ig/ml 1.0 /ig/ml 2.0 /tg/ml 3.0 /ig/ml
VP-16
0.0 /ig/ml 100 105.40 100.46 82.65 72.13
(5.29) (3.34) (5.40) (5.90) (4.62)
2.0 fig/ml 75.51 77.03 70.43 35.79 29.75
(4.07) (4.44) (4.94) (3.48) (1.05)
Table 3.11.4.3 : Effect of cyclosporin A and verapamil on VP-16 toxicity to DLKP-A. Survival was 
calculated as percentage growth relative to that measured in a drug-free control and is the mean of eight 
replicas. The values in brackets are the standard deviations on the data.
% SURVIVAL VERAPAMIL
0.0 /tg/ml 0.2 /ig/ml 1.0 /ig/ml 2.0 /ig/ml 3.0 /tg/ml
ADRIAMYCIN
0.0 /ig/ml A 100
(18.39)
71.46
(12.50)
73.54
(20.42)
36.25
(10.00)
36.46
(18.13)
B 100
(8.06)
94.95
(15.58)
68.04
(12.55)
0.05 /ig/ml B 109.74
(11.32)
104.55
(15.58)
59.24
(12.48)
1.0 /tg/ml A 93.54
(21.04)
69.79
(21.67)
45.63
(13.96)
28.54
(8.33)
27.71
(9.38)
B 96.03
(8.32)
82.03
(7.58)
47.47
(6.28)
3.0 /tg/ml B 62.48
(12.34)
14.43
(2.81)
Table 3.11.4.4 : Effect of verapamil on adriamycin toxicity to DLKP-A. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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% SURVIVAL VERAPAMIL
0.0 /tg/ml 0.2 /tg/ml 1.0 /ig/ml 2.0 /tg/ml 3.0 /tg/ml
VINCRISTINE
0.0 /tg/ml A 100
(8.80)
89.43
(11.20)
68.14
(4.89)
48.74
(6.47)
42.43
(3.79)
B 100
(24.90)
101.65
(35.53)
56.66
(15.47)
0.5 /tg/ml A 96.37
(4.89)
85.96
(6.78)
64.04
(6.78)
47.48
(4.26)
26.18
(2.52)
1.0/ig/ml B 65.26
(7.16)
57.74
(13.25)
43.62
(14.33)
3.0 /tg/ml B 18.91
(3.15)
3.30
(1.07)
Table 3.11.4.5 : Effect of verapamil on vincristine toxicity to DLKP-A. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values iu brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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3.11.5 Circumvention of drug resistance in DLKP-A clones
The ability of both cyclosporin A  and verapamil, at relatively non-toxic levels, 
to enhance the toxicity of adriamycin, vincristine and V P-16 towards the four clonal cell lines 
DLKPA5F, DLKPA11B, DLKPA6B and DLKPA2B were investigated. The results outlined 
in Tables 3.11.5.1 to 3.11.5.20 and summarised in Tables 3.11.6.1 to 3.11.6.4.
W ith respect to the toxicity of the circumventing agents, cyclosporin A , at a 
concentration of 1.0^g/ml, resulted in approximately 90% cell growth of DLKPA5F. A t the 
highest concentration used (2.0/ig/ml), the percentage cell survival dropped to approximately 
70% (Tables 3.11.5.1 -3 .11 .5 .3 ). Approximately 70% cell survival was also observed with 
the highest concentration (3.0/ig/ml) of verapamil (Tables 3.11.5.3 to 3.11.5.5).
Cyclosporin A  enhanced the toxicity of adriamycin towards DLKPA5F. The 
addition of 2.0/ig/ml cyclosporin A, to a toxicity assay, decreased the percentage survival in 
the presence of 1.0^g/ml adriamycin, from 49.47 ±  10.59% to 8.17 ±  1.06% (Table 
3.11.5.1). The toxicity of vincristine was also increased by cyclosporin A; the cell survival 
observed in  the presence of 0.5/xg/ml vincristine was reduced from  40.51 ±  2.52% to 6.83 ±  
0.87% , by the addition of 2.0/xg/ml cyclosporin A  (Table 3.11.5.2). Cyclosporin A  also 
enhanced the toxicity of VP-16. The cell survival resulting from growth in  4.0/xg/ml V P -16 
was decreased from 18.36 ±  4.49% to 9.72 ±  0.75% by the presence of 2.0/xg/ml cyclosporin 
A (Table 3.11.5.3).
The addition of verapamil to DLKPA5F toxicity assays w ith V P-16 caused a 
slight increase in cell kill (Table 3.11.5.3). M ore notable effects were observed when 
combinations of verapamil and adriamycin were employed. The presence of 3.0/xg/ml 
verapamil reduced the percentage cell survival in the presence of 1.0/xg/ml adriamycin from 
52.59 +  3.96% to 12.13 ±  1.46% (Table 3.11.5.4), while the same concentration of verapamil 
reduced the survival in the presence of 0.5/xg/ml vincristine from  29.92 +  3.62% to 2.20 ±  
1.56% (Table 3.11.5.5).
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Table 3.11.5.1 : Effect of cyclosporin A on adriamycin toxicity to DLKPA5F. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A, B and C refer to repeat 
experiments and only values in a particular series are comparable.
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% SURVIVAL CYCLOSPORIN A
0.0 jig/ml 0.2 /jg/ml 1.0 fig/mX 1.5 ¿tg/ml 2.0 /jg/ml
VINCRISTINE
0.0 /ig/ml A 100 99.95 84.14 81.68 74.08
(7.28) (6.45) (6.78) (6.51) (5.19)
B , 100 98.46 96.88
(8.47) (6.28) (5.63)
0.05 fig/raX B 85.16 82.93 61.45
(4.90) (5.23) (3.12)
0.5 /ig/ml A 40.51 33.73 17.93 14.16 6.83
(2.52) (3.94) (1.48) (2.13) (0.87)
1.0/zg/inl B 56.67 47.87 26.71
(4.42) (3.28) (0.97)
3.0 jig/ml B 20.55 8.55
(2.19) (0.57)
Table 3.11.5.2 : Effect of cyclosporin A on vincristine toxicity to DLKPA5F. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL CYCLOSPORIN A
0 fig/ml 0.2 jig/ml 1.0 jug/ml 1.5 ¿tg/ml 2.0 figlm\
VP-16
0.0 jig/ml 100 106.40 88.21 79.65 67.52
(12.71) (3.74) (3.16) (6.56) (4.40)
4.0 ¿ig/ml 18.36 19.19 12.96 11.54 9.72
(4.49) (2.66) (1.33) (0.83) (0.75)
% SURVIVAL VERAPAMIL
0.0 fig/ml 0.2 fig/ml 1.0 jig/ml 2.0 fig/m\ 3.0 fig/ml
VP-16
0.0 /ig/ml 100 122.73 100.80 89.67 176.58
(18.30) (15.38) (19.06) (13.43) (32.61)
4.0 jig/ml 16.65 17.34 17.57 13.89 14.24
(2.87) (1.38) (2.99) (0.80) (2.99)
Table 3.11.5.3 : Effect of cyclosporin A and verapamil on VP-16 toxicity to DLKPA5F. Survival was
calculated as percentage growth relative to that measured in  a drug-free control and is the mean of eight
replicas. The values in  brackets are the standard deviations on the data.
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% SURVIVAL VERAPAMIL
0.0 /ig/ml 0.1 /ig/ml 0.2 fig/ml 1.0 /jg/ml 2.0 fig/ml 3.0 /jg/ml
ADRIAMYCIN
0.0 /¿g/ml A 100
(8.13)
101.06
(3.67)
91.14
(4.43)
80.27
(7.95)
79.72
(5.64)
B 100
(27.59)
104.41
(18.12)
83.06
(17.57)
C 100
(5.97)
90.33
(7.04)
89.95
(4.15)
0.05 ¿ig/ml B 105.04
(21.12)
84.00
(26.48)
54.77
(12.14)
C 76.32
(5.84)
85.87
(4.33)
84.48
(4.33)
1.0 /ig/ml A 52.59
(3.96)
45.70
(2.57)
29.84
(1.46)
16.66
(2.06)
12.13
(1.46)
B 35.46
(3.86)
26.95
(4.33)
17.10
(4.26)
C 61.62
(2.20)
61.37
(4.27)
52.64
(4.02)
3.0 ¿¿g/ml B 38.06
(15.37)
6.70
(1.73)
C 48.93
(6.16)
46.55
(2.51)
Table 3.11.5.4 : Effect of verapamil on adriamycin toxicity to DLKPA5F. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A, B and C refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL VERAPAMIL
0.0 /jg/ml 0.2 /ig/ml 1.0 jig/ml 2.0 /ig/ml 3.0 /xg/ml
VINCRISTINE
0.0 /ig/ml A 100 77.54 47.62 85.15 52.23
(18.26) (28.78) (14.85) (31.06) (19.82)
B 100 92.21 84.43
(11.05) (5.26) (10.07)
0.05 itg/ral B 71.34 76.93 39.71
(6.86) (5.99) (2.14)
0.5 fig/ml A 29.92 22.74 12.51 4.76 2.20
(3.62) (6.97) (7.17) (1.71) (1.56)
l.Ofig/ml B 29.78 18.49 9.05
(9.78) (2.38) (1.17)
3.0 /ig/ml B 5.74 1.95
(1.70) (0.39)
Table 3.11.5.5 : Effect of verapamil on vincristine toxicity to DLKPA5F. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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W ith respect to the circumvention of drug resistance by cyclosporin A  and 
verapamil, similar trends to those observed for DLKPA5F were also noted for DLKPA11B. 
Cyclosporin A enhanced the cell kill achieved by adriamycin (Tables 3 .11.5.6 and 3.11.6.2), 
and vincristine (Tables 3.11.5.7 and 3.11.6.3) and resulted in  a slight increase in the potency 
of VP-16 (Tables 3.11.5.8 and 3.11.6.4). This circumvention ability was also noted with 
verapamil, and to approximately the same level (Tables 3.11.5.8 - 3.11.5.10 and 3.11.6.1 -
3.11.6.4).
% SURVIVAL CYCLOSPORIN A
0.0 ¿tg/ml 0.1 iig/ml 0.2 ¿tg/ml 1.0 /¿g/ml 1.5 fig/ml 2.0 fig/ml
ADRIAMYCIN
0.0 /ig/ml A 100
(24.18)
77.39
(16.24)
80.78
(29.19)
80.06
(29.29)
90.85
(30.32)
B 100
(3.09)
93.97
(4.05)
76.18
(4.63)
C 100
(10.11)
95.38
(8.50)
91.96
(8.60)
0.05 figlml B 77.43
(3.14)
65.02
(2.89)
35.43
(1.78)
C 78.74
(3.23)
80.50
(4.25)
73.38
(4.25)
1.0 /jg/ml A 71.74
(10.89)
68.76
(18.91)
41.42
(13.67)
46.25
(18.40)
34.94
(15.62)
B 31.09
(1.15)
22.87
(1.89)
7.87
(1.05)
C 46.67
(2.59)
42.98
(1.76)
42.98
(2.22)
3.0 ftg/ml B 14.50
(1.64)
3.54
(0.55)
C 34.01
(2.13)
30.78
(2.31)
Table 3.11.5.6 : Effect of cyclosporin A on adriamycin toxicity to DLKPA1 IB. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A, B and C refer to repeat 
experiments and only values in a particular series are comparable.
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% SURVIVAL CYCLOSPORIN A
0.0 ¿¿g/ml 0.2 /tg/ml 1.0 jig/ml 1.5 /tg/ml 2.0 /tg/ml
VINCRISTINE
0.0 /tg/ml A 100 87.48 62.94 62.02 65.69
(6.09) (10.60) (11.44) (11.60) (10.10)
B 100 84.50 76.31
(7.95) (7.31) (5.35)
0.05 /tg/ml B 52.78 39.14 13.05
(1.64) (2.78) (2.40)
0.5 fjg/ml A 46.41 41.24 35.39 27.80 19.12
(8.76) (6.76) (4.42) (4.67) (4.17)
1.0/tg/ml B 9.93 6.60 2.29
(1.20) (0.87) (0.33)
3.0 /tg/ml B 3.71 0.60
(0.71) (0.27)
Table 3.11.5.7 : Effect of cyclosporin A on vincristine toxicity to DLKPA11B. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL CYCLOSPORIN A
0 ¿tg/ml 0.2 /tg/ml 1.0 /tg/ml 1.5 /tg/ml 2.0 /tg/ml
VP-16
0.0 ßg/ml 100 94.06 85.62 83.41 76.94
(3.76) (3.50) (5.33) (3.27) (3.81)
2.0 ¿¿g/ml 24.73 23.44 19.56 15.83 14.92
(2.21) (2.74) (1.52) (1.67) (1.67)
% SURVIVAL VERAPAMIL
0.0 /tg/ml 0.2 /tg/ml 1.0 /tg/ml 2.0 /tg/ml 3.0 /tg/ml
VP-16
0.0 /tg/ml 100 105.42 98.16 83.82 91.54
(9.99) (5.33) (11.49) (15.90) (18.75)
2.0 jig/ml 24.54 25.18 26.10 20.13 18.84
(4.41) (1.38) (1.65) (1.84) (3.95)
Table 3.11.5.8 : Effect of cyclosporin A and verapamil on VP-16 toxicity to DLKPA11B. Survival was
calculated as percentage growth relative to that measured in  a drug-free control and is the mean of eight
replicas. The values in brackets are the standard deviations on the data.
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% SURVIVAL VERAI*AMIL
0.0 jug/ml 0.1 /ig/ml 0.2 /ig/ml 1.0 fig/ml 2.0 /jg/ml 3.0 /tg/ral
ADRIAMYCIN
0.0 ftg/ml A 100
(6.87)
96.54
(6.73)
91.01
(6.92)
89.62
(4.78)
89.37
(8.24)
B 1 100 
(10.53)
106.92
(10.78)
109.69
(10.37)
C 100
(9.19)
98.28
(8.33)
92.93
(5.07)
0.05 iig/ml B 67.93
(19.19)
71.46
(10.92)
58.24
(10.92)
C 76.65
(5.84)
75.31
(6.89)
77.80
(6.60)
1.0 fig/ml A 69.50
(4.21)
65.97
(4.91)
56.60
(4.72)
45.66
(3.58)
41.32
(3.08)
B 20.41
(6.58)
17.15
(6.24)
8.27
(3.59)
C 41.91
(3.92)
38.76
(2.78)
35.22
(3.06)
3.0 jig/ml B 12.88
(2.92)
5.22
(1.63)
C 28.80
(2.87)
28.61
(2.68)
Table 3.11.5.9 : Effect of verapamil on adriamycin toxicity to DLKPA11B. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A, B and C refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL VE,RAPAMIL (jig/ml)
i 0.0 ¿ig/ml 0.2 /jg/ml 1.0 /jg/rnl 2.0 ¿ig/ml 3.0 ng/ml
VINCRISTINE
0.0 /ig/ml A 100 97.89 92.60 91.78 84.78
(5.82) (7.47) (4.21) (4.76) (5.91)
B 100 27.25 56.12
(16.46) (14.63) (23.83)
0.05 /ig/ml B 36.67 21.08 10.02
(12.55) (9.80) (5.35)
0.5 pg/ml A 53.74 54.15 44.16 34.99 26.90
(5.71) (3.67) (2.17) (2.17) (2.17)
1.0/jg/ml C 55.61 51.74
(5.13) (5.03)
3.0 fig/ml B 2.69 0.37
(0.82) (0.45)
Table 3.11.5.10 : Effect of verapamil on vincristine toxicity to DLKPA11B. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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In relation to the cell line DLKPA6B (Tables 3.11.5.11 - 3.11.5.15 and 
summarised in Tables 3.11.6.1 - 3.11.6.4), both cyclosporin A  and verapamil enhanced the 
toxicities of adriamycin and vincristine. However, with respect to VP-16 toxicity, neither 
verapamil nor cyclosporin A  caused a notable enhancement of toxicity. Cyclosporin A  appeared 
to cause neither a synergistic nor an antagonistic effect on cell kill by V P-16, as determined 
using the Chou and Talalay (1984) method of analysis of two compounds in combination, while 
verapamil caused a slight decrease in the toxicity of VP-16 to the cells (Tables 3.11.5.13 and
3.11.6.4).
% SURVIVAL CYCLOSPORIN A
0.0 ng/ml 0.1 /ig/ml 0.2 ¿ig/ml 1.0 fig/ml 1.5 ng/ml 2.0 /jg/ml
ADRIAMYCIN
0.0 ¿ig/ml A 100
(23.43)
88.89
(17.30)
77.53
(23.36)
64.77
(17.42)
51.01
(19.57)
B 100
(6.45)
91.91
(6.57)
82.93
(4.42)
C 100
(4.00)
91.73
(7.38)
100.18
(5.07)
0.05 jug/ml B 77.13
(4.35)
69.25
(3.73)
39.88
(3.11)
C 89.42
(3.56)
85.33
(3.64)
88.00
(6.40)
1.0 fig/ml A 56.06
(11.11)
38.13
(15.03)
15.53
(3.03)
14.14
(5.18)
9.22
(1.06)
B 34.62
(3.11)
25.78
(3.32)
6.63
(0.69)
C 58.40
(3.82)
54.22
(2.49)
48.53
(2.48)
3.0 ng/ml B 18.38
(2.14)
2.14
(0.62)
C 42.13
(3.64)
35.20
(2.04)
Table 3.11.5.11: Effect of cyclosporin A on adriamycin toxicity to DLKPA6B. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments 
and only values in a particular series are comparable.
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% SURVIVAL CYCLOSPORIN A
0.0 /ig/ml 0.2 /ig/ml 1.0 /ig/ml 1.5 /ig/ml 2.0 /ig/ml
VINCRISTINE
0.0 ßg/ml A 100 93.82 78.26 74.93 64.56
(4.19) (6.12) (4.59) (4.26) (6.25)
B 100 92.77 90.01
(9.13) (6.86) (9.55)
0.05 /ig/ml B i 72.93 54.29 18.29
(11.04) (5.29) (2.68)
0.5 fig/ml A 28.32 20.35 5.45 2.59 1.26
(1.26) (1.00) (0.80) (0.53) (0.20)
1.0/ig/ml B 16.63 13.27 4.10
(2.39) (1.34) (0.30)
3.0 pig/ml B 5.96 2.83
(0.75) (0.52)
Table 3.11.5.12 : Effect of cyclosporin A on vincristine toxicity to DLKPA6B. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL CYCLOSPORIN A
0 /tg/ml 0.2 /ig/ml 1.0 /ig/ml 1.5 /ig/ml 2.0 /tg/ml
VP-16
0.0 /tg/ml 100 94.19 80.38 79.21 68.64
(3.56) (3.80) (4.19) (1.73) (1.57)
2.0 /ig/ml 21.24 21.69 15.20 11.96 14.42
(1.29) (1.62) (0.84) (1.17) (2.68)
% SURVIVAL VERAPAMIL
0.0 /ig/ml 0.2 /ig/ml 1.0 /tg/ml 2.0 /ig/ml 3.0 /tg/ml
VP-16
0.0 /ig/ml 100 111.51 108.84 93.77 88.66
(6.54) (3.86) (3.68) (12.34) (12.88)
2.0 /ig/ml 21.90 23.74 27.42 23.86 25.04
(2.02) (1.72) (1.13) (3.56) (3.92)
Table 3.11.5.13 : Effect of cyclosporin A and verapamil on VP-16 toxicity to DLKPA6B. Survival was
calculated as percentage growth relative to that measured in a drug-free control and is the mean of eight
replicas. The values in  brackets are the standard deviations on the data.
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% SURVIVAL VERAPAMIL
0.0 /xg/ml 0.1 /ig/ml 0.2 ftg/ml 1.0 fig/ml 2.0 fig/ml 3.0 /jg/ml
ADRIAMYCIN
0.0 ^g/ml A 100
(9.83)
100.94
(5.61)
94.60
(6.98)
96.22
(6.87)
96.17
(6.30)
B 100
(11.74)
112.88
(15.47)
91.68
(10.11)
C 100
(6.77)
93.80
(8.48)
88.94
(4.10)
0.05 fig/ml B 65.83
(9.57)
90.34
(11.27)
64.40
(9.48)
C 80.65
(6.77)
83.13
(5.43)
74.26
(13.92)
1.0 ¿ig/ml A 46.80
(3.83)
44.86
(3.62)
29.28
(2.62)
21.77
(1.52)
19.78
(1.42)
B 32.29
(6.71)
19.50
(4.38)
8.68
(2.77)
C 51.86
(7.34)
47.66
(3.05)
44.23
(2.96)
3.0 fig/ml B 11.63
(3.58)
4.11
(2.42)
C 31.94
(4.29)
32.22
(3.62)
Table 3.11.5.14 : Effect of verapamil on adriamycin toxicity to DLKPA6B. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A, B and C refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL VERAPAMIL
0.0 fig/ml 0.2 fig/ml 1.0 fig/ml 2.0 jig/m] 3.0 /tg/ml
VINCRISTINE
0.0 ng/ml A 100 95.31 84.60 71.63 74.07
(4.05) (9.56) (10.53) (18.23) (15.60)
B 100 85.59 79.74
(20.72) (26.24) (23.49)
0.05 ftg/ral B 47.60 42.62 33.89
(12.93) (18.17) (8.73)
0.5 /tg/ml A 25.10 21.95 10.98 6.48 4.88
(1.41) (2.25) (2.12) (1.48) (0.83)
1.0fig/ml B 9.87 8.30 4.80
(3.84) (1.57) (1.66)
3.0 /jg/ml B 2.88 1.57
(1.05) (0.44)
Table 3.11.5.15 : Effect of verapamil on vincristine toxicity to DLKPA6B. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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W ith respect to DLKPA2B, both cyclosporin A and verapamil caused a 
significant enhancement of the toxicities of adriamycin (Tables 3.11.4.16 - 3.11.4.19 and 
summarised in Table 3.11.6.2) and vincristine (Tables 3.11.4.17 - 3.11.4.20 and summarised 
in  Table 3.11.6.3). Cyclosporin A, at a concentration of 2.0/ig/ml, decreased cell survival in 
the presence of 1.0/tg/ml adriamycin, from 35.30 ±  2.81% when the cells were exposed to 
adriamycin alone, to 6.94 ±  2.58% in the presence of the combination, while the cell survival 
in the presence of cyclosporin A  alone was 72.08% . The presence of cyclosporin A , at 
1.0/xg/ml, reduced cell survival in the presence of 0.05/xg/ml vincristine from 41.11 ± 4 .6 5 % , 
in the presence of vincristine alone, to 5.90 ±  0.71 % in the presence of the combination, while 
the cyclosporin A  alone supported 72.61 _+ 11.64% cell growth. In terms of VP-16 toxicity, 
while cyclosporin A enhanced its toxicity, the combination of verapamil and V P-16 resulted in 
an antagonistic effect with respect to cell kill, as determined by the Chou and Talalay (1984) 
method of analysis (Tables 3.11.5.18 and 3.11.6.4).
% SURVIVAL CYCLOSPORIN A
0.0 figlm\ 0.1 0.2 ng/ml 1.0 ¿ig/ml 1.5 ^g/ml 2.0 /ig/ml
ADRIAMYCIN
0.0 /jg/ml A 100
(12.00)
96.97
(7.02)
88.63
(7.09)
84.05
(6.72)
72.08
(7.90)
B 100
(12.36)
92.36
(5.18)
90.19
(4.22)
C 100
(3.14)
98.09
(3.78)
96.77
(4.04)
0.05 fig/ml B 65.64
(3.92)
59.37
(1.54)
36.49
(2.30)
C 59.41
(5.69)
51.55
(4.16)
46.66
(3.95)
1.0 ng/ml A 35.30
(2.81)
27.33
(1.92)
10.27
(2.07)
8.64
(0.74)
6.94
(2.58)
B 24.55
(1.42)
16.54
(0.88)
5.09
(0.29)
C 20.10
(2.93)
14.62
(2.12)
9.31
(0.98)
3.0 fig/ml B 9.69
(0.75)
0.63
(0.17)
C 3.82
(0.64)
3.31
(0.51)
Table 3.11.5.16 : Effect of cyclosporin A on adriamycin toxicity to DLKPA2B. Survival was calculated 
as percentage growth relative to that measured in a drag-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A, B and C refer to repeat 
experiments and only values in a particular series are comparable.
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% SURVIVAL CYCLOSPORIN A
0.0 ng/ml 0.2 /ig/ml 1.0 ftg/ml 1.5 /jg/ml 2.0 /ig/ml
VINCRISTINE
0.0 fjg/ml A 100 94.03 72.61 73.86 60.74
(5.47) (8.61) (11.64) (20.56) (13.11)
B 100 95.35 84.09
(8.73) (4.42) (6.97)
0.05 ng/ml B 41.11 29.18 5.90
(4.65) (2.28) (0.71)
0.5 fig/ml A 17.38 12.72 4.42 3.41 2.64
(1.71) (2.56) (0.47) (0.47) (0.39)
1.0^g/ml B 8.09 6.08 5.05
(0.54) (0.89) (0.89)
3.0 ng/ml B 4.78 3.57
(0.40) (0.36)
Table 3.11.5.17 : Effect of cyclosporin A on vincristine toxicity to DLKPA2B. Survival was calculated 
as percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. 
The values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments 
and only values in a particular series are comparable.
% SURVIVAL CYCLOSPORIN A
0 /¿g/ml 0.2 jig/ml 1.0 fig/ml 1.5 Mg/ml 2.0 /ig/ml
VP-16
0.0 fig/ml 100 88.09 34.18 17.27 11.91
(5.31) (9.08) (5.88) (2.61) (1.86)
1.0 fig/ml 31.76 12.29 4.02 2.83 2.23
(1.34) (1.27) (0.60) (0.67) (0.67)
% SURVIVAL VERAPAMIL
0.0 ftg/ml 0.2 /ig/ml 1.0 iig/ml 2.0 /tg/ml 3.0 fig/ml
VP-16
0.0 /jg/ml 100 89.01 79.78 60.94 45.98
(7.35) (7.94) (12.28) (7.74) (9.60)
1.0 /jg/ml 17.27 20.50 17.08 15.24 10.90
(2.31) (3.60) (3.42) (2.12) (1.94)
Table 3.11.5.18 : Effect of cyclosporin A and verapamil on VP-16 toxicity to DLKPA2B. Survival was
calculated as percentage growth relative to that measured in  a drug-free control and is the mean of eight
replicas. The values in  brackets are the standard deviations on the data.
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%
% SURVIVAL VEIIAPAMIL
0.0 /ig/ml 0.1 /ig/ml 0.2 fig/ml 1.0 ¿ig/ml 2.0 /ig/ml 3.0 fig!mi
ADRIAMYCIN
0.0 /tg/ml A 1 100 
! (6.56)
98.01
(14.21)
88.70
(10.66)
71.86
(23.31)
77.11
(20.82)
B 100
(12.42)
80.85
(7.73)
80.16
(8.32)
C 100
(16.56)
100.28
(4.05)
104.00
(6.44)
0.05 /ig/ml B 38.29
(11.57)
57.01
(9.92)
55.31
(5.12)
C 39.04
(13.12)
60.25
(4.09)
60.91
(6.63)
1.0 /ig/ml A 27.86
(3.27)
23.81
(3.69)
16.92
(1.78)
12.86
(2.20)
10.09
(2.77)
B 15.73
(4.11)
14.99
(2.99)
7.04
(1.81)
C 12.42
(2.92)
12.94
(3.15)
8.04
(1.46)
3.0 /ig/ml B 4.57
(1.65)
2.45
(0.80)
C 1.65
(0.66)
2.07
(0.33)
Table 3.11.5.19 : Effect of verapamil on adriamycin toxicity to DLKPA2B. Survival was calculated as 
percentage growth relative to that measured in a drug-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A, B and C refer to repeat experiments 
and only values in  a particular series are comparable.
% SURVIVAL VERAPAMIL
0.0 /ig/ml 0.2 /ig/ml 1.0 /ig/ml 2.0 /ig/ml 3.0 /ig/ml
VINCRISTINE
0.0 /ig/ml A 100 77.35 57.83 50.42 68.62
(22.95) (21.75) (15.32) (19.28) (33.44)
B 100 86.11 90.34
(9.41) (16.30) (10.45)
0.05 /tg/ml B 22.98 15.68 12.32
(4.52) (3.07) (2.41)
0.5 /ig/ml A 13.76 11.78 6.10 4.45 3.20
(2.97) (2.31) (2.06) (1.73) (0.99)
1.0/ig/ml B 3.90 2.90 2.70
(0.91) (0.46) (0.71)
3.0 /ig/ml B 2.41 1.87
(0.46) (0.29)
Table 3.11.5.20 : Effect of verapamil on vincristine toxicity to DLKPA2B. Survival was calculated as 
percentage growth relative to that measured in a drag-free control and is the mean of eight replicas. The 
values in brackets are the standard deviations on the data. Series A and B refer to repeat experiments and 
only values in a particular series are comparable.
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3.11.6 Conclusions
This study showed that both cyclosporin A  and verapamil possessed the ability 
to modify the toxicity of adriamycin, vincristine and V P-16 of the DLKP cell line and its M DR 
variants. Both circumventing agents were less toxic to the drug-sensitive DLKP cells than to 
any of the M DR cell lines (Table 3.11.1). Cyclosporin A  and verapamil were also more 
effective at enhancing the toxicity of adriamycin, vincristine and V P-16 to DLKP, in 
comparison with the drug-resistant cell lines (Tables 3.11.6.2 - 3.11.6.4). In all cases studied, 
the level of alteration in  the drug’s toxicity depended on both the concentration of the 
chemotherapeutic drug and the circumvention agent.
Cyclosporin A  enhanced the toxicity of adriamycin, vincristine and VP-16, in 
all cell lines examined, as outlined in Table 3.11.6.1. Verapamil also enhanced adriamycin and 
vincristine toxicity to all the cell lines. However, verapamil exhibited an antagonistic effect on 
V P-16 toxicity to DLKP/VP-3, DLKP/VP-8, DLKPA2B and DLKPA6B.
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Effect of 
circumventing 
agent on the 
toxicity of drugs
Verapamil Cyclosporin A
Adriamycin Vincristine VP-16 Adriamycin Vincristine VP-16
DLKP Synergistic1 Synergistic1 Synergistic1 Synergistic1 Synergistic1 Synergistic1
DLKP-A Synergistic1 Synergistic2,3 Synergistic1 Synergistic1 Synergistic1 Synergistic1
DLKPA2B Synergistic1 Synergistic1 Antagonistic2,3 Synergistic1 Synergistic1 Synergistic1
DLKPA6B Synergistic1 Synergistic1 Antagonistic2,3 Synergistic1 Synergistic1 Synergistic2,3
DLKPA1 IB Synergistic1 Synergistic1 Synergistic2,3 Synergistic1 Synergistic1 Synergistic1
DLKPA5F Synergistic1 Synergistic1 Synergistic2-3 Synergistic1 Synergistic1 Synergistic1,3
DLKP/VP-3 Synergistic1 Synergistic1 Antagonistic2 Synergistic1 Synergistic1 Synergistic1
DLKP/VP-8 Synergistic1 Synergistic1 Antagonistic2 Synergistic1 Synergistic1 Synergistic1
1 Determined by the multiple product method of analysis.
2 As determined using the Chou and Talalay (1984) method of dose-effects analysis.
3 A slight effect was noted at higher concentrations of the circumventing agent.
Table 3.11.6.1 : Summary table of circumvention of adriamycin, vincristine and VP-16 resistance in DLKP variants.
Adriamycin
conc.
Cyclosporin A Verapamil
0.0
/ig/ml
0.2
/ig/ml
1.0
/ig/ml
2.0
/ig/ml
0.0
/tg/ml
0.2
Mg/ml
1.0
/tg/ml
3.0
/tg/ml
DLKP
0.02/tg/ml
45.06 27.52 14.53 13.03 41.98 37.40 35.54 24.94
DLKP/VP-3
2.0/tg/ml
71.40 68.77 38.30 10.93 71.16 63.35 31.68 12.09
DLKP/VP-8
5.0/ig/ml
74.49 69.95 47.53 12.88 82.74 84.03 28.17 6.83
DLKP-A
1.0/tg/ml
100.74 102.60 90.52 50.56 93.54 69.79 45.63 27.71
DLKPA5F
1.0/tg/ml
49.47 40.04 20.05 8.17 52.59 45.70 29.84 12.13
DLKPA11B
1.0/xg/ml
71.74 68.76 41.42 34.94 69.50 65.97 56.60 41.32
DLKPA6B
1.0/tg/ml
56.06 38.13 15.53 9.22 46.80 44.86 29.28 19.78
DLKPA2B
1.0/tg/ml
35.30 27.33 10.27 6.94 27.86 23.81 16.92 10.09
Table 3.11.6.2 : The enhancement of the toxicity of adriamycin to variants of DLKP, by various 
concentrations of cyclosporin A and verapamil. The data presented in this table is a summary of the data 
in Tables 3.11.2.1-3.11.5.20. The toxicity of adriamycin to the cells, at the concentration stated in the 
table, below the respective cell line, is presented and the toxicity of the circumvention agents to the cells 
may be determined from the summary table, Table 3.11.1. A more detailed analysis of the ability of the 
circumventing agents to enhance the toxicity of adriamycin to the cells, including the standard deviation 
on the data, may be found in the relevant tables mentioned above.
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Vincristine Cyclos] >orin A Vera E>amil
conc.
0 .0
/xg/ml
0 .2
Mg/ml
1 .0
#<g/ml
2 .0
¿<g/inl
0 .0
Atg/ml
0 .2
¿tg/ml
1 .0
/ig/ml
3.0
M g/m l
DLKP
0 .0 1 p g /m l
98.44 86.52 21.52 3.63 94.12 94.79 81.53 51.48
DLKP/VP-3
2 .0 / ig /m l
53.59 48.13 28.14 11.89 61.16 53.27 31.72 11.97
DLKP/VP-8
2.0/xg/ml
48.54 48.03 24.11 9.27 45.80 48.17 11.65 5.22
DLKP-A
0.5ftg/ml
102.79 91.63 77.98 34.89 96.37 85.96 64.04 26.18
DLKPA5F
0.5/tg/ml
40.51 33.73 17.93 6.83 29.92 22.74 12.51 2.20
DLKP A1 IB 
0.5iig/ml
46.41 41.24 35.39 19.12 53.74 54.15 44.16 26.90
DLKPA6B
0.5^g/ml
28.32 20.35 5.45 1.26 25.10 21.95 10.98 4.88
DLKPA2B
0.5/ig/ml
17.38 12.72 4.42 2.64 13.76 11.78 6.10 3.20
Table 3.11.6.3 : The enhancement of the toxicity of vincristine to variants of DLKP, by various 
concentrations of cyclosporin A and verapamil. The data presented in this table is a summary of the data 
in Tables 3.11.2.1 - 3.11.5.20. The toxicity of vincristine to the cells, at the concentration stated in the 
table, below the respective cell line, is presented and the toxicity of the circumvention agents to the cells 
may be determined from the summary table, Table 3.11.1. A more detailed analysis of the ability of the 
circumventing agents to enhance the toxicity of vincristine to the cells, including the standard deviation 
on the data, may be found in the relevant tables mentioned above.
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VP-16 conc. Cyclosporin A Verapamil
0.0
/tg/ml
0.2 
n  g/mi
1.0
Aig/ml
2.0  
H g/ml
0.0
Atg/ml
0.2
/tg/ml
1.0
/tg/ml
3.0
Hg/ml
DLKP
0.075/tg/ml
91.69 86.10 65.35 50.04 98.61 98.81 96.26 90.62
DLKP/VP-3
5.0/ig/ml
51.60 48.15 24.39 8.05 50.65 48.88 42.49 32.51
DLKP/VP-8
8.0/tg/mI
69.09 69.67 50.65 26.36 61.32 59.98 42.25 16.28
DLKP-A
2.0pg/ml
69.01 67.76 45.66 13.45 75.51 77.03 70.43 29.75
DLKPA5F
4.0/tg/ml
18.36 19.19 12.96 9.72 16.65 17.34 17.57 14.24
DLKPA11B
2.0/tg/ml
24.73 23.44 19.56 14.92 24.54 25.18 26.10 18.84
DLKPA6B
2.0/tg/ml
21.24 21.69 15.20 14.42 21.90 23.74 27.42 25.04
DLKPA2B
1.0jig/ml
31.76 12.29 4.02 2.23 17.29 20.50 17.08 10.90
Table 3.11.6.4 : The enhancement of the toxicity of VP-16 to variants of DLKP by cyclosporin A and 
verapamil, at varying concentrations. The data presented in this table is a summary of the data in Tables 
3.11.2.1 - 3.11.5.20. The toxicity of VP-16 to the cells, at the concentration stated in  the table, below 
the respective cell line, in the absence of cyclosporin A and verapamil is presented and the toxicity of 
the circumvention agents to the cells may be determined from the summary table, Table 3.11.1. A more 
detailed analysis of the ability of circumventing agents to enhance VP-16 toxicity to the cells, including 
the standard deviation on the data, may be found in the relevant tables mentioned above.
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3.12 Camptothecin toxicity to DLKP variants
The toxicity of camptothecin, a topoisomerase I inhibitor, to DLKP variants, 
was examined to determine if  cell lines which were resistant to topoisomerase II inhibitors 
exhibited alterations in their sensitivity to topoisomerase I poisons. The experiment was 
performed twice with eight intra-assay replicas per assay.
Camptothecin proved to be least toxic to the parental cell line DLKP (which was 
also most sensitive to the topoisomerase II inhibitors) and the M DR clone of DLKP-A, 
DLKPA5F (which was highly resistant to both adriamycin and VP-16) (Figure 3.12.1). It 
exhibited slightly higher toxicity to DLKP-A, was even more toxic to DLKP/VP-3 and proved 
to be highly toxic to DLKP/VP-8. However, the range increase in  toxicity, from the most 
sensitive to the most resistant cell line with respect to camptothecin, was small; a maximum of 
a 2-fold increase in the IC50 values was noted.
W hen the toxicity of camptothecin in combination with adriamycin, to the cells 
was examined, no synergism or antagonism between the two compounds was observed (Figure
3.12.2 - 3.12.6). The cell kill observed in  DLKP, DLKP-A, DLKPA5F, DLKP/VP-3 and 
DLKP/VP-8, following exposure to the two drugs in combination, may be explained by the 
individual toxicity of the two compounds acting in  an non-synergistic manner, when analyzed 
by the Chou and Talalay method of analysis of two compounds in  combination at a fixed ratio 
(Chou and Talalay, 1984).
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Figure 3.12.1: Toxicity of camptothecin to DLKP, DLKP-A, DLKPA5F, DLKP/VP-3 and DLKP/VP-8. 
The error bars represent the standard deviation on the mean of eight replicas.
Adriamycin (ng/ml) Camptothecin (ng/ml) Combination*
Cone. %
Survival
Std.
Dev.
Cone. %
Survival
Std.
Dev.
%
Survival
Std.
Dev.
A 1.875 99.72 4.04 A 0.5 91.92 4.96 A 91.46 3.90
B 3.75 96.51 7.99 B 1.0 57.56 1.88 B 52.41 3.08
C 5.625 99.49 5.01 C 1.5 24.21 1.56 C 21.50 1.52
D 7.5 93.59 5.61 D 2.0 8.41 0.67 D 6.77 0.31
E 9.375 85.53 5.30 E 2.5 4.10 0.71 E 3.43 0.53
F 11.25 68.17 11.53 F 3.0 3.47 0.62 F 3.43 0.49
Figure 3.12.2 : Effect of adriamycin and camptothecin, in combination, on DLKP. Analysis by the Chou 
and Talalay (1984) method of analysis of two compounds in combination, shows no synergistic or 
antagonistic effect over their individual toxicides.
* Adriamycin and camptothecin were combined at a fixed ratio, such that the data presented for 
combination A pertains to the percentage cell survival in the presence of the concentration of adriamycin 
and camptothecin corresponding to that letter.
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Adriamycin (jig/ml) Camptothecin (ng/ml) Combination*
Cone. %
Survival
Std,
Dev.
Cone. %
Survival
Std.
Dev.
%
Survival
Std.
Dev.
A 0.75 83.62 7.06 A 0.5 74.66 8.45 A 64.24 9.21
B 1.5 68.20 9.66 B 1.0 40.18 7.06 B 27.64 5.89
C 2.25 57.97 12.41 C 1.5 19.96 5.95 C 15.87 2.88
D 3.0 80.20 6.60 D 2.0 19.61 0.95 D 16.24 1.40
E 3.75 83.44 5.33 E 2.5 15.48 0.63 E 15.61 0.70
F 4.5 75.25 6.60 F 3.0 14.28 0.95 F 15.99 1.46
Figure 3.12.3 : Effect of adriamycin and camptothecin, in combination, on DLKPA. Analysis by the 
Chou and Talalay (1984) method of analysis of two compounds in combination, shows no significant 
synergistic or antagonistic effect over their individual toxicities.
’ Adriamycin and camptothecin were combined at a fixed ratio, such that the data presented for 
combination A pertains to the percentage cell survival in the presence of the concentration of adriamycin 
and camptothecin corresponding to that letter.
Adriamycin (/¿g/ml) Camptothecin (ng/ml) Combination*
Cone. %
Survival
Std.
Dev.
Cone. %
Survival
Std.
Dev.
%
Survival
Std.
Dev.
A 1.5 54.73 9.74 A 0.5 86.51 5.84 A 43.14 5.44
B 3.0 38.25 3.47 B 1.0 61.91 6.55 , B 19.40 2.37
C 4.5 26.58 4.42 C 1.5 36.12 6.15 C 9.31 1.66
D 6.0 21.96 4.62 D 2.0 25.16 1.42 D 7.47 0.62
E 7.5 21.96 3.56 E 2.5 15.47 1.69 E 6.67 0.53
F 9.0 17.79 2.84 F 3.0 11.02 1.16 F 7.02 0.44
Figure 3.12.4 : Effect of adriamycin and camptothecin, in combination, on DLKPA5F. Analysis by the 
Chou and Talalay (1984) method of analysis of two compounds in combination, shows no significant 
synergistic or antagonistic effect over their individual toxicities.
* Adriamycin and camptothecin were combined at a fixed ratio, such that the data presented for 
combination A pertains to the percentage cell survival in the presence of the concentration of adriamycin 
and camptothecin corresponding to that letter.
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A driam ycin  (/xg/ml) Camptothecin (ng/m l) Combination*
Cone. %
Survival
Std.
Dev.
Cone. %
Survival
Std.
Dev.
%
Survival
Std.
Dev.
A 0.375 92.43 11.86 A 0.5 71.00 10.86 A 59.97 10.14
B 0.75 80.43 8.00 B 1.0 28.57 6.00 B 18.14 2.57
C 1.125 69.43 12.86 C 1.5 11.29 2.43 C 9.00 1.14
D 1.5 75.06 7.23 D 2.0 7.61 0.37 D 6.36 1.00
E 1.875 70.32 14.46 E 2.5 5.61 0.25 E 6.23 0.50
F 2.25 64.96 11.35 F 3.0 6.86 0.75 F 6.75 0.75
Figure 3.12.5 : Effect of adriamycin and camptothecin, in combination, on DLKP/VP-3. Analysis by 
the Chou and Talalay (1984) method of analysis of two compounds in combination, shows no significant 
synergistic or antagonistic effect over their individual toxicities.
* Adriamycin and camptothecin were combined at a fixed ratio, such that the data presented for 
combination A pertains to the percentage cell survival in the presence of the concentration of adriamycin 
and camptothecin corresponding to that letter.
Adriamycin (/xg/ml) Camptothecin (ng/ml) Combination*
Cone. %
Survival
Std.
Dev.
Cone. %
Survival
Std.
Dev.
%
Survival
Std.
Dev.
A 1.0 76.04 15.43 A 0.5 53.75 9.95 A 24.58 5.40
B 2.0 55.80 12.65 B 1.0 10.59 2.74 B 3.59 0.91
C 3.0 31.77 7.90 C 1.5 2.37 0.47 C 0.95 0.32
D 4.0 27.71 8.60 D 2.0 2.07 0.32 D 1.75 0.32
E 5.0 23.09 9.71 E 2.5 1.75 0.16 E 2.07 0.48
F 6.0 14.01 4.62 F 3.0 1.75 0.16 F 1.91 0.48
Figure 3.12.6 : Effect of adriamycin and camptothecin, in combination, on DLKP/VP-8. Analysis by 
the Chou and Talalay (1984) method of analysis of two compounds in combination, shows no significant 
synergistic or antagonistic effect over their individual toxicities.
* Adriamycin and camptothecin were combined at a fixed ratio, sucli that the data presented for 
combination A pertains to the percentage cell survival in the presence of the concentration of adriamycin 
and camptothecin corresponding to that letter.
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3.13 Plating density effects on toxicity profiles of the cells
To determine if the sensitivity of the cell line, DLKP and its drug-resistant 
variants, to various chemotherapeutic drugs, was a cell density-dependent phenomenon, the 
toxicity of the drugs to the cell lines, when plated at 200 and 2000 cells/well, was investigated. 
All experiments were carried out in duplicate, with triplicate repeats in each assay and the 
results of both experiments were found to correlate.
3 .13 .1  Adriam ycin toxicity o f DLK P, DLK P-A  and its clones
The effect of the initial cell plating density on the cells’ ability to grow in the 
presence of adriamycin, was examined. W hen DLKP was plated at high (2000 cells/well) and 
low (200 cells/well) cell density in an adriamycin toxicity assay, slightly greater kill was 
observed in  the toxicity assay set up at low plating density (Figure 3.13.1.1(a)). W hile 
0.01^g/m l adriamycin resulted in 50% kill in DLKP at a plating density of 2000 cells/well, the 
IC50 value for the cells at a plating density of 200 cells/well was reduced to approximately 
0.0075/xg/ml. A greater difference in cell kill at high and low cell plating densities was 
observed for DLKP-A (Figure 3.13.1.1 (b)). 4/*g/ml resulted in 50 % cell kill when cells were 
plated at 2000 cells/well, one fifth of this concentration (approximately 0.8/xg/ml) resulted in 
the same level of kill at a plating density of 200 cells/well. The shape of the adriamycin 
toxicity curves generated by DLKP at high and low cell plating densities were similar. 
However, the shapes of the toxicity curves generated by DLKP-A at high and low plating 
densities differed (Figure 3.13.1.1 (b)). High cell kill occurred at low adriamycin concentration 
when DLKP-A cells were plated at 200 cells/well, whereas low cell kill was noted at low drug 
concentrations at a plating density of 2000 cells/well.
The adriamycin toxicity profiles ofthe DLKP-A clones, DLKPA2B, DLKPA6B, 
DLKPA11B and DLKPA5F, were also cell density-dependent (Figure 3.13.1.2, 3.13.1.3). 
Although the cell density-dependent effect was generally greater than that observed for DLKP, 
it was substantially less than that noted for DLKP-A. The greatest cell density-dependent effect 
noted in the clones was observed in DLKPA5F and DLKPA2B. For DLKPA5F (unlike DLKP- 
A), at low adriamycin concentrations the shape of the toxicity profiles generated by high and 
low cell plating densities were similar and it was only at higher adriamycin concentrations that 
the profiles deviated (Figure 3.13.1.3(b)). The shape of the toxicity profiles generated when 
DLKPA2B was plated at high and low cell density were similar (Figure 3.13.1.2(a)).
a.
Adriamycin conc. (fig/ml)
b.
Adriamycin conc. (pg/ml)
Figure 3.13.1.1 : Adriamycin toxicity to DLKP (a) and DLKP-A (b), when cells are plated at 2000
cells/well and 200 cells/well. The error bars represent the standard deviation on the mean of three
replicas.
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a.
Adriamycin conc. (jig/ml)
b.
Adriamycin conc. (|ig/ml)
fig u re  3.13.1.2 : Adriamycin toxicity to DLKPA2B (a) and DLKPA6B (b), when cells are plated at 2000
cells/well and 200 cells/well. The error bars represent the standard deviation on the mean o f three
replicas.
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a.
Adrlamycln conc. (fig/ml)
b.
Adrlamycin conc. (jig/ml)
Figure 3.13.1.3 : Adriamycin toxicity to DLKPA11B (a) and DLKPA5F (b), when cells are plated at
2000 cells/well and 200 cells/well. The error bars represent the standard deviation on the mean o f three
replicas.
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3.13.2 Adriamycin toxicity profiles with continuous drug replacement
To ensure that the alterations in the toxicity profiles observed at different cell 
plating densities were not due to cell cycle variations, adriamycin toxicity assays were set up 
in  which fresh drug was added every 48h. and the toxicity profiles analyzed. This ensured that 
the cells were continuously exposed to the initial drug concentration and therefore, cells could 
not have survived by being at a more resistant stage of the cell cycle, with respect to adriamycin 
toxicity, during the initial addition of adriamycin.
Refeeding with fresh adriamycin every 48h. did not alter the toxicity profile of 
DLKP at high cell plating density (Figure 3 .13.2(a)). However, a slight decrease in  the cells’ 
resistance to adriamycin was observed when the cells were fed with fresh drug, at a low cell 
plating density. In both cases, the shape of the toxicity curves were similar to that noted when 
the toxicity profile was generated with only one drug addition.
Refeeding the DLKP-A toxicity assay with fresh adriamycin every 48h. resulted 
in a reduction of the adriamycin toxicity profile generated when the cells were plated at high 
density, in comparison with the toxicity profile generated by a single addition of adriamycin 
(Figure 3 .13.2(b)). The toxicity profile obtained by refeeding with fresh drug maintained the 
shape of the curve generated by one addition of adriamycin. The DLKP-A cells still appeared 
significantly more resistant to adriamycin, when plated at high cell density and refed with fresh 
adriamycin every 48h., than when the cells were exposed to the same concentration of drug, 
at low cell plating density. Refeeding the low cell density assay with fresh drug resulted in 
negligible deviation from the toxicity profile generated by a single exposure to adriamycin.
The toxicity profiles generated by DLKPA5F at high cell plating density were 
similar whether they were obtained from one addition of adriamycin or refeeding with fresh 
drug every 48h. (Figure 3.13.2(c)). A  slight decrease in the toxicity profile was observed at 
low cell plating density when fresh adriamycin was added, in  comparison to the toxicity profile 
generated by one drug addition. Again, although the shape of the adriamycin toxicity profile 
was cell density-dependent, the addition of fresh drug did not alter the shape of the toxicity 
profile from that generated by a single addition of adriamycin.
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Adriamycin conc. (ng/ml)
DLKP
□ 2000 cells/well 
■ 2000 ce lls /w e ll, re fe e d  
0 200 c e lls /w e ll 
♦ 200 ce lla /w e ll, re fe e d
A driam ycin  conc. (|ig /m l)
D LK PA
□ 2000 ce lls /w ell 
■ 2000 c e lls /w e ll, r e fe e d  
o 200 cells /w ell 
♦ 200 ce lls /w e ll, re fe e d
A driam ycin  conc. (iig/m l)
C. D L K PA 5F
□ 2000 cells/w ell 
■ 2000 ce lls/w ell, re feed  
0 200 cells /w ell 
♦ 200 ce lls/w ell, re fe e d
Figure 3.13.2 : The effect of the readdition, 
every 48h, of fresh adriamycin to a toxicity 
assay of DLKP (a), DLKP-A (b) and DLKPA5F 
(c), set np at plating densities of 2000 cells/well 
and 200 cells/well. The error bars represent the 
standard deviation on the mean of three replicas.
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3.13.3 Effect of cell density on VP-16 toxicity to DLKP and DLKP-A
The cell lines, DLKP and DLKP-A were analyzed to determine if  the cell 
plating density affected the cells’ sensitivity to VP-16. As found for adriamycin, V P -16 was 
more toxic to both DLKP and DLKP-A at low cell plating density, than at high cell plating 
density (Figure 3.13.3(a)). An IC50 of approximately 0.075^ig/ml VP-16 was noted when 
DLKP cells were plated at 200 cells/well, whereas the IC50 value was approximately 0 .15/xg/ml 
when the cells were plated at 2000 cells/well. The sensitivity of DLKP-A cells to VP-16 was 
also dependent on the plating density used in the assay, and to approximately the same extent 
as observed in DLKP (Figure 3 .13.3(b)). An IC50 value of approximately 1.5/ig/ml VP-16 was 
observed at a plating density of 200 cells/well and this was increased to 3.0/xg/ml when the cell 
plating density was increased to 2000 cells/well. The shape of the toxicity curves generated by 
exposure of either DLKP or DLKP-A to increasing concentrations of V P-16 at high and low 
plating density were similar.
1
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a.
VP-16 conc. (fig/ml)
b.
VP-16 conc. (|ig/ml)
Figure 3.13.3 : VP-16 toxicity to DLKP (a) and DLKP-A (b), when cells are plated at 2000 cells/well
and 200 cells/well. The error bars represent the standard deviation on the mean of three replicas.
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3.13.4 Effect of cell density on VP-16 toxicity to VP-16-selected MDR cell lines
The VP-16-selected M DR cell lines, DLKP/VP-3 and DLKP/VP-8, were 
analyzed to determine if  the cell density effects noted in DLKP and DLKP-A also occurred in 
the VP-16-selected cell lines. Cell toxicity profiles to V P-16, generated at low plating densities, 
in DLKP/VP-3, resulted in only slight increases in toxicity in  comparison to that observed at 
high plating density (Figure 3.13.4(a)). The increase in the VP-16 sensitivity of DLKP/VP-3 
cells resulted in a decrease in  the IC50 from approximately 3.5/xg/ml to 2.75/*g/ml when the 
cells were plated at densities of 2000 cells/well and 200 cells/well, respectively. No significant 
alteration in  VP-16 toxicity was observed in DLKP/VP-8 (Figure 3.13.4(b)).
3.13.5 Effect of cell density on adriamycin toxicity in VP-16 selected MDR cells
DLKP/VP-3 and DLKP/VP-8 were analyzed to determine if  cell plating 
densities affected their sensitivity to adriamycin. Both cell lines’ sensitivities to adriamycin 
were found to be cell density-dependent (Figure 3.13.5). In both cell lines, the IC50 values were 
decreased from approximately 3/xg/ml adriamycin to 1/xg/ml adriamycin when toxicity was 
analyzed at plating densities of 2000 cells/well and 200 cells/well, respectively. Adriamycin 
toxicity profiles generated by DLKP/VP-3 appeared to be more cell density-dependent than 
those generated by DLKP/VP-8. The shape of the DLKP/VP-8 adriamycin toxicity profile was 
similar at high and low plating densities. W hen DLKP/VP-8 were set up at 2000 cells/well, 
less than 10% kill occurred up to 1/xg/ml adriamycin, with a rapid increase in cell kill noted 
at drug concentrations above this level. W hen the same cell line was exposed to adriamycin at 
200 cells/well, high cell kill was observed even at very low drug concentrations. In relation 
to DLKP/VP-3, at high cell plating density, little cell kill occurred at adriamycin concentrations 
below 2.25/xg/ml, after which an increase in  drug caused a large increase in cell kill. The 
initial rate of cell kill noted for DLKP/VP-3 and DLKP/VP-8 were similar, at low plating 
densities, but the percentage cell survival fell to lower levels at a relatively low drug 
concentration in DLKP/VP-3 in comparison to DLKP/VP-8.
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a.
b.
VP-16 conc. (fig/ml)
Figure 3.13.4 : VP-16 toxicity to DLKP/VP-3 (a) and DLKP/VP-8 (b), when cells are plated at 2000
cells/well and 200 cells/well. The error bars represent the standard deviation on the mean o f three
replicas.
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Adriamycin conc. (fig/ml)
b.
Adriamycin conc. (jig/ml)
Figure 3.13.5 : Adriamycin toxicity to DLKP/VP-3 (a) and DLKP/VP-8 (b), when cells are plated at
2000 cells/well and 200 cells/well. The error bars represent the standard deviation on the mean of three
replicas.
157
3.13.6 Conclusions
The sensitivity of DLKP and its drug-resistant variants to chemotherapeutic 
agents was cell density-dependent. The toxicity of adriamycin to adriamycin-selected M DR cell 
lines, was dependent on the cells’ density. Adriamycin was more toxic to cells which were 
plated at low density, by comparison with cells plated at high density. Adriamycin toxicity to 
DLKP cells was independent of the plating density of the cells. Cell density-dependent toxicity 
of adriamycin was also observed in the VP-16-selected cell lines. The differential adriamycin 
toxicity was not due to cell cycle effects. Changes in cell density caused only slight alterations 
to the toxicity of VP-16 to VP-16-selected, M DR variants of DLKP. However, VP-16 induced 
toxicity in DLKP and DLKP-A was cell density-dependent. The increased toxicity observed 
in DLKP-A at low cell plating density, by comparison with the level of VP-16 induced cell kill 
noted at high plating density, was less than that seen in the comparable study on cell density- 
dependent toxicity of adriamycin. Conversely, in the DLKP cells, the toxicity of V P-16 was 
found to be more strongly associated with the cell plating density, than the association observed 
for adriamycin toxicity.
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3.14 Gap Junctional Communication
To determine if metabolic co-operation was occurring between cells, invariants 
of the cell line DLKP, the existence of functional gap junctions within the population was 
examined by means of lucifer yellow transfer. The literature has cited many examples of 
altered gap junctional intercellular communication in cancer cells. Therefore the existence of 
active gap junctions was investigated in  a range of other cell lines established from  solid 
tumours. Intercellular adriamycin transfer was examined in DLKP variants to determine if 
adriamycin was transported within the cell lines via active gap junctions.
3.14.1 Microscopic analysis of functional gap junctional communication
W hen lucifer yellow, in a calcium-free solution, was added to DLKP cells, for
2 minutes at 37°C, the dye was observed to be transported from scrape-loaded cells, in a
confluent monolayer, to surrounding cells (Figure 3.14.1.1). This is a classical test for 
functional gap junctional communications in cells (El-Fouly et al. , 1987) and the ability of the 
fluorescent dye to be transferred from one cell to surrounding cells in  which it is in  physical 
contact, suggested the presence of active gap junctions in these cells. The adriamycin-selected 
M DR variant of DLKP, DLKP-A, also exhibited the ability to transfer lucifer yellow from 
scrape-loaded cells, in a calcium-free solution, to surrounding cells. This implied that they also 
possess active gap junctions (Figure 3.14.1.2). Two of the M DR clones isolated from  DLKP- 
A, DLKPA5F and DLKPA2B and the cell line generated by mixing clones DLKPA5F, 
DLKPA2B, DLKPA11B and DLKPA6B in the ratio 2:1:1:1, respectively (Section 3.13), was 
also observed to possess functional gap junctional intercellular communications (Figure 3.14.1.3 
-3 .14 .1 .5 ).
The literature has cited many cases of a decrease or absence of functional gap
junctions in cancer cells (Klann et al., 1989; Borek et al., 1969). However, functional gap
junctions were observed in all variants of DLKP i.e. the parental cell line, the adriamycin- 
selected M DR variant, the clones of the M DR variant and the cell line generated by mixing the 
clones. To determine if  functional gap junctions existed in other lung cell lines, cell lines 
established from other tumours and in other M DR cell lines established by adriamycin-selection 
of the parental cells, a range of cell lines were examined to determine if  they also possessed the 
ability to intercellularly transfer lucifer yellow.
No detectable lucifer yellow intercellular transfer was noted in the human lung 
squamous cell carcinoma, SKMES1. Fluorescence was confined to cells damaged by the scrape
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(3.14.1.6). The human colon (HT29), bladder (T24) and ovarian (OAW42) cell lines also 
exhibited no transfer of the fluorescent dye from damaged to intact cells, with which they were 
in physical contact (Figures 3.14.1.6 and 3.14.1.7). Therefore, no functional gap junctions 
were detectable in these cells. When the human epidermoid carcinoma of the larynx, Hep-2, 
and its adriamycin-selected MDR variant, Hep-2A (Redmond et al. , 1990) were examined to 
determine if they contained active gap junctional intercellular communications, no lucifer yellow 
transfer, from the scrape-loaded cells, was observed (Figure 3.14.1.7).
The ability of variants of DLKP to transfer adriamycin from scrape-loaded cells 
to surrounding cells, with which they were in physical contact, was also examined. The 
adriamycin was loaded into the cells by scraping a confluent monolayer of cells, in the presence 
of 100//M adriamycin in a calcium-free solution and incubating the cells for 10 minutes at 37°C, 
to allow transfer of the drug via active gap junctions. Gap junction transfer was than stopped 
by washing the cells in a calcium-containing solution. W hen the cells were examined by 
fluorescent microscopy, only cells containing adriamycin fluoresced.
DLKP cells bordering the scrape were observed to fluoresce strongly, with 
weaker background fluorescence also noted, implying that, unlike lucifer yellow, adriamycin 
readily diffused into the cells (Figure 3.14.1.1). Physically damaged cells fluoresced more 
intensely than the background intact cells, but this stronger fluorescence was confined to cells 
bordering the scrape and was not transferred to neighbouring cells. This implied that the 
adriamycin was not being transferred intercellularly, via active gap junctions, that have been 
shown to exist by lucifer yellow intercellular transfer, even though the molecular size of 
adriamycin would, theoretically, allow gap junctional transfer. As was observed for DLKP, 
the M DR cell line DLKP-A, its clones DLKPA5F and DLKPA2B and the cell line consisting 
of mixed DLKP-A clones, did not intercellularly transfer adriamycin via active gap junction 
communication (Figure 3.14.1.2 - 3.14.1.5). The intensity of the background fluorescence, due 
to adriamycin diffusing into, and remaining in the cells, was lower in all the M DR cell lines 
examined. Again, only the cells bordering the scrape fluoresced intensely.
As previously shown, all M DR variants of DLKP exhibit the characteristic of 
over-expressing P-glycoprotein (Section 3.9) which functions by pumping a broad range of 
chemotherapeutic drugs, including adriamycin, out of cells and therefore renders them more 
resistant to the drug. To ensure that the effect of drug efflux was not masking the gap 
junctional transfer of adriamycin in the M DR cell lines, the cellular localisation of the 
adriamycin, in the presence of 30/ig/ml cyclosporin A, was examined. No intercellular transfer 
of adriamycin was observed following scrape loading of cells in  the concurrent presence of both 
adriamycin and cyclosporin A. A similar fluorescence pattern, to that observed in the presence 
of 100/xM adriamycin alone, was noted (Figure 3.13.1.1 - 3.14.1.5).
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Figure 3.14.1.1 : Gap junction intercellular communication in DLKP, as determined by the transfer of 
scrape-loaded luciter yellow in confluent monolayers (a). The intercellular transfer of lucifer yellow was 
blocked by the presence of the gap junction inhibitor, heptanol, at a concentration of 1.5mM (c). 
Intercellular transfer of adriamycin was not observed (e) when the cells were scrape-loaded in the 
presence of 100/xM adriamycin. When the cells were co-incubated with adriamycin and 30/xg/ml 
cyclosporin A, a drug efflux circumventing agent, gap junctional mediated intercellular transfer of the 
drug was not observed (g). Figures b, d, f and h are the light microscope views of Figure a, c, e and 
g, respectively.
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Figure 3.14.1.2 : Gap junction intercellular communication in DLKP-A, as determined by the transfer 
of scrape-loaded lucifer yellow in confluent monolayers (a). The intercellular transfer of lucifer yellow 
was blocked by the presence of the gap junction inhibitor, heptanol, at a concentration of 1.5mM (c). 
Intercellular transfer of adriamycin was not observed (e) when the cells were scrape-loaded in the 
presence of lOOjtM adriamycin. When the cells were co-incubated with adriamycin and 30/xg/ml 
cyclosporin A, a drug efflux circumventing agent, gap junctional mediated intercellular transfer of the 
drug was not observed (g). Figures b, d, f and h are the light microscope views of Figure a, c, e and 
g, respectively.
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Figure 3.14.1.3 : Gap junction intercellular communication in DLKPA2B, as determined by the transfer 
of scrape-loaded lucifer yellow in confluent monolayers (a). The intercellular transfer of lucifer yellow 
was blocked by the presence of the gap junction inhibitor, heptanol, at a concentration of 1.5mM (c). 
Intercellular transfer of adriamycin was not observed (e) when the cells were scrape-loaded in the 
presence of lOOftM adriamycin. When the cells were co-incubated with adriamycin and 30/ig/ml 
cyclosporin A, a dnig efflux circumventing agent (g), gap junctional mediated intercellular transfer of 
the drug was not observed. Figures b, d f  and h are the light microscope views of figure a, c e and g, 
respectively.
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Figure 3.14.1.4 : Gap junction intercellular communication in DLKPA5F, as determined by the transfer 
of scrape-loaded hicifer yellow in confluent monolayers (a). The intercellular transfer of lucifer yellow 
was blocked by the presence of the gap junction inhibitor, heptanol, at a concentration of 1.5mM (c). 
Intercellular transfer of adriamycin was not observed (e) when the cells were scrape-loaded in the 
presence of 100/tM adriamycin. When the cells were co-incubated with adriamycin and 30/xg/ml 
cyclosporin A, a drug efflux circumventing agent, gap junctional mediated intercellular transfer of the 
drug was not observed (g). Figures b, d, f and h are the light microscope views of Figure a, c, e and 
g, respectively.
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Figure 3.14.1.5 : Gap junction intercellular communication in the cell line generated by mixing the 
DLKP-A clones, as determined by the transfer of scrape-loaded lucifer yellow in confluent monolayers 
(a). The intercellular transfer of lucifer yellow was blocked by the presence of the gap junction inhibitor, 
heptanol, at a concentration of 1.5mM (c). Intercellular transfer of adriamycin was not observed (e) 
when the cells were scrape-loaded in the presence of 100/xM adriamycin. When the cells were co­
incubated with adriamycin and 30ftg/ml cyclosporin A, a drug efflux circumventing agent, gap junctional 
mediated intercellular transfer of the drug was not observed (g). Figures b, d, f  and h are the light 
microscope views of figure a, c, e and g, respectively.
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Figure 3.14.1.6 : Gap junction intercellular communication in cell lines, as determined by the transfer 
of scrape-loaded lucifer yellow, in confluent monolayer cultures. The intercellular transfer of lucifer 
yellow in the human squamous lung carcinoma, SKMES1 (a), the human colon HT29 cell line (c) and 
the human bladder cell line, T24 (e), was examined. Figures b, d, and f are the light microscopic view 
of Figures a, c and e, respectively.
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Figure 3.14.1.7 : Gap junction intercellular communication in cell lines, as determined by the transfer 
of scrape-loaded lucifer yellow, in confluent monolayer cultures. The intercellular transfer of lucifer 
yellow in the human ovarian carcinoma, OAW42 (a), the human epidennoid carcinoma of the larynx, 
Hep-2 (c) and its adriamycin-selected MDR variant, Hep-2A (e), was examined. Figures b, d, and f are 
the light microscopic view of Figures a, c and e, respectively.
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3.14.2 Inhibition of gap junctional communication
Gap junctional communication was blocked in all DLKP variants by pre­
incubation of the cell with 1.5mM heptanol for 1.5h. and the continual presence of 1.5mM 
heptanol during scrape loading of the fluorescent marker (Figure 3.14.1.1 -3 .1 4 .1 .5 ). When 
lucifer yellow was loaded into the cells in the presence of the gap junctional communication 
inhibitor, fluorescence was only observed in  cells bordering the scrape and so, the lucifer 
yellow was not transported via active gap junctions to surrounding cells, as had been observed 
previously. The presence of 1.5mM heptanol, under similar conditions, did not alter the 
cellular fluorescent staining patterns generated by adriatnycin, from that originally observed for 
cells scrape loaded with adriamycin alone. The adriamycin was confined to damaged cells and 
was not transferred to intact cells (photographs not shown).
3.14.3 Effect of gap junction inhibition on adriamycin toxicity
The effect of blocking intercellular communication, via gap junctions, on the 
toxicity of adriamycin to a range of DLKP variants was examined, by performing an adriamycin 
toxicity assay, at high and low plating density, in the presence of 1.5mM heptanol. The assay 
was carried out on the DLKP cell line, its adriamycin-selected M DR variant DLKP-A, the 
DLKP-A clones DLKPA2B and DLKPA5F and on the cell line generated by mixing the clones. 
The assay was carried out in duplicate with triplicate repeats performed in each duplicate. The 
graphs shown represent the data obtained from one of the repeats.
The concentration of heptanol which resulted in complete inhibition of gap 
junctional communication (1.5mM) also resulted in 50% cell kill under toxicity assay 
conditions. Therefore the cells were set up at twice the cell density required, if heptanol was 
to be added, as outlined in Section 2.11.6. The inhibition of gap junctional communication in 
cell lines did not, in general, enhance their sensitivity to adriamycin. The presence of heptanol 
resulted in a slight increase in cell survival in the presence of adriamycin, but alone did not 
appear to stimulate cell growth. In both the parental and MDR cell line DLKP-A, heptanol 
appeared to protect the cells from the toxic effect of adriamycin, at both high and low densities 
(Figure 3.14.3.1). In the cell clone DLKPA5F, heptanol did not significantly alter the 
adriamycin toxicity profile generated by the cells at both high and low plating density (Figure 
3.14.3.2(b)). W ith respect to DLKPA2B, the least resistant clone, heptanol enhanced the 
toxicity of adriamycin at high cell density and reduced its toxicity at clonal density (Figure
3.14.3.2(a)). W hen the clones were mixed to regenerate a DLKP-A-like cell line and the cells 
exposed to adriamycin in  the presence of heptanol, the toxicity profile was not significantly 
different from that observed when the cells were exposed to adriamycin alone, at the respective 
cell plating density (Figure 3.14.3.2(c)).
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□ 2000 cells/well
a.
Adriamycin conc. (ng/ml)
b.
Adriamycin conc. (fig/ml)
Figure 3.14.3.1 : The effect of pre-treatment with and continuous exposure to 1.5mM heptanol on
adriamycin toxicity to DLKP (a) and DLKP-A (b) when cells are plated at 2000 cells/well and 200
cells/well. The error bars represent the standard deviation on the mean of three replicas.
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Figure 3.14.3.2 : The effect of 1.5mM heptanol 
on adriamycin toxicity to DLKPA2B (a), 
DLKPA5F (b) and the mixed clones, generating 
a DLKP-A-like population (c), at a plating 
density of 2000 cells/well. The error bars 
represent the standard deviation on the mean of 
three replicas.
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3.15 Effect of conditioned media on adriamycin toxicity to DLKPA2B
A preliminary experiment was carried out to investigate whether the protective 
effect observed at high cell plating densities, with respect to adriamycin toxicity, was due to a 
physical or non-physical method of protection. The effect of conditioned media from 
DLKPA5F and DLKPA2B, generated both in the presence and absence of 2.5^g/ml adriamycin 
for 24h. (Table 3.15), on adriamycin toxicity to DLKPA2B at high and low cell density was 
investigated. The assay was performed once, with triplicate intra-assay repeats.
Description of conditioned 
medium, as pertaining to 
Figures 3.15.1 and 3.15.2
Preparation of the Conditioned Medium.
Fresh medium and adriamycin Adriamycin was added to fresh ATCC medium, to a final 
concentration of 2.5/jg/ml. Serial dilutions of the drug- 
containing medium were made, using fresh ATCC medium.
Cond. medium from DLKPA2B 
exposed to 2.5/jg/ml adr.
ATCC medium, containing 2.5/tg/ml adriamycin, was exposed 
to DLKPA2B for 24h. at 37°C. The conditioned medium was 
collected, filter-sterilised using a low protein-binding filter, and 
the adriamycin content of the medium determined by 
fluorometric analysis. Fresh adriamycin was then added to the 
medium to bring it to a final concentration of 2.5/ig/ml and this 
drug-containing conditioned medium diluted with drug-free 
conditioned medium.
Cond. medium from DLKPA5F 
exposed to 2.5/jg/ml adr.
ATCC medium, containing 2.5/ig/ml adriamycin, was exposed 
to DLKPA5F for 24h. at 37°C. The conditioned medium was 
collected, filter-sterilised using a low protein-binding filter, and 
the adriamycin content of the medium determined by 
fluorometric analysis. Fresh adriamycin was then added to the 
medium to bring it to a final concentration of 2.5/ig/ml and this 
drug-containing conditioned medium diluted with drug-free 
conditioned medium.
Cond. medium from DLKPA2B 
with fresh adriamycin
Fresh ATCC medium was exposed to DLKPA2B cells for 24h. 
at 37°C. The conditioned medium was collected and filter- 
sterilised through a low protein-binding filter. Adriamycin was 
added to an aliquot of the conditioned medium, to bring it to a 
final concentration of 2.5/jg/ml. Serial dilutions were 
performed on the drug-containing conditioned medium, using 
the drug-free conditioned medium.
Cond. medium from DLKPA5F 
with fresh adriamycin
Fresh ATCC medium was exposed to DLKPA5F cells for 24h. 
at 37°C. The conditioned medium was collected and filter- 
sterilised through a low protein-binding filter. Adriamycin was 
added to an aliquot of the conditioned medium, to bring to a 
final concentration of 2.5^g/ml. Serial dilutions were 
performed on the drug-containing conditioned medium, using 
the drug-free conditioned medium.
Table 3.15 : Protocol followed in generating adriamycin-free and adriamycm-containing conditioned 
medium and in determining the level of adriamycin present in  the medium.
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As previously observed (Section 3.13.1), adriamycin toxicity to DLKPA2B was 
cell density-dependent. At high plating density the IQq value obtained for adriamycin toxicity 
was approximately 0.75/xg/ml (Figure 3.15.1) but this was decreased to approximately 
0 .15/xg/ml adriamycin (Figure 3.15.2) when the cells were plated at 200 cells/well. At high 
plating density, i.e. when the cells were plated at 2000 cells/well, conditioned media from both 
DLKPA2B and DLKPA5F, generated both in the presence and absence of 2.5/ig/ml adriamycin, 
partially protected DLKPA2B cells from the toxic effect of adriamycin (Figure 3.15.1). 
However, at low plating density, only the conditioned media generated by DLKPA5F in the 
presence of 2.5/xg/ml adriamycin exerted a protective effect on DLKPA2B cells (Figure 3.15.2).
The final amount of adriamycin present in the conditioned media, generated by 
exposing DLKPA2B and DLKPA5B to 2.5/xg/ml adriamycin for 24h., was determined by the 
level of the media’s fluorescence. Any fluorescence was assumed to be active adriamycin. This 
did not account for any deactivation of adriamycin that may have occurred in the 24h. period, 
which was not reflected by a decrease in the drug’s fluorescence. When DLKPA2B was plated 
at high density, the level of cell kill caused by the presence of adriamycin, in the conditioned 
media from both DLKPA5F samples was similar, whether the adriamycin had been exposed to 
DLKPA5F for 24h. at 37°C and the conditioned medium then supplemented with fresh 
adriamycin or whether fresh adriamycin was added to drug-free conditioned medium from 
DLKPA5F, immediately prior to use in the assay. This suggests that equal levels of active 
adriamycin and/or its active metabolites, were present in both samples. Therefore, the lower 
level of cell kill observed in DLKPA2B when exposed to conditioned medium from DLKPA5F, 
which had been exposed to adriamycin for 24h. and then supplemented with fresh adriamycin, 
was not due to a lesser amount of active drug being present in that sample.
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Figure 3.15.1 : Effect of 
conditioned media from 
DLKPA2B and DLKPA5F, 
on adriamycin toxicity to 
DLKPA2B, at a cell plating 
density of 2000 cells/well.
Figure 3.15.2 : Effect of 
conditioned media from 
DLKPA2B and DLKPA5F 
on adriamycin toxicity to 
DLKPA2B, at a cell plating 
density of 200 cells/well.
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4.0 Discussion
The existence of the phenomenon of tumour cell heterogeneity has been widely 
documented in the literature (Owens et a l., 1982; Heppner and Miller, 1989) and is responsible 
for variations in the characteristics of tumour cells to a range of attributes, from growth 
properties (Fried et al., 1993) to sensitivity to chemotherapeutic drugs (Dolfini et al., 1993; 
Tsuruo and Fidler, 1981). Clonal variation has also been demonstrated in MDR cell lines 
(Yang et al., 1993) and to further investigate this phenomenon, clonal cell lines have been 
isolated from the P-glycoprotein overexpressing, adriamycin-selected MDR variant of DLKP, 
DLKP-A. VP-16-selected MDR variants of the squamous cell carcinoma of the lung have also 
been isolated and characterised, and the mechanisms underlying their resistance profile have 
been explored.
4.1 Confirm ation that M DR cell lines are variants o f DLK P
The majority of cell lines used in the course of this study are variants of DLKP. 
Cross contamination of the cells with other cell lines could result in an alteration of the 
characteristics of the cells under investigation. DNA fingerprint analysis, performed by 
Cellmark Diagnostics, confirmed that all variants of DLKP used in this study possessed DNA  
fingerprints homologous to DLKP (Section 3.3), and so were confirmed as having been derived 
from DLKP cells. The variants of DLKP share 56 identical bands in their fingerprints. DLKP, 
DLKP-A and DLKPA6B possess one additional band at different positions within their 
fingerprints. DLKP/VP-3 and DLKPA11B have two additional bands, one of which is shared 
by both cell lines. Cellmark Diagnostics concluded that all DLKP variants shared a common 
origin and that additional bands to those shared by all cells within the group may be due to 
slight clonal variation as a result of random mutational events.
4.2  Resistance Profile o f M DR cell lines
Following selection with VP-16, the DLKP variants DLKP/VP-3 and 
DLKP/VP-8 exhibited stably expressed MDR profiles. The cells were highly cross-resistant to 
vincristine (1088.98 ±  161.08 and 1737.42 ±  347.00-fold resistance, respectively), adriamycin 
(90.10 ±  13.24 and 272.42 ±  38.07-fold resistance, respectively), VP-16 (58.23 ±  2.31 and 
101.24 ±  6.54-fold resistance, respectively), hyper-sensitive to cisplatin(0.32 ±  0.17 and 0.22
176
±  0.06-fold resistance, respectively), with no significant alteration in 5-fluorouracil toxicity 
(0.47 ±  0.38 and 0.90 ±  0.43-fold resistance, respectively) (Table 3.1.2.2). This profile 
mirrors the cross resistance profile, except with respect to the cisplatin sensitivity, obtained for 
DLKP-A, the adriamycin-selected MDR variant of the squamous cell carcinoma (Clynes et al. ,
1992).
When the VP-16-selected cell line, DLKP/VP-3, was exposed over a period of 
3 months, to higher concentrations of VP-16 (up to 8.0/xg/ml for DLKP/VP-8), the cross 
resistance profile was altered. The resistance of the cells to VP-16, vincristine and adriamycin 
was increased and the ratio of fold resistance, between the three drugs, was altered. When the 
fold resistance to adriamycin was taken as one, the ratio of fold resistance to adriamycin, 
vincristine and VP-16 was 1:12.09:0.65 for DLKP/VP-3 and 1:6.38:0.37 for DLKP/VP-8 
(Section 3.1.2). However, the relative fold resistance exhibited by the VP-16 selected cell lines 
to vincristine and VP-16 remained approximately constant. When the fold resistance to VP-16 
was taken as one, DLKP/VP-3 possessed a ratio of vincristine fold resistance to VP-16 fold 
resistance of 18.60:1, whereas DLKP/VP-8 exhibited a ratio of 17.24:1. The relative sensitivity 
to cisplatin and 5-fluorouracil exhibited by the VP-16-selected cell lines was not significantly 
altered by exposing the cells to VP-16, at a higher concentration and for a longer time period.
Similarities also existed between DLKP-A and DLKP/VP-8 in relation to their 
relative cross resistance ratios towards vincristine, adriamycin and VP-16 (Tables 3 .1 .2 .2  and
3.2.2.2). While DLKP/VP-8 possessed the aforementioned fold resistance ratio of 1:6.38:0.37 
to adriamycin, vincristine and VP-16, respectively, DLKP-A cells exhibited a ratio of 
1:5.92:0.24. Allowing for the standard deviations observed within the IC50 calculations, both 
cell lines exhibited similar cross-resistance profiles. Neither DLKP-A, DLKP/VP-3 nor 
DLKP/VP-8 were most resistant to their specific selective agents, adriamycin for DLKP-A and 
VP-16 for the remaining cells. All possessed similar resistance profiles: most resistant to 
vincristine; followed by adriamycin; least resistant to VP-16; no cross resistance to 5- 
fluorouracil and only the VP-16-selected cells exhibiting sensitivity to cisplatin. This suggests 
that the cross resistance profile obtained for the MDR variants of the DLKP cell line, when 
selected with MDR associated drugs, was dictated by more than one mechanism of resistance. 
However, the resistance to adriamycin, vincristine and VP-16 exhibited by the DLKP-A and 
DLKP/VP-8 cells may be due to one mode of resistance, while the collateral sensitivity to 
cisplatin, exhibited by VP-16-selected cells, may be due to a second mechanism, not displayed 
by DLKP-A cells.
The altered toxicity profiles exhibited by the MDR cells may be due to the 
selective agents used to derive the drug-resistant cell lines. The two chemotherapeutic drugs 
used in the selective process share some common modes of action. Adriamycin, as depicted
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in Figure 4 .1(a), produced by a species of Streptomyces, is a four ring anthracycline molecule, 
linked to a sugar, daunosamine. It has a wide range of clinical activities for many types of solid 
tumours and leukaemia. A number of mechanisms contribute to the cytocidal effect of 
adriamycin (Speth et al., 1988; Booser and Nortobagyi, 1994). It intercalates with DNA  
causing partial unwinding of DNA, single- and double-strand breaks (adriamycin is a 
topoisomerase II inhibitor) and inhibition of DNA and RNA synthesis. It undergoes metabolism 
of its quinone ring to a semiquinone radical, which in turn reacts with oxygen to yield 
superoxide, leading to oxidative damage of cell membranes and DNA. It binds to cell 
membranes and kills cells through membrane-related effects (Tritton and Yee, 1982). VP-16 
(Figure 4.1(b)) is a semi-synthetic glycoside derivative of podophyllotoxin, which is an 
antimitotic derivative of the mandrake plant. It is used for the treatment of small cell lung 
carcinoma, testicular cancer and lymphomas (O’Dwyer et a l., 1985). The drug arrests cells in 
late S or early G2 phase of the cell cycle. It is a potent topoisomerase II inhibitor, causing 
DNA strand breaks. It also inhibits nucleoside transport into cells and nucleoside incorporation 
into RNA and DNA. However, although adriamycin functions as a topoisomerase II inhibitor 
by binding to the DNA in the cleavable complex formed by the DNA, enzyme and drug, VP-16 
blocks topoisomerase II action by binding to the enzyme. Exposure of cells to both drugs has 
also resulted in the overexpression of the P-glycoprotein drug efflux pump, as a mechanism of 
resistance (Twentyman et al., 1986; Takigawa et al., 1992).
Figure 4.1 : The structures of adriamycin (a) and VP-16 (b).
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Cell line Cell type Selective drug 
fold resistance
ADR. DAUN. VCR. VBL. VP-16 VM-26 5-FU CDDP References
NCIH69/Dau8 SCLC DAUN 9.5X * * * * # # Jensen et al., 1989
H69/LX4 SCLC ADR 5X * * Twentyman et al., 1986a
H69AR SCLC ADR 35X * * * * NC Mirski et a l. , 1987
g l c 4/a d r SCLC ADR 44X 5.7 37.5 2.1 Zijlstra el a l., 1987
U1690-40 SCLC ADR 5.5X 40.1 16.3 1.4 Nygren el a l. , 1991
U1690-150 SCLC ADR 7.0 245.6 Nygren et a l. , 1991
U1285/100 SCLC ADR 3.4X 4.9 8.2 3.63 Nygren et a l., 1991
U1285/250 SCLC ADR 3 .IX 16.7 Nygren e ta l ., 1991
COR L23/R LCLC ADR 16.9X 9.9 25.5 12.1 Twentyman et a l. , 1986a
SW1573/50 SqCLC ADR 10X 3.6 5.5 23 0.6 Keizer et a l., 1989
SW1573/500 SqCLC ADR 250X 70 540 270 0.25 Keizer et a l. , 1989
SW1573/10000 SqCLC ADR 2000X 750 0.7 Keizer e ta l . ,  1989
H69/VPR-2 SCLC VP-16 20X 5.5 20 1.5 1 Glisson and Alpeter, 1992
HCIH69/VP SCLC VP-16 17X 6.3 7.9 Jensen et a l. , 1992
SBC-3/ETP SCLC VP-16 52. IX 39.5 172 147 1 1 Takagawa et a l. , 1992
A549(VP)28 Adenocarc. VP-16 8X 8.1 3.1 0.08 Long et al., 1991
A549(VM)28 Adenocarc. VM-26 8X 8.4 3.1 0.35 Long et a l. , 1991
OC-NYH/VM SCLC VM-26 10.7X 2.9 0.9 12.0 Jensen e ta l ., 1991,1993
H69/CDDP SCLC CDDP 10.9X 1.01 1 0.7 Hong et a l. , 1988
A549/CTP Adenocarc. CTP 1.8X 2.3 2.1 Sugimoto et a l., 1990(a,b)
Cross resistance (*) and collateral sensitivity (//) was observed, but the inherent heterogeneity of the cells makes exact quantification of the degree of resistance difficult. 
SCLC = Small cell lung carcinoma, SqCLC =  Squamous cell carcinoma of the lung, Adenocarc.= Adenocarcinoma of the lung, NC =  No change,
ADR. =  Adriamycin, DAUN.= Daunorubicin, VCR. =  Vincristine, VBL. =  Vinblastine, 5-FU =  5-Fluorouracil, CDDP =  Cisplatin, CTP =  Camptothecin.
Table 4.2 : Resistance profiles of MDR cell lines, established by exposing lung cell lines to chemotherapeutic drugs.
Table 4.2 presents the cross-resistance profile of drug-selected MDR human 
lung cancer cell lines. When the cell lines shown in the table are compared to MDR variants 
of DLKP-A, similarities and differences in their resistance profiles are evident. Long et al.
(1991) established a MDR variant of the human lung adenocarcinoma cell line A549 by 
selection with VP-16. The resulting MDR cell line was 8-fold resistant to VP-16, cross 
resistant to adriamycin (3.1-fold) and hypersensitive to cisplatin (0.08-fold resistance). In the 
work described in this thesis, selection by VP-16 also conferred sensitivity to cisplatin on MDR 
variants of DLKP, but the adriamycin-selected MDR variant exhibited no alteration in its 
cisplatin sensitivity. However, adriamycin-selected variants of the squamous cell carcinoma of 
the lung, SW1573, also exhibited collateral sensitivity to cisplatin. Takigawa et al. (1992) 
found that selection of a MDR variant of a human small cell lung carcinoma, SBC-3, with 
increasing concentrations of VP-16, resulted in a cell line with cross resistance to a similar 
range of drugs and in a similar rank order, with respect to adriamycin and vincristine, as 
DLKP/VP-3 and DLKP/VP-8, but the sensitivity to cisplatin was unaltered. Although the fold 
resistance to VP-16 (52.1-fold) was similar to that exhibited by DLKP/VP-3 cells (58.23-fold), 
the relative levels of resistance to vincristine and adriamycin were substantially lower than that 
observed for DLKP/VP-3. Mirski et al. (1993) found that the MDR cell line resulting from 
the H209 human small cell lung carcinoma’s selection with VP-16, produced a similar MDR 
profile to that obtained by Takigawa et al. (1992).
Both the adriamycin- and VP-16-selected DLKP cells exhibited high levels of 
cross resistance to vincristine. Generally, such high levels of resistance to vincristine result 
following selection by that drug, or where an equally high level of resistance to the selective 
agent is noted (Nielsen and Skovsgaard, 1992; Beck and Danks, 1991). However, a number 
of MDR cell lines have been isolated by selection with drugs other than vincristine, which also 
exhibit high levels of cross-resistance to vincristine and where the resistance to the selective 
agent is substantially lower. Keizer et al. (1989) found that the adriamycin-selected human 
squamous lung carcinoma, SW-1573/500, was 540-fold cross resistant to vincristine. However, 
the magnitude of resistance, in comparison to adriamycin resistance (250-fold), was not as high 
as that observed in the DLKP variants or by Nygren et al. (1991). They noted that the cell 
lines, resulting from the exposure of the small cell lung carcinoma cell line, U1690, to varying 
concentrations of adriamycin, were cross-resistant to vincristine at a higher magnitude than their 
resistance to adriamycin. While the cell line U 1690-40 was 5.5-fold resistant to adriamycin, 
it was 40.1-fold resistant to vincristine and 16.3-fold resistant to VP-16 and although U1690- 
150 was only 7-fold resistant to adriamycin it was 245.6-fold resistant to vincristine. Benard 
et al. (1989) have noted a similar intensity, and rank order, in relative resistance levels, of a 
vincristine-selected MDR variant of a human ovarian carcinoma, IGORVI, to that observed in
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the DLKP variants. The cell line described by Benard et al. (1989) was 750-fold resistant to 
vincristine, 30-fold resistant to adriamycin and 20-fold resistant to VP-16, by comparison with 
their drug sensitive parental cell line.
4.3  Resistance profile o f clones
Marked variation existed within the DLKP-A clones, with respect to their 
sensitivity to adriamycin-induced cell kill (Section 3.2.2). Characterisation of the clonal 
variants of the DLKP-A cell line, with respect to their drug sensitivity profiles, indicated that 
cells within the MDR population all possessed individual cross resistance profiles. All clones 
were highly resistant to the selective agent, adriamycin, and also to vincristine and VP-16 and 
all possessed a similar rank order of resistance to these drugs, as that exhibited by DLKP-A. 
The clones were all most resistant to vincristine, next to adriamycin and less so to VP-16. Most 
exhibited no, or slight, alteration in their cross resistance profiles to 5-fluorouracil or cisplatin, 
by comparison with their toxicity to either DLKP or DLKP-A. DLKPA1 IB exhibited collateral 
sensitivity to 5-fluorouracil, by comparison with DLKP-A, but no significant alteration in its 
5-fluorouracil resistance level, when compared to DLKP. DLKPA5D was the only 
subpopulation isolated from DLKP-A which exhibited differential resistance to cisplatin, by 
comparison with both DLKP and DLKP-A (it exhibited a 2-fold resistance to cisplatin, by 
comparison with DLKP). Although cross-resistance to 5-fluorouracil and cisplatin is not a 
characteristic of MDR, most MDR cells exhibit slight alterations in their resistance to the two 
drugs. The MDR small cell lung carcinoma isolated by exposing U1285 cells to adriamycin 
(Nygren et al., 1991) was 3.63-fold resistant to cisplatin and the GLC4/ADR MDR cells, 
derived by exposing a small cell lung cancer cell line to adriamycin (Zijlstra et al., 1987) 
exhibited an increase in its cisplatin resistance (2.1-fold). The VP-16-selected variant of NCI 
H69, isolated by Glisson and Alpeter (1992) exhibited slight resistance to 5-fluorouracil (1.5- 
fold).
A 9-fold variation in adriamycin resistance existed between the most and least 
resistant clone, which spanned the level of adriamycin resistance exhibited by DLKP-A. As 
DLKPA5F maintained a stable resistance profile throughout extensive subculturing and 
cryopreservation (Section 3.4.2), it is unlikely that the resistance profiles of the other DLKP-A 
clones were not stably maintained. This implies that the variation in the resistance profile of 
DLKP-A clones is a characteristic of the DLKP-A population and did not arise due to their 
isolation and being maintained separately and in the absence of adriamycin, whereby instability 
in the cells’ resistance to adriamycin would have led to a decline in their resistance levels.
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Therefore, within the DLKP-A cell line, subpopulations are existing which possess individual 
resistance profiles. Some subpopulations are more resistant to the chemotherapeutic drugs than 
the DLKP-A cell line, while some subpopulations possess substantially reduced resistance 
profiles.
A notable feature, common to all variants of DLKP, was the substantial 
variation in their resistance to a given chemotherapeutic drug noted in replicate assays. This 
variation was most notable in the case of the cells’ sensitivity to vincristine, where up to 50% 
variation was observed in day-to-day repeats. When MDR variants of the small cell lung 
carcinoma, NCI H69, were selected by exposing the cells to daunomycin (Jensen et al., 1989) 
and adriamycin (Twentyman et al., 1986a; Mirski et al., 1987), the resulting cell lines all 
exhibited cross resistance to a range of chemotherapeutic drugs. However, exact quantification 
of the degree of resistance was hindered by the high level of variation in the cells. This 
variation in resistance levels was possibly due to the inherent heterogeneity of the uncloned cell 
lines. Heterogeneity within the DLKP, DLKP-A, DLKP/VP-3 and DLKP/VP-8 cell lines may 
explain the high variation in resistance levels in these uncloned cell lines, but this cannot be the 
cause of the variation observed in the cloned variants of DLKP-A. The low intra-assay 
variability and the good correlation between repeat assays performed simultaneously (results not 
shown), argues against the assay method being the cause of the variability.
As no one clone accurately mirrored the toxicity profile of DLKP-A with 
respect to the range of chemotherapeutic drugs, it implied that it was the combined 
characteristics of the clones which were responsible for the MDR profile of the DLKP-A cells. 
However, the drug resistance of the remixed clones could not completely account for the 
toxicity profile of the parental cells, DLKP-A. At low adriamycin concentrations, the toxicity 
profile generated by the mixed clones and the DLKP-A cell line deviated significantly (Section 
3.7). This implied that a factor, or factors, which was important in determining the cells ability 
to survive in the presence of adriamycin, was absent in the mixed clones. This missing factor(s) 
may be the extra degree of resistance provided by an additional clone, either characterised in 
this study or still unknown, or may by due to the interaction of the clones within the DLKP-A 
population.
4 .4  Clonal Heterogeneity
Two possibilities as to the origin of drug resistance in cells are that it is an 
inherent property of the cells or that it may be acquired following exposure to drug. The 
chemotherapeutic drugs may therefore act as mutagens, causing genetic changes which result
182
in MDR cells and/or as selective agents, eliminating the sensitive cells from the population. 
DLKP was established from a primary human squamous lung carcinoma and exhibited high 
levels of cytogenetic variability (Law et a l., 1992). DLKP-A was established by exposing the 
uncloned DLKP cell line to increasing concentrations of adriamycin over a prolonged time 
period (Clynes et al. , 1992). Consequently, the potential existed for the drug resistant cells to 
have been selected from a pre-existing resistant population or to have been acquired following 
exposure to adriamycin. DLKP-A exhibit cytogenetic aberrations, consistent with mutagenic 
events associated with the acquisition of an MDR phenotype (Clynes et a l., 1992).
Heterogeneity within tumours, with respect to drug sensitivity, has been widely 
documented in the literature (Allalunis-Turner ei al., 1993; Tanigawa et al., 1984; Trope 1982). 
Trope (1982) detailed a study in which eighteen mouse sarcoma tumours were quartered and 
each section used to prepare a cell suspension. When the cell suspensions were tested in vitro 
for sensitivity to melphalan, the level of sensitivity varied markedly between individual tumours. 
As regards individual tumours, some appeared nearly homogeneous, while others showed high 
levels of intra-tumour variation in their sensitivities. Dolfini et al. (1993) isolated two clones 
of the colon adenocarcinoma cell line, LoVo. While clone LoVo Cl .7 was intrinsically resistant 
to adriamycin, clone LoVo Cl .5 showed the same resistance level as the mixed population. In 
an investigation of clonal variation within an MDR cell line, Yang et al. (1993) isolated two 
distinct subclones from a cisplatin-resistant human colon carcinoma cell line, LoVo, as 
distinguished by morphology. It was found that the clones exhibited varying drug resistance 
levels and cross-resistance profiles, to a variety of anticancer agents. Both clones were resistant 
to the selective agent, cisplatin and also to 5-fluorouracil and mustargen, but to varying levels 
in each clone. The most resistant clone, with respect to cisplatin toxicity, was also cross 
resistant to adriamycin and vincristine, whereas the least resistant clone exhibited a slightly 
enhanced sensitivity to the two chemotherapeutic drugs.
However, research has shown that the sensitivity of mixed cell populations to 
chemotherapeutic drugs is dictated by an additional factor, other than the sensitivity o f the 
individual clones. Miller et al. (1989) observed that when subpopulations of a murine 
mammary tumour (with varying intrinsic sensitivity to methotrexate), were mixed and injected 
into nude mice, the resulting tumours exhibited altered sensitivity to methotrexate. The tumours 
resulting from the mixture of cell lines 66 and 4T 07, tended to be as sensitive as tumours 
arising from homogenous 4T07 cells (these were the most sensitive tumours). However, 
tumours arising following injection of mixtures of 168 and 4T07 cells tended to be more 
resistant than tumours derived from 4T07 cells. Alterations in the melphalan sensitivity of 
tumours derived from mixtures of this murine mammary cell lines, have also been documented 
(Miller et al. , 1991).
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Heterogeneity within the DLKP-A cell line was not limited to the cells’ 
sensitivity to a range of chemotherapeutic agents. Variation within the growth rates of 
subpopulations of DLKP-A was also observed. Although the doubling time of DLKP-A was 
determined to be 31.72h., the doubling time of clones of DLKP-A ranged from 15.60h. for 
DLKPA2D to 32.91h. for DLKPA6B. Wilson et al. (1993) observed intra-tumoural 
heterogeneity in the doubling time in 30 colorectal cancers. Miller et al. (1989, 1991) also 
observed variation, not only in the drug sensitivity of a murine mammary cell line, but also in 
the growth rate (Miller et al. , 1988) and noted that the growth rate of the clonal cell lines was 
modified when clonal subpopulations were grown in contact with other sub-populations.
When DLKP-A clones were compared in terms of their growth rate, it is clear 
that cells with a low doubling time (DLKPA2D, DLKPA10C) should outgrow cells which 
possess longer growthrates (DLKPA2B, DLKPA6B, DLKPA5F). However, this did not occur 
in the DLKP-A population. While the ratio of the cell mixes in the DLKP-A cell line is 
unknown, it is clear that subpopulations of various growth rates are co-existing. This may be 
due to modification of the growth rates of the clonal subpopulations (as a result o f sub­
population interactions), as observed by Miller et al. (1988).
However, it must also be noted that cells which were existing in the DLKP-A 
population were also undergoing selective pressure, due to the presence of adriamycin. 
Therefore, in mixed populations, cells may not only be modified to alter their growthrates, but 
modification of the cells’ sensitivities to adriamycin may be occurring consecutively. However, 
no apparent association existed between the resistance of the cells to drugs and their doubling 
time. Both the most and least resistant cell line (with respect to adriamycin toxicity), 
DLKPA2B and DLKPA5F, respectively, exhibited similar doubling times (31.74h. and 32.86h., 
respectively), while DLKPA3C, a cell line which exhibited comparable adriamycin-resistance 
as DLKPA5F, possessed a much shorter doubling time (20.63h.).
4 .5  Irradiation
The literature is divided in relation to the correlation between resistance to 
chemotherapeutic drugs and radiation. Tanio et al. (1990) have described cells which are 
inherently drug and radiation resistant, and drug resistance has been acquired by cells following 
exposure to radiation (Mattern et al., 1991; Hill et al., 1990(a, b)), implying shared or related 
mechanisms of resistance. However, drug resistant cells have also been characterised which 
possess unaltered sensitivity to radiation (Sognier et a l., 1992; Mitchell et a l., 1988).
When DLKP cells were exposed to increasing doses of radiation, with the cells
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allowed to recover between each exposure, the resulting cell line exhibited neither cross 
resistance nor collateral sensitivity, to a range of chemotherapeutic drugs (Section 3.5.1). The 
ICjo values obtained for adriamycin, vincristine, VP-16, cisplatin and 5-fluorouracil toxicity to 
radiation exposed DLKP cells, did not deviate significantly, from those observed in DLKP.
Exposure of the human ovarian carcinoma JA-T and SK-OV-3 cell lines to 
radiation resulted in cells resistant to VP-16 and vincristine but which exhibited unaltered 
sensitivity to adriamycin and irradiation. The JA-T cells were collaterally sensitive to cisplatin, 
5-fluorouracil and methotrexate but the SK-OV-3 cells were resistant to cisplatin (Dempke et 
al., 1992(a, b); 1993). Hill et al. (1988) noted that radiation exposure of the lymphoblasts, 
L5178Y, the breast carcinoma cells, MCF-7 and the squamous cell carcinoma of the tongue, 
HN-1, resulted in the acquisition by the cells of resistance to vincristine and VP-16. They were 
collaterally sensitive to cisplatin, and adriamycin sensitivity was unaltered. In contrast, 
radiation exposure of the testicular teratoma cell line, SuSa, resulted in cells with a similar 
resistance profile (resistant to vincristine and VP-16 with unaltered sensitivity to adriamycin), 
except the cells were also resistant to cisplatin. Eichholtz et al. (1993) observed that radiation 
exposed murine fibrosarcoma cells, SSIL, exhibited transient resistance to cisplatin.
In general, when radiation exposure of cells resulted in the acquisition of 
resistance to chemotherapeutic drugs, resistance to a range of drugs associated with an MDR 
profile was observed, with the exception of resistance to adriamycin. Mattern et al. (1991) 
found that exposure of the human epidermoid lung carcinoma xenograft, HXL-55, to radiation, 
resulted in the acquisition of resistance to vincristine and overexpression of P-glycoprotein. 
When Hill et al. (1990) exposed the Chinese hamster ovary cell line, AuxBl, to radiation, the 
resulting cell line possessed an MDR profile and overexpressed P-glycoprotein but sensitivity 
to adriamycin was unaltered. This suggests that radiation-induced cross resistance to 
chemotherapy is mediated by P-glycoprotein, but if so, the lack of resistance to adriamycin is 
difficult to explain. However, Gros et al. (1991) have reported that a single mutation in mdrl, 
changing the serine^ to phenylalanine in P-glycoprotein, altered the capability of the gene to 
confer drug resistance. It retained the ability to confer vinblastine-resistance but lost the ability 
to confer resistance to adriamycin and colchicine. Devine et al. (1992) and Dhir et al. (1993) 
have also reported the modulation of drug resistance profiles due to sequence alterations in the 
P-glycoprotein gene. Therefore, mutations within the mdrl gene, whether specifically 
introduced or randomly induced, as a result of exposing the cells to drug or radiation, may alter 
the proteins ability to recognise and transport specific substrate. McClean and Hill (1994) 
reported that the MDR cell line that resulted following radiation exposure of Chinese hamster 
cells overexpressed P-glycoprotein, but again, adriamycin sensitivity was unaltered. When these 
cells were then exposed to vincristine, the level of P-glycoprotein expression was further
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increased and the resulting cell line was resistant to adriamycin. This implies that the P- 
glycoprotein overexpressed following radiation exposure, does not possess the same functions 
as the protein overexpressed following chemotherapeutic drug exposure, in that it is incapable 
of supporting resistance to adriamycin.
The radiation sensitivity of the adriamycin-selected MDR squamous cell 
carcinoma of the lung, DLKP-A, was unaltered, with respect to the parental cell line (Section
3.5.2). The sensitivity of DLKP and its drug-resistant variants to radiation, was comparable 
to that observed in the literature for other human cells. A  large number of cell survival curves 
have been derived for malignant and normal cell populations, following exposure to radiation. 
These demonstrate that D0 values (see Appendix B for a definition) for most mammalian cells 
are quite similar, about 1-2 Gy. Although DLKP-A exhibited unaltered radiation sensitivity, 
with respect to DLKP, within the DLKP-A cell line, clones existed which possessed altered 
sensitivities to radiation. DLKPA5F was resistant to radiation, DLKPA5D exhibited collateral 
sensitivity and the radiation sensitivity of the remaining clones was unaltered, by comparison 
with DLKP-A and DLKP. Tumour cell heterogeneity with respect to radiation sensitivity has 
been documented. Allam et al. (1993) observed significant intra-tumoural heterogeneity in the 
radiation sensitivity of malignant gliomas and Powell and McMillan (1991) noted clonal 
variation in response to ionising radiation, in a human glioma cell line, IN859. Allalunis- 
Turner et al. (1993) concurrently established two cell lines from a single specimen from a 
patient with glioblastoma, and the two subpopulations differed in their sensitivity to radiation 
and chemotherapeutic agents.
No obvious correlation existed between the drug resistance level or the growth 
rate of the clones and their sensitivity to radiation. DLKPA5F was the most resistant clone, 
with respect to both drug- and radiation-induced cell kill. However, the ranking order of 
clones, in terms of radiation resistance and resistance to any of the chemotherapeutic drugs, 
does not correlate. DLKPA5F and DLKP-A possessed comparable sensitivities to cisplatin but 
had significantly differing radiation sensitivities. In this study, no correlation appeared to exist 
between adriamycin-induced drug-resistance and radiation-resistance and it is probable that, as 
the literature has shown, the link between adriamycin-resistance and radiation-resistance is 
weak. Louie et al. (1985) noted that the radiation sensitivity of the adriamycin-resistant variant 
of the human ovarian carcinoma cell line, A2780, was not altered, with respect to the parental 
cells. Belli (1989) showed that adriamycin-resistant variants of the Chinese hamster cell line, 
V79, had increased sensitivity to radiation, but the degree of sensitivity did not relate to their 
level of adriamycin resistance. However, Lehnert et al. (1989) noted that adriamycin-selected 
MDR variants of the breast cell line, MCF-7, exhibited resistance to radiation and adriamycin- 
resistant HT-1080 cells were also cross resistant to radiation (Miller et al. , 1992). When Tanio
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et al. (1990) investigated the chemosensitivity and radiosensitivity of three small cell lung 
carcinomas, established from biopsy samples, a correlation was observed. Cells which appeared 
resistant to radiation also exhibited resistance to chemotherapeutic drugs, including adriamycin.
In this study, the cells’ sensitivity to radiation did not correlate with their 
doubling time. It has been documented that cells exhibit a cell cycle-associated sensitivity to 
radiation. Cells were most resistant to radiation during the S-phase of the cell cycle (Iliakis and 
Okayasu, 1990) and eliminating the S-phase cells from a cell population increased the radiation 
sensitivity of the population (Nothdurft et al., 1992). Quiet et al. (1991) observed that a 
radioresistant squamous cell carcinoma of the head and neck had twice the number of cells in 
the S-phase of the cell cycle, by comparison with a radiosensitive cell line, while Gillies 
McKenna et al. (1991) noted that cell lines which were resistant to radiation underwent a 
significantly longer arrest in the G2-phase of the cell cycle after radiation exposure, than the 
radiation sensitive cells. However, though the DLKP variants exhibited differing doubling 
times, implying perturbed cell cycle, no correlation was apparent between their growth rate and 
their ability to survive following exposure to radiation.
4 .6  Altered biochem ical properties o f M D R  cells
Differential expression of P-glycoprotein and topoisomerase II are two of the 
main mechanisms of MDR exhibited by a broad range of cells. The VP-16-selected variants 
of DLKP, overexpressed P-glycoprotein and exhibited a reduction in their topoisomerase II 
levels, by comparison with their drug-sensitive parents. DLKP-A has been shown to 
overexpress P-glycoprotein and to possess cytogenetic aberrations associated with gene 
amplification (Clynes et al., 1993). In the course of this research work, DLKP-A cells have 
also been shown to possess reduced topoisomerase II levels. The clonal populations, derived 
from DLKP-A, exhibited variable levels of P-glycoprotein and topoisomerase II. A ll clones 
overexpressed the P-glycoprotein drug efflux pump and possessed altered levels of nuclear 
topoisomerase n . Cell lines with multiple mechanisms of resistance have previously been 
detailed in the literature. Takigawa et al. (1992) described a VP-16-selected MDR variant of 
the human small cell carcinoma line SBC-3, which overexpressed both mdrl mRNA and its 
protein product, P-glycoprotein and had reduced topoisomerase II activity. Hoban et al. (1992) 
showed that an MDR Chinese hamster ovary cell line, derived by exposure to increasing 
concentrations of adriamycin, exhibited several mechanisms of resistance, including mdrl and 
GST overexpression and a reduction in transcripts coding for topoisomerase II.
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4.6.1 P-glycoprotein levels
A general characteristic of many MDR cells is the overexpression of bothmdrl 
mRNA and P-glycoprotein (Lemontt et a l., 1988; Bradley et a l., 1989; Reeve et a l., 1989; Baas 
et a l ,  1990). P-glycoprotein levels (determined by Western blot analysis using the C219 
antibody) and the mRNA levels coding for the protein (determined by RT-PCR) were 
overexpressed in all MDR cell lines examined. Neither the mRNA nor the protein was detected 
in the drug sensitive parental cell line, DLKP (Section 3.8 and 3.9). The level of mRNA 
detected in the drug resistant cell lines did not correlate precisely with the level of protein 
detected. No significant differences in mdr 1 mRNA levels were noted between any of the MDR 
cell lines, except in the case of DLKPA6B. Western blot analysis of the cell line, using the 
C219 monoclonal antibody, showed that these cells possessed levels of P-glycoprotein 
comparable to the other three clones of DLKP-A, which had been analyzed. However, RT- 
PCR analysis of the cells’ mdr 1 mRNA showed that the cell line exhibited reduced levels of the 
mdrl homologous transcript. The VP-16-selected MDR cell lines expressed significantly higher 
levels of P-glycoprotein, by comparison with the adriamycin-selected cell lines, but this 
difference was not reflected in their mdrl mRNA levels.
The level of P-glycoprotein expressed by DLKP-A cells was low, by comparison 
with the VP-16-selected cells and the clonal variants of DLKP-A. However, the densitometrical 
analysis of P-glycoprotein levels in DLKP-A cells gave a substantially lower reading for P- 
glycoprotein in DLKP-A cells, than other cell lines. Through visual analysis, a difference in 
the level of P-glycoprotein in DLKP-A and the VP-16-selected cells could be seen, but the 
difference did not appear as great as that shown by the densitometrical analysis. In all cases, 
mdrl mRNA levels were determined by RT-PCR analysis and so detected the presence of a 
157bp fragment of mRNA, specific to mdrl (O’Driscoll et al., 1993). As such, it is unclear 
whether full length mRNAs were present and/or truncated mRNA fragments were detected, 
which in turn may have coded for a non-immunodetectable protein. The PCR reaction was 
allowed to proceed for 30 cycles. It is not known if the reaction was still undergoing 
exponential growth at the end of this number of cycles. Therefore, the level of PCR product 
may not be a true reflection of the level of template present in the cells. The levels of template 
can only be correlated to product during the exponential phase of the PCR reaction. Post- 
translational modifications, alterations in the location of the protein and/or partial protein 
degradation, may also account for the discrepancy between the implied P-glycoprotein level (as 
determined from mRNA analysis) and the detected P-glycoprotein level (as determined by the 
immunological reactivity of the protein).
P-glycoprotein levels present in the VP-16-selected cell lines inversely correlated 
with their level of adriamycin accumulation (Section 3.10). DLKP/VP-3, the less resistant 
variant, expressed higher levels of mdrl mRNA and immunodetectable P-glycoprotein and 
accumulated less adriamycin than the more resistant DLKP/VP-8 cells, which possessed lower 
levels of mdrl mRNA and P-glycoprotein. The levels of immunodetectable P-glycoprotein in 
the clones, established from DLKP-A, did not correlate with their toxicity profiles or their level 
of adriamycin accumulation (I. Cleary, personal communication). Although the clones 
DLKPA2B, DLKPA6B, DLKPA11B and DLKPA5F exhibited approximately equal levels of 
P-glycoprotein, the rank order of their drug accumulation levels, was inversely related to the 
rank order of their adriamycin sensitivity, neither of which correlated with their levels of 
detectable P-glycoprotein or mdrl mRNA.
4 .6 .2  Topoisom erase II levels
In general, the level of topoisomerase II and its a  subunit are reduced in MDR 
cell lines resistant to topoisomerase II poisons (Deffie et a l., 1989a; deJong et a l., 1990; Mirski 
et al., 1993; Per et al., 1987). As has been noted in the literature, the reduction in 
immunodetectable topoisomerase II in DLKP variants was generally mirrored by a reduction 
in the a  form of the enzyme (Section 3.9.1). Topoisomerase II levels varied in the cell lines, 
depending on whether the level of the enzyme present in the isolated nucleus or whole cell 
extract, was examined. In general, the level of the enzyme was reduced in resistant cells, with 
respect to the sensitive parents. The levels of both topoisomerase II and its a  subunit detected 
in nuclear and total cell extracts, were reduced in DLKP-A and DLKP/VP-8, by comparison 
with DLKP. Although both cell lines exhibited similar resistance to adriamycin, vincristine and 
VP-16, DLKP-A had the lowest levels of both topoisomerase II and its a  subunit while 
DLKP/VP-8 had higher levels of P-glycoprotein (Section 3.9.2). DLKP/VP-3 possessed levels 
of topoisomerase II and its a  subunit similar to that detected in DLKP, as determined from their 
total cell extracts, but the level of enzyme confined to the nucleus in DLKP/VP-3 cells, was 
reduced to 50-60% that detected in DLKP. The amount of topoisomerase II present in 
DLKPA6B was reduced to 55-70% of that observed in DLKP, in both nuclear and total cell 
extracts and the ratio of topoisomerase II-a to total topoisomerase II protein was similar, in both 
nuclear and total cell extractions of DLKPA6B. The level of topoisomerase II present in total 
cell lysates of the remaining clones, DLKPA2B, DLKPA1 IB and DLKPA5F was similar to that 
present in DLKP, but the level of the a  subunit was reduced. However, in nuclear extracts, 
all of these cell lines exhibited a reduction in both topoisomerase II and its a  subunit, by
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comparison to DLKP. The rank order of topoisomerase II levels in the nuclear extracts of 
DLKPA2B, DLKPA1 IB and DLKPA5F was mirrored by that observed in the total cell extracts. 
DLKPA2B, the most adriamycin-sensitive clone, had levels of nuclear topoisomerase II and 
topoisomerase II-a similar to that observed for DLKP-A. However, both DLKPA2B and DLKP- 
A possessed reduced levels of the enzyme by comparison with DLKP, yet the cell lines 
DLKPA2B and DLKP-A exhibited significantly different resistances to drugs associated with 
topoisomerase Il-mediated cell kill.
Using antiserum to topoisomerase II, Berrios et al. (1985) found that 
topoisomerase II was differentially localised in Drosophila larva, during various stages of the 
cell cycle. Though generally localised in the nucleus, during mitosis the enzyme was distributed 
diffusely throughout the cell. Petrov et al. (1993) localised both the topoisomerase II-a and the 
B subunits to the nucleus, in Chinese hamster fibroblasts, using polyclonal antibodies described 
by Chung et al. (1989), but they also found that during mitosis, both forms were detected in 
the cytoplasm. In this research work, the cells from which topoisomerase II was isolated were 
in the exponential phase of growth, but were not synchronised. It may, therefore, be assumed 
that a small percentage of the cells were undergoing mitosis, and so cytoplasmic topoisomerase 
II would be present.
Both a 180 kDa. and a 150 kDa. immunoreactive protein was detected using the 
topoisomerase II-B specific monoclonal antibody (Section 3.9). The 150 kDa. form of 
topoisomerase II-B was only detected in total cell extract and not in nuclear extracts (Figures
3.9.1.1.2 and 3.9.1.2.2), implying that it is cytoplasmic associated. When Coutts et al. (1993) 
used the topoisomerase II-B antibody raised by Negri et al. (1992) to study topoisomerase II 
levels in non-small cell lung cancer cell lines, they detected a 150 kDa. form of topoisomerase 
II-B, which was assumed to be due to protein degradation. Proteolytic degradation of the 180 
kDa. form of topoisomerase II had previously been described by Holden et al. (1992), who 
detected a 180 and 160 kDa. form of topoisomerase II-B using the polyclonal antibody described 
by Drake et al. (1987). However, in this research, the polyclonal antibody, which detects both 
the a  and B forms of the topoisomerase II enzyme, detected only the 180 kDa. form of 
topoisomerase II-B, whereas the topoisomerase II-B monoclonal antibody detected either both 
a 180 kDa. and a 150 kDa. form, or only the 150 kDa. form of the enzyme, in the same cell 
extract as examined with the polyclonal antibody. All topoisomerase II isolations were carried 
out on ice, in the presence of proteolytic inhibitors (PMSF, benzamidine, soybean trypsin 
inhibitor, leupeptin, pepstatin A  and aprotinin) and all Western blotting procedures were carried 
out immediately following protein isolation. The fact that no degradation of the 170 kDa. form 
of topoisomerase II was observed, that no degradation of the 180 kDa. form of topoisomerase 
II in the nuclear extract was noted and that the polyclonal antibody which detects both
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topoisomerase II-a and -fi, only detected the 180 kDa. form of topoisomerase 11- f t  in total cell 
extract, all argue against random proteolytic degradation, due to the isolation procedure. 
Therefore, either the 150 kDa. form was a specific precursor or breakdown product of the 180 
kDa. form of the protein and the polyclonal and monoclonal antibodies recognise different 
epitopes on the 180 kDa. form of the protein, thereby differentiating between various forms of 
the topoisomerase II-B enzyme, or the monoclonal antibody directed against topoisomerase II-B 
was cross-reacting with a homologous protein. When Chung et al. (1989) raised antibodies to 
topoisomerase II-B using a synthetic dodecapeptide homologous to a section of the 
topoisomerase II-B protein (starting at amino acid 748 and consisting of the following sequence: 
NVRRMLDGLDPH), the resulting antibody recognised both a 180 kDa. protein and a protein 
of approximately 145 kDa. However, a second topoisomerase II-B antibody (raised against the 
synthetic peptide beginning at amino acid residue 785 and reading EIFVVDRNTVEIT) 
selectively recognised the 180 kDa. form of the enzyme, suggesting the first antibody cross­
reacted with a homologous protein.
Therefore, the presence of no detectable 150 kDa. form of topoisomerase II-B 
in the nuclear extract may have resulted from either the isolation procedure, or its cytoplasmic 
location. As the nucleus was isolated from the cytoplasm, prior to lysis in a high salt solution, 
cytoplasmic- and cytoplasmic organelle-associated proteolytic enzymes were removed before the 
topoisomerase II was exposed to them. The high salt solution and the presence of proteolytic 
inhibitors may have exerted an inhibitory effect on any remaining proteolytic enzyme activity, 
further protecting the topoisomerase II enzyme from degradation. However, differing cell 
location-associated forms of topoisomerase II-a have been described in the literature. Feldhoff 
et al. (1994) demonstrated that the human small cell lung cancer cell line, H209 contained the 
170 kDa. form of topoisomerase II-a, which was located in the nucleus but its VP-16-selected 
variants contained a 160 kDa. cytoplasmic-located form of the enzyme. The cytoplasmic form 
exhibited similar catalytic activity as the 170 kDa. form, suggesting that the missing sequence 
was only necessary for nuclear localisation of the enzyme. Perhaps a mutated form of 
topoisomerase II-B is present in the DLKP variants, and the mutation caused a differential 
cellular localisation of the enzyme.
As previously noted in relation to P-glycoprotein and its mRNA levels, gene 
transcript levels for topoisomerase II enzymes do not correlate to protein expression (Sections 
3.8, 3.9). Both DLKP and DLKP-A had similar levels of topoisomerase II mRNA, but DLKP- 
A  had vastly reduced levels of the immunodetectable protein, in both its total cell extract and 
nuclear extract. Alhough DLKP/VP-3 and DLKP/VP-8 also had similar levels of topoisomerase 
II mRNA, the protein level was lower in DLKP/VP-8. The level of immunodetectable 
topoisomerase II present in total cell extracts of DLKPA6B was only 50% of that present in the
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other clones of DLKP-A, yet all of the cell lines had similar transcript levels. This lack of 
correlation between protein and mRNA levels was also observed for topoisomerase II-a and 
topoisomerase II-B. This variation may be due to the fact that different detection methods were 
employed to examine protein and gene transcript levels. The mRNA levels of the genes of 
interest were determined by RT-PCR analysis, whereby only a small but specific fragment of 
the mRNA (O’Driscoll et a l., 1993) was detected. It was assumed that this section was located 
on a stretch of RNA, which coded for the complete sequence for immunodetectable protein, and 
was not a truncated mRNA. Defile et al. (1989a) showed that topoisomerase II levels were 
reduced in adriamycin-resistant P388 leukaemia cells and that northern blot analysis (1989b) 
revealed two mRNA splices: a 6.6kb transcript in sensitive cells, which was reduced 7-fold to 
8-fold in resistant cells and accounted for the decrease in protein levels and a second shorter 
transcript, only present in the resistant cells. Post-translational modifications which may alter 
the immunodetectability of the protein were not taken into account e.g. partial degradation or 
the possibility of protein cross-reactivity by the antibody used for detection. Deffie et al. (1992) 
noted that topoisomerase II levels were reduced in adriamycin-selected Chinese hamster ovary 
cells and in mitoxantrone-resistant HeLa cells, in comparison with the parental populations, 
though no differences were observed in the levels of complete mRNA, as determined by 
northern analysis, implying post-translational modifications of the protein. In the course of this 
research, PCR analysis of topoisomerase II mRNA, and that of its a  and B subunits, was carried 
out using 30 cycles of PCR and it is not known if the reaction is still exponentially amplifying 
the template at the end of this number of cycles. Therefore, the mRNA levels can only be 
assumed to be semi-quantitative.
4.7  Correlation o f resistance profiles to biochem ical properties o f  the cells
The adriamycin and VP-16 resistance of DLKP/VP-3 and DLKP/VP-8, may be 
explained by their combined levels of P-glycoprotein and topoisomerase II. DLKP/VP-8 was 
the more resistant cell line, with respect to the two drugs mentioned above, and although it had 
slightly lower levels of P-glycoprotein than DLKP/VP-3, it had substantially reduced levels of 
immunodetectable topoisomerase II and its a  subunit. The level of P-glycoprotein expression 
by the cells can not fully explain their resistance profile to vincristine, implying other 
mechanisms of resistance must be present. DLKP/VP-8 was approximately 1.75-fold more 
resistant to vincristine than DLKP/VP-3, yet it possessed slightly lower levels of both P- 
glycoprotein and mdrl mRNA. Vincristine is not associated with topoisomerase II-mediated 
toxicity. Therefore, the level of vincristine resistance exhibited by the cells should be mirrored
by their P-glycoprotein levels, if P-glycoprotein was the only mechanism of vincristine 
resistance associated with the cells. Alterations other than that of P-glycoprotein and 
topoisomerase II, must have occurred in DLKP/VP-8, which account for its extra resistance to 
vincristine. Cole et al. (1991) found that an adriamycin-selected MDR NCI-H69 cell line, 
which was cross resistant to vinca alkaloids, had reduced levels of topoisomerase II but did not 
overexpress P-glycoprotein, in comparison with its parental cell line. The adriamycin-selected 
MDR variants derived from the human small cell lung cancer cell lines, U1690 and U1285, by 
Nygren et al. (1991) also exhibited cross resistance to vincristine but overexpressed neither 
mdrl mRNA nor P-glycoprotein. Twentyman et al. (1986a) described resistance to vincristine 
without P-glycoprotein or mdrl mRNA overexpression in the adriamycin-selected MDR variant 
of the large cell lung carcinoma, COR L23.
A range of proteins, other than P-glycoprotein, have been detailed in the 
literature, whose expression have been altered in drug-resistant cells by comparison with their 
sensitive counterparts. Bhalla et al. (1985), Marsh et al. (1986, 1987) and McGrath and Center
(1988) have detailed the presence of a membrane-associated 150 kDa. protein in resistant cells. 
Proteins with sequence homology to P-glycoprotein have also been observed in drug-resistant 
cells. Overexpression of the multidrug resistant-associated protein (MRP) has been noted in the 
small cell lung carcinoma H69/AR cells (Cole et al. , 1992b) and Krishnamachry and Center
(1992) have observed overexpression of a 150 kDa. and 130 kDa. protein in the leukaemia cell 
line HL69/ADR. The overexpression of a 110 kDa. cytoplasmic protein in the lung cell lines 
SW1573/2R120 and GLC4/R has been detailed by Versantvoort et al. (1992).
Although both DLKP-A and DLKP/VP-8 exhibit similar resistance to 
adriamycin, vincristine and VP-16, DLKP-A had lower levels of P-glycoprotein than DLKP/VP- 
8, it also had substantially reduced levels of topoisomerase II. Therefore, although both cells 
possessed similar levels of resistance to similar drugs, differing biochemical alterations were 
responsible for conferring the MDR profile. An analysis of MDR variants of NCI-H69 selected 
by exposure to the anthracyclines, both adriamycin and daunomycin, by Jensen et al. (1989,
1993), Mirski et al. (1987) and Twentyman et al. (1986a), showed that while populations of 
multidrug resistant cells may possess similar cross resistance profiles, the underlying mechanism 
of resistance may vary. The resulting MDR cell lines, in these cases, exhibited similar cross 
resistance profiles but the inherent heterogeneity of the MDR variant of NCI-H69 made exact 
quantitation of the degree of cross resistance difficult. The cell lines selected by Jensen et al.
(1989) and Twentyman et al. (1986) overexpressed the drug pump, P-glycoprotein, while the 
NCI-H69 variant derived by Mirski et al. (1987) had no detectable overexpression of P- 
glycoprotein (Reeve et al., 1989). The clones of DLKP-A all exhibited differential expression 
of P-glycoprotein and topoisomerase II and both its subunits. Therefore, the DLKP-A cell line
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is not only heterogeneous in terms of its chemotherapeutic drug and radiation resistance levels 
and its cell growth rates, but also in respect to its mechanisms of drug resistance. When Yang 
et al. (1993) characterised cell clones of the MDR variant of LoVo, one of the two distinct 
subpopulations overexpressed P-glycoprotein, while the other displayed no alteration.
4 .8  Effect o f topoisom erase II poisons on the toxicity o f topoisom erase I
inhibitors
Increased resistance to topoisomerase II inhibitors, exhibited by MDR variants 
of DLKP, could, in part, be accounted for by alterations in the level of the topoisomerase II 
enzyme. Decreased immunodetectable topoisomerase II was noted in nuclear extracts of all 
MDR cell lines. In order to maintain the biological activity of the topoisomerase enzymes at 
a constant level, alterations in the level of topoisomerase II have often been paralleled by an 
opposite alteration in topoisomerase I (Ferguson et al., 1988; Sugimoto et al., 1990(a, b); 
Lefevre et al., 1991). However, some researchers have reported alterations in topoisomerase 
II levels independently of topoisomerase I (Matsuo et al., 1990; de Jong et al., 1990). In 
general, acquisition of an MDR profile by cells is not associated with modification of 
topoisomerase I (reviewed by Pessina, 1993). In this study, cells that were highly resistant to 
topoisomerase II inhibitors, exhibited minimal alterations in their sensitivity to topoisomerase 
I poisons, suggesting alterations in topoisomerase II levels were not balanced by an opposite 
alteration in topoisomerase I levels. Although DLKP/VP-8 was 272-fold resistant to adriamycin 
and 101-fold resistant to VP-16, it was only a maximum of 2-fold more sensitive to 
camptothecin than the drug sensitive parental cell line, DLKP. This implies that the 
topoisomerase I levels may be increased 2-fold, to compensate for the 2-fold to 3-fold decrease 
in topoisomerase II levels observed in these cells (Section 3.9). When both the MDR and 
sensitive cell lines were exposed to combinations of a topoisomerase II and topoisomerase I 
inhibitors (adriamycin and camptothecin respectively), no enhanced toxicity was observed over 
the product of their individual toxicities. This suggests that the two classes of drug acted in an 
independent, non-synergistic manner and that exposure of cells to topoisomerase II poisons does 
not render DLKP variants more susceptible to cell kill by a topoisomerase I inhibitor, with the 
converse also holding true.
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4.9 Drug accumulation
Decreased drug accumulation has been found to be a property of some drug 
resistant cells (Toffoli et al., 1991; Zijlstra et al., 1987; Kuiper et a l., 1990). The level of 
adriamycin accumulated by VP-16-selected MDR cells was decreased by comparison with the 
drug sensitive DLKP cell line (Section 3.10). However, the level of adriamycin present within 
the cells did not present a true indication of the cells’ resistance, suggesting multiple 
mechanisms of resistance to adriamycin were operating. DLKP/VP-3, the least resistant of the 
VP-16-selected MDR cell lines, surprisingly accumulated less adriamycin than the more resistant 
DLKP/VP-8 cell line. The level of adriamycin accumulated by both cell lines was reflected in 
their levels of immunodetectable P-glycoprotein. DLKP/VP-3 expressed higher levels of mdrl 
mRNA, immunodetectable P-glycoprotein and accumulated less adriamycin than DLKP/VP-8. 
However, in order to achieve 50% cell kill in DLKP/VP-8, the cells required exposure to nearly 
twice the concentration of adriamycin as that required to achieve the same level of kill in 
DLKP/VP-3, implying that extra mechanisms of resistance are present in the DLKP/VP-8 cell 
line. It has been shown that topoisomerase II levels were reduced in DLKP/VP-8 by 
comparison with DLKP/VP-3. Adriamycin is a topoisomerase II poison, exerting its toxicity 
by blocking the triplex cleavable complex formed by adriamycin, topoisomerase II and DNA  
and resulting in DNA strand breaks. Therefore, reduced levels o f topoisomerase II in 
DLKP/VP-8, even in the presence of higher levels of intracellular adriamycin, may result in an 
extra protective effect towards the cells, with respect to adriamycin toxicity.
Alternatively, although adriamycin accumulation is higher in DLKP/VP-8 cells, 
in comparison with DLKP/VP-3 cells, altered cellular distribution of the adriamycin may result 
in the cells possessing the capability to survive in the presence of higher drug concentrations, 
than their total intercellular drug levels would imply. As adriamycin exerts its toxicity by 
intercalating with DNA, the nucleus is the prime target for the drug. Therefore, exclusion of 
the adriamycin from the nucleus, may result in a cell protective effect. Keizer et al. (1989) 
investigated a range of MDR variants of the human non-small cell lung cell line, SW-1573 and 
found that with increasing adriamycin resistance, cellular adriamycin accumulation decreased 
and the subcellular adriamycin distribution shifted from mainly nuclear to a mainly cytoplasmic 
pattern. When Schuurhuis et al. (1991) examined the ratio of nuclear to cytoplasmic 
fluorescence in the MDR variants, it was noted that the ratio was reduced in both P- 
glycoprotein overexpressing and non-P-glycoprotein overexpressing MDR cell lines, by 
comparison with the drug sensitive parental cells. Gervasoni et al. (1991) found that exposure 
of the cell lines HL-60, P388 and MCF-7 and their MDR counterparts to daunorubicin resulted 
in rapid drug distribution from the plasma membrane to the perinuclear region. This was
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followed by redistribution of the drug, in the sensitive cells, to the nucleus and cytoplasm. In 
the MDR variants, redistribution of the daunorubicin occurred to vesicles distinct from the 
nucleus, in an energy dependent manner. Reduced levels of drug accumulation in the nucleus 
of MDR cells, by comparison with their sensitive parental cells, was also noted by Coley et al.
(1993), Boiocchi et al. (1992) and Weaver et al. (1991).
Alterations in the level of adriamycin metabolising enzymes could also account 
for increased resistance to adriamycin, in the presence of intracellular drug. Vasanthakumar 
and Ahmed (1985) showed that although a range of human myeloid leukaemia cell lines, 
erythroleukemia cell lines and myeloblasts from two untreated patients with acute myelogenous 
leukaemia accumulated similar levels of daunorubicin, their metabolism of daunorubicin to 
daunorubicinol and their levels of reductase activity were extremely variable. Therefore, 
possible alterations in the level of drug metabolising and deactivation enzymes in VP-16-selected 
MDR cells may partially account for their altered drug resistance.
Adriamycin accumulation by the MDR clones of DLKPA, DLKPA2B, 
DLKPA6B, DLKPA1 IB and DLKPA5F, was decreased, by comparison with DLKP (I. Cleary, 
personal communication). The cell line most resistant to MDR-associated chemotherapeutic 
drugs, DLKPA5F, accumulated least adriamycin, in comparison to the remaining clones and 
DLKP. DLKPA5F cells accumulated one fifth to one quarter the amount of drug accumulated 
by DLKP. Of the cloned cell lines, the least resistant clone, DLKPA2B, accumulated highest 
levels of adriamycin, which was slightly lower than the level of adriamycin accumulated by 
DLKP (DLKPA2B accumulated approximately 75% of the adriamycin accumulated by DLKP). 
DLKPA6B and DLKPA1 IB exhibited similar, but intermediate, levels of adriamycin resistance, 
by comparison to DLKPA5F and DLKPA2B. Both cell lines also accumulated an intermediate 
level of adriamycin, by comparison with the two extreme clones. However, DLKPA6B 
accumulated slightly higher levels of adriamycin than DLKPA11B.
In contrast to the VP-16-selected MDR cell lines, where their levels of drug 
accumulation reflected the level of immunodetectable P-glycoprotein, and not the cells’ 
resistance to adriamycin, adriamycin accumulation by the DLKP-A clones reflected their level 
of drug resistance i. e. the most resistant clone accumulated the least adriamycin and the least 
resistant clone accumulated the highest level of adriamycin. Adriamycin accumulation by the 
clonal subpopulations of DLKP-A did not reflect their individual levels of P-glycoprotein. No 
significant variation existed within the four clones, with respect to immunodetectable P- 
glycoprotein, but a 3-fold reduction in adriamycin accumulation in DLKPA5F, in comparison 
to DLKPA2B, was observed.
In the VP-16-selected MDR cell lines, the presence of circumvention agents 
reverted the level of adriamycin accumulated to that observed in the drug sensitive DLKP cell
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line. Both verapamil and cyclosporin A caused an increase in adriamycin accumulation, to 
levels comparable with DLKP, and in the case of DLKP/VP-8, the presence of verapamil 
resulted in higher adriamycin accumulation than that observed in the parental cells. Verapamil 
and cyclosporin A have been widely used in vitro to overcome drug resistance (Larsson and 
Nygren, 1990; Tsuruo et al., 1983) and with both circumventing agents, the increase in the 
cells’ sensitivity to the drug of interest has been paralleled by an increase in drug accumulation 
(Van de Vrie et al., 1993; Ross et al., 1993). In this study, both verapamil and cyclosporin 
A enhanced the toxicity of adriamycin to DLKP/VP-8 and DLKP/VP-3 (Section 3.11). This 
increase in sensitivity was, at least partially, due to increased adriamycin accumulation.
4 .10  Circum vention o f drug resistance
Both verapamil and cyclosporin A proved to be potent enhancers of adriamycin 
toxicity in drug sensitive and MDR variants of DLKP (Section 3.10). Both compounds were 
less toxic to DLKP than its MDR variants. Schuurhuis et al. (1990) also observed that calcium 
channel blockers, including verapamil, were more toxic to several MDR cell lines than to their 
parental cells, and Twentyman et al. (1986b) noted that the growth inhibitory effect of 
verapamil was greater in MDR variants of the small cell lung cell line, NCI-H69, than in the 
parental cell line. In the research described in this thesis, both circumvention agents were 
observed to potentiate the toxicity of adriamycin in DLKP cells, but it must occur by a 
mechanism other than increased drug accumulation, as neither cyclosporin A nor verapamil 
altered the level of adriamycin accumulated by the cells (Section 3.10). This suggests that in 
the drug sensitive cells, P-glycoprotein is neither the target for verapamil or cyclosporin A  nor 
the mode by which they sensitise the cells. Cole et al. (1989) noted that verapamil enhanced 
adriamycin toxicity in non-P-glycoprotein overexpressing MDR variants of the fibrosarcoma cell 
line, HT-1080 and the small cell lung cancer cell line, NCI-H69. Twentyman et al. (1986b) 
also found that verapamil was capable of sensitising MDR variants of the large cell lung 
carcinoma, COR-L23, to adriamycin toxicity even though the cells did not overexpress P- 
glycoprotein. Cyclosporin A and verapamil both possess P-glycoprotein binding activities 
(Foxwell et al., 1989; Qian and Beck, 1990), which may be responsible, at least in part, for 
their ability to enhance drug toxicity in the MDR cells.
Both cyclosporin A and verapamil appeared to modulate adriamycin and 
vincristine toxicity to a greater extent than that of VP-16 and both circumventing agents 
enhanced adriamycin and vincristine toxicity in DLKP cells to a greater degree than in the MDR 
cells. Cyclosporin A enhanced the toxicity of adriamycin, vincristine and VP-16 in all variants
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of DLKP but the toxicity of VP-16 was modified to a lesser extent than that of either 
adriamycin or vincristine. Verapamil also enhanced adriamycin- and vincristine-induced cell 
kill in all DLKP variants. However, the effect exerted by verapamil, on the enhancement of 
the toxicity of VP-16, was cell line dependent. Verapamil enhanced the toxicity of VP-16 to 
the parental cell line, DLKP and also to DLKP-A and DLKPA11B. A slight enhancement of 
the toxicity of VP-16 to DLKPA5F, by the presence of verapamil, was observed, while the 
presence of verapamil decreased VP-16 toxicity to DLKPA2B, DLKPA6B and, most notably, 
to DLKP/VP-3 and DLKP/VP-8. In no instance was the magnitude of the effect of verapamil 
on VP-16 toxicity in the order of that observed for verapamil with vincristine or adriamycin or 
when cyclosporin A was combined with VP-16. Larsson and Nygren (1990) also noted that 
neither verapamil nor cyclosporin A potentiated the toxicity of VP-16 to the same degree as that 
observed for vincristine. Chao et al. (1990) observed that verapamil was less effective than 
cyclosporin A at enhancing VP-16 toxicity to a human leukaemic cell line and to normal bone 
marrow cells.
In cases where verapamil appeared to diminish VP-16 toxicity in this study, 
verapamil was toxic to the cells in its own right and the level of apparent reduction in VP-16 
toxicity was most notable in cells to which verapamil alone was most toxic. Whether VP-16 
was decreasing the toxicity of verapamil towards the cell lines or whether verapamil was 
modulating VP-16’s toxicity, or a combination of both, was unclear. Glisson and Alpeter 
(1992) noted that both cyclosporin A and verapamil enhanced the accumulation of V P-16 in a 
VP-16-selected MDR variant of the small cell lung cancer cell line, NCI-H69, yet only 
cyclosporin A was effective at enhancing VP-16 toxicity to the cell line, relative to its parental 
cells. Although the effect of verapamil on VP-16 accumulation by the cells was not investigated 
in this work, verapamil caused increased adriamycin accumulation in DLKP/VP-3 cells, to 
levels comparable with the parental cell line and resulted in even higher intracellular levels of 
adriamycin in DLKP/VP-8 cells. This implied that verapamil was active at blocking adriamycin 
efflux via the P-glycoprotein pump, probably by competitive inhibition, in DLKP/VP-3 and 
DLKP/VP-8 cell lines and it may be assumed to have a similar effect on VP-16 accumulation.
As previously mentioned, verapamil was highly toxic to all the cell lines where 
its combination with VP-16 resulted in an antagonistic effect, with respect to cell kill. The 
degree of antagonism observed was relative to the toxicity of verapamil to the individual cells. 
In these cells, exposure to VP-16 and low concentrations of verapamil, resulted in an apparent 
potentiation of VP-16 toxicity. An increase in the concentration of verapamil resulted in no 
alteration in toxicity, other than that due to the toxicity of verapamil and VP-16 alone, while 
a further increase in verapamil caused an antagonistic effect between VP-16 and verapamil, with 
respect to cell kill. Therefore, the masking of toxicity was dependent on the concentration of
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verapamil and paralleled verapamil toxicity to the cells.
The pH of the extracellular environment is capable of influencing the toxicity 
of drugs to cells and the effectiveness of toxicity modulating agents. Hamilton et al. (1993a) 
noted that acidic extracellular media reduced the toxicity of adriamycin to drug resistant variants 
of HT-29 and SW-420 cells. Decreased pH values also diminished the ability of verapamil and 
cyclosporin A to enhance drug toxicity and cellular uptake of verapamil was also reduced. In 
all circumvention assays carried out in this research project, the chemotherapeutic drug and the 
circumvention agent were added to cells, after they were 24h. in culture. Therefore, the pH 
of the growth media would be reduced, due to cell metabolism. The addition of verapamil, 
especially at the higher concentrations, would further decrease the pH (verapamil in solution 
is acidic, a 0.1 % aqueous solution has a pH of 5.25 (Merck Index)), possibly to a level capable 
of modulating the toxicity of the drug and the effectiveness of the chemotherapeutic agent. As 
verapamil was extremely toxic to the cells in which antagonistic combinations of V P-16 and 
verapamil were noted, any reduction in the intracellular concentration of the circumventing 
agent may enhance cell survival. An increase in the concentration of the circumventing agent 
to which the cells were exposed, may result in a decrease in the extracellular pH, resulting in 
a reduction in verapamil uptake and toxicity, and a reduction in the enhancement of V P-16 
toxicity, as was noted in these cases. However, this does not fully explain the effect observed 
in the cells in this study, whereby at low verapamil concentrations an enhancement of VP-16 
toxicity was noted. This implies that at low concentrations, verapamil was acting as an effective 
VP-16-toxicity enhancing agent.
It has been shown extensively that verapamil circumvents drug resistance by 
competing with the drug for efflux via the P-glycoprotein pump, resulting in increased cellular 
accumulation of the drug and cell kill (Tsuruo et al., 1981; Harker et al., 1986; Sikic et al., 
1989; Barrand et al., 1993). However, an optimum concentration of the circumventing agent 
generally resulted in maximum drug accumulation-associated cell kill. In this case, perhaps 
maximum enhancement of VP-16 toxicity was produced by a low intercellular concentration of 
verapamil. This would account for the synergistic effect observed between VP-16 and 
verapamil at low concentrations of the circumventing agent. At higher intercellular levels of 
the circumventing agent, the beneficial effects exerted regarding enhancement of drug toxicity 
may be balanced by the toxicity exerted by the verapamil itself, resulting in no apparent 
enhancement of VP-16’s toxicity. At high verapamil concentrations, the acidity of the media 
would affect the cells’ accumulation of verapamil and modulate the effectiveness of verapamil, 
resulting in the increased cell survival observed.
However, the toxicity of VP-16, in the presence of verapamil, may also be 
modulated via its action as a topoisomerase II poison. Alterations in the function of
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topoisomerase II, caused by verapamil, may alter cell survival in the presence of VP-16. 
Verapamil is a calcium antagonist, which alters the level of intracellular Ca2+. Therefore, as 
the concentration of verapamil increased, the level of intracellular Ca2+ may have decreased. 
Topoisomerase II activity requires the presence of divalent cations (Osheroff, 1986; 1987) and 
Ca2+ has been shown to be capable of supporting topoisomerase II activity (Osheroff and 
Zechiedrich, 1987). If calcium levels were decreased, the levels of enzyme activity may be 
reduced, resulting in decreased VP-16 toxicity to the cells. Meech and Thomas (1977) have 
shown that an increase in intracellular Ca2+ levels resulted in a decrease in the intracellular pH 
of cells and a decrease in intracellular pH has also been associated with verapamil-mediated 
enhanced cell kill (Hamilton et al., 1993a; Keizer et al., 1989). Therefore, if  the converse 
holds true, a decrease in intracellular Ca2+ would result in a decreased intracellular acidification 
and increased cell survival in the presence of drug.
Adriamycin and vincristine have alternative modes of toxicity, other than 
intercalating with the topoisomerase II cleavable complex. Therefore, verapamil may enhance 
the toxicity of these drugs by increasing their presence in the cell and thereby allowing them 
to induce a topoisomerase IT-independent mode of cell kill. Cyclosporin A is not a calcium 
antagonist and therefore would not affect the topoisomerase II-mediated toxicity of V P-16.
In this research work, it has been shown that the combination of VP-16 and 
verapamil enhanced toxicity in some of the lung cell lines and diminished toxicity in others. 
An alternative explanation for this phenomenon, other than that outlined above, is that the 
topoisomerase II enzyme was altered in the cell lines where diminished toxicity, resulting from 
the combination of the chemotherapeutic drug and the circumventing agent, was observed. A 
mutated topoisomerase II enzyme has been described in MDR cells that requires increased ATP 
to sustain equal topoisomerase II activity as that observed in the sensitive cell line (Danks et al. , 
1989). In relation to the modification of VP-16 toxicity in this study, perhaps the topoisomerase 
II enzyme is altered in DLKP/VP-8, DLKP/VP-3, DLKPA2B and DLKPA6B such that higher 
concentrations of divalent cation are required for its activity. Therefore, topoisomerase II- 
mediated toxicity by chemotherapeutic drugs would be decreased in the presence of agents that 
decrease levels of intracellular Ca2+.
However, this does not explain why adriamycin toxicity is enhanced by 
verapamil, in the same cell lines. Perhaps the adriamycin toxicity is mediated by a mechanism 
other then as a topoisomerase II poison in these cell lines, when co-exposed to verapamil (as 
suggested previously). To further elucidate the phenomenon that is occurring between VP-16 
and verapamil in these cell lines, the toxicity of various combinations of verapamil and other 
drugs (both topoisomeraseII poisons e.g. VM-26, amsacrine and non-topoisomeraseII-mediated 
toxins e.g. vinblastine) could be studied.
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4.11 Cell density effects
The toxicity of chemotherapeutic drugs to variants of DLKP was observed to be a 
function of the density at which the cells were exposed to the drug (Section 3.13). All cells 
investigated in this work were more sensitive to adriamycin when exposed at low density than 
at higher densities. Cell density dependent adriamycin toxicity was also noted in the VP-16- 
selected cells and VP-16 toxicity was subject to the cells’ plating density in both DLKP and 
DLKP-A cell lines. This implies that a cell density dependent mechanism of resistance, or 
enhanced sensitivity, existed in the cell lines.
This alteration in the cells’ sensitivity to chemotherapeutic drugs may have 
resulted from a physical and/or biochemical modification of the cells and/or their environment. 
Decreased adriamycin toxicity to cells, at high cell densities, may have resulted from decreased 
intracellular accumulation, thus allowing the adriamycin sensitive cells to survive in the 
presence of drug levels which would cause cell kill, when analyzed under the non-confluent 
conditions associated with the toxicity assays. Dimanche-Boitrel et al. (1992) observed a 
confluency-dependent resistance to adriamycin, vincristine and VP-16, in the human colon 
cancer cell line, HT-29. The decrease in sensitivity was reflected in a lower intracellular level 
of drug and the altered drug penetration with confluency could be related to a decrease in 
plasma membrane fluidity. Pelletier et al. (1990) also noted that both the cytotoxic efficacies 
of adriamycin, and the nuclear drug concentration, progressively decreased with increasing 
confluency, in the human and rat colon cell line HT-29 and DHD/K12/TRb, respectively.
During routine maintenance of the DLKP and DLKP-A cell lines in culture, it 
was noted that better growth occurred when the serum-supplemented medium was left on the 
cells for a number of days, as opposed to daily changes of the media (results not shown). At 
the stage of the initial isolation of the DLKP-A clones, it was also observed that better cell 
growth occurred when the cells, plated at the low density required to isolate clones, were 
partially fed with conditioned medium produced by the DLKP-A population (50% conditioned 
medium and 50% fresh medium). This suggests that DLKP variants may be producing an 
autocrine growth stimulating factor (or factors). This factor may also be involved in altering 
their sensitivity to adriamycin. Huang and Wright (1994) observed that NIH3T3 cells 
transfected with BFGF, a non-oncogene member of the fibroblastic growth factor family, 
exhibited a significant elevation in N-(phosphonacetyl)-L-aspartate resistance, while Zuckier and 
Tritton (1983) demonstrated a drug-dependent increase in the capacity of HeLa and 3T3 cells, 
grown in the presence of lethal and sub-lethal concentrations of adriamycin, to bind EGF. Shin 
et al. (1991) noted the simultaneous amplification of EGF receptor and mdrl genes, in a poorly 
differentiated adenocarcinoma of the human lung. Meyers et al. (1993) have also observed an
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increase (3-fold) in the number of EGF receptors in MDR variants of the Chinese hamster lung 
DC-3F cell line, which overexpresses P-glycoprotein.
The pH of the extracellular environment is capable of influencing the toxicity of 
drugs to cells. Hamilton et al. (1993a) noted that acidic extracellular media reduced the toxicity 
of adriamycin to drug resistant variants of HT-29 and SW-420 cells. At high densities, cells 
would modify the pH of the growth medium to a greater extent than comparable cells at low cell 
densities, due to the breakdown of nutrients present in the medium and the production of waste 
products. Therefore, at high cell plating densities, adriamycin may be less effective at inducing 
cell kill, due to modification of the extracellular environment.
Alterations in drug toxicity to cells, in a density dependent manner, may also be 
associated with intercellular transfer of protective compounds by cells in contact, via gap 
junctions. Loewenstein (1979) has shown that thioguanine sensitivity can be transferred from 
thioguanine sensitive cells to resistant cells, by a mechanism involving cell contact, suggesting 
that the modification may be due to intercellular transport of toxic compounds, via gap junctions. 
If cell contact can increase the cells’ sensitivity to a toxin, then perhaps the converse holds true, 
whereby cell contact may allow the exchange of compounds which would protect sensitive cells 
from toxins.
4.12 Gap junctional intercellular com m unication
Gap junctions are intercellular communication ports, through which small organic 
molecules, inorganic ions and electrical signals pass (Gilula et al., 1972). Gap junctions occur 
where the cell surface membrane of adjacent cells are separated by a gap of approximately 15nm 
(Darnell et al. , 1986) and the interior of the two cells are linked as a result of the joining of two 
structural units, one on each cell membrane. The structural unit of the gap junction, termed 
connexon, is a collection of six protein subunits (connexin), spanning the plasma membrane, 
which are paired, end to end, with an identical hexamer on the adjacent cell, forming a 
cylindrical channel of approximately 1.5-2.0 nanometers in inner diameter, across the 
intercellular gap (Revel et al. , 1986). Hydrophilic amino acid residues line the inner channel of 
the gap junction and the channel is insulated by peripherally organised hydrophobic amino acid 
residues (Goodenough and Revel, 1970), allowing the intercellular flow of hydrophilic molecules 
of molecular weights less than approximately 1000, by passive diffusion.
The gap junction may be composed of mixes of different proteins (Nicholson et 
al. , 1987) and a wide range of connexin proteins have been identified in the same and in different 
tissues (Table 4.3). The naming system of the connexin proteins consist of the use of the word
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connexin in conjunction with the predicted molecular weight of the protein.
Protein Tissue Reference
Connexin 70 Lens Fibres Kistler et al., 1988
MP 70 Lens Fibres Gruijters et a l., 1987
Connexin 56 Lens Rup et al., 1993
Connexin 43 Heart 
Lung 
Pancreas 
Bone Marrow
Beyer et al., 1987 
Chaudhuri et al., 1993 
Meda eta l., 1991 
Dorshkind et al., 1993
Connexin 40 Heart Beyer et al., 1992
Connexin 37 Blood vessel 
endothelial cells
Reed et a l., 1993
Connexin 32 Liver Paul, 1986
Connexin 28 Liver Heynkes et al., 1986
Connexin 26 Liver Zhang and N icholson, 1989
Major Intrinsic Protein 26 Lens Gorin et a l., 1984
Connexin 16 Liver
Heart
Finbow eta l., 1985
Table 4.3 : Tissue distribution o f  putative gap junction proteins.
Heterologous cells in culture, from differing tissues, can form gap junctions 
(Epstein and Gilula, 1977). Connexons can exhibit both functional (open) and non-functional 
(closed) states and studies have produced evidence that cells joined by gap junctional structures 
may not be functionally coupled (Flagg-Newton and Loewenstein, 1979). Gap junction function 
is regulated by Ca2+ and closure of the intercellular communication port is induced by increased 
levels of intercellular Ca2+. Spray et al. (1982) found that both H+ and Ca2+ could act as 
independent gap junctional blockers in blastomere cell pairs. Intercellular gap junction 
communication may also be blocked by other cellular secondary messengers, such as cAMP 
(Murray and Fletcher, 1984) and the phosphoinositide signal pathway compounds (Yada et al., 
1985). Certain anaesthetics also inhibit gap junction mediated intercellular communication 
(Mantz et a l., 1993; Bohrmann and Haas-Assenbaum, 1993; Meda et al., 1990). The down- 
regulation of functional gap junctions has been detected as a conformational change, whereby the 
connexon straightens and slides radially, in a shutter-like system (Unwin and Ennis, 1984). 
However, Loewenstein and Rose (1978) observed that functional uncoupling of gap junctions may
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result from increased intracellular concentrations of Ca2+ in the vicinity of the junction, without 
detectable alterations of the structure of the gap junctions.
The literature has shown that various cancer cells have lost or decreased gap 
junction intercellular communication capacities (Klann et a l., 1989; Boreli et a l., 1969), but not 
all tumorigenic or transformed cells exhibit this decreased intercellular communication (Yamasaki 
et al., 1987; Katoh and Yamasaki, 1991). When Chaudhuri et al. (1993) examined gap 
junctional intercellular communication in non-transformed and transformed mouse lung epithelial 
cells and in a non-transformed cell line treated with tumour promoters, a correlation was 
observed between the in vitro inhibition of gap junctional intercellular communication and lung 
tumour promotion.
Heptanol is a long chain alcohol which reversibly closes gap junctions by 
physically reacting with the gap junction plasma membrane assembly, abolishing cell to cell 
coupling (Nathanson and Burgstahler, 1992; Perez-Armendariz et a l., 1991; Christ el a l., 1991). 
Bastiaane et al. (1993) suggested that a heptanol-induced decrease of gap junctional-intercellular 
communication in rat cardiac cells was mediated by a decrease in the fluidity of the cholesterol- 
rich domain of the membrane, in which the gap junction channels were embedded. Heptanol did 
not perturb intracellular pH or Ca2+ (Meda et a l., 1990) and did not cause detectable changes in 
the actual structure and size of the gap junctions (Meda et a l., 1986).
To determine if gap junction intercellular communication was occurring in the 
squamous cell carcinoma of the lung, DLKP, and its drug-resistant variants, the intercellular 
transfer of lucifer yellow was investigated (El-Fouly et a l., 1987). In the course of the research 
described in this thesis (Section 3.14), functional gap junctional intercellular channels were 
observed in DLKP and its MDR variants, as determined by lucifer yellow transfer. When the 
cells were pre-incubated with 1.5mM heptanol for 1.5h. and continually exposed to heptanol 
during detection of active gap junctions, no intercellular communication was observed, implying 
that heptanol inhibited the gap junctional intercellular communication previously noted in DLKP 
variants.
Although active intercellular communication was observed in all cell lines, the 
intercellular transfer of fluorescent adriamycin was not observed in any DLKP variant. In the 
course of assaying for intercellular communication in DLKP variants, adriamycin was observed 
to diffuse into all variants of DLKP when the cells were incubated in a calcium-free solution 
containing 100/xM adriamycin, for 10 minutes. When the cells were examined by fluorescent 
microscopy, DLKP cells were observed to possess a brighter background than the drug-resistant 
variants, suggesting that the DLKP cells accumulate more adriamycin than the resistant cells. 
The protocol followed to detect the presence of active intercellular transport of adriamycin did 
not allow the exact intracellular localisation of the adriamycin within the cells to be ascertained.
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As all MDR variants of DLKP have been shown to overexpress P-glycoprotein, the decreased 
background fluorescence in the drug-resistant cells could be explained by a higher level of drug 
efflux from the cells. However, cells damaged by the scrape-loading of the adriamycin 
fluoresced much more brightly than the background fluorescence, in all cell lines, and this more 
intense fluorescence was not transferred to neighbouring cells. In the presence of cyclosporin 
A, which would block the rapid efflux of adriamycin from the cells via P-glycoprotein in the 
MDR cells, an absence of intercellular transfer of adriamycin was still found. Therefore, the 
lack of detectable intercellular transfer of adriamycin, in the MDR cells, was not due to a 
masking of the effect by the drug’s P-glycoprotein-mediated drug efflux. This implies that 
adriamycin is not transferred from cell to cell via gap junctions, even though it is a water soluble 
compound and within the size range of molecules transferred by gap junctions. However, the 
ability of a molecule to be transferred intercellularly also depends on it’s shape (P. Meda, 
personal communication). A molecule must have a diameter of less than 1.8nm to enable it to 
be transferred via gap junctions. An extensive literature survey has revealed a lack of scientific 
papers detailing gap junctional intercellular transfer of chemotherapeutic drugs. In this study, 
the intercellular transfer of any non-fluorescent adriamycin degradation products produced by the 
cell or of small molecules or inorganic ions which may have resulted from the presence of 
adriamycin in the cells, was not detectable by the experimental procedures.
Gap junction intercellular communication can only occur in cells which are in 
contact. At plating density routinely used in assays, cells were not in contact, resulting in no gap 
junctional communication and any cells which formed contacts under these circumstances are 
generally derived from the same single cell, resulting in gap junctional communication between 
homologous cells. For gap junctional intercellular communication to function in potentiating or 
diminishing the toxicity of chemotherapeutic drugs to cells, functional gap junctions must exist 
between heterologous cells, with respect to their toxicity to adriamycin, allowing toxic, or 
protective, molecules to be transferred from sensitive to resistant cells, or vice versa. Heptanol 
can only be assumed to alter the toxicity of adriamycin to cells via a gap junctional mediated 
mode of action, if a differential toxicity change is observed in the cell line in both the presence 
and absence of heptanol, and at both a high and low plating density. Heptanol induced alterations 
in adriamycin toxicity occurring at low plating density may be assumed to be mediated by a 
mechanism, or mechanisms, other than gap junctional communication.
The inhibition of gap junctional intercellular communication by heptanol neither 
potentiated nor diminished the toxicity of adriamycin to DLKP, its MDR variant DLKP-A, the 
cloned cell line DLKPA5F or the cell line generated by mixing the clones, at high density, over 
that observed at low plating density. Exposure of the DLKPA5F and the cell line generated by 
mixing the clones, to both adriamycin and heptanol resulted in no significant alteration to
adriamycin-associated toxicity, by comparison with that observed in the absence of heptanol. In 
both the parental DLKP cell line and its MDR variant DLKP-A, heptanol exhibited a protective 
effect on the cells, with respect to adriamycin toxicity. This effect was observed at both high and 
low plating density, implying that the heptanol associated decrease in adriamycin toxicity, was 
by a means other than the gap junctional intercellular communication pathway.
Heptanol appeared to enhance the toxicity of adriamycin to DLKPA2B at high 
cell density and reduced its toxicity at low plating density, which implies that gap junctional 
intercellular communication may alter the cells’ susceptibility to kill by adriamycin. At low cell 
plating density, heptanol exhibited a protective effect towards DLKPA2B with respect to 
adriamycin. The effect also seen in DLKP and DLKP-A at both high and low cell plating 
densities implying that it may have mediated a cellular mechanism other than gap junctional 
communication, which in turn resulted in reduced cell sensitivity to adriamycin.
Intercellular transfer of adriamycin via gap junctional communication ports was 
not observed in DLKPA2B, implying that any gap junction associated alterations in adriamycin- 
induced cell kill, were mediated by other small molecular weight compounds. Gap junctional 
transfer of H+ has been widely documented in the literature (Hertzberg et al., 1981) and 
alterations in intercellular pH has been associated with enhanced cell kill. Barry et al. (1993) 
observed that VP-16-induced apoptosis in human HL-60 cells was associated with intracellular 
acidification. MDR cells have been reported to exhibit an increase in intracellular pH 
(Boscoboinik et al., 1990) and circumvention agents have been shown to decrease the cytosolic 
pH (Hamilton et al., 1993(a, b); Keizer and Joenje, 1989), resulting in increased drug 
accumulation (Simon et al., 1994) and therefore, cell kill. Therefore, any modification in the 
H+ intercellular transfer pathway may result in alterations in cell kill. Perhaps H+ was 
transported from sensitive cells to more resistant variants, thereby increasing the resistance of the 
sensitive cells. However, if gap junctional transfer of protective agents to sensitive cells, or of 
toxins away from the sensitive cells is occurring, the molecule may be other than H+. For gap 
junctional intercellular transfer of cell-protective compounds to occur in DLKPA2B, but not in 
DLKP-A or the other clones derived from it, the cell line must be assumed to be a very different 
variant of DLKP-A and must also be composed of a sub-population of cells which exhibit altered 
capabilities to survive in the presence of adriamycin. However, the cell line DLKPA2B was 
established as a cloned cell line of DLKP-A. The fact that heptanol enhanced adriamycin toxicity 
to DLKPA2B implies that the drug’s toxicity is being masked by a gap junction associated 
function. Alternatively, heptanol may be acting via a hitherto undiscovered mechanism. 
DLKPA2B was also one of the cell lines where the combination of VP-16 and verapamil resulted 
in diminished overall toxicity, in the circumventing assays, a phenomenon which may also be 
associated with alterations in intracellular pH and Ca2+.
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4.13 Cell contact independent modification of adriamycin toxicity
Cell contact-mediated intercellular communication could not fully explain the 
differential adriamycin toxicity profdes obtained at high and low cell plating densities. 
Therefore, the effect of intercellular communication by means other than direct cell contact, on 
the cells’ sensitivity to adriamycin, was investigated in a preliminary assay, which was only 
performed once.
Conditioned media generated by the more resistant cell clone DLKPA5F, during 
its exposure to adriamycin, modified the adriamycin sensitivity of the least resistant clone 
DLKPA2B. The decrease in the sensitivity of DLKPA2B to adriamycin toxicity, when exposed 
in the presence of conditioned media produced by DLKPA5F, was observed at high and low 
DLKPA2B plating densities. When the adriamycin sensitivity of DLKPA2B was examined at 
high cell density, the conditioned media from both DLKPA2B and DLKPA5F, generated in the 
presence and absence of adriamycin, caused a slight increase in the ability of DLKPA2B to 
survive in the presence of adriamycin.
Therefore, it appears that both DLKPA2B and DLKPA5F secrete a compound, 
or compounds, that modifies adriamycin toxicity to DLKPA2B and this product is more active, 
or is secreted to higher concentrations, by DLKPA5F, when the cells are grown in the presence 
of adriamycin. Interactions between the two cell populations affected the sensitivity of the most 
sensitive cell line to the chemotherapeutic agent, adriamycin, and the interaction was mediated 
by a means independent of cell contact.
As previously mentioned, it was noted that better growth occurred in DLKP and 
DLKP-A cells when the medium was left on the cells for a number of days, as opposed to being 
changed daily and that better cell growth occurred when the cells (plated at the low density 
required to isolate clones), were fed with conditioned medium produced by the DLKP-A 
population. These observations imply that DLKP variants may be producing an autocrine growth 
stimulating factor (or factors), which may also be involved in altering their sensitivity to 
adriamycin. Zuckier and Tritton (1983) noted that cells grown in the presence of adriamycin 
possessed increased EGF binding capacities. Meyers et al. (1993) and Shin et al. (1991) have 
associated the expression of EGF receptors and P-glycoprotein. However, Kwok and Sutherland
(1991) found that EGF increased the sensitivity of a human squamous carcinoma cell line, A431, 
to adriamycin. The relative enhancement of sensitivity by EGF was greater in two adriamycin- 
resistant variants, which also possessed increased numbers of EGF receptors, in comparison with 
the parental cells. When Ogawa et al. (1993) investigated the relationship between EGF receptor 
and cisplatin sensitivity in 84 lung carcinomas, the expression of EGF receptors and proliferating
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cell nuclear antigen was significantly lower in cisplatin-sensitive non-small cell carcinomas and 
squamous cell carcinomas. Alterations in TGF-/5 levels have also been associated with the 
sensitivity of cells to chemotherapeutic drugs (Su et al., 1991; Huang and Wright, 1994).
The literature has shown that cells interact and modify the drug sensitivity of 
other cells. This has been widely demonstrated when cells of differing sensitivity are grown in 
contact (Miller et al., 1989; 1991), but the phenomenon has also been noted when cells are 
grown physically separated but sharing the same host. Miller et al. (1981b) observed that the 
presence of a sensitive subpopulation of a mouse mammary tumour, enhanced the 
cyclophosphamide sensitivity of a more resistant subpopulation, when the two populations were 
located on opposite flanks of male BALB/cfC3H mice, implying a cell-contact independent 
mechanism of enhancement of cyclophosphamide toxicity.
4 .14  Co-existence o f populations o f differing adriainycin sensitivity in D LK P-A
Clones have been isolated from the DLKP-A population and the toxicity profiles 
of these clones imply that cells of varying adriamycin sensitivity are existing within the DLKP-A 
cell line. When the clones were examined in isolation, some of the cell lines were sensitive to 
the concentration of adriamycin to which the DLKP-A cell line has been selected. Yet, in the 
cell mixture that makes up DLKP-A, the cells survive just as well as clones that possess higher 
adriamycin resistance. Cells which possess a level of adriamycin resistance greater than the 
concentration of adriamycin to which DLKP-A has been exposed, survive because they have not 
been exposed to the level of toxin required to cause cell kill. However, the clones which are 
sensitive to the level of adriamycin to which DLKP-A has been exposed, can only have survived 
due to assistance from other cells and this assistance may have taken a number of forms.
The DLKP-A cell line was established by exposing the uncloned squamous cell 
carcinoma of the lung, DLKP, to increasing concentrations of adriamycin over a prolonged time 
period, resulting in stable genetic alterations, associated with the acquisition of an MDR 
phenotype (Clynes et al. , 1992). Therefore, the possibility exists that the drug sensitive DLKP 
cells consist of a heterogenous population, with respect to their adriamycin sensitivity. Variation 
with respect to drug sensitivity within tumours has been widely documented in the literature 
(Dolfini et al., 1993; Tanigawa et al., 1984; Allalunis-Turner et al., 1993). Consequently, the 
potential existed for the drug resistant cell line, DLKP-A, to have been selected from one pre­
existing resistant cell or to have been induced following exposure to adriamycin. In both cases, 
adriamycin exposure may have caused mutations, which could alter the resistance o f either an 
initially homologous population, or a population which originally exhibited heterogeneity in its
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adriamycin resistance profile.
During the initial selection process, by which the MDR cell line was derived, the 
DLKP cells were grown at high density, approximately 50-70% confluent, prior to the initial 
drug exposure. The initial drug concentration, to which the cells were exposed, reduced the cell 
population to approximately 5 %. However, the cells remaining were generally clumped in small 
colonies and did not consist of single, dispersed cells. These colonies were then grown, at that 
drug concentration, until they had attained high cell numbers and appeared healthy. At this stage, 
the adriamycin concentration was doubled (A. Redmond, Ph.D. thesis, Dublin City University, 
1991). During selection of the DLKP-A cell line for resistance to adriamycin, the cells also 
underwent a change in their growth patterns, from monolayer sub-confluent growth to a state 
where areas of confluency occurred, in a dispersed manner. Therefore, during the induction of 
an MDR phenotype in DLKP areas of confluency constantly existed. Consequently, some less 
resistant cells may have been protected from adriamycin-induced cell kill, by having their 
sensitivity to adriamycin altered, by the physical protection of a layer of surrounding cells.
DLKP-A is a cell line composed of a mixture of cells, with respect to their level 
of resistance to chemotherapeutic drugs, mode of resistance to these drugs and cell doubling 
times. Yet the subpopulations were stably co-existing within the MDR cell line. Therefore, it 
must be assumed that intercellular communication is occurring, whether mediated by a cell 
contact independent means e.g. growth factor- or hormone-mediated communication, and/or a 
cell contact means e.g. intercellular gap junction communication, as outlined previously.
The literature has revealed a vast supply of information on intercellular 
interactions, resulting in the modification of the characteristics of the individual cells involved 
in the interactions and the generation of a population with its own distinctive attributes. These 
interactions have modified growth properties of the cells (Leith et a l. , 1987; 1988) and the cells’ 
drug sensitivity (Miller et al., 1981b; 1989), and these interactions are a probable means by 
which cells in the DLKP-A population, that are individually not capable of surviving, can grow 
in the presence of specific adriamycin concentrations. Decreased adriamycin toxicity to cells, 
in areas of confluency, may have resulted from decreased intracellular accumulation. This may 
have allowed sensitive cells to survive at drug levels which should cause cell kill, when analyzed 
under the sub-confluent conditions associated with the toxicity assays. Dimanche-Boitrel et al. 
(1992) noted confluency-dependent resistance to a range of chemotherapeutic drugs, in human 
colon cancer cells. The decrease in the cells’ sensitivity to adriamycin, vincristine and VP-16 
was reflected in a lower intracellular level of drug. The altered drug penetration with confluency 
could be related to a decrease in plasma membrane fluidity. Pelletier et al. (1990) also noted that 
both the cytotoxicity of adriamycin, and the concentration of drug located in the nucleus, 
progressively decreased with increasing confluency, in the human and rat colon cell lines, HT-29
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and DHD/K12/TRb, respectively.
The density at which DLKP-A were exposed to both adriamycin and VP-16 
affected the toxicity of drugs to a greater extent than the density-associated alterations in drug 
toxicity observed in the sensitive cell line, DLKP or in the DLKP-A cell clones (Section 3.13). 
As greater cell survival resulted at higher cell densities, in the presence of drug, it implies that 
the heterogeneity of the DLKP-A cells allowed the more sensitive cells to survive, especially at 
high cell density. Although gap junction intercellular transfer of adriamycin does not appear to 
occur, transfer of toxicity-related small molecules may be occurring, as previously discussed. 
Gap junctional-associated modifications to adriamycin toxicity to DLKP-A, however, were not 
detected. As drug toxicity has been linked with intracellular acidification (Hamilton et al., 
1993(a, b); Boscoboinik et a l., 1990), gap junctional transfer of ions could modulate the toxicity 
of individual cells, generating an apparent uniform population, with respect to adriamycin 
toxicity, at high cell density or areas of confluency. In the DLKP-A cell line, during selection 
with adriamycin, the more sensitive cells may have survived if a cell population, or populations, 
existed which could modify the drugs’ toxicity to the sensitive cells. Therefore, if the degree of 
adriamycin toxicity to DLKP-A is associated with the intracellular pH of the cells, the transfer 
of ions e.g. H+, Ca2+, from less resistant to more resistant cells, via gap junctions, in areas of 
confluency, may have allowed the sensitive cells e.g. DLKPA2B, to survive at adriamycin 
concentrations which, individually, would cause cell kill.
Modifications to the extracellular environment may also have allowed the more 
sensitive cells to be maintained in the DLKP-A population. During the adriamycin selection 
process, DLKP-A cells were exposed to fresh drug only when cells were over 50% confluent and 
appeared healthy. Therefore, the cells were producing and secreting metabolites and so, were 
constantly altering the extracellular pH, changing it to a more acidic environment. Adriamycin 
accumulation by cells is not only dependent on intracellular pH but also on the extracellular pH. 
A decrease in the pH of the extracellular environment has been shown to protect cells from 
cytotoxicity (Jahde et al., 1990). Consequently, acidification of the extracellular media, alone 
or in conjunction with the possible intracellular alterations previously mentioned, may have 
enabled the more sensitive cells to survive.
Adriamycin-sensitive cells may also survive in the presence o f toxic 
concentrations of the drug, in the DLKP-A population, due to modification of the medium in 
which the cells are grown, by the production of specific compounds by subpopulations within 
DLKP-A. The research work presented in this thesis, showed that conditioned medium, 
produced by DLKPA5F, when grown in the presence of adriamycin, partially protected 
DLKPA2B cells from the toxic effects of the drug (Section 3.15). Miller et al. (1981) have also 
shown that factor(s) produced by cells, not growing in contact, can modify each others sensitivity
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to drugs. Therefore, as factor(s) produced by DLKPA5F can modify the sensitivity of DLKPA2B 
to adriamycin, it would follow that factor(s) produced by the DLKPA5F population, or other 
subpopulations of DLKP-A, while in the DLKP-A cell line, would also modify the sensitivity of 
cell subpopulations. This would alter the sensitivity of the overall DLKP-A population to 
adriamycin, and so, cells may be surviving in the presence of concentrations of adriamycin 
which, if the cell ’protective’ factor(s) were removed, would cause cell kdl. The factor(s) 
produced by DLKP-A subpopulations may be growth stimulatory factors, growth inhibitory 
factors or other, as yet undefined, factors. Growth factors have been shown to modify the 
sensitivity of cells to drugs, both enhancing their sensitivity (Kwok and Sutherland, 1991) and 
resistance (Huang and Wright, 1994). Overexpression of growth factor receptors has also been 
associated with MDR (Shin et al., 1991; Meyers et al., 1993; Ogawa et al., 1993). Growth 
inhibitory factors would decrease the growth rate of the cell subpopulations, and so alter their 
sensitivity to chemotherapeutic drugs. The sensitivity of cells to a range of chemotherapeutic 
drugs is correlated to their growth rate. Cell undergoing active proliferation are more sensitive 
to drug-induced cell kill, than quiescent cells (Chambers et al., 1984).
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4.15 Implications for clinical therapy of cancer.
The acquisition by cancer cells of resistance to a broad range of chemotherapeutic 
drugs, or their inherent resistance, is a major problem in the effective treatment of cancer. Much 
research has been carried out in developing mechanisms of overcoming this resistance and 
improving patient therapy. However, the characteristics of the individual cancer cells themselves 
are not the only important factors to be considered when devising effective treatment regimes, 
the extracellular environment, the structural organisation of the tumours and cell heterogeneity 
and interactions must also be considered.
Tumour heterogeneity has been widely documented in the literature and has been 
reflected by cell variations observed in established cell lines, derived from tumour samples. 
Perhaps the most important considerations of tumour cell heterogeneity is the variability in drug 
and radiation resistance, growth properties and tumourogenicity exhibited by clonal 
subpopulations (Dolfini et a l., 1993; Allam et a l., 1993; Fried et a l., 1993; Okabe et a l., 1983). 
To effectively treat cancer, the most resistant subpopulation must be killed, otherwise the tumour 
may regrow, with altered properties, giving rise to not only a regenerated tumour, but possibly 
metastasis, with altered properties.
The existence of variation within MDR cell lines (Yang et a l., 1993 and as shown 
in this thesis, with respect to DLKP-A) may add an extra variable to the problem of treating 
drug-resistant cancers. The ability of subpopulations to interact and modify each other’s drug 
sensitivity, when grown either in contact or separately, may further complicate the situation. Cell 
interactions have been shown to enhance the sensitivity of cells to chemotherapeutic agents, when 
the cells are grown both in contact and separately (Miller et al., 1981; 1988; 1991), thereby 
exhibiting an optimistic prospect for cancer chemotherapy, especially that of combination 
chemotherapy, whereby cells which are resistant to one drug may be sensitive to another drug. 
However, in this study, interactions between subpopulations of the MDR cell line DLKP-A, have 
been shown to enhance the resistance of the most sensitive subpopulation. Therefore, the efficacy 
of drugs to cells may be decreased by the presence of surrounding, or distant, cells.
Before chemotherapeutic drugs can be effective in the treatment of cancers, they 
must be capable of reaching their cellular target. Most drugs used in cancer treatment possess 
cell cycle specific targets, so that the drug is more effective against growing cells than those in 
quiescence. Therefore, the target is generally the cell nucleus and factors which enhance drug 
accumulation by the cells, or alter cell growth, may act as chemotherapeutic agents.
Solid tumours consist of clumps of cells, in which the cells at the centre of the 
tumour are either necrotic or quiescent and those at the outer edges undergo cell division.
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Therefore, the inability of drugs to penetrate into the inner cells results in these cells not being 
exposed to chemotherapeutic drugs. Erlichman and Vidgan (1984) investigated the cytotoxic 
activity of adriamycin on the human bladder carcinoma cell line, MGH-U1, growing as 
monolayers, as spheroids and as xenografts in nude mice. The cells growing as spheroids were 
much more resistant to adriamycin than when treated as monolayers and adriamycin fluorescence 
was demonstrated only in the outer two layers of cells forming the spheroids, suggesting limited 
drug penetration. Durand (1981) observed that in Chinese hamster V79 cells grown as spheroids, 
a gradient of adriamycin uptake existed, with only the one or two outer layers brightly 
fluorescing after lh. exposure. Growth of cells as spheroids seemed to impart an additional 
degree of drug resistance relative to cells grown as monolayers, in that equal toxicity required 
greater intracellular fluorescence for spheroids. Cells grown as spheroids are in general more 
resistant to a range of drugs than their counterparts, growing as monolayer cultures (Wilson et 
al., 1981; Nederman, 1984; Sasaki et al. , 1984). Lack of drug penetration in tumour masses 
may be due to the inability of cells to intercellularly transfer the drug, via gap junctions. Gap 
junctional communication in some cancer cells has been decreased or abolished (Klann et al., 
1989; Borek et al., 1969), but even in the DLKP-A cells, where functional gap junctional 
communication was demonstrated, intercellular transfer of adriamycin was not observed. 
Therefore, any agent that would enhance the intercellular transfer of chemotherapeutic drugs, 
may also be effective enhancers of cell toxicity and may be of use in the treatment of cancers.
Solid tumours consist of densely packed cells, with only the outer layers dividing. 
Confluent cells have been shown to accumulate lower levels of drugs (Dimanche-Boitrel et al. , 
1992; Pelletier et al., 1990) and confluent, non-proliferating cells are less sensitive to 
chemotherapeutic agents than proliferating cells (Chambers et al. , 1984; Drewinko et al. , 1981). 
In the course of research undertaken for this thesis, it was noted that adriamycin and VP-16 
toxicity to variants of DLKP was cell density dependent. This cell density dependent toxicity of 
chemotherapeutic drugs may also be due to physiological alterations that have occurred to the 
extracellular environment. Drug accumulation is decreased at reduced pH values (Hamilton et 
al. , 1993b) and cell growth, both in culture and tumours, may result in the production of waste 
products which would alter the pH of the surrounding environment. A decrease in the pH of the 
extracellular environment may therefore result in decreased drug accumulation and enhanced cell 
survival.
In culture, and therefore possibly in tumours, the effectiveness of 
chemotherapeutic agents in inducing cell kill is dependent not only on the sensitivity of individual 
cells, but on the ability of the cell populations to alter the chemosensitivity of surrounding cells 
and to modify the environment in which the cells exist. Intercellular interactions, whether 
mediated via cell contact-independent or -dependent mechanisms, are also capable of modulating 
the cells’ characteristics. Therefore, when analyzing the toxicity of chemotherapeutic drugs to
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cells in culture, interactions capable of altering the cells’ sensitivity must be considered, when 
correlating the findings of cell culture systems to in vivo situations.
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Conclusion
This project investigated mechanisms by which subpopulations of the human 
squamous cell lung carcinoma, DLKP, exert their drug-resistance phenotypes. The existence 
of heterogeneous cell populations within the adriamycin-selected MDR variant of DLKP was 
studied, by isolating and characterising subpopulations of the cell line. The ability of cells of 
varying characteristics to exist as a cell line was investigated, by examining possible cell 
interaction mechanisms.
Variants of DLKP, selected by exposure to VP-16, exhibited an MDR 
phenotype, in that the cell lines were resistant to VP-16, adriamycin and vincristine, but they 
exhibited hyper-sensitivity to cisplatin. The drug resistance of the cell lines was mediated by 
the over-expression of P-glycoprotein, reduced drug accumulation and decreased levels of 
topoisomerase II. Cyclosporin A and verapamil reversed the accumulation of adriamycin to 
levels observed in the sensitive parental cells and caused partial reversal of the cells’ resistance 
to adriamycin and vincristine. Verapamil proved to be highly toxic to the VP-16-selected MDR 
cell lines and the simultaneous exposure of VP-16 and verapamil to the cells resulted in less cell 
kill than their individual toxicities would indicate.
Clonal subpopulations of the adriamycin-selected MDR cell line, DLKP-A, all 
exhibited an MDR profile. The resistance to adriamycin, displayed by the clonal 
subpopulations, spanned a 9-fold range, from less resistant than DLKP-A cells to more resistant. 
The MDR profile observed in the clonal populations was mediated, at least in part, by 
alterations in the levels of both P-glycoprotein and topoisomerase II, with each cell clone 
possessing an individual profile. Further characterisation of the clones revealed that the DLKP- 
A cell line was also heterogeneous in terms of its drug- and radiation-sensitivity and with 
respect to its cell doubling time. Exposure of the DLKP cells to adriamycin and the conferring 
of a P-glycoprotein and topoisomerase II mediated MDR profile, did not alter the combined 
(DLKP-A) cells’ sensitivity to radiation. Similarly, irradiation of the DLKP cell line did not 
confer drug resistance on the cells. Even though the DLKP-A cell line exhibited a similar cell 
doubling time and radiation sensitivity as the parental DLKP cell line, clones of DLKP-A 
showed individual cell doubling times and radiation sensitivity.
All variants of the DLKP cell line possessed functional gap junctional 
communication, but adriamycin was not transferred intercellularly. The inhibition of gap 
junctional communications did not result in an enhancement of the cells’ sensitivity to 
adriamycin, suggesting other toxic or protective molecules were not being transferred 
intercellularly via gap junctions. However, cell density-dependent toxicity was observed in all 
cell lines; cells at high density were more resistant to the cytocidal and/or cytostatic effects of 
chemotherapeutic drugs than the same cells when exposed at low cell densities. A  substance 
produced by the most resistant subpopulation of DLKP-A and secreted into the growth medium,
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was apparently capable of masking the toxicity of adriamycin to DLKPA2B cells.
Although the primary characterisation of the VP-16-selected MDR variants of 
DLKP has been carried out during the course of this research work, the knowledge attained, 
pertaining to the mechanisms of resistance exhibited by the cells, may have many implications. 
The most striking of these relates to what is happening when the MDR cells are exposed to 
verapamil and VP-16, simultaneously. Both verapamil and VP-16 were highly toxic to the cell 
lines, but the combination of both was less toxic than was expected. Whether this was as a 
result of less accumulation of one or both of the toxins or was due to an alternative 
modification, could be investigated. The level of accumulation of verapamil and VP-16, by the 
VP-16-selected cells and their effect on the accumulation of each other, could be determined by 
using radiolabelled analogues of the drugs.
Other interesting future areas of research include the cellular localisation of 
adriamycin and other drugs within the cells. Circumventing agents have been shown to 
enhance the toxicity of adriamycin to DLKP cells while the same agents exhibited no alteration 
on the level of adriamycin accumulation by the cells. In contrast, the same circumventing 
agents reverse the adriamycin accumulation by MDR cells to the level observed in the drug- 
sensitive parents, but drug resistance was not completely reversed. The first case implies that 
the circumventing agents possess the ability to enhance drug toxicity in a manner independent 
from a drug accumulation mechanism. The second case implies that an enhancement of drug 
accumulation is not paralleled by an increase in toxicity. In order to determine if  altered drug 
localisation is a mechanism of resistance displayed by the cells, the intracellular location of 
adriamycin (determined by fluorescent microscopic analysis), in the absence and presence of 
toxicity-enhancers, should be studied.
The existence of alternative mechanisms of resistance (e.g. GST-7T, MRP) could 
be determined by RT-PCR and/or Western blotting analysis. This would result in a more 
complete profile of the mechanisms of resistance by the cells and would help to explain the 
cross-resistance profiles more completely.
Gap junctional communication has been demonstrated in cell variants of DLKP. 
However, intercellular transfer of adriamycin was not noted. This technique involved placing 
confluent cell populations in an adriamycin-containing Ca2+-free solution, scoring through some 
centrally located cells with a blade and monitoring the transfer of adriamycin from these scrape 
loaded cells to surrounding cells. Adriamycin diffuses into cells. Hence, this an indefinitive 
experiment as the level of fluorescence in cells boardering the scrape was being compared with 
the background fluorescence. Further work, using micro-injection techniques to insert a 
fluorescent probe into an individual cell and examining the surrounding cells for fluorescence, 
which would have resulted from the intercellular transfer of the fluorescent probe, would result
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in more definitive answers regarding gap junctional transfer of adriamycin. This would also 
act as a more exact quantification of the level of gap junctional transfer of lucifer yellow  
between cells.
The final, and perhaps most interesting aspect of the results, which could lead 
to further research, pertains to the conditioned medium experiment. Firstly, an expanded assay 
could be performed to establish whether, in addition to the conditioned medium produced by 
DLKPA5F modulating the drug-sensitivity of DLKPA2B cells, the converse also holds true. 
An expanded range of cell lines could be examined, not only for the production of a toxicity 
modulating factor (or factors) but for their responsiveness to this factor. The expression of 
growth factor receptors by the cells and the effect of growth factors on the toxicity of 
adriamycin to the cells should also be studied and may indicate whether the unknown 
adriamycin toxicity modulating factor is a growth factor or another type of compound. Partial, 
or fall purification of the factor from the conditioned medium (by filtration through molecular 
weight cut-off membranes, gel filtration and/or high performance liquid chromatography 
purification), followed by the analysis and identification of the factor, would be important in 
determining its significance as a factor in modulating drug toxicity. An analysis of other drug- 
sensitive and drug-resistant cell lines could then be performed to determine the extent of 
production of this molecule by cells, either naturally or when stimulated by exposure to 
chemotherapeutic drugs.
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Appendix A
Determination of the IC50 value.
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The polynomial equations illustrated in the above diagram, present the best 
correlation between cell survival, on the Y-axis and the drug concentration, on the X-axis. This 
equation has been obtained from the graphical curve fitting carried out by the Cricket Graph 
computer software package. The correlation coefficient, r, conveys information about the state 
of the fitness of the equation, in relation to the data obtained from the assay. Thus, the drug 
concentration corresponding to any percentage of the cell survival, can be calculated by solving 
the polynomial best fit curve. The determination of the IC^, which denotes the drug 
concentration corresponding to 50% cell survival, has been carried out by taking Y = 50 and 
solving the best fit curve equation, with respect to Y. The Newton-Raphson method for 
numerical solution of «th. order polynomial equations has been employed for this determination. 
A computer program was developed in-house, by Dr. Mohamad Saleh, to execute and perform 
the calculation. The IC50 values, from replica assays, were determined in this manner and used 
to ascertain the average IC*, value and the standard deviation on the average value.
Appendix B
Description of D0, Dq and n values.
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The above diagram represents a typical survival curve for cells treated with 
radiation. The survival is plotted on a logarithmic scale against dose, plotted on a linear scale. 
The survival curve is characterised by a shoulder region, followed by a terminal exponential 
region, the slope of which is defined by a D0 value. D0 is referred to as the radiosensitivity of 
the cell or tissue under investigation, and is the dose required to reduce cell survival from any 
value N  to 0.37V, in the straight-line region of the survival curve. The quasi-threshold dose, 
Dq, is the irradiation dose corresponding to the intercept of the extrapolated straight-line region 
of the survival curve with the 100% survival level. The extrapolation number, n, is defined by 
the intercept of the straight-line region, extrapolated back to the 0 dose axis. Both Dq and n 
define the width of the shoulder on the survival curve.
Appendix C
amsacrine 4’-(-9-Acridinylamino)methanesulfin-m-anaiside
ATCC American Tissue Culture Collection
ATP Adenosine tri-phosphate
bp base pair
CaCl2 Calcium chloride
cDNA Complementary deoxyribonucleic acid
DEM Minimum essential medium eagle’s
DMEM Dulbeccos minimum eagle’s medium
DNA Deoxyribonucleic acid
EDTA Ethylene glycol-bis(Ji-aminoethylether)-N,N,N’,N’-tetraacetic
acid
EGF Epidermal growth factor
FCS Foetal calf serum
GST Glutathione-S-transferase
Gy Gray
HC1 Hydrochloric acid
Hepes 4-(2-hydroxyethyl)-l-piperazine ethane sulfonic acid
MDR Multidrug resistant, Multiple drug resistant
MgCl2 Magnesium chloride
mRNA Messanger ribonucleic acid
MRP Multidrug resistant related protein
NaHC02 Sodium bicarbonate
NaOH Sodium Hydroxide
OD Optical Density
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PMSF Phenylmethylsulfonyl fluoride
SDS Sodium dodedecyl sulphate
TEMED N,N,N’, N ’ -Tetramethy 1-ethylened i am i ne
Topoisomerase II DNA Topoisomerase II enzyme
Tris Tris(hydroxymethyl)aminomethane hydrochloride
Abbreviations
Appendix D
Molecular weights of compounds used in this research
Adriamycin 580.0
Camptothecin 348.4
Cisplatin 300.0
5-Fhiorouracil 130.1
Lucifer yellow 457.2
Verapamil 491.1
Vincristine 923.0
VP-16 588.6
